{"bca9f4ffe445882f2de559b938d83a69e90d2224": [["INTRODUCTIONDuring the last two decades, protein aggregation at all organismal levels, from viruses to humans, has emerged from a neglected area of protein science to become a central issue in biology and biomedicine The expanding knowledge in the field has particularly benefited our understanding of neurodegenerative disorders (NDDs) .", [["neurodegenerative disorders", "DISEASE", 302, 329], ["NDDs", "DISEASE", 331, 335], ["humans", "ORGANISM", 103, 109], ["humans", "SPECIES", 103, 109], ["humans", "SPECIES", 103, 109], ["protein aggregation", "PROBLEM", 41, 60], ["neurodegenerative disorders", "PROBLEM", 302, 329], ["organismal levels", "OBSERVATION", 68, 85], ["neurodegenerative", "OBSERVATION_MODIFIER", 302, 319]]], ["At the present time, it is widely acknowledged that templating (the basic mechanism generating protein misfolding, aggregation, deposit, and cell-to-cell transfer of certain pathogenic proteins) would be able to explain many features of the subclinical course and clinical manifestations of NDDs (Warren et al., 2013) .", [["cell", "ANATOMY", 141, 145], ["cell", "ANATOMY", 149, 153], ["aggregation", "DISEASE", 115, 126], ["NDDs", "DISEASE", 291, 295], ["cell", "CELL", 141, 145], ["cell", "CELL", 149, 153], ["pathogenic proteins", "PROTEIN", 174, 193], ["protein misfolding", "PROBLEM", 95, 113], ["aggregation", "PROBLEM", 115, 126], ["certain pathogenic proteins", "PROBLEM", 166, 193]]], ["Transcellular disease propagation of the pathogenic protein along existing anatomic structures (neural networks) would also explain the progression from the varied clinical patterns of NDDs (denoted as phenotypic heterogeneity) to a phenotypically converging, similar status, where a wide loss of cognitive, motor and sensory functions occur (Warren et al., 2013) .INTRODUCTIONIn a prior article, we selected 11 neurodegenerative conditions defined by clinical, neuropathological and biochemical features expressing different sets of single or combined misfolded protein deposits, and described lifecourse-related epidemiologic features (age-specific incidences and disease risk factors or disease progression predictors), thereby allowing for a meaningful, framed and unifying view of each disorder and its post-mortem biochemical signature (de Pedro-Cuesta et al., 2015) .", [["Transcellular", "ANATOMY", 0, 13], ["anatomic structures", "ANATOMY", 75, 94], ["neural networks", "ANATOMY", 96, 111], ["NDDs", "DISEASE", 185, 189], ["loss of cognitive, motor and sensory functions", "DISEASE", 289, 335], ["anatomic structures", "MULTI-TISSUE_STRUCTURE", 75, 94], ["neural networks", "MULTI-TISSUE_STRUCTURE", 96, 111], ["NDDs", "GENE_OR_GENE_PRODUCT", 185, 189], ["pathogenic protein", "PROTEIN", 41, 59], ["Transcellular disease propagation", "PROBLEM", 0, 33], ["the pathogenic protein", "PROBLEM", 37, 59], ["NDDs", "PROBLEM", 185, 189], ["a wide loss of cognitive", "PROBLEM", 282, 306], ["11 neurodegenerative conditions", "PROBLEM", 409, 440], ["clinical, neuropathological and biochemical features", "PROBLEM", 452, 504], ["combined misfolded protein deposits", "PROBLEM", 544, 579], ["epidemiologic features", "PROBLEM", 614, 636], ["disease risk factors", "PROBLEM", 666, 686], ["disease progression predictors", "PROBLEM", 690, 720], ["each disorder", "PROBLEM", 786, 799], ["disease", "OBSERVATION", 14, 21], ["pathogenic protein", "OBSERVATION", 41, 59], ["progression", "OBSERVATION_MODIFIER", 136, 147], ["misfolded protein deposits", "OBSERVATION", 553, 579]]], ["At a second step, we used a modified definition of the driver concept proposed by Sutherland to identify risk factors of specific proteins affecting different NDDs (Sutherland et al., 2011) and, having in mind the common amyloid nature of the pathogenic proteins involved, we identified selected traits of the epidemiology of sporadic, protein-associated, i.e., conformational, NDDs (sCNDD) useful for interpreting epidemiologic findings and relationships of the entities listed in Table 1 (Gunnarsson et al., 1996; Marmorstein et al., 2002; Peng et al., 2005; Irwin et al., 2013; Prusiner et al., 2015; de Pedro-Cuesta et al., 2016) .", [["pathogenic proteins", "PROTEIN", 243, 262], ["specific proteins", "PROBLEM", 121, 138]]], ["In this third article we face a cumulative etiologic approach taking into account recent experimental data on transmissibility of multiple system atrophy (MSA; Prusiner et al., 2015) .INTRODUCTIONAccordingly, the purpose of this work was: (a) to complement and anchor the interpretation of each driver with selected results of clinical or animal-model research; (b) to propose etiologic theory pointing to basic mechanisms and specific causal hypotheses testable by study designs, for epidemiologic or experimental research; and (c) in line with recent initiatives, to propose public health developments.SEARCH STRATEGY AND SELECTION CRITERIAReferences for this review were identified by searches used in prior articles (de Pedro-Cuesta et al., 2015 , by diverse searches of MEDLINE with limits from 1995 to September 2015, relevant for entities on study, and reference lists from relevant articles.", [["multiple system atrophy", "DISEASE", 130, 153], ["MSA", "DISEASE", 155, 158], ["a cumulative etiologic approach", "TREATMENT", 30, 61], ["multiple system atrophy", "PROBLEM", 130, 153], ["study", "TEST", 849, 854], ["atrophy", "OBSERVATION", 146, 153]]], ["Reports in MEDLINE in all languages, using each of the following diagnostic search terms combined with etiology, i.e., dementia, Creutzfeldt-Jakob syndrome, motor neurone disease (MND), amyotrophic lateral sclerosis (ALS), fronto-temporal dementia (FTD), MSA, Parkinson's disease (PD), Lewy body disease (LBD), Alzheimer's disease (AD), rapid progressive dementia, age-related macular degeneration (AMD) and Huntington's disease (HD).", [["body", "ANATOMY", 291, 295], ["macular", "ANATOMY", 377, 384], ["dementia", "DISEASE", 119, 127], ["Creutzfeldt-Jakob syndrome", "DISEASE", 129, 155], ["motor neurone disease", "DISEASE", 157, 178], ["MND", "DISEASE", 180, 183], ["amyotrophic lateral sclerosis", "DISEASE", 186, 215], ["ALS", "DISEASE", 217, 220], ["fronto-temporal dementia", "DISEASE", 223, 247], ["FTD", "DISEASE", 249, 252], ["MSA", "DISEASE", 255, 258], ["Parkinson's disease", "DISEASE", 260, 279], ["PD", "DISEASE", 281, 283], ["Lewy body disease", "DISEASE", 286, 303], ["LBD", "DISEASE", 305, 308], ["Alzheimer's disease", "DISEASE", 311, 330], ["AD", "DISEASE", 332, 334], ["dementia", "DISEASE", 355, 363], ["macular degeneration", "DISEASE", 377, 397], ["AMD", "DISEASE", 399, 402], ["Huntington's disease", "DISEASE", 408, 428], ["HD", "DISEASE", 430, 432], ["motor neurone", "CANCER", 157, 170], ["amyotrophic lateral sclerosis", "CANCER", 186, 215], ["macular", "TISSUE", 377, 384], ["dementia", "PROBLEM", 119, 127], ["Creutzfeldt", "PROBLEM", 129, 140], ["Jakob syndrome", "PROBLEM", 141, 155], ["motor neurone disease (MND)", "PROBLEM", 157, 184], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 186, 221], ["fronto-temporal dementia (FTD)", "PROBLEM", 223, 253], ["MSA", "PROBLEM", 255, 258], ["Parkinson's disease", "PROBLEM", 260, 279], ["PD)", "PROBLEM", 281, 284], ["Lewy body disease (LBD)", "PROBLEM", 286, 309], ["Alzheimer's disease", "PROBLEM", 311, 330], ["rapid progressive dementia", "PROBLEM", 337, 363], ["macular degeneration", "PROBLEM", 377, 397], ["AMD)", "PROBLEM", 399, 403], ["Huntington's disease", "PROBLEM", 408, 428], ["HD)", "TREATMENT", 430, 433], ["dementia", "OBSERVATION", 119, 127], ["motor neurone disease", "OBSERVATION", 157, 178], ["amyotrophic", "OBSERVATION_MODIFIER", 186, 197], ["lateral", "OBSERVATION_MODIFIER", 198, 205], ["sclerosis", "OBSERVATION", 206, 215], ["temporal", "ANATOMY", 230, 238], ["dementia", "OBSERVATION", 239, 247], ["Parkinson's disease", "OBSERVATION", 260, 279], ["Lewy body disease", "OBSERVATION", 286, 303], ["LBD", "ANATOMY", 305, 308], ["Alzheimer's disease", "OBSERVATION", 311, 330], ["rapid", "OBSERVATION_MODIFIER", 337, 342], ["progressive", "OBSERVATION_MODIFIER", 343, 354], ["dementia", "OBSERVATION", 355, 363], ["macular degeneration", "OBSERVATION", 377, 397]]], ["There were no language restrictions.", [["no", "UNCERTAINTY", 11, 13], ["language restrictions", "OBSERVATION", 14, 35]]], ["The final reference list consisted of a compendium of an approximately twice the size of full-text consultation work.", [["size", "OBSERVATION_MODIFIER", 81, 85]]], ["As a literature review based proposal, the study does not require ethical assessment.SEARCH STRATEGY AND SELECTION CRITERIADATA SUPPORTING AMYLOID-RELATED ETIOLOGY ACCORDING TO SPECIFIC DRIVERS AND SUCCINCT THEORY Driver 1.", [["the study", "TEST", 39, 48], ["ethical assessment", "TEST", 66, 84]]], ["Low Age-at-Exposure Related Susceptibility to Environmental Exposure Effects Driver 1 builds on the following specific epidemiologic observations: (a) age at first major whooping cough epidemic and PD incidence in Iceland; (b) bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease (vCJD); (c) age at first human growth hormone (hGH) treatment and accidentally transmitted CJD (atCJD) in the UK; and (d) risk of sporadic Creutzfeldt-Jakob disease (sCJD) from routine surgery followed by a \u226520-year latency period in Denmark and Sweden.SEARCH STRATEGY AND SELECTION CRITERIAWhen fitted to a linear model, risk of PD increased with age at first whooping cough epidemic, a proxy of median age at BP infection .", [["whooping cough", "DISEASE", 170, 184], ["PD", "DISEASE", 198, 200], ["spongiform encephalopathy", "DISEASE", 234, 259], ["Creutzfeldt-Jakob disease", "DISEASE", 272, 297], ["vCJD", "DISEASE", 299, 303], ["CJD", "DISEASE", 389, 392], ["atCJD", "DISEASE", 394, 399], ["Creutzfeldt-Jakob disease", "DISEASE", 437, 462], ["sCJD", "DISEASE", 464, 468], ["PD", "DISEASE", 628, 630], ["whooping cough", "DISEASE", 659, 673], ["BP infection", "DISEASE", 709, 721], ["bovine spongiform encephalopathy", "ORGANISM", 227, 259], ["human", "ORGANISM", 323, 328], ["bovine", "SPECIES", 227, 233], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 323, 328], ["Low Age", "PROBLEM", 0, 7], ["whooping cough epidemic", "PROBLEM", 170, 193], ["PD incidence in Iceland", "PROBLEM", 198, 221], ["bovine spongiform encephalopathy", "PROBLEM", 227, 259], ["Jakob disease (vCJD)", "PROBLEM", 284, 304], ["hGH) treatment", "TREATMENT", 345, 359], ["accidentally transmitted CJD", "PROBLEM", 364, 392], ["sporadic Creutzfeldt", "PROBLEM", 428, 448], ["Jakob disease (sCJD", "PROBLEM", 449, 468], ["routine surgery", "TREATMENT", 475, 490], ["a linear model", "TREATMENT", 604, 618], ["PD", "PROBLEM", 628, 630], ["whooping cough", "PROBLEM", 659, 673], ["BP infection", "PROBLEM", 709, 721], ["spongiform encephalopathy", "OBSERVATION", 234, 259], ["infection", "OBSERVATION", 712, 721]]], ["The susceptibility function for vCJD followed an inverted V shaped profile peaking at approximately 10 years.", [["vCJD", "DISEASE", 32, 36], ["The susceptibility function", "TEST", 0, 27], ["vCJD", "PROBLEM", 32, 36], ["V shaped", "OBSERVATION_MODIFIER", 58, 66], ["profile", "OBSERVATION_MODIFIER", 67, 74], ["peaking", "OBSERVATION_MODIFIER", 75, 82]]], ["For sCJD, we observed that surgery at juvenile age (<30 years) yielded the highest risk (OR 12.80; .", [["sCJD", "DISEASE", 4, 8], ["sCJD", "PROBLEM", 4, 8], ["surgery", "TREATMENT", 27, 34]]], ["Associations between developmental factors and risk of AD (Savica et al., 2013) and PD (Barlow et al., 2007) might support driver 1 validity for late-life sCNDD (for a review see de Pedro-Cuesta et al., 2016) .Complementary Findings\u2022 Neuropathologically proven AD associated with atCJD has been reported in a young patient who received a dura mater graft (Preusser et al., 2006) . \u2022 A significantly high incidence of MND (based on three cases) has recently been described in a young cohort of hGH recipients in the USA (Irwin et al., 2013) . \u2022 Potential host-to-cell induction of \u03b1-synuclein degeneration from patients diagnosed with PD who received fetal/embryonic tissue grafts, and disease induction by seeding in the \u03b1-synuclein and tau mouse models, supported the inference of induction of late-life sCNDD in fetal cells (Luk et al., 2012b; Morales et al., 2012; Olanow and Brundin, 2013) .", [["dura mater", "ANATOMY", 338, 348], ["cell", "ANATOMY", 562, 566], ["fetal", "ANATOMY", 650, 655], ["embryonic tissue grafts", "ANATOMY", 656, 679], ["fetal cells", "ANATOMY", 814, 825], ["AD", "DISEASE", 55, 57], ["PD", "DISEASE", 84, 86], ["sCNDD", "DISEASE", 155, 160], ["AD", "DISEASE", 261, 263], ["atCJD", "DISEASE", 280, 285], ["MND", "DISEASE", 417, 420], ["PD", "DISEASE", 634, 636], ["atCJD", "CANCER", 280, 285], ["patient", "ORGANISM", 315, 322], ["dura mater graft", "TISSUE", 338, 354], ["hGH", "ORGANISM", 493, 496], ["cell", "CELL", 562, 566], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 580, 591], ["patients", "ORGANISM", 610, 618], ["fetal", "TISSUE", 650, 655], ["embryonic tissue grafts", "TISSUE", 656, 679], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 721, 732], ["tau", "GENE_OR_GENE_PRODUCT", 737, 740], ["mouse", "ORGANISM", 741, 746], ["fetal cells", "CELL", 814, 825], ["\u03b1-synuclein", "PROTEIN", 580, 591], ["\u03b1-synuclein", "PROTEIN", 721, 732], ["fetal cells", "CELL_TYPE", 814, 825], ["patient", "SPECIES", 315, 322], ["patients", "SPECIES", 610, 618], ["mouse", "SPECIES", 741, 746], ["mouse", "SPECIES", 741, 746], ["developmental factors", "PROBLEM", 21, 42], ["a dura mater graft", "TREATMENT", 336, 354], ["A significantly high incidence of MND", "PROBLEM", 383, 420], ["\u03b1-synuclein degeneration", "PROBLEM", 580, 604], ["PD", "PROBLEM", 634, 636], ["fetal/embryonic tissue grafts", "TREATMENT", 650, 679], ["disease induction", "TREATMENT", 685, 702], ["graft", "OBSERVATION", 349, 354], ["significantly", "OBSERVATION_MODIFIER", 385, 398], ["high", "OBSERVATION_MODIFIER", 399, 403], ["MND", "OBSERVATION", 417, 420], ["host-to-cell", "OBSERVATION_MODIFIER", 554, 566], ["embryonic tissue grafts", "OBSERVATION", 656, 679], ["fetal cells", "ANATOMY", 814, 825]]], ["US human growth hormone treated cohort (Irwin et al., 2013) Parkinson's disease (PD), \u03b1 synuclein --100 10 1.5-2.5/1 Lewy body disease (LBD) for PD and multiple system atrophy (MSA) (Peng et al., 2005) Lactadherin -----Transmission among individuals proven for CJD and PD, not for MSAFrom PD patient to fetal grafted cells.", [["body", "ANATOMY", 122, 126], ["fetal grafted cells", "ANATOMY", 303, 322], ["Parkinson's disease", "DISEASE", 60, 79], ["PD", "DISEASE", 81, 83], ["Lewy body disease", "DISEASE", 117, 134], ["LBD", "DISEASE", 136, 139], ["PD", "DISEASE", 145, 147], ["multiple system atrophy", "DISEASE", 152, 175], ["MSA", "DISEASE", 177, 180], ["CJD", "DISEASE", 261, 264], ["PD", "DISEASE", 269, 271], ["PD", "DISEASE", 289, 291], ["human", "ORGANISM", 3, 8], ["Parkinson's disease", "CANCER", 60, 79], ["Lactadherin", "GENE_OR_GENE_PRODUCT", 202, 213], ["individuals", "ORGANISM", 238, 249], ["patient", "ORGANISM", 292, 299], ["fetal grafted cells", "CELL", 303, 322], ["fetal grafted cells", "CELL_TYPE", 303, 322], ["human", "SPECIES", 3, 8], ["patient", "SPECIES", 292, 299], ["human", "SPECIES", 3, 8], ["US", "TEST", 0, 2], ["Parkinson's disease (PD)", "PROBLEM", 60, 84], ["synuclein", "TEST", 88, 97], ["Lewy body disease", "PROBLEM", 117, 134], ["PD", "PROBLEM", 145, 147], ["multiple system atrophy", "PROBLEM", 152, 175], ["Lactadherin", "TREATMENT", 202, 213], ["CJD", "PROBLEM", 261, 264], ["PD", "TREATMENT", 269, 271], ["fetal grafted cells", "TREATMENT", 303, 322], ["multiple system", "ANATOMY", 152, 167], ["atrophy", "OBSERVATION", 168, 175], ["grafted cells", "OBSERVATION", 309, 322]]], ["Brain extracts of MSA cases transmitted \u03b1 synuclein proteinopathy to TgM83 +/\u2212 mice (Prusiner et al., 2015) . \u2020 For SSA.Complementary Findings\u2022 Age-at-exposure related effect is a common characteristic of neurodegeneration induced by neurotropic agents (Fishman et al., 1985) .", [["Brain extracts", "ANATOMY", 0, 14], ["neurodegeneration", "DISEASE", 205, 222], ["Brain extracts", "ORGANISM_SUBSTANCE", 0, 14], ["\u03b1 synuclein", "SIMPLE_CHEMICAL", 40, 51], ["TgM83", "GENE_OR_GENE_PRODUCT", 69, 74], ["mice", "SPECIES", 79, 83], ["MSA cases", "PROBLEM", 18, 27], ["TgM83", "TEST", 69, 74], ["SSA", "PROBLEM", 116, 119], ["neurodegeneration", "PROBLEM", 205, 222], ["neurodegeneration", "OBSERVATION", 205, 222]]], ["In a 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) parkinsonism model, selective nigral neuronal toxicity in laboratory animals was highest for the older rats and macaques (Langston et al., 1987) .", [["neuronal", "ANATOMY", 93, 101], ["1-methyl-4-phenyl-1,2,3,6tetrahydropyridine", "CHEMICAL", 5, 48], ["MPTP", "CHEMICAL", 50, 54], ["parkinsonism", "DISEASE", 56, 68], ["neuronal toxicity", "DISEASE", 93, 110], ["1-methyl-4-phenyl-1,2,3,6tetrahydropyridine", "CHEMICAL", 5, 48], ["MPTP", "CHEMICAL", 50, 54], ["1-methyl-4-phenyl-1,2,3,6tetrahydropyridine", "SIMPLE_CHEMICAL", 5, 48], ["MPTP", "SIMPLE_CHEMICAL", 50, 54], ["neuronal", "CELL", 93, 101], ["rats", "ORGANISM", 159, 163], ["macaques", "ORGANISM", 168, 176], ["rats", "SPECIES", 159, 163], ["macaques", "SPECIES", 168, 176], ["phenyl", "TREATMENT", 16, 22], ["tetrahydropyridine (MPTP", "TREATMENT", 30, 54], ["parkinsonism model", "PROBLEM", 56, 74], ["selective nigral neuronal toxicity", "PROBLEM", 76, 110], ["selective", "OBSERVATION_MODIFIER", 76, 85], ["nigral neuronal toxicity", "OBSERVATION", 86, 110]]], ["This was attributed to age-related neuronal pigmented deposit (relevant for accumulation of metabolic residue and advanced glycation end-products), which increases with age. \u2022 Intracerebral injection of brain extracts containing aggregated \u03b1-synuclein into young, \u03b1-synuclein-transgenic mice stimulates the formation of \u03b1-synuclein lesions in the host (Luk et al., 2012a; Mougenot et al., 2012) . \u2022 Experiments on different neurodegenerative disease models supporting prion-like mechanisms (Jucker and Walker, 2013) : in seeding experiments with APP mice, the age of the host at the time of inoculation can be a strong determinant of the result (Jucker and Walker, 2013) .", [["neuronal", "ANATOMY", 35, 43], ["Intracerebral", "ANATOMY", 176, 189], ["brain extracts", "ANATOMY", 203, 217], ["\u03b1-synuclein lesions", "ANATOMY", 320, 339], ["neurodegenerative disease", "DISEASE", 424, 449], ["neuronal", "CELL", 35, 43], ["pigmented deposit", "TISSUE", 44, 61], ["brain extracts", "ORGANISM_SUBSTANCE", 203, 217], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 240, 251], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 264, 275], ["mice", "ORGANISM", 287, 291], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 320, 331], ["lesions", "PATHOLOGICAL_FORMATION", 332, 339], ["APP mice", "ORGANISM", 546, 554], ["\u03b1-synuclein", "PROTEIN", 240, 251], ["\u03b1-synuclein", "PROTEIN", 264, 275], ["APP", "PROTEIN", 546, 549], ["mice", "SPECIES", 287, 291], ["mice", "SPECIES", 550, 554], ["mice", "SPECIES", 550, 554], ["neuronal pigmented deposit", "PROBLEM", 35, 61], ["metabolic residue", "PROBLEM", 92, 109], ["advanced glycation end-products", "TREATMENT", 114, 145], ["Intracerebral injection of brain extracts", "TREATMENT", 176, 217], ["\u03b1-synuclein", "TREATMENT", 264, 275], ["\u03b1-synuclein lesions", "PROBLEM", 320, 339], ["different neurodegenerative disease", "PROBLEM", 414, 449], ["neuronal pigmented deposit", "OBSERVATION", 35, 61], ["metabolic residue", "OBSERVATION", 92, 109], ["brain", "ANATOMY", 203, 208], ["lesions", "OBSERVATION", 332, 339], ["neurodegenerative disease", "OBSERVATION", 424, 449]]], ["A similar feature is displayed by the male-mouse castration model of PD, which is only efficient when castration is performed on 4-to 6-week-old mice (Khasnavis et al., 2013) . \u2022 MSA, an \u03b1-synucleinopathy, has recently been transmitted in cell and mouse models (Prusiner et al., 2015) .TheoryEarly-and midlife proteinopathies and late-life sCNDD could be induced or modulated by early-age exposures, regardless of anatomic organs for contact and following a log-linear age-related function.", [["cell", "ANATOMY", 239, 243], ["organs", "ANATOMY", 423, 429], ["PD", "DISEASE", 69, 71], ["MSA", "DISEASE", 179, 182], ["sCNDD", "DISEASE", 340, 345], ["mouse", "ORGANISM", 43, 48], ["mice", "ORGANISM", 145, 149], ["cell", "CELL", 239, 243], ["mouse", "ORGANISM", 248, 253], ["organs", "ORGAN", 423, 429], ["mouse", "SPECIES", 43, 48], ["mice", "SPECIES", 145, 149], ["mouse", "SPECIES", 248, 253], ["mouse", "SPECIES", 248, 253], ["PD", "PROBLEM", 69, 71], ["MSA", "PROBLEM", 179, 182], ["an \u03b1-synucleinopathy", "PROBLEM", 184, 204], ["TheoryEarly", "TEST", 286, 297], ["midlife proteinopathies", "PROBLEM", 302, 325], ["late-life sCNDD", "PROBLEM", 330, 345], ["\u03b1-synucleinopathy", "OBSERVATION", 187, 204], ["proteinopathies", "OBSERVATION", 310, 325]]], ["Tridimensional Pattern: Direct Relationships between Age at Peak Incidence (or Age at Clinical Onset), Incidence Magnitude, and Course (Clinical Disease Duration)TheoryThe driver, described on the basis of sCJD, FTD, PD, LBD, AD, and AMD data suggest that:Theory(a) the duration of the subclinical and clinical courses are related; (b) low-incidence sCNDD progress rapidly, and those with highest incidence progress slowly; and, (c) agents (including modifiers) generating aggressive forms might be less frequent or require more susceptibility than those lying behind less severe forms which may display high attack rates, i.e., they will affect large proportions of the population.Complementary Findings\u2022 Age at peak age-specific incidence appears to be related to protein propagation, as supported by observations of familial AD, where mean ages at onset are determined by the Ab40/42 ratio (Duering et al., 2005) . \u2022 Prion models suggests that a lower prion protein inoculum correlates with a longer incubation period (Gravenor et al., 2003) .", [["sCJD", "DISEASE", 206, 210], ["FTD", "DISEASE", 212, 215], ["PD", "DISEASE", 217, 219], ["AD", "DISEASE", 226, 228], ["AMD", "DISEASE", 234, 237], ["familial AD", "DISEASE", 819, 830], ["sCJD", "PROBLEM", 206, 210], ["FTD", "PROBLEM", 212, 215], ["PD", "PROBLEM", 217, 219], ["LBD", "TEST", 221, 224], ["agents (including modifiers)", "TREATMENT", 433, 461], ["high attack rates", "PROBLEM", 604, 621], ["protein propagation", "PROBLEM", 766, 785], ["familial AD", "PROBLEM", 819, 830], ["Prion models", "TEST", 920, 932], ["a lower prion protein inoculum", "PROBLEM", 947, 977], ["LBD", "ANATOMY", 221, 224], ["protein propagation", "OBSERVATION", 766, 785], ["lower prion", "OBSERVATION_MODIFIER", 949, 960], ["protein inoculum", "OBSERVATION", 961, 977]]], ["Slow subclinical and clinical progression might correspond to long incubation period from low inoculum exposures in experiments with animal models of prion diseases (Gravenor et al., 2003) . \u2022 Acute toxic effects followed by residual effects might better fit MPTP model patterns (Langston et al., 1987) than those suggesting a persistently active etiologic mechanism or multiple hits across the life course. \u2022 After request to authors of recent surveys (Bjornsdottir et al., 2013; Caslake et al., 2014 ) and positive answer for Icelandic data, normalized reported age-specific incidence and median age-at-onset of MSA in Iceland where plotted at a reported figure for other CNDDs (de Pedro-Cuesta et al., 2015) .", [["prion diseases", "DISEASE", 150, 164], ["MPTP", "CHEMICAL", 259, 263], ["MSA", "DISEASE", 614, 617], ["CNDDs", "DISEASE", 674, 679], ["MPTP", "CHEMICAL", 259, 263], ["MPTP", "SIMPLE_CHEMICAL", 259, 263], ["Slow subclinical and clinical progression", "PROBLEM", 0, 41], ["low inoculum exposures", "PROBLEM", 90, 112], ["prion diseases", "PROBLEM", 150, 164], ["Acute toxic effects", "PROBLEM", 193, 212], ["residual effects", "PROBLEM", 225, 241], ["a persistently active etiologic mechanism", "PROBLEM", 325, 366], ["MSA", "PROBLEM", 614, 617], ["long incubation", "OBSERVATION_MODIFIER", 62, 77], ["low inoculum", "OBSERVATION_MODIFIER", 90, 102], ["toxic", "OBSERVATION_MODIFIER", 199, 204], ["active", "OBSERVATION_MODIFIER", 340, 346], ["multiple", "OBSERVATION_MODIFIER", 370, 378], ["hits", "OBSERVATION", 379, 383]]], ["The MSA incidence curve fitted curves and peak values intermediate between those for sCJD and PD (Figure 1 ; Granieri et al., 1991; Gao et al., 1998; Baldereschi et al., 2000; Will et al., 2000; Benito-Le\u00f3n et al., 2004; de Lau et al., 2004; Pocchiari et al., 2004; Fang et al., 2009; Chen and Lai, 2010; Steenland et al., 2010; Owen et al., 2012; Bjornsdottir et al., 2013; de Pedro-Cuesta et al., 2015) .TheoryThis driver might point to two distinct etiologic sCNDD forms differentiated by rapid progression, such as sCJD, ALS, and some sporadic rapidly-progressing neurodegenerative dementias (sRPNDds) with peak onset at age 70-75 years, and disease duration <3 years and late-life sCNDD with later age at onset and slower progression.", [["sCJD", "DISEASE", 85, 89], ["PD", "DISEASE", 94, 96], ["sCJD", "DISEASE", 519, 523], ["ALS", "DISEASE", 525, 528], ["neurodegenerative dementias", "DISEASE", 568, 595], ["sRPNDds", "DISEASE", 597, 604], ["sCNDD", "DISEASE", 686, 691], ["sRPNDds", "CANCER", 597, 604], ["The MSA incidence curve", "TEST", 0, 23], ["fitted curves", "TEST", 24, 37], ["peak values", "TEST", 42, 53], ["sCJD", "PROBLEM", 85, 89], ["rapid progression", "PROBLEM", 492, 509], ["sCJD", "PROBLEM", 519, 523], ["ALS", "PROBLEM", 525, 528], ["some sporadic rapidly-progressing neurodegenerative dementias", "PROBLEM", 534, 595], ["peak onset", "PROBLEM", 611, 621], ["disease duration", "PROBLEM", 646, 662], ["slower progression", "PROBLEM", 720, 738], ["rapid", "OBSERVATION_MODIFIER", 492, 497], ["progression", "OBSERVATION_MODIFIER", 498, 509], ["progressing", "OBSERVATION_MODIFIER", 556, 567], ["neurodegenerative", "OBSERVATION_MODIFIER", 568, 585], ["dementias", "OBSERVATION", 586, 595], ["slower", "OBSERVATION_MODIFIER", 720, 726], ["progression", "OBSERVATION_MODIFIER", 727, 738]]], ["When links with vascular lesions or vascular risk factors (VRF) are considered, sCJD, LBD, AD, and AMD would present and perhaps share vascular protein deposits: this would not, however, apply to FTD, PD and MSA, which are epidemiologically less closely related to VRF.", [["vascular lesions", "ANATOMY", 16, 32], ["vascular", "ANATOMY", 36, 44], ["vascular", "ANATOMY", 135, 143], ["sCJD", "DISEASE", 80, 84], ["LBD", "DISEASE", 86, 89], ["AD", "DISEASE", 91, 93], ["AMD", "DISEASE", 99, 102], ["FTD", "DISEASE", 196, 199], ["PD", "DISEASE", 201, 203], ["MSA", "DISEASE", 208, 211], ["VRF", "DISEASE", 265, 268], ["vascular", "MULTI-TISSUE_STRUCTURE", 16, 24], ["lesions", "PATHOLOGICAL_FORMATION", 25, 32], ["vascular risk factors", "GENE_OR_GENE_PRODUCT", 36, 57], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["VRF", "CANCER", 265, 268], ["vascular risk factors", "PROTEIN", 36, 57], ["VRF", "PROTEIN", 59, 62], ["vascular lesions", "PROBLEM", 16, 32], ["vascular risk factors", "PROBLEM", 36, 57], ["VRF", "PROBLEM", 59, 62], ["sCJD", "PROBLEM", 80, 84], ["LBD", "PROBLEM", 86, 89], ["AD", "PROBLEM", 91, 93], ["AMD", "PROBLEM", 99, 102], ["vascular protein deposits", "PROBLEM", 135, 160], ["FTD", "PROBLEM", 196, 199], ["PD", "PROBLEM", 201, 203], ["MSA", "PROBLEM", 208, 211], ["VRF", "PROBLEM", 265, 268], ["vascular", "ANATOMY", 16, 24], ["lesions", "OBSERVATION", 25, 32], ["vascular", "ANATOMY", 36, 44], ["LBD", "ANATOMY", 86, 89], ["vascular", "ANATOMY", 135, 143], ["protein deposits", "OBSERVATION", 144, 160]]], ["Type 2 diabetes mellitus (T2DM) and vascular disease would be particularly seen in sCNDD (including sRPNDds) with incidence peaking after age 85 years.", [["vascular", "ANATOMY", 36, 44], ["Type 2 diabetes mellitus", "DISEASE", 0, 24], ["T2DM", "DISEASE", 26, 30], ["vascular disease", "DISEASE", 36, 52], ["sCNDD", "DISEASE", 83, 88], ["vascular", "MULTI-TISSUE_STRUCTURE", 36, 44], ["sCNDD", "CANCER", 83, 88], ["Type 2 diabetes mellitus", "PROBLEM", 0, 24], ["T2DM)", "PROBLEM", 26, 31], ["vascular disease", "PROBLEM", 36, 52], ["diabetes mellitus", "OBSERVATION", 7, 24], ["vascular", "ANATOMY", 36, 44], ["disease", "OBSERVATION", 45, 52]]], ["Prion strains and diverse entry routes would determine the large variation of age at onset in hGHrelated atCJD, vCJD, and sCJD.", [["vCJD", "DISEASE", 112, 116], ["sCJD", "DISEASE", 122, 126], ["Prion strains", "PROBLEM", 0, 13], ["diverse entry routes", "TREATMENT", 18, 38], ["vCJD", "PROBLEM", 112, 116], ["sCJD", "PROBLEM", 122, 126], ["large", "OBSERVATION_MODIFIER", 59, 64], ["vCJD", "OBSERVATION", 112, 116]]], ["High incidence of late-onset sCNDD might correspond to high attack rates from ubiquitous or widespread, tiny or low inoculum exposures and the opposite or a combination (low incidence, high inoculum exposures) for midlife-onset sCNDD, i.e., earlier-onset sCJD, ALS and earliestonset sRPNDd may share prion-like entry or spread mechanisms.Driver 3.", [["sCNDD", "DISEASE", 29, 34], ["sCNDD", "DISEASE", 228, 233], ["sCJD", "DISEASE", 255, 259], ["ALS", "DISEASE", 261, 264], ["late-onset sCNDD", "PROBLEM", 18, 34], ["high attack rates", "PROBLEM", 55, 72], ["tiny or low inoculum exposures", "PROBLEM", 104, 134], ["high inoculum exposures", "PROBLEM", 185, 208], ["midlife-onset sCNDD", "PROBLEM", 214, 233], ["sCJD", "PROBLEM", 255, 259], ["ALS", "PROBLEM", 261, 264], ["late", "OBSERVATION_MODIFIER", 18, 22], ["-onset", "OBSERVATION_MODIFIER", 22, 28], ["high attack", "OBSERVATION", 55, 66], ["widespread", "OBSERVATION_MODIFIER", 92, 102], ["tiny", "OBSERVATION_MODIFIER", 104, 108], ["low inoculum", "OBSERVATION_MODIFIER", 112, 124]]], ["Shared, Age-at-Onset Related, Genetic Risk FactorsWe postulate that driver 3 reflects the effect of different genes, which, either separately or by interaction, determine the excess risk of several sCNDD, such as AD, CJD, and LBD FIGURE 1 | Normalized age-specific incidence, incidence per million and survival for selected neurodegenerative disorders (NDDs).", [["sCNDD", "DISEASE", 198, 203], ["AD", "DISEASE", 213, 215], ["CJD", "DISEASE", 217, 220], ["neurodegenerative disorders", "DISEASE", 324, 351], ["NDDs", "DISEASE", 353, 357], ["sCNDD", "CANCER", 198, 203], ["several sCNDD", "PROBLEM", 190, 203], ["CJD", "PROBLEM", 217, 220], ["selected neurodegenerative disorders", "PROBLEM", 315, 351], ["LBD", "ANATOMY", 226, 229], ["neurodegenerative", "OBSERVATION_MODIFIER", 324, 341]]], ["Normalized age-specific incidence, age-adjusted incidence, and median clinical disease duration of different sporadic protein-associated neurodegenerative disorders (sCNDDs), obtained either from reported data [amyotrophic lateral sclerosis (ALS), personally modified by Fang F, sporadic Creutzfeldt-Jakob disease (sCJD)] or from registries [sporadic rapid progressive neurodegenerative dementia (sRPNDd) notified as suspected sCJD in Spain for 1995-2011, obtained from the Spanish CJD surveillance registry] and obtained from authors for multiple system atrophy (MSA).", [["neurodegenerative disorders", "DISEASE", 137, 164], ["amyotrophic lateral sclerosis", "DISEASE", 211, 240], ["ALS", "DISEASE", 242, 245], ["Creutzfeldt-Jakob disease", "DISEASE", 288, 313], ["sCJD", "DISEASE", 315, 319], ["neurodegenerative dementia", "DISEASE", 369, 395], ["sRPNDd", "DISEASE", 397, 403], ["sCJD", "DISEASE", 427, 431], ["CJD", "DISEASE", 482, 485], ["multiple system atrophy", "DISEASE", 539, 562], ["MSA", "DISEASE", 564, 567], ["sporadic protein", "PROTEIN", 109, 125], ["median clinical disease duration", "PROBLEM", 63, 95], ["different sporadic protein-associated neurodegenerative disorders (sCNDDs)", "PROBLEM", 99, 173], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 211, 246], ["Jakob disease (sCJD)", "PROBLEM", 300, 320], ["sporadic rapid progressive neurodegenerative dementia", "PROBLEM", 342, 395], ["multiple system atrophy", "PROBLEM", 539, 562], ["neurodegenerative disorders", "OBSERVATION", 137, 164], ["sclerosis", "OBSERVATION", 231, 240], ["progressive", "OBSERVATION_MODIFIER", 357, 368], ["neurodegenerative", "OBSERVATION_MODIFIER", 369, 386], ["dementia", "OBSERVATION", 387, 395], ["atrophy", "OBSERVATION", 555, 562]]], ["References for Figure 1 ( Granieri et al., 1991; Gao et al., 1998; Baldereschi et al., 2000; Will et al., 2000; Benito-Le\u00f3n et al., 2004; Pocchiari et al., 2004; de Lau et al., 2004; Fang et al., 2009; Chen and Lai, 2010; Steenland et al., 2010; Owen et al., 2012; Bjornsdottir et al., 2013) . (a) 85-89 years is equivalent to 85 years and older for sCJD, ALS, Lewy body disease (LBD), Parkinson's disease (PD), and sRPNDd; (b) 90-94 years is equivalent to 90 years and older for age-related macular degeneration (AMD) and frontotemporal dementia (FTD).Driver 3.", [["body", "ANATOMY", 366, 370], ["macular", "ANATOMY", 492, 499], ["sCJD", "DISEASE", 350, 354], ["ALS", "DISEASE", 356, 359], ["Lewy body disease", "DISEASE", 361, 378], ["LBD", "DISEASE", 380, 383], ["Parkinson's disease", "DISEASE", 386, 405], ["PD", "DISEASE", 407, 409], ["macular degeneration", "DISEASE", 492, 512], ["AMD", "DISEASE", 514, 517], ["frontotemporal dementia", "DISEASE", 523, 546], ["FTD", "DISEASE", 548, 551], ["macular", "TISSUE", 492, 499], ["sCJD", "PROBLEM", 350, 354], ["ALS", "PROBLEM", 356, 359], ["Lewy body disease (LBD)", "PROBLEM", 361, 384], ["Parkinson's disease (PD)", "PROBLEM", 386, 410], ["macular degeneration (AMD)", "PROBLEM", 492, 518], ["frontotemporal dementia (FTD)", "PROBLEM", 523, 552], ["Lewy body disease", "OBSERVATION", 361, 378], ["LBD", "ANATOMY", 380, 383], ["macular degeneration", "OBSERVATION", 492, 512], ["frontotemporal", "ANATOMY", 523, 537], ["dementia", "OBSERVATION", 538, 546]]], ["For instance, positive findings in sCJD and AD for APOE\u03b54, CALHM1 and BACE1 polymorphisms underscore the interplay between APP, A\u03b2 oligomers, ApoE, PrP, and BACE1 in sCJD and AD, and suggest that aging may partly modulate disease pathologies through these key players (Calero et al., 2012a,b) .Complementary Findings\u2022 It is accepted today that the animal models which best reproduce atherothrombotic disease and AD are those based on ApoE-knockout mice (Zaragoza et al., 2011) . \u2022 Diverse reviews on APOE gene effects show that the ApoE4 allele is linked to moderate excess risk for arterial hypertension and ischemic heart disease (Haan and Mayeda, 2010) , intracerebral and lobar bleeding (Biffi et al., 2010) , coronary heart disease, stroke, peripheral artery disease, and diabetes mellitus (Eichner et al., 2002) . \u2022 The common presence of APOE, BACE1 (and other genes, as suggested by total genome studies) linked to \u03b2A and other proteins calls for a role for these or other genes in a selected group of sCNDD, as well as in atherosclerosis. \u2022 sCJD was initially misdiagnosed 4% of times as a vascular, non-autoimmune disease, including stroke (Paterson et al., 2012) , perhaps indicating the presence of a vasculopathy in sCJD.TheoryAPOE4 interacts with etiologic environmental factors for several disorders, i.e., sporadic AD, LBD, AMD, vascular dementia, atherosclerosis, or other forms of vascular disease such as heart failure, myocardial infarction, senile systemic angiopathy, and aortic aneurism.", [["arterial", "ANATOMY", 583, 591], ["heart", "ANATOMY", 618, 623], ["intracerebral", "ANATOMY", 658, 671], ["lobar", "ANATOMY", 676, 681], ["coronary", "ANATOMY", 714, 722], ["heart", "ANATOMY", 723, 728], ["peripheral artery", "ANATOMY", 746, 763], ["vascular", "ANATOMY", 1099, 1107], ["vascular", "ANATOMY", 1345, 1353], ["vascular", "ANATOMY", 1399, 1407], ["heart", "ANATOMY", 1424, 1429], ["myocardial", "ANATOMY", 1439, 1449], ["aortic", "ANATOMY", 1494, 1500], ["sCJD", "DISEASE", 35, 39], ["AD", "DISEASE", 44, 46], ["sCJD", "DISEASE", 166, 170], ["AD", "DISEASE", 175, 177], ["atherothrombotic disease", "DISEASE", 383, 407], ["AD", "DISEASE", 412, 414], ["hypertension", "DISEASE", 592, 604], ["ischemic heart disease", "DISEASE", 609, 631], ["intracerebral and lobar bleeding", "DISEASE", 658, 690], ["coronary heart disease", "DISEASE", 714, 736], ["stroke", "DISEASE", 738, 744], ["peripheral artery disease", "DISEASE", 746, 771], ["diabetes mellitus", "DISEASE", 777, 794], ["atherosclerosis", "DISEASE", 1031, 1046], ["sCJD", "DISEASE", 1050, 1054], ["non-autoimmune disease", "DISEASE", 1109, 1131], ["stroke", "DISEASE", 1143, 1149], ["vasculopathy", "DISEASE", 1213, 1225], ["sCJD", "DISEASE", 1229, 1233], ["TheoryAPOE4", "CHEMICAL", 1234, 1245], ["AD", "DISEASE", 1331, 1333], ["LBD", "DISEASE", 1335, 1338], ["AMD", "DISEASE", 1340, 1343], ["vascular dementia", "DISEASE", 1345, 1362], ["atherosclerosis", "DISEASE", 1364, 1379], ["vascular disease", "DISEASE", 1399, 1415], ["heart failure", "DISEASE", 1424, 1437], ["myocardial infarction", "DISEASE", 1439, 1460], ["senile systemic angiopathy", "DISEASE", 1462, 1488], ["aortic aneurism", "DISEASE", 1494, 1509], ["APOE\u03b54", "GENE_OR_GENE_PRODUCT", 51, 57], ["CALHM1", "GENE_OR_GENE_PRODUCT", 59, 65], ["BACE1", "GENE_OR_GENE_PRODUCT", 70, 75], ["APP", "GENE_OR_GENE_PRODUCT", 123, 126], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 128, 130], ["ApoE", "GENE_OR_GENE_PRODUCT", 142, 146], ["PrP", "GENE_OR_GENE_PRODUCT", 148, 151], ["BACE1", "GENE_OR_GENE_PRODUCT", 157, 162], ["ApoE", "GENE_OR_GENE_PRODUCT", 434, 438], ["mice", "ORGANISM", 448, 452], ["APOE", "GENE_OR_GENE_PRODUCT", 500, 504], ["ApoE4", "GENE_OR_GENE_PRODUCT", 532, 537], ["arterial", "MULTI-TISSUE_STRUCTURE", 583, 591], ["heart", "ORGAN", 618, 623], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 658, 671], ["heart", "ORGAN", 723, 728], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 746, 763], ["APOE", "GENE_OR_GENE_PRODUCT", 845, 849], ["BACE1", "GENE_OR_GENE_PRODUCT", 851, 856], ["\u03b2A", "GENE_OR_GENE_PRODUCT", 923, 925], ["sCNDD", "GENE_OR_GENE_PRODUCT", 1010, 1015], ["vascular", "MULTI-TISSUE_STRUCTURE", 1099, 1107], ["TheoryAPOE4", "GENE_OR_GENE_PRODUCT", 1234, 1245], ["vascular", "MULTI-TISSUE_STRUCTURE", 1345, 1353], ["vascular", "MULTI-TISSUE_STRUCTURE", 1399, 1407], ["heart", "ORGAN", 1424, 1429], ["myocardial", "MULTI-TISSUE_STRUCTURE", 1439, 1449], ["aortic", "MULTI-TISSUE_STRUCTURE", 1494, 1500], ["BACE1", "PROTEIN", 70, 75], ["APP", "PROTEIN", 123, 126], ["A\u03b2", "PROTEIN", 128, 130], ["ApoE", "PROTEIN", 142, 146], ["PrP", "PROTEIN", 148, 151], ["BACE1", "PROTEIN", 157, 162], ["ApoE", "PROTEIN", 434, 438], ["APOE gene", "DNA", 500, 509], ["ApoE4 allele", "DNA", 532, 544], ["APOE", "DNA", 845, 849], ["BACE1", "PROTEIN", 851, 856], ["\u03b2A", "PROTEIN", 923, 925], ["TheoryAPOE4", "PROTEIN", 1234, 1245], ["mice", "SPECIES", 448, 452], ["mice", "SPECIES", 448, 452], ["sCJD", "PROBLEM", 35, 39], ["APOE", "TEST", 51, 55], ["CALHM1", "TREATMENT", 59, 65], ["BACE1 polymorphisms", "PROBLEM", 70, 89], ["PrP", "TREATMENT", 148, 151], ["BACE1", "TREATMENT", 157, 162], ["sCJD", "PROBLEM", 166, 170], ["modulate disease pathologies", "PROBLEM", 213, 241], ["atherothrombotic disease", "PROBLEM", 383, 407], ["AD", "PROBLEM", 412, 414], ["APOE gene effects", "TREATMENT", 500, 517], ["arterial hypertension", "PROBLEM", 583, 604], ["ischemic heart disease", "PROBLEM", 609, 631], ["intracerebral and lobar bleeding", "PROBLEM", 658, 690], ["coronary heart disease", "PROBLEM", 714, 736], ["stroke", "PROBLEM", 738, 744], ["peripheral artery disease", "PROBLEM", 746, 771], ["diabetes mellitus", "PROBLEM", 777, 794], ["total genome studies", "TEST", 891, 911], ["atherosclerosis", "PROBLEM", 1031, 1046], ["sCJD", "PROBLEM", 1050, 1054], ["a vascular, non-autoimmune disease", "PROBLEM", 1097, 1131], ["stroke", "PROBLEM", 1143, 1149], ["a vasculopathy in sCJD", "PROBLEM", 1211, 1233], ["several disorders", "PROBLEM", 1297, 1314], ["sporadic AD", "PROBLEM", 1322, 1333], ["LBD", "PROBLEM", 1335, 1338], ["AMD", "PROBLEM", 1340, 1343], ["vascular dementia", "PROBLEM", 1345, 1362], ["atherosclerosis", "PROBLEM", 1364, 1379], ["vascular disease", "PROBLEM", 1399, 1415], ["heart failure", "PROBLEM", 1424, 1437], ["myocardial infarction", "PROBLEM", 1439, 1460], ["senile systemic angiopathy", "PROBLEM", 1462, 1488], ["aortic aneurism", "PROBLEM", 1494, 1509], ["atherothrombotic", "OBSERVATION_MODIFIER", 383, 399], ["disease", "OBSERVATION", 400, 407], ["arterial", "ANATOMY", 583, 591], ["hypertension", "OBSERVATION", 592, 604], ["ischemic", "OBSERVATION_MODIFIER", 609, 617], ["heart", "ANATOMY", 618, 623], ["disease", "OBSERVATION", 624, 631], ["intracerebral", "ANATOMY", 658, 671], ["lobar", "OBSERVATION_MODIFIER", 676, 681], ["bleeding", "OBSERVATION", 682, 690], ["coronary heart", "ANATOMY", 714, 728], ["disease", "OBSERVATION", 729, 736], ["stroke", "OBSERVATION", 738, 744], ["peripheral artery", "ANATOMY", 746, 763], ["disease", "OBSERVATION", 764, 771], ["diabetes", "OBSERVATION", 777, 785], ["APOE", "OBSERVATION", 845, 849], ["atherosclerosis", "OBSERVATION", 1031, 1046], ["vascular", "ANATOMY", 1099, 1107], ["non-autoimmune disease", "OBSERVATION", 1109, 1131], ["vasculopathy", "OBSERVATION", 1213, 1225], ["sCJD", "OBSERVATION", 1229, 1233], ["LBD", "ANATOMY", 1335, 1338], ["vascular", "ANATOMY", 1345, 1353], ["dementia", "OBSERVATION", 1354, 1362], ["atherosclerosis", "OBSERVATION", 1364, 1379], ["vascular", "ANATOMY", 1399, 1407], ["disease", "OBSERVATION", 1408, 1415], ["heart", "ANATOMY", 1424, 1429], ["failure", "OBSERVATION", 1430, 1437], ["myocardial", "ANATOMY", 1439, 1449], ["infarction", "OBSERVATION", 1450, 1460], ["senile", "OBSERVATION_MODIFIER", 1462, 1468], ["systemic angiopathy", "OBSERVATION", 1469, 1488], ["aortic", "ANATOMY", 1494, 1500], ["aneurism", "OBSERVATION", 1501, 1509]]], ["We also hypothesize that shared susceptibility genes for selected sCNDD and atherosclerosis mediate the effects of single pluripotential exposures, i.e., due to the same inoculum, or generated by the same mechanism.", [["atherosclerosis", "DISEASE", 76, 91], ["sCNDD", "GENE_OR_GENE_PRODUCT", 66, 71], ["susceptibility genes", "DNA", 32, 52], ["selected sCNDD", "PROBLEM", 57, 71], ["atherosclerosis", "PROBLEM", 76, 91], ["single pluripotential exposures", "PROBLEM", 115, 146], ["the same inoculum", "PROBLEM", 161, 178], ["atherosclerosis", "OBSERVATION", 76, 91], ["pluripotential exposures", "OBSERVATION", 122, 146], ["inoculum", "OBSERVATION", 170, 178]]], ["High-risk birth cohorts might share excess risk for several conformational disorders.Driver 4.", [["several conformational disorders", "PROBLEM", 52, 84]]], ["Personal Risk FactorsThis driver is related to a set of multiple variables, such as clinical signs and symptoms (diagnoses), behavioral patterns (health-related habits), and educational factors, which constitute the group of well-established associations with specific sCNDD.", [["sCNDD", "DISEASE", 269, 274], ["sCNDD", "CANCER", 269, 274], ["multiple variables", "PROBLEM", 56, 74], ["clinical signs and symptoms", "PROBLEM", 84, 111]]], ["When discussing driver 1, reference was made to some personal factors potentially due to an age-at-exposure related effect, fitting under the umbrella of developmentally-related effects, i.e., education in AD, cranial perimeter in north-Korean women, or early symptoms, such as scoliosis or constipation in PD (Stern et al., 2012) .", [["cranial", "ANATOMY", 210, 217], ["AD", "DISEASE", 206, 208], ["scoliosis", "DISEASE", 278, 287], ["constipation", "DISEASE", 291, 303], ["PD", "DISEASE", 307, 309], ["women", "ORGANISM", 244, 249], ["women", "SPECIES", 244, 249], ["early symptoms", "PROBLEM", 254, 268], ["scoliosis", "PROBLEM", 278, 287], ["constipation in PD", "PROBLEM", 291, 309], ["cranial", "ANATOMY", 210, 217], ["scoliosis", "OBSERVATION", 278, 287], ["constipation", "OBSERVATION", 291, 303]]], ["This multifaceted and disperse panorama might be too wide for a satisfactory etiologically oriented approach to sCNDD.", [["sCNDD", "DISEASE", 112, 117], ["sCNDD", "PROBLEM", 112, 117]]], ["Insofar as the focus is AD or dementia, however, the driver notion constitutes the best structured etiologic and public health approach.", [["AD", "DISEASE", 24, 26], ["dementia", "DISEASE", 30, 38], ["AD", "PROBLEM", 24, 26], ["dementia", "PROBLEM", 30, 38]]], ["A recent review addressing arterial hypertension, T2DM, hypercholesterolemia, physical activity, depression educational attainment, and smoking history (all personal factors) and risk of AD emphasized the non-independent nature of such factors (Norton et al., 2014) .", [["arterial", "ANATOMY", 27, 35], ["arterial hypertension", "DISEASE", 27, 48], ["T2DM", "DISEASE", 50, 54], ["hypercholesterolemia", "DISEASE", 56, 76], ["depression", "DISEASE", 97, 107], ["smoking", "CHEMICAL", 136, 143], ["AD", "DISEASE", 187, 189], ["arterial", "MULTI-TISSUE_STRUCTURE", 27, 35], ["arterial hypertension", "PROBLEM", 27, 48], ["T2DM", "PROBLEM", 50, 54], ["hypercholesterolemia", "PROBLEM", 56, 76], ["depression", "PROBLEM", 97, 107], ["arterial", "ANATOMY", 27, 35], ["hypertension", "OBSERVATION", 36, 48], ["T2DM", "OBSERVATION", 50, 54], ["hypercholesterolemia", "OBSERVATION", 56, 76]]], ["Correcting for dependence, the authors estimated that, assuming causality underlying the associations, the AD attributable proportion reduced by a control of 10% of risk factors per decade would be 8.3% worldwide in 2050 (Norton et al., 2014) .", [["AD", "DISEASE", 107, 109], ["dependence", "PROBLEM", 15, 25]]], ["For instance, no excess risk for PD from T2DM was observed, when PD onset was controlled for Simon et al. (2007) and Palacios et al. (2011) .", [["PD", "DISEASE", 33, 35], ["T2DM", "DISEASE", 41, 45], ["PD", "DISEASE", 65, 67], ["excess risk", "PROBLEM", 17, 28], ["PD", "PROBLEM", 33, 35], ["T2DM", "PROBLEM", 41, 45], ["PD onset", "PROBLEM", 65, 73], ["T2DM", "OBSERVATION", 41, 45]]], ["In contrast, other studies reported modest increases (Schernhammer et al., 2011; Sun et al., 2012) .", [["other studies", "TEST", 13, 26], ["modest", "OBSERVATION_MODIFIER", 36, 42], ["increases", "OBSERVATION_MODIFIER", 43, 52]]], ["We believe that the outline shown in Figure 2 (Norton et al., 2014) illustrates the state of art in public health prevention of sCNDD (entity-specific and mainly based on type-4 drivers).", [["sCNDD", "DISEASE", 128, 133], ["sCNDD", "PROBLEM", 128, 133]]], ["We propose that a complementary etiologic overview of sCNDD from personal factors should incorporate goals and interpretations from other drivers, and driver 1 in particular, for late-life sCNDD, as illustrated by a potential multiple outcome that combines (though not necessarily in the same individual) protein deposits generating sCNDD, T2DM as a result of Islet amyloid peptide (IAPP), and vascular wall lesions from amyloid deposits such as A\u03b2, lactadherin (Peng et al., 2005) and transthyretin (TTR; Coelho et al., 2013) .Complementary Findings\u2022 There is increasing biologic evidence supporting the contention that fibrillar amyloid beta protein present in atheroma promotes atherogenesis (Medeiros et al., 2004) . \u2022 Bacterial vectors may transport inclusion bodies having amyloid-like properties able to seed their soluble counterparts FIGURE 2 | Outline of a proposed Public Health Prevention Model I for a single neurodegenerative disorder (Norton et al., 2014) , e.g., Alzheimer's disease (AD).", [["vascular wall lesions", "ANATOMY", 394, 415], ["atheroma", "ANATOMY", 663, 671], ["sCNDD", "DISEASE", 54, 59], ["sCNDD", "DISEASE", 189, 194], ["sCNDD", "DISEASE", 333, 338], ["T2DM", "DISEASE", 340, 344], ["atheroma", "DISEASE", 663, 671], ["atherogenesis", "DISEASE", 681, 694], ["neurodegenerative disorder", "DISEASE", 922, 948], ["Alzheimer's disease", "DISEASE", 979, 998], ["AD", "DISEASE", 1000, 1002], ["sCNDD", "CANCER", 54, 59], ["Islet amyloid peptide", "GENE_OR_GENE_PRODUCT", 360, 381], ["IAPP", "GENE_OR_GENE_PRODUCT", 383, 387], ["vascular wall lesions", "PATHOLOGICAL_FORMATION", 394, 415], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 446, 448], ["lactadherin", "SIMPLE_CHEMICAL", 450, 461], ["transthyretin", "GENE_OR_GENE_PRODUCT", 486, 499], ["fibrillar amyloid beta", "GENE_OR_GENE_PRODUCT", 621, 643], ["atheroma", "PATHOLOGICAL_FORMATION", 663, 671], ["fibrillar amyloid beta protein", "PROTEIN", 621, 651], ["protein deposits generating sCNDD", "PROBLEM", 305, 338], ["T2DM", "PROBLEM", 340, 344], ["Islet amyloid peptide", "PROBLEM", 360, 381], ["vascular wall lesions", "PROBLEM", 394, 415], ["amyloid deposits", "PROBLEM", 421, 437], ["fibrillar amyloid beta protein", "PROBLEM", 621, 651], ["atheroma promotes atherogenesis", "PROBLEM", 663, 694], ["Bacterial vectors", "TREATMENT", 723, 740], ["amyloid", "PROBLEM", 779, 786], ["a single neurodegenerative disorder", "PROBLEM", 913, 948], ["Alzheimer's disease", "PROBLEM", 979, 998], ["vascular", "ANATOMY", 394, 402], ["wall", "ANATOMY_MODIFIER", 403, 407], ["lesions", "OBSERVATION", 408, 415], ["amyloid deposits", "OBSERVATION", 421, 437], ["increasing", "OBSERVATION_MODIFIER", 561, 571], ["fibrillar", "OBSERVATION_MODIFIER", 621, 630], ["amyloid beta protein", "OBSERVATION", 631, 651], ["atheroma", "OBSERVATION", 663, 671], ["atherogenesis", "OBSERVATION_MODIFIER", 681, 694]]], ["Arrows indicate assumed direct causality.Complementary FindingsFrontiers in Aging Neuroscience | www.frontiersin.org and induce cytotoxicity in eukaryotic cells (for a review see Wang, 2009 ). \u2022 A growing body of evidence suggests that platelet activation can mediate angiopathy in AD (Zhang et al., 2013) .", [["cells", "ANATOMY", 155, 160], ["platelet", "ANATOMY", 236, 244], ["angiopathy", "DISEASE", 268, 278], ["AD", "DISEASE", 282, 284], ["eukaryotic cells", "CELL", 144, 160], ["platelet", "CELL", 236, 244], ["eukaryotic cells", "CELL_TYPE", 144, 160], ["cytotoxicity in eukaryotic cells", "PROBLEM", 128, 160], ["platelet activation", "PROBLEM", 236, 255], ["angiopathy", "PROBLEM", 268, 278], ["eukaryotic cells", "OBSERVATION", 144, 160], ["evidence suggests that", "UNCERTAINTY", 213, 235], ["platelet activation", "OBSERVATION", 236, 255]]], ["Medindeposits, i.e., lactadherin, underlie age-associated arterial lesions (Peng et al., 2005) . \u2022 Colocalization studies of IAPP and A\u03b2 in islet amyloid in type 2 diabetic patients, and A\u03b2 deposits in brains of patients with AD show heterologous seeding between IAPP and A\u03b2, a phenomenon that may represent a molecular link between T2DM and AD (Oskarsson et al., 2015) .TheoryThe view based on personal factors and the amyloid perspective on sCNDD suggests that a considerable part of the associations with late-life sCNDD, atherosclerosis, and T2DM might conceal confounding or reverse association (early manifestations of subclinical disease).", [["arterial lesions", "ANATOMY", 58, 74], ["islet", "ANATOMY", 140, 145], ["brains", "ANATOMY", 202, 208], ["Medindeposits", "DISEASE", 0, 13], ["type 2 diabetic", "DISEASE", 157, 172], ["AD", "DISEASE", 226, 228], ["T2DM", "DISEASE", 333, 337], ["AD", "DISEASE", 342, 344], ["sCNDD", "DISEASE", 518, 523], ["atherosclerosis", "DISEASE", 525, 540], ["T2DM", "DISEASE", 546, 550], ["lactadherin", "GENE_OR_GENE_PRODUCT", 21, 32], ["arterial lesions", "PATHOLOGICAL_FORMATION", 58, 74], ["IAPP", "GENE_OR_GENE_PRODUCT", 125, 129], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 134, 136], ["islet", "MULTI-TISSUE_STRUCTURE", 140, 145], ["patients", "ORGANISM", 173, 181], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 187, 189], ["brains", "ORGAN", 202, 208], ["patients", "ORGANISM", 212, 220], ["IAPP", "GENE_OR_GENE_PRODUCT", 263, 267], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 272, 274], ["lactadherin", "PROTEIN", 21, 32], ["IAPP", "PROTEIN", 125, 129], ["A\u03b2", "PROTEIN", 134, 136], ["IAPP", "PROTEIN", 263, 267], ["A\u03b2", "PROTEIN", 272, 274], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 212, 220], ["Medindeposits", "TREATMENT", 0, 13], ["lactadherin", "TREATMENT", 21, 32], ["associated arterial lesions", "PROBLEM", 47, 74], ["Colocalization studies", "TEST", 99, 121], ["IAPP", "TEST", 125, 129], ["islet amyloid", "PROBLEM", 140, 153], ["type 2 diabetic patients", "PROBLEM", 157, 181], ["A\u03b2 deposits in brains", "PROBLEM", 187, 208], ["heterologous seeding between IAPP", "PROBLEM", 234, 267], ["a phenomenon", "PROBLEM", 276, 288], ["T2DM", "PROBLEM", 333, 337], ["The view", "TEST", 377, 385], ["late-life sCNDD", "PROBLEM", 508, 523], ["atherosclerosis", "PROBLEM", 525, 540], ["T2DM", "PROBLEM", 546, 550], ["subclinical disease)", "PROBLEM", 625, 645], ["arterial", "ANATOMY", 58, 66], ["lesions", "OBSERVATION", 67, 74], ["islet", "ANATOMY", 140, 145], ["amyloid", "OBSERVATION", 146, 153], ["may represent", "UNCERTAINTY", 294, 307], ["atherosclerosis", "OBSERVATION", 525, 540]]], ["This view, if confirmed, might complement the rationale for prevention of sCNDD, T2DM, and part of atherosclerosis, where measures for control of shared etiologic mechanisms underlying sCNDD, T2DM, and various angiopathies are proposed.", [["sCNDD", "DISEASE", 74, 79], ["T2DM", "DISEASE", 81, 85], ["atherosclerosis", "DISEASE", 99, 114], ["sCNDD", "DISEASE", 185, 190], ["T2DM", "DISEASE", 192, 196], ["angiopathies", "CANCER", 210, 222], ["This view", "TEST", 0, 9], ["sCNDD", "PROBLEM", 74, 79], ["T2DM", "PROBLEM", 81, 85], ["atherosclerosis", "PROBLEM", 99, 114], ["sCNDD", "PROBLEM", 185, 190], ["T2DM", "PROBLEM", 192, 196], ["various angiopathies", "PROBLEM", 202, 222], ["T2DM", "OBSERVATION", 81, 85], ["atherosclerosis", "OBSERVATION", 99, 114], ["T2DM", "OBSERVATION", 192, 196]]], ["Driver 4 contribution to theory is summarized as a potential switch of the roles attributed to a direct relationship between risk factors and sCNDD in Figure 2 , to those outlined in Figure 3 .", [["sCNDD", "DISEASE", 142, 147]]], ["Most of these associations are in part interpreted as confounding or reverse causality, and direct causality is assigned to a higher level shared by defined amyloid disorders.Driver 5.", [["amyloid disorders", "DISEASE", 157, 174], ["amyloid", "GENE_OR_GENE_PRODUCT", 157, 164], ["amyloid disorders", "PROBLEM", 157, 174], ["amyloid disorders", "OBSERVATION", 157, 174]]], ["Environmental Risk FactorsAs a relevant part of our hypothesis we selected invasive medical procedures (mainly surgery) as a risk factor for sCJD and BP infection as a risk factor for PD.Invasive Medical Procedures and Risk of Midlife sCNDDThe hypothesis of a surgical (and blood-transfusion-related) risk of sCJD is based on a few reports on CJD among patients exposed to neurosurgical instruments used on a patient with subclinical or clinically manifested CJD, and on observations from a register-based population case-control study on routine hospital surgery followed by a lag of over 20 years, with retina surgery being associated with sCJD, on the basis of three cases with a mean latency of 11 years (de Pedro-Cuesta et al., 2011) .", [["blood", "ANATOMY", 274, 279], ["retina", "ANATOMY", 605, 611], ["sCJD", "DISEASE", 141, 145], ["BP infection", "DISEASE", 150, 162], ["PD", "DISEASE", 184, 186], ["sCJD", "DISEASE", 309, 313], ["CJD", "DISEASE", 343, 346], ["CJD", "DISEASE", 459, 462], ["sCJD", "DISEASE", 642, 646], ["blood", "ORGANISM_SUBSTANCE", 274, 279], ["patients", "ORGANISM", 353, 361], ["patient", "ORGANISM", 409, 416], ["retina", "MULTI-TISSUE_STRUCTURE", 605, 611], ["patients", "SPECIES", 353, 361], ["patient", "SPECIES", 409, 416], ["invasive medical procedures", "TREATMENT", 75, 102], ["mainly surgery", "TREATMENT", 104, 118], ["a risk factor", "PROBLEM", 123, 136], ["sCJD", "PROBLEM", 141, 145], ["BP infection", "PROBLEM", 150, 162], ["PD", "PROBLEM", 184, 186], ["Invasive Medical Procedures", "TREATMENT", 187, 214], ["a surgical (and blood-transfusion", "TREATMENT", 258, 291], ["sCJD", "PROBLEM", 309, 313], ["CJD", "PROBLEM", 343, 346], ["neurosurgical instruments", "TREATMENT", 373, 398], ["subclinical or clinically manifested CJD", "PROBLEM", 422, 462], ["routine hospital surgery", "TREATMENT", 539, 563], ["retina surgery", "TREATMENT", 605, 619], ["sCJD", "PROBLEM", 642, 646], ["infection", "OBSERVATION", 153, 162], ["surgical", "OBSERVATION", 260, 268], ["sCJD", "OBSERVATION", 309, 313], ["CJD", "OBSERVATION", 459, 462]]], ["Aside from one Italian study (Puopolo et al., 2011) , however, confounding by surgically-linked blood transfusion was not controlled for, and no positive association between neurosurgical procedures and CJD has been shown.", [["blood", "ANATOMY", 96, 101], ["CJD", "DISEASE", 203, 206], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["blood transfusion", "TREATMENT", 96, 113], ["neurosurgical procedures", "TREATMENT", 174, 198], ["CJD", "PROBLEM", 203, 206]]], ["Inconsistent findings for risk from blood transfusion have been reported.Complementary Findings\u2022 In 1994, infectivity from tissues such as liver and lung was shown in CJD mouse models (Brown et al., 1994) .", [["blood", "ANATOMY", 36, 41], ["tissues", "ANATOMY", 123, 130], ["liver", "ANATOMY", 139, 144], ["lung", "ANATOMY", 149, 153], ["CJD", "DISEASE", 167, 170], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["tissues", "TISSUE", 123, 130], ["liver", "ORGAN", 139, 144], ["lung", "ORGAN", 149, 153], ["mouse", "ORGANISM", 171, 176], ["mouse", "SPECIES", 171, 176], ["mouse", "SPECIES", 171, 176], ["blood transfusion", "TREATMENT", 36, 53], ["liver", "ANATOMY", 139, 144], ["lung", "ANATOMY", 149, 153]]], ["Subsequently, transmission of prion disease from tissue remnants adhered to surgical instruments was confirmed (Weissmann et al., 2002) . \u2022 Injection of mouse brain extract containing A\u03b2 seeds (similar to those found in the AD brain) into the peritoneal cavity of mice genetically engineered to develop amyloid plaques (murine model of AD) accelerates A\u03b2 deposition in the host brain (Eisele et al., 2010) . \u2022 \u03b2A deposition can be induced by injection of AD brain extracts into animals, which, without exposure to this material, would never otherwise develop these alterations (Morales et al., 2012) . \u2022 An independent line of evidence builds on seeding experiments from curli for E. coli and other organisms in Amyloidosis A (Lundmark et al., 2005) . \u2022 The long incubation suggested for sCJD from routine surgery undergone at high-susceptibility ages would suggest that such mechanisms may only be relevant for rapid-course sCNDD, so that the latency period for late-life NDDs might exceed the human life course. \u2022 The increased resistance to protein degradation in amyloid may provide some consistency with prion theory. \u2022 Recently some patients treated with cadaveric hGH who subsequently developed iatrogenic CJD also showed evidence of \u03b2A deposition in their pituitary glands (Jaunmuktane et al., 2015; Frontzek et al., 2016) . \u2022 Brain extracts of MSA cases, in general aged at onset \u226475 years, transmitted an \u03b1-synuclein proteinopathy to TgM83+/\u2212 mice being the prionic nature of some \u03b1-synuclein recognized (Prusiner et al., 2015) .TheoryOn the basis of register-based epidemiologic studies on surgical risk of sCJD suggesting age-related susceptibility, the suggested associations of ALS and incidence peaking at a similar age, we propose that sCJD, ALS and some sRPNDds and MSA with onset below age 75-79 years are transmitted by routine surgery and transfusion of blood or blood derivatives at juvenile age.Host-Adapted Human Pathogens.", [["tissue remnants", "ANATOMY", 49, 64], ["brain extract", "ANATOMY", 159, 172], ["A\u03b2 seeds", "ANATOMY", 184, 192], ["brain", "ANATOMY", 227, 232], ["peritoneal cavity", "ANATOMY", 243, 260], ["amyloid plaques", "ANATOMY", 303, 318], ["brain", "ANATOMY", 378, 383], ["brain extracts", "ANATOMY", 458, 472], ["pituitary glands", "ANATOMY", 1264, 1280], ["Brain extracts", "ANATOMY", 1335, 1349], ["blood", "ANATOMY", 1874, 1879], ["blood", "ANATOMY", 1883, 1888], ["prion disease", "DISEASE", 30, 43], ["amyloid plaques", "DISEASE", 303, 318], ["AD", "DISEASE", 336, 338], ["Amyloidosis", "DISEASE", 712, 723], ["sCJD", "DISEASE", 788, 792], ["CJD", "DISEASE", 1213, 1216], ["sCJD", "DISEASE", 1618, 1622], ["ALS", "DISEASE", 1692, 1695], ["sCJD", "DISEASE", 1752, 1756], ["ALS", "DISEASE", 1758, 1761], ["sRPNDds", "DISEASE", 1771, 1778], ["MSA", "DISEASE", 1783, 1786], ["tissue", "TISSUE", 49, 55], ["mouse", "ORGANISM", 153, 158], ["brain extract", "ORGANISM_SUBSTANCE", 159, 172], ["A\u03b2 seeds", "ORGANISM", 184, 192], ["brain", "ORGAN", 227, 232], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 243, 260], ["mice", "ORGANISM", 264, 268], ["amyloid plaques", "PATHOLOGICAL_FORMATION", 303, 318], ["murine", "ORGANISM", 320, 326], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 352, 354], ["brain", "ORGAN", 378, 383], ["\u03b2A", "GENE_OR_GENE_PRODUCT", 410, 412], ["brain extracts", "ORGANISM_SUBSTANCE", 458, 472], ["E. coli", "ORGANISM", 681, 688], ["human", "ORGANISM", 995, 1000], ["amyloid", "GENE_OR_GENE_PRODUCT", 1067, 1074], ["patients", "ORGANISM", 1139, 1147], ["hGH", "GENE_OR_GENE_PRODUCT", 1171, 1174], ["\u03b2A", "GENE_OR_GENE_PRODUCT", 1241, 1243], ["pituitary glands", "ORGAN", 1264, 1280], ["Brain extracts", "ORGANISM_SUBSTANCE", 1335, 1349], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 1415, 1426], ["TgM83", "GENE_OR_GENE_PRODUCT", 1444, 1449], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 1491, 1502], ["blood", "ORGANISM_SUBSTANCE", 1874, 1879], ["blood", "ORGANISM_SUBSTANCE", 1883, 1888], ["Human", "ORGANISM", 1930, 1935], ["\u03b2A", "PROTEIN", 1241, 1243], ["TgM83", "PROTEIN", 1444, 1449], ["mouse", "SPECIES", 153, 158], ["mice", "SPECIES", 264, 268], ["murine", "SPECIES", 320, 326], ["E. coli", "SPECIES", 681, 688], ["human", "SPECIES", 995, 1000], ["patients", "SPECIES", 1139, 1147], ["mice", "SPECIES", 1453, 1457], ["Human", "SPECIES", 1930, 1935], ["mouse", "SPECIES", 153, 158], ["mice", "SPECIES", 264, 268], ["E. coli", "SPECIES", 681, 688], ["human", "SPECIES", 995, 1000], ["prion disease from tissue remnants", "PROBLEM", 30, 64], ["surgical instruments", "TREATMENT", 76, 96], ["mouse brain extract", "TREATMENT", 153, 172], ["A\u03b2 seeds", "TREATMENT", 184, 192], ["amyloid plaques", "PROBLEM", 303, 318], ["A\u03b2 deposition in the host brain", "PROBLEM", 352, 383], ["AD brain extracts", "TREATMENT", 455, 472], ["seeding experiments", "TREATMENT", 646, 665], ["E. coli", "PROBLEM", 681, 688], ["other organisms in Amyloidosis", "PROBLEM", 693, 723], ["The long incubation", "TREATMENT", 754, 773], ["sCJD", "PROBLEM", 788, 792], ["routine surgery", "TREATMENT", 798, 813], ["late-life NDDs", "TREATMENT", 963, 977], ["the human life course", "TREATMENT", 991, 1012], ["The increased resistance to protein degradation in amyloid", "PROBLEM", 1016, 1074], ["cadaveric hGH", "TREATMENT", 1161, 1174], ["iatrogenic CJD", "PROBLEM", 1202, 1216], ["A deposition in their pituitary glands", "PROBLEM", 1242, 1280], ["MSA cases", "PROBLEM", 1353, 1362], ["an \u03b1-synuclein proteinopathy", "PROBLEM", 1412, 1440], ["epidemiologic studies", "TEST", 1576, 1597], ["sCJD", "PROBLEM", 1618, 1622], ["age-related susceptibility", "PROBLEM", 1634, 1660], ["ALS", "PROBLEM", 1692, 1695], ["sCJD", "PROBLEM", 1752, 1756], ["ALS", "PROBLEM", 1758, 1761], ["some sRPNDds", "PROBLEM", 1766, 1778], ["MSA", "PROBLEM", 1783, 1786], ["routine surgery", "TREATMENT", 1839, 1854], ["transfusion of blood", "TREATMENT", 1859, 1879], ["blood derivatives", "TREATMENT", 1883, 1900], ["prion disease", "OBSERVATION", 30, 43], ["tissue", "OBSERVATION_MODIFIER", 49, 55], ["remnants", "OBSERVATION_MODIFIER", 56, 64], ["brain", "ANATOMY", 159, 164], ["brain", "ANATOMY", 227, 232], ["peritoneal cavity", "ANATOMY", 243, 260], ["amyloid plaques", "OBSERVATION", 303, 318], ["deposition", "OBSERVATION", 355, 365], ["host", "ANATOMY_MODIFIER", 373, 377], ["brain", "ANATOMY", 378, 383], ["independent", "OBSERVATION_MODIFIER", 607, 618], ["line", "OBSERVATION", 619, 623], ["Amyloidosis", "OBSERVATION", 712, 723], ["increased", "OBSERVATION_MODIFIER", 1020, 1029], ["resistance", "OBSERVATION_MODIFIER", 1030, 1040], ["protein degradation", "OBSERVATION", 1044, 1063], ["iatrogenic CJD", "OBSERVATION", 1202, 1216], ["deposition", "OBSERVATION", 1244, 1254], ["pituitary glands", "ANATOMY", 1264, 1280], ["MSA cases", "OBSERVATION", 1353, 1362]]], ["BP and Late-Life sCNDDThe association between age at first major whooping cough outbreak (MWCO) and PD constitutes an important observation in Iceland, reinforced by negative results for birth-cohort effects in continental populations.", [["whooping cough", "DISEASE", 65, 79], ["PD", "DISEASE", 100, 102], ["BP", "TEST", 0, 2], ["PD", "TREATMENT", 100, 102], ["Late", "OBSERVATION_MODIFIER", 7, 11]]], ["Considered as a quasi-experiment, it is consistent with the high prevalence and incidence of PD among the Faroe Islanders and Greenland Inuit (Wermuth et al., 2002 (Wermuth et al., , 2008 .", [["PD", "DISEASE", 93, 95], ["PD", "PROBLEM", 93, 95], ["consistent with", "UNCERTAINTY", 40, 55]]], ["The excess risk of PD as a long-term biological effect of BP infection was attributed to Pertussis toxin (de .", [["PD", "DISEASE", 19, 21], ["BP infection", "DISEASE", 58, 70], ["Pertussis toxin", "CHEMICAL", 89, 104], ["BP", "SIMPLE_CHEMICAL", 58, 60], ["Pertussis toxin", "SIMPLE_CHEMICAL", 89, 104], ["Pertussis toxin", "PROTEIN", 89, 104], ["PD", "PROBLEM", 19, 21], ["a long-term biological effect", "TREATMENT", 25, 54], ["BP infection", "PROBLEM", 58, 70], ["Pertussis toxin", "PROBLEM", 89, 104], ["infection", "OBSERVATION", 61, 70]]], ["Since PD shares protein deposits (for a review see Sutherland et al., 2011 ) with MSA, LBD, and AD, BP infection in genetically susceptible young individuals might be proposed as an environmental driver for late-life sCNDD such as MSA, PD, LBD, AD, and AMD.Complementary findings\u2022 BP has historically been harbored by human populations and its dynamic still remains uncontrolled by vaccines.", [["PD", "DISEASE", 6, 8], ["AD", "DISEASE", 96, 98], ["BP infection", "DISEASE", 100, 112], ["MSA", "DISEASE", 231, 234], ["PD", "DISEASE", 236, 238], ["LBD", "DISEASE", 240, 243], ["AD", "DISEASE", 245, 247], ["AMD", "DISEASE", 253, 256], ["human", "ORGANISM", 318, 323], ["LBD", "PROTEIN", 87, 90], ["BP", "PROTEIN", 281, 283], ["human", "SPECIES", 318, 323], ["human", "SPECIES", 318, 323], ["PD shares protein deposits", "PROBLEM", 6, 32], ["MSA", "PROBLEM", 82, 85], ["LBD", "PROBLEM", 87, 90], ["AD", "PROBLEM", 96, 98], ["BP infection", "PROBLEM", 100, 112], ["MSA", "PROBLEM", 231, 234], ["PD", "PROBLEM", 236, 238], ["LBD", "PROBLEM", 240, 243], ["AD", "PROBLEM", 245, 247], ["AMD", "PROBLEM", 253, 256], ["BP", "TEST", 281, 283], ["protein deposits", "OBSERVATION", 16, 32], ["LBD", "ANATOMY", 87, 90], ["infection", "OBSERVATION", 103, 112], ["LBD", "ANATOMY", 240, 243]]], ["Despite the fact that undesired protein aggregation can have negative consequences for the cell, functional aggregationprone regions and aggregates are essential for life.", [["cell", "ANATOMY", 91, 95], ["cell", "CELL", 91, 95], ["undesired protein aggregation", "PROBLEM", 22, 51], ["the cell", "PROBLEM", 87, 95]]], ["For example, in some enterobacteria, amyloid aggregates appear to mediate bacterial adhesion, biofilm development, and host invasion (de Groot et al., 2012) .", [["biofilm", "ANATOMY", 94, 101], ["amyloid aggregates", "GENE_OR_GENE_PRODUCT", 37, 55], ["some enterobacteria", "PROBLEM", 16, 35], ["amyloid aggregates", "PROBLEM", 37, 55], ["bacterial adhesion", "PROBLEM", 74, 92], ["host invasion", "PROBLEM", 119, 132], ["some", "OBSERVATION_MODIFIER", 16, 20], ["enterobacteria", "OBSERVATION", 21, 35], ["amyloid aggregates", "OBSERVATION", 37, 55], ["bacterial adhesion", "OBSERVATION", 74, 92], ["biofilm", "OBSERVATION_MODIFIER", 94, 101], ["host", "OBSERVATION_MODIFIER", 119, 123], ["invasion", "OBSERVATION_MODIFIER", 124, 132]]], ["Human coexistence with commensal or pathogenic bacteria such as BP might have led to the interaction of bacterial aggregated proteins with aggregationprone sequences from the host, resulting in xeno-templating. \u2022 A mutation in the PS2 gene (M239V) neutralizes the toxicity mediated by the Pertussis toxin, suggesting that this toxin shares pathological mechanisms with some AD-mutant variants (Abe et al., 2004) . \u2022 Biological agents acting in the distant past may have changed as a result of human interventions, such as vaccination (Cummings et al., 2004) . \u2022 Horizontal gene transfer research on the Tohama I strain of BP dating back to 1950 may provide source information for understanding the pathobiology of BP and the potential effect in Japanese cohorts currently aged 70 years (Preston, 2005) , particularly if curli can be identified in such strain. \u2022 The rationale suggested for E. coli (see ''Driver 7.", [["toxicity", "DISEASE", 264, 272], ["Human", "ORGANISM", 0, 5], ["BP", "SIMPLE_CHEMICAL", 64, 66], ["PS2", "GENE_OR_GENE_PRODUCT", 231, 234], ["AD", "GENE_OR_GENE_PRODUCT", 374, 376], ["human", "ORGANISM", 493, 498], ["Tohama I", "ORGANISM", 603, 611], ["E. coli", "ORGANISM", 890, 897], ["BP", "PROTEIN", 64, 66], ["bacterial aggregated proteins", "PROTEIN", 104, 133], ["aggregationprone sequences", "DNA", 139, 165], ["PS2 gene", "DNA", 231, 239], ["Pertussis toxin", "PROTEIN", 289, 304], ["BP", "PROTEIN", 622, 624], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 493, 498], ["E. coli", "SPECIES", 890, 897], ["human", "SPECIES", 493, 498], ["E. coli", "SPECIES", 890, 897], ["pathogenic bacteria", "PROBLEM", 36, 55], ["BP", "TEST", 64, 66], ["bacterial aggregated proteins", "PROBLEM", 104, 133], ["aggregationprone sequences", "TREATMENT", 139, 165], ["A mutation in the PS2 gene", "PROBLEM", 213, 239], ["the toxicity", "PROBLEM", 260, 272], ["the Pertussis toxin", "PROBLEM", 285, 304], ["this toxin shares pathological mechanisms", "PROBLEM", 322, 363], ["some AD-mutant variants", "PROBLEM", 369, 392], ["Biological agents", "TREATMENT", 416, 433], ["human interventions", "TREATMENT", 493, 512], ["BP", "TEST", 714, 716], ["E. coli", "PROBLEM", 890, 897], ["mutation", "OBSERVATION", 215, 223]]], ["Invariant ratio of sCNDD Incidence/Genetic CNDD Incidence, Across Entities'' Section) would also be valid for BP.", [["BP", "PROTEIN", 110, 112], ["BP", "TEST", 110, 112]]], ["Seeding of naturally occurring protein fibrils from BP, as experimentally observed with curli from E. coli (Lundmark et al., 2005) , might be hypothesized as biological pluripotential mechanisms underlying BP infection as a causal factor of PD, AD, and diverse late-life sCNDD. \u2022 Mechanisms for adaptation to humans seem to have occurred in the BP precursor, B. pseudopertussis, at an earlier time, taking place for BP by gene loss (Diavatopoulos et al., 2005) .", [["BP infection", "DISEASE", 206, 218], ["PD", "DISEASE", 241, 243], ["AD", "DISEASE", 245, 247], ["sCNDD", "DISEASE", 271, 276], ["protein fibrils", "GENE_OR_GENE_PRODUCT", 31, 46], ["BP", "SIMPLE_CHEMICAL", 52, 54], ["E. coli", "ORGANISM", 99, 106], ["BP", "SIMPLE_CHEMICAL", 206, 208], ["humans", "ORGANISM", 309, 315], ["B. pseudopertussis", "ORGANISM", 359, 377], ["protein fibrils", "PROTEIN", 31, 46], ["BP", "PROTEIN", 52, 54], ["BP", "PROTEIN", 416, 418], ["E. coli", "SPECIES", 99, 106], ["humans", "SPECIES", 309, 315], ["B. pseudopertussis", "SPECIES", 359, 377], ["E. coli", "SPECIES", 99, 106], ["humans", "SPECIES", 309, 315], ["B. pseudopertussis", "SPECIES", 359, 377], ["protein fibrils", "PROBLEM", 31, 46], ["BP", "TEST", 52, 54], ["E. coli", "PROBLEM", 99, 106], ["BP infection", "PROBLEM", 206, 218], ["PD", "PROBLEM", 241, 243], ["AD", "PROBLEM", 245, 247], ["B. pseudopertussis", "PROBLEM", 359, 377], ["protein fibrils", "OBSERVATION", 31, 46], ["infection", "OBSERVATION", 209, 218]]], ["B. pertussis infection damages nasal ciliated epithelium, a structure which transfers uranium to brain along olfactory nerve bundles (Wilson et al., 1991; Ib\u00e1\u00f1ez et al., 2014) .Complementary findings\u2022 The clear, saw-teeth, birth-cohort pattern seen for PD incidence and attributed to the periodic pattern of BP epidemics in Iceland suggests that a similar effect of agents, other than airborne BP epidemic agents, such as influenza or measles, is unlikely.", [["nasal ciliated epithelium", "ANATOMY", 31, 56], ["brain", "ANATOMY", 97, 102], ["olfactory nerve bundles", "ANATOMY", 109, 132], ["infection", "DISEASE", 13, 22], ["uranium", "CHEMICAL", 86, 93], ["PD", "DISEASE", 253, 255], ["BP epidemics", "DISEASE", 308, 320], ["influenza", "DISEASE", 422, 431], ["measles", "DISEASE", 435, 442], ["uranium", "CHEMICAL", 86, 93], ["B. pertussis", "ORGANISM", 0, 12], ["nasal ciliated epithelium", "TISSUE", 31, 56], ["brain", "ORGAN", 97, 102], ["olfactory nerve bundles", "MULTI-TISSUE_STRUCTURE", 109, 132], ["teeth", "ORGAN", 216, 221], ["B. pertussis", "SPECIES", 0, 12], ["B. pertussis", "SPECIES", 0, 12], ["B. pertussis infection damages nasal ciliated epithelium", "PROBLEM", 0, 56], ["PD incidence", "PROBLEM", 253, 265], ["BP epidemics", "PROBLEM", 308, 320], ["agents", "TREATMENT", 366, 372], ["airborne BP epidemic agents", "TREATMENT", 385, 412], ["influenza", "PROBLEM", 422, 431], ["measles", "PROBLEM", 435, 442], ["pertussis", "OBSERVATION_MODIFIER", 3, 12], ["infection", "OBSERVATION", 13, 22], ["ciliated epithelium", "OBSERVATION", 37, 56], ["uranium", "OBSERVATION", 86, 93], ["brain", "ANATOMY", 97, 102], ["olfactory nerve", "ANATOMY", 109, 124], ["bundles", "ANATOMY_MODIFIER", 125, 132], ["clear", "OBSERVATION", 205, 210], ["teeth", "ANATOMY", 216, 221]]], ["However, a supplementary action through the gastrointestinal tract is not ruled out.", [["gastrointestinal tract", "ANATOMY", 44, 66], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 44, 66], ["gastrointestinal tract", "ANATOMY", 44, 66], ["not ruled", "UNCERTAINTY", 70, 79]]], ["The shared early loss of olfactory function and lesions described in sCJD, FTD, PD, and AD might point to a potential effect of BP infection on the clinical profile of sCNDD (Magerova et al., 2014) . \u2022 In addition to airborne agents, synthetic amyloid-like biomaterials and oral agents such as those described for vCJD or food have been proposed, given the high content in protein fibrils (Westermark and Westermark, 2010) . \u2022 In accordance with the induction of AApoAII amyloidosis by various amyloid fibrils, though best by mouse AApoAII(C) amyloid (Fu et al., 2004) , the expected key active element mediated by the human microbiome might be a natural fibril genetically related to human pathology.TheoryHuman-adapted agents integrating human genome such as BP able to generate natural protein fibrils might generate different late-life sCNDD by pluripotential mechanisms in accordance with the individual susceptibility.", [["olfactory", "ANATOMY", 25, 34], ["lesions", "ANATOMY", 48, 55], ["oral", "ANATOMY", 274, 278], ["loss of olfactory function", "DISEASE", 17, 43], ["sCJD", "DISEASE", 69, 73], ["FTD", "DISEASE", 75, 78], ["PD", "DISEASE", 80, 82], ["AD", "DISEASE", 88, 90], ["BP infection", "DISEASE", 128, 140], ["sCNDD", "DISEASE", 168, 173], ["vCJD", "DISEASE", 314, 318], ["amyloidosis", "DISEASE", 471, 482], ["olfactory", "ANATOMICAL_SYSTEM", 25, 34], ["lesions", "PATHOLOGICAL_FORMATION", 48, 55], ["BP", "SIMPLE_CHEMICAL", 128, 130], ["oral", "ORGANISM_SUBDIVISION", 274, 278], ["AApoAII", "GENE_OR_GENE_PRODUCT", 463, 470], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 494, 509], ["mouse", "ORGANISM", 526, 531], ["AApoAII(C) amyloid", "GENE_OR_GENE_PRODUCT", 532, 550], ["human", "ORGANISM", 619, 624], ["human", "ORGANISM", 685, 690], ["human", "ORGANISM", 740, 745], ["BP", "GENE_OR_GENE_PRODUCT", 761, 763], ["amyloid fibrils", "PROTEIN", 494, 509], ["human genome", "DNA", 740, 752], ["BP", "PROTEIN", 761, 763], ["mouse", "SPECIES", 526, 531], ["human", "SPECIES", 619, 624], ["human", "SPECIES", 685, 690], ["human", "SPECIES", 740, 745], ["mouse", "SPECIES", 526, 531], ["human", "SPECIES", 619, 624], ["human", "SPECIES", 685, 690], ["human", "SPECIES", 740, 745], ["The shared early loss of olfactory function", "PROBLEM", 0, 43], ["lesions", "PROBLEM", 48, 55], ["sCJD", "PROBLEM", 69, 73], ["FTD", "PROBLEM", 75, 78], ["PD", "PROBLEM", 80, 82], ["BP infection", "PROBLEM", 128, 140], ["airborne agents", "TREATMENT", 217, 232], ["synthetic amyloid-like biomaterials", "TREATMENT", 234, 269], ["oral agents", "TREATMENT", 274, 285], ["vCJD", "PROBLEM", 314, 318], ["AApoAII amyloidosis", "PROBLEM", 463, 482], ["various amyloid fibrils", "PROBLEM", 486, 509], ["mouse AApoAII(C) amyloid", "PROBLEM", 526, 550], ["TheoryHuman-adapted agents", "TREATMENT", 701, 727], ["BP", "TEST", 761, 763], ["natural protein fibrils", "TREATMENT", 781, 804], ["early", "OBSERVATION_MODIFIER", 11, 16], ["loss", "OBSERVATION_MODIFIER", 17, 21], ["olfactory function", "OBSERVATION", 25, 43], ["lesions", "OBSERVATION", 48, 55], ["infection", "OBSERVATION", 131, 140], ["amyloidosis", "OBSERVATION", 471, 482], ["amyloid fibrils", "OBSERVATION", 494, 509], ["pluripotential mechanisms", "OBSERVATION", 849, 874]]], ["BP may act through nasal and gastrointestinal epithelia.", [["nasal", "ANATOMY", 19, 24], ["gastrointestinal epithelia", "ANATOMY", 29, 55], ["BP", "SIMPLE_CHEMICAL", 0, 2], ["nasal", "ORGANISM_SUBDIVISION", 19, 24], ["gastrointestinal epithelia", "TISSUE", 29, 55], ["BP", "PROTEIN", 0, 2], ["BP", "TEST", 0, 2], ["nasal", "ANATOMY", 19, 24], ["gastrointestinal epithelia", "ANATOMY", 29, 55]]], ["Systemic action across the endoplasmic reticulum (ER) and vascular endothelium might be plausible.Driver 6.", [["endoplasmic reticulum", "ANATOMY", 27, 48], ["ER", "ANATOMY", 50, 52], ["vascular endothelium", "ANATOMY", 58, 78], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 27, 48], ["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["vascular endothelium", "TISSUE", 58, 78], ["Systemic action", "TEST", 0, 15], ["endoplasmic reticulum", "OBSERVATION", 27, 48], ["vascular endothelium", "ANATOMY", 58, 78]]], ["Endoplasmic Reticulum Stressors or General DriversProtein folding is a basic mechanism regulating cell function and survival (Bernales et al., 2012) .", [["Endoplasmic Reticulum", "ANATOMY", 0, 21], ["cell", "ANATOMY", 98, 102], ["cell", "CELL", 98, 102], ["Endoplasmic Reticulum Stressors", "PROBLEM", 0, 31], ["Protein folding", "PROBLEM", 50, 65], ["Reticulum Stressors", "OBSERVATION", 12, 31], ["cell function", "OBSERVATION", 98, 111]]], ["Variables related to the unfolding protein response (UPR) in ER and mitochondria, acting either as stressors or as a result of altered pathways might be epidemiologically captured, reflecting some of the most characteristic drivers of the expanded NDD paradigm.", [["ER", "ANATOMY", 61, 63], ["mitochondria", "ANATOMY", 68, 80], ["UPR", "GENE_OR_GENE_PRODUCT", 53, 56], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["mitochondria", "CELLULAR_COMPONENT", 68, 80], ["NDD", "CANCER", 248, 251], ["UPR", "PROTEIN", 53, 56], ["ER", "PROTEIN", 61, 63], ["the unfolding protein response", "PROBLEM", 21, 51], ["altered pathways", "PROBLEM", 127, 143]]], ["They may affect sCNDD, T2DM, and atherosclerosis potentially related with senile systemic angiopathy and cerebral amyloid\u03b2 (A\u03b2) angiopathy (CAA; linked to myocardial infarction and dementia or AD, respectively), with different underlying amyloid deposits, i.e., wild-type TTR, lactadherin, and beta amyloid.", [["cerebral", "ANATOMY", 105, 113], ["myocardial", "ANATOMY", 155, 165], ["T2DM", "DISEASE", 23, 27], ["atherosclerosis", "DISEASE", 33, 48], ["systemic angiopathy", "DISEASE", 81, 100], ["angiopathy", "DISEASE", 128, 138], ["CAA", "DISEASE", 140, 143], ["myocardial infarction", "DISEASE", 155, 176], ["dementia", "DISEASE", 181, 189], ["AD", "DISEASE", 193, 195], ["cerebral amyloid\u03b2", "GENE_OR_GENE_PRODUCT", 105, 122], ["A\u03b2", "MULTI-TISSUE_STRUCTURE", 124, 126], ["myocardial", "MULTI-TISSUE_STRUCTURE", 155, 165], ["amyloid", "GENE_OR_GENE_PRODUCT", 238, 245], ["TTR", "GENE_OR_GENE_PRODUCT", 272, 275], ["lactadherin", "GENE_OR_GENE_PRODUCT", 277, 288], ["beta amyloid", "GENE_OR_GENE_PRODUCT", 294, 306], ["wild-type TTR", "PROTEIN", 262, 275], ["lactadherin", "PROTEIN", 277, 288], ["beta amyloid", "PROTEIN", 294, 306], ["sCNDD", "PROBLEM", 16, 21], ["T2DM", "PROBLEM", 23, 27], ["atherosclerosis", "PROBLEM", 33, 48], ["senile systemic angiopathy", "PROBLEM", 74, 100], ["cerebral amyloid\u03b2 (A\u03b2) angiopathy", "PROBLEM", 105, 138], ["CAA", "PROBLEM", 140, 143], ["myocardial infarction", "PROBLEM", 155, 176], ["dementia", "PROBLEM", 181, 189], ["AD", "PROBLEM", 193, 195], ["different underlying amyloid deposits", "PROBLEM", 217, 254], ["type TTR", "PROBLEM", 267, 275], ["lactadherin", "TREATMENT", 277, 288], ["beta amyloid", "PROBLEM", 294, 306], ["T2DM", "OBSERVATION", 23, 27], ["atherosclerosis", "OBSERVATION", 33, 48], ["potentially related with", "UNCERTAINTY", 49, 73], ["senile", "OBSERVATION_MODIFIER", 74, 80], ["systemic", "OBSERVATION_MODIFIER", 81, 89], ["angiopathy", "OBSERVATION", 90, 100], ["cerebral amyloid\u03b2", "ANATOMY", 105, 122], ["angiopathy", "OBSERVATION", 128, 138], ["myocardial", "ANATOMY", 155, 165], ["infarction", "OBSERVATION", 166, 176], ["dementia", "OBSERVATION", 181, 189], ["amyloid deposits", "OBSERVATION", 238, 254], ["beta amyloid", "OBSERVATION", 294, 306]]], ["In accordance with the original general proposal, such drivers may affect membrane or secretory tissues such as those resulting in estrogen and testosterone deficits, and midlife VRF such as metabolic syndrome and T2DM.", [["membrane", "ANATOMY", 74, 82], ["secretory tissues", "ANATOMY", 86, 103], ["estrogen", "CHEMICAL", 131, 139], ["testosterone", "CHEMICAL", 144, 156], ["metabolic syndrome", "DISEASE", 191, 209], ["T2DM", "DISEASE", 214, 218], ["estrogen", "CHEMICAL", 131, 139], ["testosterone", "CHEMICAL", 144, 156], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["secretory tissues", "TISSUE", 86, 103], ["estrogen", "SIMPLE_CHEMICAL", 131, 139], ["testosterone", "SIMPLE_CHEMICAL", 144, 156], ["secretory tissues", "PROBLEM", 86, 103], ["estrogen and testosterone deficits", "PROBLEM", 131, 165], ["midlife VRF", "PROBLEM", 171, 182], ["metabolic syndrome", "PROBLEM", 191, 209], ["T2DM", "PROBLEM", 214, 218], ["metabolic syndrome", "OBSERVATION", 191, 209]]], ["Relationships may be complex if some of the ER stress effects or causes constitute T2DM or sCNDD comorbidity, i.e., obesity.Complementary Findings\u2022 The role of endocrine factors in sCNDDs risk is supported by clinical and animal research.", [["endocrine", "ANATOMY", 160, 169], ["T2DM", "DISEASE", 83, 87], ["obesity", "DISEASE", 116, 123], ["sCNDDs", "DISEASE", 181, 187], ["ER", "GENE_OR_GENE_PRODUCT", 44, 46], ["endocrine", "ANATOMICAL_SYSTEM", 160, 169], ["ER", "PROTEIN", 44, 46], ["the ER stress effects", "PROBLEM", 40, 61], ["T2DM", "PROBLEM", 83, 87], ["sCNDD comorbidity", "PROBLEM", 91, 108], ["obesity", "PROBLEM", 116, 123], ["endocrine factors", "PROBLEM", 160, 177], ["obesity", "OBSERVATION", 116, 123]]], ["Since premenopausal oophorectomy is an iatrogenic factor, at least some associations of estrogen deficit may be considered to act outside the most susceptible lifetime points (driver 1), such as juvenile age. \u2022 In addition to the estrogen deficit in dementia, AD pathology, T2DM, and atherosclerosis discussed elsewhere (de Pedro-Cuesta et al., 2016) , an impact on synuclein-related sCNDD may be suggested, since some animal studies implicate a role for estrogen in protecting the nigrostriatal dopaminergic functions (Becker, 1990; Morissette and Di Paolo, 1993) . \u2022 However, estrogen therapy with esterified estrogen use in combination with progestin was recently linked to a 6-fold excess risk of PD (Lundin et al., 2014) .", [["nigrostriatal", "ANATOMY", 482, 495], ["estrogen", "CHEMICAL", 88, 96], ["estrogen", "CHEMICAL", 230, 238], ["dementia", "DISEASE", 250, 258], ["AD", "DISEASE", 260, 262], ["T2DM", "DISEASE", 274, 278], ["atherosclerosis", "DISEASE", 284, 299], ["sCNDD", "DISEASE", 384, 389], ["estrogen", "CHEMICAL", 455, 463], ["estrogen", "CHEMICAL", 578, 586], ["esterified estrogen", "CHEMICAL", 600, 619], ["progestin", "CHEMICAL", 644, 653], ["PD", "DISEASE", 701, 703], ["estrogen", "CHEMICAL", 88, 96], ["estrogen", "CHEMICAL", 230, 238], ["estrogen", "CHEMICAL", 455, 463], ["estrogen", "CHEMICAL", 578, 586], ["estrogen", "CHEMICAL", 611, 619], ["progestin", "CHEMICAL", 644, 653], ["estrogen", "SIMPLE_CHEMICAL", 88, 96], ["estrogen", "SIMPLE_CHEMICAL", 230, 238], ["synuclein", "SIMPLE_CHEMICAL", 366, 375], ["sCNDD", "GENE_OR_GENE_PRODUCT", 384, 389], ["estrogen", "SIMPLE_CHEMICAL", 455, 463], ["estrogen", "SIMPLE_CHEMICAL", 578, 586], ["esterified", "SIMPLE_CHEMICAL", 600, 610], ["estrogen", "SIMPLE_CHEMICAL", 611, 619], ["progestin", "SIMPLE_CHEMICAL", 644, 653], ["premenopausal oophorectomy", "TREATMENT", 6, 32], ["an iatrogenic factor", "PROBLEM", 36, 56], ["estrogen deficit", "PROBLEM", 88, 104], ["the estrogen deficit", "PROBLEM", 226, 246], ["dementia", "PROBLEM", 250, 258], ["AD pathology", "PROBLEM", 260, 272], ["T2DM", "PROBLEM", 274, 278], ["atherosclerosis", "PROBLEM", 284, 299], ["some animal studies", "TEST", 414, 433], ["estrogen", "TREATMENT", 455, 463], ["estrogen therapy", "TREATMENT", 578, 594], ["esterified estrogen use", "TREATMENT", 600, 623], ["progestin", "TREATMENT", 644, 653], ["PD", "PROBLEM", 701, 703], ["oophorectomy", "OBSERVATION", 20, 32], ["iatrogenic", "OBSERVATION_MODIFIER", 39, 49], ["at least", "OBSERVATION_MODIFIER", 58, 66], ["estrogen deficit", "OBSERVATION", 88, 104], ["dementia", "OBSERVATION", 250, 258], ["atherosclerosis", "OBSERVATION", 284, 299]]], ["While castration, conducted no later than at 4-5 weeks, makes the malemouse model support the etiologic role of testosterone deficit in PD (Khasnavis et al., 2013) , it may also convey insights into the driver-1 effect better than does andropause mimicry. \u2022 The fact that some endocrine deficits, i.e., testosterone, are linked to risk of other endocrine disorders raises questions about a shared, unidentified etiologic cause affecting secretory systems. \u2022 Complex links are suggested for T2DM: T2DM could be also taken as a general driver, since it is associated with risk of both FTD (Golimstok et al., 2014) and AD (Jayaraman and Pike, 2014) , and at the same time constitutes an outcome of testosterone depletion (Kapoor et al., 2006; Lage et al., 2007) . \u2022 The relationship of ER stress and vascular wall pathology may be persistent, since increased ER stress was identified in atherosclerotic plaques linked to coronary syndrome (Myoishi et al., 2007) . \u2022 The UPR in ER may be affected by environmental insults and genetic modifiers which hamper biosynthesis of steroids, cholesterol and many lipids (Kaufman, 2002) . \u2022 We believe that the amyloid perspective may serve as a reference for etiologic thinking, where shared determinants of early amyloid deposits in myocardial or cerebral vessels, i.e., the tau/AD pathology (Chui et al., 2012) are plausible.Complementary FindingsChronic endocrine disorders such as estrogen or testosterone deficits might not yet have been identified as conformational disorders.Complementary FindingsTheory Figure 3 depicts a hypothetical etiologic scenario modified from Figure 2 , where different amyloid deposits shared by sCNDD, vascular disorders and a number of endocrine entities or functions, determine late-life human pathology as a result of ER stressors or poor UPR.", [["endocrine", "ANATOMY", 277, 286], ["endocrine", "ANATOMY", 345, 354], ["secretory systems", "ANATOMY", 437, 454], ["vascular wall", "ANATOMY", 797, 810], ["atherosclerotic plaques", "ANATOMY", 884, 907], ["coronary", "ANATOMY", 918, 926], ["ER", "ANATOMY", 974, 976], ["myocardial", "ANATOMY", 1271, 1281], ["cerebral vessels", "ANATOMY", 1285, 1301], ["endocrine", "ANATOMY", 1394, 1403], ["vascular", "ANATOMY", 1674, 1682], ["endocrine", "ANATOMY", 1709, 1718], ["testosterone", "CHEMICAL", 112, 124], ["PD", "DISEASE", 136, 138], ["endocrine deficits", "DISEASE", 277, 295], ["testosterone", "CHEMICAL", 303, 315], ["endocrine disorders", "DISEASE", 345, 364], ["T2DM", "DISEASE", 490, 494], ["T2DM", "DISEASE", 496, 500], ["FTD", "DISEASE", 583, 586], ["AD", "DISEASE", 616, 618], ["testosterone", "CHEMICAL", 695, 707], ["atherosclerotic plaques", "DISEASE", 884, 907], ["coronary syndrome", "DISEASE", 918, 935], ["steroids", "CHEMICAL", 1069, 1077], ["cholesterol", "CHEMICAL", 1079, 1090], ["AD", "DISEASE", 1317, 1319], ["Chronic endocrine disorders", "DISEASE", 1386, 1413], ["estrogen", "CHEMICAL", 1422, 1430], ["testosterone", "CHEMICAL", 1434, 1446], ["amyloid", "DISEASE", 1640, 1647], ["vascular disorders", "DISEASE", 1674, 1692], ["testosterone", "CHEMICAL", 112, 124], ["testosterone", "CHEMICAL", 303, 315], ["testosterone", "CHEMICAL", 695, 707], ["steroids", "CHEMICAL", 1069, 1077], ["cholesterol", "CHEMICAL", 1079, 1090], ["estrogen", "CHEMICAL", 1422, 1430], ["testosterone", "CHEMICAL", 1434, 1446], ["testosterone", "SIMPLE_CHEMICAL", 112, 124], ["endocrine", "ANATOMICAL_SYSTEM", 277, 286], ["testosterone", "SIMPLE_CHEMICAL", 303, 315], ["endocrine", "ANATOMICAL_SYSTEM", 345, 354], ["testosterone", "SIMPLE_CHEMICAL", 695, 707], ["ER", "GENE_OR_GENE_PRODUCT", 783, 785], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 797, 810], ["ER", "GENE_OR_GENE_PRODUCT", 856, 858], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 884, 907], ["coronary", "MULTI-TISSUE_STRUCTURE", 918, 926], ["UPR", "GENE_OR_GENE_PRODUCT", 967, 970], ["ER", "GENE_OR_GENE_PRODUCT", 974, 976], ["steroids", "SIMPLE_CHEMICAL", 1069, 1077], ["cholesterol", "SIMPLE_CHEMICAL", 1079, 1090], ["amyloid", "GENE_OR_GENE_PRODUCT", 1251, 1258], ["myocardial", "MULTI-TISSUE_STRUCTURE", 1271, 1281], ["cerebral vessels", "MULTI-TISSUE_STRUCTURE", 1285, 1301], ["tau", "GENE_OR_GENE_PRODUCT", 1313, 1316], ["estrogen", "SIMPLE_CHEMICAL", 1422, 1430], ["testosterone", "SIMPLE_CHEMICAL", 1434, 1446], ["vascular", "MULTI-TISSUE_STRUCTURE", 1674, 1682], ["human", "ORGANISM", 1762, 1767], ["ER", "GENE_OR_GENE_PRODUCT", 1793, 1795], ["ER", "PROTEIN", 783, 785], ["ER", "PROTEIN", 856, 858], ["UPR", "PROTEIN", 967, 970], ["ER", "PROTEIN", 974, 976], ["ER", "PROTEIN", 1793, 1795], ["UPR", "PROTEIN", 1814, 1817], ["human", "SPECIES", 1762, 1767], ["human", "SPECIES", 1762, 1767], ["castration", "TREATMENT", 6, 16], ["testosterone deficit", "PROBLEM", 112, 132], ["some endocrine deficits", "PROBLEM", 272, 295], ["testosterone", "TREATMENT", 303, 315], ["other endocrine disorders", "PROBLEM", 339, 364], ["secretory systems", "PROBLEM", 437, 454], ["T2DM", "PROBLEM", 490, 494], ["T2DM", "PROBLEM", 496, 500], ["both FTD", "PROBLEM", 578, 586], ["testosterone depletion", "PROBLEM", 695, 717], ["ER stress and vascular wall pathology", "PROBLEM", 783, 820], ["increased ER stress", "PROBLEM", 846, 865], ["atherosclerotic plaques", "PROBLEM", 884, 907], ["coronary syndrome", "PROBLEM", 918, 935], ["environmental insults", "PROBLEM", 996, 1017], ["genetic modifiers", "TREATMENT", 1022, 1039], ["steroids", "TREATMENT", 1069, 1077], ["cholesterol", "TREATMENT", 1079, 1090], ["early amyloid deposits", "PROBLEM", 1245, 1267], ["the tau/AD pathology", "PROBLEM", 1309, 1329], ["Chronic endocrine disorders", "PROBLEM", 1386, 1413], ["estrogen or testosterone deficits", "PROBLEM", 1422, 1455], ["conformational disorders", "PROBLEM", 1494, 1518], ["different amyloid deposits", "PROBLEM", 1630, 1656], ["vascular disorders", "PROBLEM", 1674, 1692], ["ER stressors", "PROBLEM", 1793, 1805], ["poor UPR", "PROBLEM", 1809, 1817], ["some", "OBSERVATION_MODIFIER", 272, 276], ["endocrine deficits", "OBSERVATION", 277, 295], ["vascular", "ANATOMY", 797, 805], ["wall", "ANATOMY_MODIFIER", 806, 810], ["pathology", "OBSERVATION", 811, 820], ["may be", "UNCERTAINTY", 821, 827], ["persistent", "OBSERVATION_MODIFIER", 828, 838], ["increased", "OBSERVATION_MODIFIER", 846, 855], ["atherosclerotic", "OBSERVATION_MODIFIER", 884, 899], ["plaques", "OBSERVATION", 900, 907], ["coronary", "ANATOMY", 918, 926], ["may be", "UNCERTAINTY", 977, 983], ["amyloid", "OBSERVATION", 1147, 1154], ["early", "OBSERVATION_MODIFIER", 1245, 1250], ["amyloid deposits", "OBSERVATION", 1251, 1267], ["myocardial", "ANATOMY", 1271, 1281], ["cerebral vessels", "ANATOMY", 1285, 1301], ["Chronic", "OBSERVATION_MODIFIER", 1386, 1393], ["endocrine disorders", "OBSERVATION", 1394, 1413], ["amyloid deposits", "OBSERVATION", 1640, 1656], ["vascular", "ANATOMY", 1674, 1682], ["disorders", "OBSERVATION", 1683, 1692]]], ["As a complement, some endocrine factors of a different origin (i.e., oophorectomy or specific estrogen therapies) might also constitute risk factors for conformational disorders.Driver 7.", [["endocrine", "ANATOMY", 22, 31], ["estrogen", "CHEMICAL", 94, 102], ["estrogen", "CHEMICAL", 94, 102], ["estrogen", "SIMPLE_CHEMICAL", 94, 102], ["endocrine factors", "PROTEIN", 22, 39], ["oophorectomy", "TREATMENT", 69, 81], ["specific estrogen therapies", "TREATMENT", 85, 112], ["conformational disorders", "PROBLEM", 153, 177], ["oophorectomy", "OBSERVATION", 69, 81]]], ["Invariant Ratio of sCNDD Incidence/Genetic CNDD Incidence, Across EntitiesThis driver applies basically to genetic CNDDs determined by point mutations.", [["CNDDs", "DISEASE", 115, 120], ["CNDDs", "CANCER", 115, 120]]], ["The ratio, best known when defined by a proxy value, namely, the proportion of incident disease corresponding to familial forms, tends to increase due to the progressive improvement in the identification of such mutations, and may reach 25% in selected sCNDD.", [["sCNDD", "DISEASE", 253, 258], ["sCNDD", "CANCER", 253, 258], ["The ratio", "TEST", 0, 9], ["incident disease", "PROBLEM", 79, 95], ["familial forms", "PROBLEM", 113, 127], ["such mutations", "PROBLEM", 207, 221], ["progressive", "OBSERVATION_MODIFIER", 158, 169], ["improvement", "OBSERVATION_MODIFIER", 170, 181]]], ["This feature, emphasized by Soto and Estrada (2008) , has long been recognized, despite the fact that this proportion is higher in a few populations (Israeli Jews, or populations with genetic clusters, e.g., Slovenia for CJD).", [["CJD", "DISEASE", 221, 224], ["CJD", "PROBLEM", 221, 224], ["higher", "OBSERVATION_MODIFIER", 121, 127]]], ["Similarly low proportions have been described for genetic vs. sporadic forms of T2DM.", [["T2DM", "DISEASE", 80, 84], ["T2DM", "PROBLEM", 80, 84], ["low proportions", "OBSERVATION_MODIFIER", 10, 25], ["T2DM", "OBSERVATION", 80, 84]]], ["The proportion is less clearly perceived for AMD where mutated or wild-type EFEMP1 has been described, and atherosclerosis forms, such as SSA, heart failure and aortic aneurysm (Westermark and Westermark, 2010) , where wild-type TTR deposits have been described but an incidence or case series reference for the sporadic form is lacking.Complementary Findings\u2022 The ecologic relationship between sporadic genetic forms may suggest a causal link between genetic CNDDs resulting from point mutations and the corresponding sCNDD forms.Complementary FindingsSince the predominant protein signature of a specific sCNDD frequently corresponds to that of its genetic CNDD form, one might speculate that, ontogenically speaking, sCNDD forms might be considered secondary to genetic ones in terms of numbers and biochemical similarity (Parcerisas et al., 2014) . \u2022 In a prior article (de Pedro-Cuesta et al., 2016), we proposed that the most relevant field of knowledge for driver 7 and assessment of the role of vectors in sCNDD might be gene transfer from human to bacterial human pathogens.", [["heart", "ANATOMY", 143, 148], ["aortic aneurysm", "ANATOMY", 161, 176], ["AMD", "DISEASE", 45, 48], ["atherosclerosis", "DISEASE", 107, 122], ["heart failure", "DISEASE", 143, 156], ["aortic aneurysm", "DISEASE", 161, 176], ["CNDDs", "DISEASE", 460, 465], ["EFEMP1", "GENE_OR_GENE_PRODUCT", 76, 82], ["heart", "ORGAN", 143, 148], ["aortic", "ORGAN", 161, 167], ["TTR", "GENE_OR_GENE_PRODUCT", 229, 232], ["sCNDD", "CANCER", 607, 612], ["sCNDD", "GENE_OR_GENE_PRODUCT", 1014, 1019], ["human", "ORGANISM", 1048, 1053], ["human", "ORGANISM", 1067, 1072], ["EFEMP1", "PROTEIN", 76, 82], ["sCNDD forms", "RNA", 519, 530], ["sCNDD", "DNA", 607, 612], ["sCNDD", "DNA", 1014, 1019], ["human", "SPECIES", 1048, 1053], ["human", "SPECIES", 1067, 1072], ["human", "SPECIES", 1048, 1053], ["human", "SPECIES", 1067, 1072], ["AMD", "PROBLEM", 45, 48], ["mutated or wild-type EFEMP1", "PROBLEM", 55, 82], ["atherosclerosis", "PROBLEM", 107, 122], ["SSA", "PROBLEM", 138, 141], ["heart failure", "PROBLEM", 143, 156], ["aortic aneurysm", "PROBLEM", 161, 176], ["type TTR deposits", "PROBLEM", 224, 241], ["a causal link between genetic CNDDs", "PROBLEM", 430, 465], ["point mutations", "PROBLEM", 481, 496], ["bacterial human pathogens", "PROBLEM", 1057, 1082], ["less clearly", "OBSERVATION_MODIFIER", 18, 30], ["atherosclerosis", "OBSERVATION", 107, 122], ["heart", "ANATOMY", 143, 148], ["failure", "OBSERVATION", 149, 156], ["aortic", "ANATOMY", 161, 167], ["aneurysm", "OBSERVATION", 168, 176], ["TTR deposits", "OBSERVATION", 229, 241]]], ["A first key issue would be the potential of human sequences to make the hosted agent generate misfolded proteins, resulting in infective natural fibrils with a biochemical signature determined by the transferred genetic material.", [["fibrils", "ANATOMY", 145, 152], ["human", "ORGANISM", 44, 49], ["misfolded proteins", "PROTEIN", 94, 112], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["human sequences", "TREATMENT", 44, 59], ["misfolded proteins", "PROBLEM", 94, 112], ["infective natural fibrils", "PROBLEM", 127, 152], ["a biochemical signature", "PROBLEM", 158, 181], ["infective natural fibrils", "OBSERVATION", 127, 152]]], ["The hypothesis would require an impact on sporadic atherosclerosis of mutations other than those seen in the TTR gene and Notch 1 present in Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), but the high nonspecific potential of natural and synthetic protein fibrils to enhance the amyloid response during inflammation might explain cross-effects (Fu et al., 2004) . \u2022 In this essay, we provide an example of such a potential process which might have been identified, namely, that of E. coli.", [["Subcortical", "ANATOMY", 187, 198], ["atherosclerosis", "DISEASE", 51, 66], ["Cerebral Autosomal-Dominant Arteriopathy", "DISEASE", 141, 181], ["Subcortical Infarcts", "DISEASE", 187, 207], ["Leukoencephalopathy", "DISEASE", 212, 231], ["CADASIL", "DISEASE", 233, 240], ["amyloid", "DISEASE", 334, 341], ["inflammation", "DISEASE", 358, 370], ["TTR", "GENE_OR_GENE_PRODUCT", 109, 112], ["Notch 1", "GENE_OR_GENE_PRODUCT", 122, 129], ["protein fibrils", "GENE_OR_GENE_PRODUCT", 303, 318], ["amyloid", "GENE_OR_GENE_PRODUCT", 334, 341], ["E. coli", "ORGANISM", 536, 543], ["TTR gene", "DNA", 109, 117], ["Notch 1", "PROTEIN", 122, 129], ["E. coli", "SPECIES", 536, 543], ["E. coli", "SPECIES", 536, 543], ["sporadic atherosclerosis of mutations", "PROBLEM", 42, 79], ["Cerebral Autosomal-Dominant Arteriopathy", "PROBLEM", 141, 181], ["Subcortical Infarcts", "PROBLEM", 187, 207], ["Leukoencephalopathy (CADASIL)", "PROBLEM", 212, 241], ["natural and synthetic protein fibrils", "PROBLEM", 281, 318], ["the amyloid response", "PROBLEM", 330, 350], ["inflammation", "PROBLEM", 358, 370], ["a potential process", "PROBLEM", 466, 485], ["E. coli", "PROBLEM", 536, 543], ["sporadic", "OBSERVATION_MODIFIER", 42, 50], ["atherosclerosis", "OBSERVATION", 51, 66], ["Cerebral", "ANATOMY", 141, 149], ["Autosomal", "OBSERVATION", 150, 159], ["Dominant", "OBSERVATION_MODIFIER", 160, 168], ["Arteriopathy", "OBSERVATION", 169, 181], ["Subcortical", "ANATOMY_MODIFIER", 187, 198], ["Infarcts", "OBSERVATION", 199, 207], ["Leukoencephalopathy", "OBSERVATION", 212, 231], ["amyloid response", "OBSERVATION", 334, 350], ["E. coli", "OBSERVATION", 536, 543]]], ["It has been estimated that more than 17% of the genetic material of E. coli (an enterobacterium hosted by humans; Lawrence and Ochman, 1997) , whose curli, natural protein fibrils, have been used in animal models of A-amyloidosis by natural fibril-seeding, is the result of horizontally transferred, protein-coding DNA over several million years (Lawrence and Ochman, 1997; Lundmark et al., 2005) . \u2022 Since inflammation is required for templating, the role of E. coli might be mediated by gastrointestinal infections at a young age.", [["gastrointestinal", "ANATOMY", 489, 505], ["A-amyloidosis", "DISEASE", 216, 229], ["inflammation", "DISEASE", 407, 419], ["gastrointestinal infections", "DISEASE", 489, 516], ["E. coli", "ORGANISM", 68, 75], ["humans", "ORGANISM", 106, 112], ["A-amyloidosis", "CANCER", 216, 229], ["DNA", "CELLULAR_COMPONENT", 315, 318], ["E. coli", "ORGANISM", 460, 467], ["gastrointestinal", "ORGAN", 489, 505], ["curli", "PROTEIN", 149, 154], ["natural protein fibrils", "PROTEIN", 156, 179], ["protein-coding DNA", "DNA", 300, 318], ["E. coli", "SPECIES", 68, 75], ["humans", "SPECIES", 106, 112], ["E. coli", "SPECIES", 460, 467], ["E. coli", "SPECIES", 68, 75], ["humans", "SPECIES", 106, 112], ["E. coli", "SPECIES", 460, 467], ["E. coli", "PROBLEM", 68, 75], ["natural protein fibrils", "TREATMENT", 156, 179], ["A-amyloidosis", "PROBLEM", 216, 229], ["natural fibril-seeding", "PROBLEM", 233, 255], ["inflammation", "PROBLEM", 407, 419], ["templating", "TREATMENT", 436, 446], ["E. coli", "PROBLEM", 460, 467], ["gastrointestinal infections", "PROBLEM", 489, 516], ["E. coli", "OBSERVATION", 68, 75], ["protein fibrils", "OBSERVATION", 164, 179], ["inflammation", "OBSERVATION", 407, 419], ["E. coli", "OBSERVATION", 460, 467], ["gastrointestinal", "ANATOMY", 489, 505], ["infections", "OBSERVATION", 506, 516]]], ["In 2003, Braak and associates proposed that transneuronal transmission of pathologically altered \u03b1-synuclein from the enteric nervous system to the brainstem might occur in PD (Braak et al., 2003) .", [["transneuronal", "ANATOMY", 44, 57], ["enteric nervous system", "ANATOMY", 118, 140], ["brainstem", "ANATOMY", 148, 157], ["PD", "DISEASE", 173, 175], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 97, 108], ["enteric nervous system", "ANATOMICAL_SYSTEM", 118, 140], ["brainstem", "ORGAN", 148, 157], ["\u03b1-synuclein", "PROTEIN", 97, 108], ["pathologically altered \u03b1-synuclein", "PROBLEM", 74, 108], ["enteric nervous", "ANATOMY", 118, 133], ["brainstem", "ANATOMY", 148, 157]]], ["Various heterogeneous, natural and synthetic amyloid fibrils induced AApoAII amyloidosis (Fu et al., 2004) .", [["amyloidosis", "DISEASE", 77, 88], ["amyloid fibrils", "SIMPLE_CHEMICAL", 45, 60], ["Various heterogeneous, natural and synthetic amyloid fibrils", "PROBLEM", 0, 60], ["AApoAII amyloidosis", "PROBLEM", 69, 88], ["heterogeneous", "OBSERVATION_MODIFIER", 8, 21], ["natural", "OBSERVATION_MODIFIER", 23, 30], ["synthetic", "OBSERVATION_MODIFIER", 35, 44], ["amyloid fibrils", "OBSERVATION", 45, 60], ["amyloidosis", "OBSERVATION", 77, 88]]], ["This process could be compatible with a proportion of cases being determined by other mechanisms or entry sites such as the oral cavity (Olsen and Singhrao, 2015) .", [["oral cavity", "ANATOMY", 124, 135], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 124, 135], ["entry sites", "PROBLEM", 100, 111], ["oral cavity", "ANATOMY", 124, 135]]], ["In contrast, SB Prusiner suggests that the late onset of heritable NDDs, like their sporadic counterparts, may reflect a stochastic nature of prion formation (Prusiner, 2013) . \u2022 Based on epidemiologic and laboratory research, it has been proposed that several infectious agents are linked to different NDDs: Nocardia sp. and BP to parkinsonism (Kohbata and Beaman, 1991; de Pedro-Cuesta et al., 1996) , and recent adeno-associated viral vectors provide excellent \u03b1-synuclein models of PD (Lindgren et al., 2012) .", [["NDDs", "DISEASE", 67, 71], ["NDDs", "DISEASE", 303, 307], ["parkinsonism", "DISEASE", 332, 344], ["PD", "DISEASE", 486, 488], ["NDDs", "GENE_OR_GENE_PRODUCT", 67, 71], ["Nocardia sp", "ORGANISM", 309, 320], ["\u03b1-synuclein", "SIMPLE_CHEMICAL", 464, 475], ["heritable NDDs", "PROBLEM", 57, 71], ["laboratory research", "TEST", 206, 225], ["several infectious agents", "TREATMENT", 253, 278], ["Nocardia", "PROBLEM", 309, 317], ["BP", "TEST", 326, 328], ["parkinsonism", "PROBLEM", 332, 344], ["recent adeno-associated viral vectors", "TREATMENT", 408, 445], ["heritable", "OBSERVATION_MODIFIER", 57, 66], ["NDDs", "OBSERVATION", 67, 71], ["may reflect", "UNCERTAINTY", 107, 118], ["several", "OBSERVATION_MODIFIER", 253, 260], ["infectious", "OBSERVATION", 261, 271], ["Nocardia", "OBSERVATION", 309, 317], ["parkinsonism", "OBSERVATION", 332, 344]]], ["Similarly, Herpes simplex virus type 1 (HSV-1), in conjunction with apolipoprotein E4 (ApoE4) from a murine acute infection model, has recently been proposed as a risk factor for AD (Burgos et al., 2006; Harris and Harris, 2015) .", [["Herpes simplex virus", "DISEASE", 11, 31], ["acute infection", "DISEASE", 108, 123], ["AD", "DISEASE", 179, 181], ["Herpes simplex virus type 1", "ORGANISM", 11, 38], ["HSV-1", "ORGANISM", 40, 45], ["apolipoprotein E4", "GENE_OR_GENE_PRODUCT", 68, 85], ["ApoE4", "GENE_OR_GENE_PRODUCT", 87, 92], ["murine", "ORGANISM", 101, 107], ["apolipoprotein E4", "PROTEIN", 68, 85], ["ApoE4", "PROTEIN", 87, 92], ["Herpes simplex virus type 1", "SPECIES", 11, 38], ["HSV-1", "SPECIES", 40, 45], ["murine", "SPECIES", 101, 107], ["Herpes simplex virus type 1", "SPECIES", 11, 38], ["HSV-1", "SPECIES", 40, 45], ["Herpes simplex virus type", "TEST", 11, 36], ["HSV", "TEST", 40, 43], ["apolipoprotein E4 (ApoE4", "PROBLEM", 68, 92], ["a murine acute infection model", "PROBLEM", 99, 129], ["AD", "PROBLEM", 179, 181], ["Herpes", "OBSERVATION_MODIFIER", 11, 17], ["simplex virus", "OBSERVATION", 18, 31], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["infection", "OBSERVATION", 114, 123]]], ["A similar relationship has been suggested for fungal infection and AD or ALS (Alonso et al., 2015a,b; Pisa et al., 2015a,b) .", [["fungal infection", "DISEASE", 46, 62], ["AD", "DISEASE", 67, 69], ["ALS", "DISEASE", 73, 76], ["fungal infection", "PROBLEM", 46, 62], ["suggested for", "UNCERTAINTY", 32, 45], ["fungal", "OBSERVATION_MODIFIER", 46, 52], ["infection", "OBSERVATION", 53, 62]]], ["The field of potential vectors, if restricted to well-adapted human pathogens, remains yet undefined but many are already sequenced.TheoryCurli from some human-adapted pathogens correspond to multiple potentially infective natural misfolded protein fibrils resulting from horizontal gene transfer (HGT) from agents well adapted to the human host, acting at young ages as pluripotential agents facilitating invasion, particularly during inflammatory conditions (infections).", [["infections", "DISEASE", 461, 471], ["human", "ORGANISM", 62, 67], ["human", "ORGANISM", 154, 159], ["human", "ORGANISM", 335, 340], ["protein fibrils", "PROTEIN", 241, 256], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 335, 340], ["potential vectors", "TREATMENT", 13, 30], ["human pathogens", "PROBLEM", 62, 77], ["adapted pathogens", "PROBLEM", 160, 177], ["multiple potentially infective natural misfolded protein fibrils", "PROBLEM", 192, 256], ["horizontal gene transfer (HGT", "TREATMENT", 272, 301], ["pluripotential agents", "TREATMENT", 371, 392], ["inflammatory conditions (infections", "PROBLEM", 436, 471], ["misfolded protein fibrils", "OBSERVATION", 231, 256], ["invasion", "OBSERVATION", 406, 414]]], ["These mechanisms may be shared by some angiopathies and T2DM exhibiting a similar driver, as well as by multiple similar pathogenic processes among humans.", [["T2DM", "DISEASE", 56, 60], ["humans", "ORGANISM", 148, 154], ["humans", "SPECIES", 148, 154], ["humans", "SPECIES", 148, 154], ["some angiopathies", "PROBLEM", 34, 51], ["T2DM", "PROBLEM", 56, 60], ["may be", "UNCERTAINTY", 17, 23], ["similar driver", "OBSERVATION", 74, 88], ["multiple", "OBSERVATION_MODIFIER", 104, 112], ["similar", "OBSERVATION_MODIFIER", 113, 120], ["pathogenic", "OBSERVATION", 121, 131]]], ["An essential condition for bacterial agents being candidates for HGT is that they themselves or their close ancestors must have been well adapted to human hosts by integrating pathogenic DNA (deoxyribonucleic acid) from different niches (gingival, nasal, respiratory mucosae or gut epithelium, and other).", [["gingival", "ANATOMY", 238, 246], ["nasal", "ANATOMY", 248, 253], ["respiratory mucosae", "ANATOMY", 255, 274], ["gut epithelium", "ANATOMY", 278, 292], ["deoxyribonucleic acid", "CHEMICAL", 192, 213], ["human", "ORGANISM", 149, 154], ["DNA", "CELLULAR_COMPONENT", 187, 190], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 192, 213], ["gingival", "TISSUE", 238, 246], ["nasal", "MULTI-TISSUE_STRUCTURE", 248, 253], ["respiratory mucosae", "TISSUE", 255, 274], ["gut epithelium", "TISSUE", 278, 292], ["pathogenic DNA", "DNA", 176, 190], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["bacterial agents", "TREATMENT", 27, 43], ["pathogenic DNA (deoxyribonucleic acid", "TREATMENT", 176, 213], ["gingival, nasal, respiratory mucosae", "PROBLEM", 238, 274], ["nasal", "ANATOMY", 248, 253], ["respiratory mucosae", "ANATOMY", 255, 274]]], ["In essence, infection by E. coli or coexistent with E. coli as a part of the intestinal microbiome, and other well adapted human hosts carrying pathogenic human genetic material and natural protein fibrils might induce diverse sCNDD, T2DM, and atherosclerosis, following an age-atinfection pattern.MAIN FEATURES OF A CAUSAL HYPOTHESIS FOR sCNDD, ATHEROSCLEROSIS, AND T2DMWe propose that sCNDD, T2DM, a relevant proportion of atherosclerosis, as well as other late-life endocrine disorders resulting in andropause and estrogen deficit, constitute organlimited amyloid disorders, where conformational mimicry leads to misfolding of a limited number of proteins such as PrP, Langerhans Islet peptide, amyloid beta (A\u03b2), tau, \u03b1synuclein, SOD1, FTP-43, medin, TTR, and wild-type EFMP1 (Marmorstein et al., 2002) .", [["intestinal microbiome", "ANATOMY", 77, 98], ["endocrine", "ANATOMY", 469, 478], ["infection", "DISEASE", 12, 21], ["T2DM", "DISEASE", 234, 238], ["atherosclerosis", "DISEASE", 244, 259], ["T2DM", "DISEASE", 394, 398], ["atherosclerosis", "DISEASE", 425, 440], ["endocrine disorders", "DISEASE", 469, 488], ["estrogen", "CHEMICAL", 517, 525], ["amyloid disorders", "DISEASE", 559, 576], ["estrogen", "CHEMICAL", 517, 525], ["E. coli", "ORGANISM", 25, 32], ["E. coli", "ORGANISM", 52, 59], ["intestinal", "ORGAN", 77, 87], ["human", "ORGANISM", 123, 128], ["human", "ORGANISM", 155, 160], ["estrogen", "SIMPLE_CHEMICAL", 517, 525], ["PrP", "GENE_OR_GENE_PRODUCT", 667, 670], ["Langerhans Islet peptide", "GENE_OR_GENE_PRODUCT", 672, 696], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 698, 710], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 712, 714], ["tau", "GENE_OR_GENE_PRODUCT", 717, 720], ["\u03b1synuclein", "GENE_OR_GENE_PRODUCT", 722, 732], ["SOD1", "GENE_OR_GENE_PRODUCT", 734, 738], ["FTP-43", "GENE_OR_GENE_PRODUCT", 740, 746], ["medin", "GENE_OR_GENE_PRODUCT", 748, 753], ["TTR", "GENE_OR_GENE_PRODUCT", 755, 758], ["EFMP1", "GENE_OR_GENE_PRODUCT", 774, 779], ["PrP", "PROTEIN", 667, 670], ["amyloid beta", "PROTEIN", 698, 710], ["A\u03b2", "PROTEIN", 712, 714], ["tau", "PROTEIN", 717, 720], ["\u03b1synuclein", "PROTEIN", 722, 732], ["SOD1", "PROTEIN", 734, 738], ["FTP", "PROTEIN", 740, 743], ["medin", "PROTEIN", 748, 753], ["TTR", "PROTEIN", 755, 758], ["wild-type EFMP1", "PROTEIN", 764, 779], ["E. coli", "SPECIES", 25, 32], ["E. coli", "SPECIES", 52, 59], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 155, 160], ["E. coli", "SPECIES", 25, 32], ["E. coli", "SPECIES", 52, 59], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 155, 160], ["infection", "PROBLEM", 12, 21], ["E. coli", "PROBLEM", 25, 32], ["E. coli", "PROBLEM", 52, 59], ["pathogenic human genetic material", "PROBLEM", 144, 177], ["natural protein fibrils", "TREATMENT", 182, 205], ["diverse sCNDD", "PROBLEM", 219, 232], ["T2DM", "PROBLEM", 234, 238], ["atherosclerosis", "PROBLEM", 244, 259], ["sCNDD", "PROBLEM", 339, 344], ["ATHEROSCLEROSIS", "PROBLEM", 346, 361], ["sCNDD", "PROBLEM", 387, 392], ["T2DM", "PROBLEM", 394, 398], ["atherosclerosis", "PROBLEM", 425, 440], ["other late-life endocrine disorders", "PROBLEM", 453, 488], ["andropause", "PROBLEM", 502, 512], ["estrogen deficit", "PROBLEM", 517, 533], ["organlimited amyloid disorders", "PROBLEM", 546, 576], ["PrP", "TEST", 667, 670], ["amyloid beta (A\u03b2)", "TEST", 698, 715], ["FTP", "TEST", 740, 743], ["medin", "TREATMENT", 748, 753], ["TTR", "TEST", 755, 758], ["infection", "OBSERVATION", 12, 21], ["E. coli", "OBSERVATION_MODIFIER", 25, 32], ["E. coli", "OBSERVATION", 52, 59], ["intestinal microbiome", "ANATOMY", 77, 98], ["diverse", "OBSERVATION_MODIFIER", 219, 226], ["T2DM", "OBSERVATION", 234, 238], ["atherosclerosis", "OBSERVATION", 244, 259], ["ATHEROSCLEROSIS", "OBSERVATION", 346, 361], ["atherosclerosis", "OBSERVATION", 425, 440], ["estrogen deficit", "OBSERVATION", 517, 533], ["amyloid disorders", "OBSERVATION", 559, 576]]], ["Initial biological mechanisms are rooted in human genomics.", [["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49]]], ["Eukaryotic DNA fragments implicated in genetic forms of late-life NDDs [mainly AP and PD] incorporated in the genome of potential commensal, symbiotic, and pathogenic microorganisms present in the human reservoir, i.e., E. coli and BP, constitute sequences resulting in pluripotential protein fibrils that are infective via the respiratory and gastrointestinal tract or by B lymphocyte presentation.", [["fragments", "ANATOMY", 15, 24], ["respiratory", "ANATOMY", 328, 339], ["gastrointestinal tract", "ANATOMY", 344, 366], ["B lymphocyte", "ANATOMY", 373, 385], ["respiratory and gastrointestinal tract", "DISEASE", 328, 366], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["NDDs", "GENE_OR_GENE_PRODUCT", 66, 70], ["AP", "GENE_OR_GENE_PRODUCT", 79, 81], ["human", "ORGANISM", 197, 202], ["E. coli", "ORGANISM", 220, 227], ["BP", "GENE_OR_GENE_PRODUCT", 232, 234], ["pluripotential protein fibrils", "GENE_OR_GENE_PRODUCT", 270, 300], ["gastrointestinal tract", "ORGAN", 344, 366], ["B lymphocyte", "CELL", 373, 385], ["Eukaryotic DNA fragments", "DNA", 0, 24], ["BP", "PROTEIN", 232, 234], ["pluripotential protein fibrils", "PROTEIN", 270, 300], ["human", "SPECIES", 197, 202], ["E. coli", "SPECIES", 220, 227], ["human", "SPECIES", 197, 202], ["E. coli", "SPECIES", 220, 227], ["Eukaryotic DNA fragments", "PROBLEM", 0, 24], ["AP and PD", "TREATMENT", 79, 88], ["pathogenic microorganisms", "PROBLEM", 156, 181], ["the human reservoir", "TREATMENT", 193, 212], ["E. coli", "PROBLEM", 220, 227], ["BP", "TEST", 232, 234], ["pluripotential protein fibrils", "PROBLEM", 270, 300], ["infective", "PROBLEM", 310, 319], ["the respiratory and gastrointestinal tract", "PROBLEM", 324, 366], ["DNA fragments", "OBSERVATION", 11, 24], ["pluripotential protein fibrils", "OBSERVATION", 270, 300], ["respiratory", "ANATOMY", 328, 339], ["gastrointestinal tract", "ANATOMY", 344, 366], ["lymphocyte presentation", "OBSERVATION", 375, 398]]], ["Some amyloid proteins such as APrP may additionally act parenterally by contact with human misfolded protein fibrils, generating rapid course sCNDD, such as sCJD, ALS, and some sRPNDds.", [["fibrils", "ANATOMY", 109, 116], ["APrP", "CHEMICAL", 30, 34], ["sCJD", "DISEASE", 157, 161], ["ALS", "DISEASE", 163, 166], ["amyloid proteins", "GENE_OR_GENE_PRODUCT", 5, 21], ["APrP", "GENE_OR_GENE_PRODUCT", 30, 34], ["human", "ORGANISM", 85, 90], ["amyloid proteins", "PROTEIN", 5, 21], ["APrP", "PROTEIN", 30, 34], ["human misfolded protein fibrils", "PROTEIN", 85, 116], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["Some amyloid proteins", "PROBLEM", 0, 21], ["APrP", "PROBLEM", 30, 34], ["human misfolded protein fibrils", "PROBLEM", 85, 116], ["sCJD", "PROBLEM", 157, 161], ["ALS", "PROBLEM", 163, 166], ["some sRPNDds", "PROBLEM", 172, 184], ["amyloid proteins", "OBSERVATION", 5, 21], ["protein fibrils", "OBSERVATION", 101, 116]]], ["Disease progression and spread through the central nervous system would follow reported anatomic patterns.", [["central nervous system", "ANATOMY", 43, 65], ["central nervous system", "ANATOMICAL_SYSTEM", 43, 65], ["Disease progression", "PROBLEM", 0, 19], ["spread through the central nervous system", "PROBLEM", 24, 65], ["central", "ANATOMY_MODIFIER", 43, 50], ["nervous", "ANATOMY", 51, 58]]], ["Early vascular-wall lesions determine the first steps in atherosclerotic plaque formation.", [["vascular-wall lesions", "ANATOMY", 6, 27], ["atherosclerotic plaque", "ANATOMY", 57, 79], ["atherosclerotic plaque", "DISEASE", 57, 79], ["vascular-wall lesions", "PATHOLOGICAL_FORMATION", 6, 27], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 57, 79], ["Early vascular-wall lesions", "PROBLEM", 0, 27], ["atherosclerotic plaque formation", "PROBLEM", 57, 89], ["vascular", "ANATOMY", 6, 14], ["wall", "ANATOMY_MODIFIER", 15, 19], ["lesions", "OBSERVATION", 20, 27], ["first steps", "OBSERVATION_MODIFIER", 42, 53], ["atherosclerotic", "OBSERVATION_MODIFIER", 57, 72], ["plaque", "OBSERVATION", 73, 79]]], ["Small-vessel and neuronal lesions frequently coexist.", [["Small-vessel", "ANATOMY", 0, 12], ["neuronal lesions", "ANATOMY", 17, 33], ["vessel", "MULTI-TISSUE_STRUCTURE", 6, 12], ["neuronal lesions", "CANCER", 17, 33], ["Small-vessel and neuronal lesions", "PROBLEM", 0, 33], ["-", "OBSERVATION_MODIFIER", 5, 6], ["vessel", "ANATOMY", 6, 12], ["neuronal", "ANATOMY", 17, 25], ["lesions", "OBSERVATION", 26, 33]]], ["The same pathogenic mechanisms may underlie some endocrine disorders.", [["endocrine", "ANATOMY", 49, 58], ["endocrine disorders", "DISEASE", 49, 68], ["endocrine", "ANATOMICAL_SYSTEM", 49, 58], ["some endocrine disorders", "PROBLEM", 44, 68], ["endocrine disorders", "OBSERVATION", 49, 68]]], ["Multiple degenerative disorders may share conformational pathophysiologic mechanisms linked to different, as yet unknown, UPR.", [["degenerative disorders", "DISEASE", 9, 31], ["UPR", "GENE_OR_GENE_PRODUCT", 122, 125], ["UPR", "PROTEIN", 122, 125], ["Multiple degenerative disorders", "PROBLEM", 0, 31], ["conformational pathophysiologic mechanisms", "PROBLEM", 42, 84], ["degenerative", "OBSERVATION", 9, 21]]], ["Latency intervals might frequently encompass decades. sCNDD epidemiologic patterns point to a high susceptibility in late-infancy and at juvenile ages.", [["a high susceptibility", "PROBLEM", 92, 113], ["high susceptibility", "OBSERVATION_MODIFIER", 94, 113]]], ["Risk and disease spread can be determined by the same factors, which constitute risk factors or biomarkers of disease progression, or both.", [["disease spread", "PROBLEM", 9, 23], ["disease progression", "PROBLEM", 110, 129], ["disease", "OBSERVATION", 9, 16]]], ["ER stressors and UPR-related pathology, particularly late in life, may display complex relationships, i.e., as seen for VRF, late-life sCNDD, atherosclerosis, and T2DM.", [["sCNDD", "DISEASE", 135, 140], ["atherosclerosis", "DISEASE", 142, 157], ["T2DM", "DISEASE", 163, 167], ["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["UPR", "GENE_OR_GENE_PRODUCT", 17, 20], ["ER", "PROTEIN", 0, 2], ["UPR", "PROTEIN", 17, 20], ["ER stressors", "TEST", 0, 12], ["UPR-related pathology", "PROBLEM", 17, 38], ["VRF", "PROBLEM", 120, 123], ["atherosclerosis", "PROBLEM", 142, 157], ["T2DM", "PROBLEM", 163, 167], ["atherosclerosis", "OBSERVATION", 142, 157], ["T2DM", "OBSERVATION", 163, 167]]], ["Incorporation of drivers 5,6, and 7 in the model seen in Figure 3 , would result in a comprehensive etiologic model presented in Figure 4 .IMPLICATIONS FOR RESEARCHComponents of the model seen in Figure 4 would have implications for cohort alignment and experimental animal research, as well as a for specific research outline proposals aimed to test fragments of the abovementioned hypothesis.Cohort AlignmentThe present view of sCNDD reinforces the notion of a set of neurodegenerative processes in which continuity as a form of overlap, and competition-earlier and more lethal NDDs, T2DM or vascular disease removing persons at high risk of other less lethal NDDs-act on the age axis.", [["vascular", "ANATOMY", 594, 602], ["NDDs", "DISEASE", 580, 584], ["T2DM", "DISEASE", 586, 590], ["vascular disease", "DISEASE", 594, 610], ["NDDs", "DISEASE", 662, 666], ["NDDs", "CANCER", 580, 584], ["vascular", "MULTI-TISSUE_STRUCTURE", 594, 602], ["persons", "ORGANISM", 620, 627], ["NDDs", "GENE_OR_GENE_PRODUCT", 662, 666], ["persons", "SPECIES", 620, 627], ["cohort alignment", "TEST", 233, 249], ["neurodegenerative processes", "PROBLEM", 470, 497], ["more lethal NDDs", "PROBLEM", 568, 584], ["T2DM", "PROBLEM", 586, 590], ["vascular disease", "PROBLEM", 594, 610], ["other less lethal NDDs", "PROBLEM", 644, 666], ["neurodegenerative", "OBSERVATION", 470, 487], ["vascular", "ANATOMY", 594, 602], ["disease", "OBSERVATION", 603, 610]]], ["Equivalent, observational, FIGURE 4 | Outline of an expanded Public Health Prevention Model II to Model III for various conformational neurodegenerative, vascular degenerative disorders and metabolic disorders (type 2 diabetes mellitus), assuming unfolded protein response acts as a consequence of at least two environmental causal mechanisms/agents, namely, infection/inflammation by human-adapted microbiome (examples for Bordetella pertussis (BP) and Escherichia coli) and invasive medical procedures.Cohort Alignmentproof-of-principle studies would correspond to investigations aimed at confirming that NDDs which are clinically and epidemiologically close by median age at onset, disease duration, age-specific normalized incidence profile and genetic type of change, share environmental risk factors.", [["vascular", "ANATOMY", 154, 162], ["vascular degenerative disorders", "DISEASE", 154, 185], ["metabolic disorders", "DISEASE", 190, 209], ["type 2 diabetes mellitus", "DISEASE", 211, 235], ["infection", "DISEASE", 359, 368], ["inflammation", "DISEASE", 369, 381], ["Bordetella pertussis", "DISEASE", 424, 444], ["vascular", "MULTI-TISSUE_STRUCTURE", 154, 162], ["human", "ORGANISM", 385, 390], ["Bordetella pertussis", "ORGANISM", 424, 444], ["BP", "MULTI-TISSUE_STRUCTURE", 446, 448], ["Escherichia coli", "ORGANISM", 454, 470], ["NDDs", "GENE_OR_GENE_PRODUCT", 607, 611], ["human", "SPECIES", 385, 390], ["Bordetella pertussis", "SPECIES", 424, 444], ["Escherichia coli", "SPECIES", 454, 470], ["human", "SPECIES", 385, 390], ["Bordetella pertussis", "SPECIES", 424, 444], ["Escherichia coli", "SPECIES", 454, 470], ["various conformational neurodegenerative, vascular degenerative disorders", "PROBLEM", 112, 185], ["metabolic disorders", "PROBLEM", 190, 209], ["type 2 diabetes mellitus", "PROBLEM", 211, 235], ["unfolded protein response acts", "PROBLEM", 247, 277], ["infection", "PROBLEM", 359, 368], ["inflammation", "PROBLEM", 369, 381], ["Bordetella pertussis", "PROBLEM", 424, 444], ["BP", "TEST", 446, 448], ["Escherichia coli", "PROBLEM", 454, 470], ["invasive medical procedures", "TREATMENT", 476, 503], ["principle studies", "TEST", 529, 546], ["investigations", "TEST", 567, 581], ["NDDs", "PROBLEM", 607, 611], ["disease duration", "PROBLEM", 685, 701], ["neurodegenerative", "OBSERVATION", 135, 152], ["vascular", "ANATOMY", 154, 162], ["degenerative", "OBSERVATION", 163, 175], ["metabolic disorders", "OBSERVATION", 190, 209], ["infection", "OBSERVATION", 359, 368], ["Escherichia coli", "OBSERVATION", 454, 470]]], ["The study of exposures in the first two decades of life would require approaches separated from that of the same exposures at later ages, with latency analyses being needed in both instances.", [["The study", "TEST", 0, 9], ["approaches", "TREATMENT", 70, 80], ["latency analyses", "TEST", 143, 159]]], ["Simultaneous approaches including two or more NDDs may be advantageous.", [["Simultaneous approaches", "TREATMENT", 0, 23]]], ["Different animal models have been developed to address various sCNDD, cardiovascular disease complications, and T2DM.", [["cardiovascular", "ANATOMY", 70, 84], ["sCNDD", "DISEASE", 63, 68], ["cardiovascular disease complications", "DISEASE", 70, 106], ["T2DM", "DISEASE", 112, 116], ["cardiovascular", "ANATOMICAL_SYSTEM", 70, 84], ["various sCNDD", "PROBLEM", 55, 68], ["cardiovascular disease complications", "PROBLEM", 70, 106], ["T2DM", "PROBLEM", 112, 116], ["cardiovascular", "ANATOMY", 70, 84], ["disease", "OBSERVATION", 85, 92]]], ["Models in mice targeting AD, tauopathies, and ALS are mainly based on transgenic methodologies, with those for PD and synucleinopathies being both toxic and transgenic.", [["AD, tauopathies", "DISEASE", 25, 40], ["ALS", "DISEASE", 46, 49], ["PD", "DISEASE", 111, 113], ["mice", "ORGANISM", 10, 14], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["tauopathies", "PROBLEM", 29, 40], ["ALS", "PROBLEM", 46, 49], ["transgenic methodologies", "TREATMENT", 70, 94], ["PD", "PROBLEM", 111, 113], ["synucleinopathies", "PROBLEM", 118, 135], ["synucleinopathies", "OBSERVATION", 118, 135], ["toxic", "OBSERVATION_MODIFIER", 147, 152]]], ["Animal models may exhibit a number of important limitations, mimicking phenotypic variants of AD and other sCNDD 1 .", [["AD", "DISEASE", 94, 96], ["AD", "PROBLEM", 94, 96]]], ["The validity of human drivers, i.e., age-at-exposure related susceptibility, may be tested in toxic animal models of NDD.Experimental Animal ResearchIn general, little attention has been paid to diseasenon-specific animal models based on seeding of naturally produced amyloid fibrils, such as those generated by Sup35 from Saccharomyces cerevisiae, and curli from E. coli which exert amyloid-accelerating influences in experimental murine amyloidosis (Lundmark et al., 2005) .", [["fibrils", "ANATOMY", 276, 283], ["NDD", "DISEASE", 117, 120], ["amyloidosis", "DISEASE", 439, 450], ["human", "ORGANISM", 16, 21], ["NDD", "CANCER", 117, 120], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 268, 283], ["Sup35", "GENE_OR_GENE_PRODUCT", 312, 317], ["Saccharomyces cerevisiae", "ORGANISM", 323, 347], ["curli", "GENE_OR_GENE_PRODUCT", 353, 358], ["E. coli", "ORGANISM", 364, 371], ["murine", "ORGANISM", 432, 438], ["Sup35", "PROTEIN", 312, 317], ["human", "SPECIES", 16, 21], ["Saccharomyces cerevisiae", "SPECIES", 323, 347], ["E. coli", "SPECIES", 364, 371], ["murine", "SPECIES", 432, 438], ["human", "SPECIES", 16, 21], ["Saccharomyces cerevisiae", "SPECIES", 323, 347], ["E. coli", "SPECIES", 364, 371], ["NDD", "PROBLEM", 117, 120], ["amyloid fibrils", "PROBLEM", 268, 283], ["Saccharomyces cerevisiae", "TREATMENT", 323, 347], ["E. coli", "PROBLEM", 364, 371], ["amyloid", "PROBLEM", 384, 391], ["experimental murine amyloidosis", "PROBLEM", 419, 450], ["amyloid fibrils", "OBSERVATION", 268, 283], ["amyloid", "OBSERVATION", 384, 391], ["experimental murine amyloidosis", "OBSERVATION", 419, 450]]], ["In contrast, the validity of traditional approaches is extensively considered in diseaseoriented media.", [["traditional approaches", "TREATMENT", 29, 51]]], ["A human driver-1-related, ApoE -/-mouse model, is that which best fits the study of arteriosclerosis and diabetes-accelerated arteriosclerosis (Zaragoza et al., 2011) .", [["arteriosclerosis", "DISEASE", 84, 100], ["diabetes", "DISEASE", 105, 113], ["arteriosclerosis", "DISEASE", 126, 142], ["human", "ORGANISM", 2, 7], ["driver-1", "GENE_OR_GENE_PRODUCT", 8, 16], ["ApoE", "GENE_OR_GENE_PRODUCT", 26, 30], ["mouse", "ORGANISM", 34, 39], ["ApoE", "PROTEIN", 26, 30], ["human", "SPECIES", 2, 7], ["mouse", "SPECIES", 34, 39], ["human", "SPECIES", 2, 7], ["A human driver", "TEST", 0, 14], ["the study", "TEST", 71, 80], ["arteriosclerosis", "PROBLEM", 84, 100], ["diabetes", "PROBLEM", 105, 113], ["accelerated arteriosclerosis", "PROBLEM", 114, 142], ["arteriosclerosis", "OBSERVATION", 84, 100], ["diabetes", "OBSERVATION", 105, 113], ["arteriosclerosis", "OBSERVATION", 126, 142]]], ["A similar feature displays the male-mouse castration model of PD (Khasnavis et al., 2013) .", [["PD", "DISEASE", 62, 64], ["mouse", "ORGANISM", 36, 41], ["mouse", "SPECIES", 36, 41]]], ["It would appear that the most valid NDD models are the genetically-modified, cell and animal models of AD, PD, FTD, and ALS, all of which are based on the mutations described in the familial NDD forms 2 .", [["cell", "ANATOMY", 77, 81], ["AD", "DISEASE", 103, 105], ["PD", "DISEASE", 107, 109], ["FTD", "DISEASE", 111, 114], ["ALS", "DISEASE", 120, 123], ["NDD", "DISEASE", 191, 194], ["cell", "CELL", 77, 81], ["the most valid NDD models", "PROBLEM", 21, 46], ["PD", "TEST", 107, 109], ["FTD", "PROBLEM", 111, 114], ["ALS", "PROBLEM", 120, 123], ["the mutations", "PROBLEM", 151, 164]]], ["A research goal in the experimental model context might be the identification of key elements underlying an environmentally modified, potential effect of human genes, similar to that shown by laboratory experiments on NDDs, T2DM and atherosclerosis with traditional models.Experimental Animal ResearchSpecific attempts to combine population and clinical cohorts/registries able to trace human events determining current disease might be a priority, particularly if: (a) such events can be identified by drivers; and (b) agents, similar to natural fibrils used in seeding models reproducing amyloid disease including NDDs, can be identified from historical sources, banks or libraries.NOTIONS FOR RESEARCH FRAMEWORK DEVELOPMENT EpidemiologyTraditionally, neuroepidemiologists have been used to working with surveys or cohorts geographically settled close to their residence.", [["fibrils", "ANATOMY", 547, 554], ["T2DM", "DISEASE", 224, 228], ["atherosclerosis", "DISEASE", 233, 248], ["amyloid disease", "DISEASE", 590, 605], ["NDDs", "DISEASE", 616, 620], ["human", "ORGANISM", 154, 159], ["human", "ORGANISM", 387, 392], ["human genes", "DNA", 154, 165], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 387, 392], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 387, 392], ["NDDs", "PROBLEM", 218, 222], ["T2DM", "PROBLEM", 224, 228], ["atherosclerosis", "PROBLEM", 233, 248], ["clinical cohorts/registries", "TREATMENT", 345, 372], ["trace human events", "PROBLEM", 381, 399], ["current disease", "PROBLEM", 412, 427], ["agents", "TREATMENT", 520, 526], ["natural fibrils", "TREATMENT", 539, 554], ["amyloid disease", "PROBLEM", 590, 605], ["NDDs", "PROBLEM", 616, 620], ["atherosclerosis", "OBSERVATION", 233, 248], ["amyloid disease", "OBSERVATION", 590, 605]]], ["As a novelty, assessment and alignment of cohorts for specific research purposes might be done for the first time with a high number of population or clinical cohorts gathered and offered as a potentially shared research resource 3 .", [["assessment", "TEST", 14, 24], ["specific research purposes", "TEST", 54, 80]]], ["On the basis of best clinical and epidemiologic practice, research into this avenue mighty advantageously address the etiology of and risk factors for sporadic forms of CJD, sRPNDd, MND, MSA, LBD, FTD, PD, AD, and AMD.", [["CJD", "DISEASE", 169, 172], ["MND", "DISEASE", 182, 185], ["MSA", "DISEASE", 187, 190], ["FTD", "DISEASE", 197, 200], ["PD", "DISEASE", 202, 204], ["AD", "DISEASE", 206, 208], ["AMD", "DISEASE", 214, 217], ["CJD", "PROBLEM", 169, 172], ["sRPNDd", "PROBLEM", 174, 180], ["MND", "PROBLEM", 182, 185], ["MSA", "PROBLEM", 187, 190], ["LBD", "PROBLEM", 192, 195], ["FTD", "PROBLEM", 197, 200], ["PD", "PROBLEM", 202, 204], ["AD", "PROBLEM", 206, 208], ["AMD", "PROBLEM", 214, 217], ["LBD", "ANATOMY", 192, 195]]], ["Only a few populations in the world would allow for such field studies.", [["such field studies", "TEST", 52, 70], ["few", "OBSERVATION_MODIFIER", 7, 10], ["populations", "OBSERVATION", 11, 22]]], ["To avoid misclassification of outcomes (subclinically affected controls), studies on the very old should be extremely cautious.NOTIONS FOR RESEARCH FRAMEWORK DEVELOPMENT EpidemiologyPossible factors to be weighted when considering favorable research environments are:NOTIONS FOR RESEARCH FRAMEWORK DEVELOPMENT Epidemiology\u2022 Populations with registered data on both sRPNDd and sCJD tend to be large countries where CJD surveillance has been conducted for decades, and NDD-as well as CJD-free clinical controls have been registered. \u2022 Medical procedures can be advantageously studied in countries with national health services that provide health care for the majority of their citizens. \u2022 Controls randomly selected from annual population registries are paramount for studies on risk from medical procedures. \u2022 Historically, populations exposed to agents producing point-source epidemics which are considerably separated in time and act on the young population, have been those that are geographically isolated with ancient native populations <200,000.", [["sCJD", "DISEASE", 376, 380], ["CJD", "DISEASE", 414, 417], ["CJD", "DISEASE", 482, 485], ["misclassification of outcomes (subclinically affected controls", "PROBLEM", 9, 71], ["EpidemiologyPossible factors", "PROBLEM", 170, 198], ["sCJD", "PROBLEM", 376, 380], ["CJD surveillance", "TEST", 414, 430], ["NDD", "TEST", 467, 470], ["CJD", "PROBLEM", 482, 485], ["Medical procedures", "TREATMENT", 533, 551], ["health care", "TREATMENT", 638, 649], ["medical procedures", "TREATMENT", 788, 806], ["agents", "TREATMENT", 847, 853], ["epidemics", "PROBLEM", 877, 886], ["native", "OBSERVATION_MODIFIER", 1023, 1029], ["populations", "OBSERVATION_MODIFIER", 1030, 1041]]], ["A minimum size or pooled study would be required for substantial incidence counts of late-life NDDs.", [["NDDs", "DISEASE", 95, 99], ["A minimum size", "TEST", 0, 14], ["pooled study", "TEST", 18, 30], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["Study populations of this nature are to be found in Iceland, New Caledonia, San Miguel in the Azores (Aleixo-Dias et al., 1993) , and a few other islands. \u2022 In order to reveal the causal nature of specific associations, it might be advantageous to study the synergistic effects observed between environmental exposures and selected recognized genetic risk factors for different entities.Experimental WorkResearch of this nature might encompass:Experimental Work\u2022 Identification of potential agents (well adapted, small genome) with biological samples in potential vector libraries worldwide, in cases where such agents are implicated in NDD incident in high-risk cohorts; \u2022 In silico identification of human genome fragments in vectors exhibiting curly or natural fibrils potentially involved in NDD induction, as seen from analysis of specific cohorts; \u2022 Protein aggregate characterization in biological samples (bacteria, etc.), work with biofilms; and, \u2022 development of animal models of defined or undefined amyloid disorders, based on the seeding of natural fibrils potentially involved in NDD induction.AUTHOR CONTRIBUTIONSJdP-C conceived and coordinated the study, analyzed literature, wrote first manuscript version.", [["samples", "ANATOMY", 543, 550], ["fragments", "ANATOMY", 715, 724], ["fibrils", "ANATOMY", 764, 771], ["samples", "ANATOMY", 905, 912], ["fibrils", "ANATOMY", 1062, 1069], ["NDD", "DISEASE", 637, 640], ["amyloid disorders", "DISEASE", 1011, 1028], ["human", "ORGANISM", 702, 707], ["NDD", "CANCER", 1094, 1097], ["human genome fragments", "DNA", 702, 724], ["human", "SPECIES", 702, 707], ["human", "SPECIES", 702, 707], ["potential agents", "TREATMENT", 481, 497], ["human genome fragments in vectors", "PROBLEM", 702, 735], ["curly or natural fibrils", "PROBLEM", 747, 771], ["Protein aggregate characterization", "TEST", 856, 890], ["biological samples", "TEST", 894, 912], ["bacteria", "PROBLEM", 914, 922], ["undefined amyloid disorders", "PROBLEM", 1001, 1028], ["natural fibrils", "PROBLEM", 1054, 1069], ["NDD induction", "TREATMENT", 1094, 1107], ["the study", "TEST", 1160, 1169], ["New", "OBSERVATION_MODIFIER", 61, 64], ["Caledonia", "OBSERVATION", 65, 74], ["few", "OBSERVATION_MODIFIER", 136, 139], ["islands", "OBSERVATION", 146, 153], ["human genome fragments", "OBSERVATION", 702, 724], ["natural fibrils", "OBSERVATION", 756, 771], ["amyloid disorders", "OBSERVATION", 1011, 1028], ["natural fibrils", "OBSERVATION", 1054, 1069]]], ["AR contributed with neuropathology literature and comments.", [["AR", "GENE_OR_GENE_PRODUCT", 0, 2], ["AR", "PROTEIN", 0, 2], ["AR", "PROBLEM", 0, 2]]], ["MR-T revised aspects on prion disorders and provided comments.", [["prion disorders", "DISEASE", 24, 39], ["MR", "PROTEIN", 0, 2], ["MR", "TEST", 0, 2], ["prion disorders", "PROBLEM", 24, 39]]], ["All authors read and approved the final manuscript version.FUNDINGFunding was received from the Consortium for Biomedical Research in Neurodegenerative Diseases (Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas/CIBERNED) as part of the 2014-2015 annual budget of the CIBERNED 509-group, and from the Carlos III Institute of Health (PI12/00045).", [["Neurodegenerative Diseases", "DISEASE", 134, 160], ["Neurodegenerative Diseases", "PROBLEM", 134, 160], ["Neurodegenerative Diseases", "OBSERVATION", 134, 160]]], ["The study was partially supported by a grant from the EU Joint Program-Neurodegenerative Disease Research (JPND-DEMTEST (Spanish Health Research Fund, FIS PI11/03021)).", [["Neurodegenerative Disease", "DISEASE", 71, 96], ["The study", "TEST", 0, 9], ["Neurodegenerative Disease", "PROBLEM", 71, 96], ["Joint", "ANATOMY", 57, 62], ["Neurodegenerative", "OBSERVATION_MODIFIER", 71, 88], ["Disease", "OBSERVATION", 89, 96]]], ["The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.", [["data collection", "TEST", 41, 56], ["analysis", "TEST", 61, 69], ["no", "UNCERTAINTY", 16, 18]]], ["No author other than EAC received specific funding for this work.", [["EAC", "CANCER", 21, 24]]]], "b471ce94ef2b6b092f803db29f4836b1375941a9": [["The World Health Organization has estimated that in 2011 there were 1,400,000 deaths due to tuberculosis, 1,200,000 deaths due to HIV/AIDS, and 627,000 deaths due to malaria (but other sources have estimated the number of malaria deaths to be more than 1,000,000).", [["deaths", "DISEASE", 78, 84], ["tuberculosis", "DISEASE", 92, 104], ["deaths", "DISEASE", 116, 122], ["HIV/AIDS", "DISEASE", 130, 138], ["deaths", "DISEASE", 152, 158], ["malaria", "DISEASE", 166, 173], ["malaria", "DISEASE", 222, 229], ["deaths", "DISEASE", 230, 236], ["HIV", "SPECIES", 130, 133], ["HIV", "SPECIES", 130, 133], ["tuberculosis", "PROBLEM", 92, 104], ["HIV/AIDS", "PROBLEM", 130, 138], ["malaria", "PROBLEM", 166, 173], ["malaria deaths", "PROBLEM", 222, 236], ["tuberculosis", "OBSERVATION", 92, 104], ["malaria", "OBSERVATION", 166, 173]]], ["In short, HIV, malaria, and TB account for at least 9,000 deaths each day.", [["HIV, malaria", "DISEASE", 10, 22], ["TB", "DISEASE", 28, 30], ["deaths", "DISEASE", 58, 64], ["HIV", "SPECIES", 10, 13], ["HIV", "SPECIES", 10, 13], ["HIV", "PROBLEM", 10, 13], ["malaria", "PROBLEM", 15, 22], ["TB", "PROBLEM", 28, 30], ["short", "OBSERVATION_MODIFIER", 3, 8], ["malaria", "OBSERVATION", 15, 22]]], ["The impact of vaccines can be dramatic, for example, there were 2,600,000 deaths due to measles in 1980 but only 160,000 by 2011.", [["deaths", "DISEASE", 74, 80], ["measles", "DISEASE", 88, 95], ["vaccines", "TREATMENT", 14, 22], ["measles", "PROBLEM", 88, 95]]], ["The development and availability of the measles vaccine led to a reduction in the number of deaths due to this childhood disease of nearly 94%.", [["deaths", "DISEASE", 92, 98], ["the measles vaccine", "TREATMENT", 36, 55], ["a reduction", "TREATMENT", 63, 74], ["this childhood disease", "PROBLEM", 106, 128]]]], "PMC7333599": [["INTRODUCTIONThe coronavirus disease 2019 (COVID-19) epidemic is caused by an infection with a novel coronavirus, officially named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)1.", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["infection", "DISEASE", 77, 86], ["coronavirus", "DISEASE", 100, 111], ["acute respiratory syndrome coronavirus", "DISEASE", 137, 175], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["coronavirus", "SPECIES", 100, 111], ["severe acute respiratory syndrome coronavirus", "SPECIES", 130, 175], ["SARS-COV-2)1", "SPECIES", 179, 191], ["coronavirus disease", "PROBLEM", 16, 35], ["COVID", "TEST", 42, 47], ["epidemic", "PROBLEM", 52, 60], ["an infection", "PROBLEM", 74, 86], ["a novel coronavirus", "PROBLEM", 92, 111], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 130, 175], ["SARS", "TEST", 179, 183], ["COV", "TEST", 184, 187], ["coronavirus disease", "OBSERVATION", 16, 35], ["infection", "OBSERVATION", 77, 86], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["respiratory syndrome", "OBSERVATION", 143, 163]]], ["The infection spread rapidly on all continents and was declared a pandemic by the World Health Organization.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["spread", "OBSERVATION_MODIFIER", 14, 20], ["rapidly", "OBSERVATION_MODIFIER", 21, 28]]], ["As of April 28, 2020, 2,977,294 documented cases were reported worldwide, and 207,086 patients had died.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["As there are currently no specific treatments and medications against the new virus, it is crucial to identify risk factors of severe prognosis.INTRODUCTIONOlder patients have poorer prognostic factors and are more likely to experience critical disease2,3.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["specific treatments", "TREATMENT", 26, 45], ["medications", "TREATMENT", 50, 61], ["the new virus", "PROBLEM", 70, 83], ["severe prognosis", "PROBLEM", 127, 143], ["poorer prognostic factors", "PROBLEM", 176, 201], ["critical disease2,3", "PROBLEM", 236, 255], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["Based on recent statistical data of China, among patients who were 65 years and older, the mortality rate was 34.5%, which was significantly higher than that of younger patients at 4.7%4.", [["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 169, 177], ["the mortality rate", "TEST", 87, 105]]], ["The proportion of deaths over 60 years old accounts for 81% of the total deaths in the national wide, which implicates aged people are more vulnerable to the SARS-CoV-25.", [["deaths", "DISEASE", 18, 24], ["deaths", "DISEASE", 73, 79], ["SARS", "DISEASE", 158, 162], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["SARS-CoV-25", "SPECIES", 158, 169], ["the SARS", "TEST", 154, 162], ["CoV", "TEST", 163, 166]]], ["Till present there are rare reports in literature focusing on the risk factors for poor outcomes of the elderly patients with COVID-19.INTRODUCTIONSerum prealbumin, known as transthyretin, its levels may be lowered not only by malnutrition, but also by inflammation and aging6,7.", [["COVID-19.INTRODUCTIONSerum", "CHEMICAL", 126, 152], ["malnutrition", "DISEASE", 227, 239], ["inflammation", "DISEASE", 253, 265], ["patients", "ORGANISM", 112, 120], ["COVID-19.INTRODUCTIONSerum prealbumin", "GENE_OR_GENE_PRODUCT", 126, 163], ["transthyretin", "GENE_OR_GENE_PRODUCT", 174, 187], ["transthyretin", "PROTEIN", 174, 187], ["patients", "SPECIES", 112, 120], ["COVID", "TEST", 126, 131], ["prealbumin", "TREATMENT", 153, 163], ["transthyretin", "TEST", 174, 187], ["malnutrition", "PROBLEM", 227, 239], ["inflammation", "PROBLEM", 253, 265], ["malnutrition", "OBSERVATION", 227, 239], ["inflammation", "OBSERVATION", 253, 265]]], ["Compared to albumin, prealbumin has a shorter half-life, a more rapid rate of hepatic synthesis, and predictable catabolic rate; hence, it may be a more sensitive indicator8.", [["hepatic", "ANATOMY", 78, 85], ["albumin", "GENE_OR_GENE_PRODUCT", 12, 19], ["prealbumin", "GENE_OR_GENE_PRODUCT", 21, 31], ["hepatic", "MULTI-TISSUE_STRUCTURE", 78, 85], ["albumin", "PROTEIN", 12, 19], ["albumin", "TEST", 12, 19], ["prealbumin", "TEST", 21, 31], ["hepatic synthesis", "PROBLEM", 78, 95], ["predictable catabolic rate", "PROBLEM", 101, 127], ["hepatic", "ANATOMY", 78, 85], ["synthesis", "OBSERVATION", 86, 95]]], ["However, whether prealbumin could be an independent predictor of mortality in hospitalized COVID-19 elderly patients needs to be further elucidated.INTRODUCTIONThe present study aims to describe the clinical characteristics and to investigate whether the prealbumin can serve as a valuable predictor of in-hospital mortality, which might provide evidence for the risk stratification in elderly and help to improve the clinical practice and reduce fatality.Study design and participants ::: MethodsWe designed this study as a retrospective cohort study design.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 17, 27], ["patients", "ORGANISM", 108, 116], ["prealbumin", "GENE_OR_GENE_PRODUCT", 255, 265], ["prealbumin", "PROTEIN", 17, 27], ["prealbumin", "PROTEIN", 255, 265], ["patients", "SPECIES", 108, 116], ["participants", "SPECIES", 473, 485], ["prealbumin", "TEST", 17, 27], ["The present study", "TEST", 160, 177], ["the prealbumin", "TEST", 251, 265], ["Methods", "TREATMENT", 490, 497], ["this study", "TEST", 509, 519], ["a retrospective cohort study", "TEST", 523, 551]]], ["The elderly patients with COVID-19 who were admitted to Tongji Hospital in Wuhan from January 17 to February 17, 2020 were consecutively included.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["This study was approved by the Medical Ethics Committee of Tongji Hospital (Approval Number: TJ-IRB20200328), and was complied with the Declaration of Helsinki.", [["This study", "TEST", 0, 10]]], ["The data were anonymous and the study was observational, so the informed consent was not gathered.", [["the study", "TEST", 28, 37]]], ["A flow-diagram illustrating patient selection was described in Figure 1.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["A flow-diagram", "TEST", 0, 14]]], ["Inclusion criteria included elderly patients (\u2265 65 years old) diagnosed with COVID-19 infection.", [["COVID-19", "CHEMICAL", 77, 85], ["infection", "DISEASE", 86, 95], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["COVID-19 infection", "PROBLEM", 77, 95], ["infection", "OBSERVATION", 86, 95]]], ["A total of 893 participants have been obtained.", [["participants", "ORGANISM", 15, 27], ["participants", "SPECIES", 15, 27]]], ["Patients having missing baseline or outcome data, died on admission or being transferred to other designated hospitals during hospitalization were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["There were 446 patients were included in the final analyses.Data collection ::: MethodsData collection of participants was performed using hospital electronic medical record system.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["participants", "SPECIES", 106, 118], ["the final analyses", "TEST", 41, 59]]], ["Information included medical history, demographic data, physical examination, and hematological, biochemical, radiological and microbiological evaluation results were reviewed.", [["demographic data", "TEST", 38, 54], ["physical examination", "TEST", 56, 76], ["microbiological evaluation", "TEST", 127, 153]]], ["The data collection forms were reviewed independently by 2 researchers (CL and LYY).", [["The data collection", "TEST", 0, 19]]], ["Blood examinations were assessed at the central laboratory of Tongji Hospital following standard operative procedures.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood examinations", "TEST", 0, 18], ["standard operative procedures", "TREATMENT", 88, 117]]], ["The routine blood test was analyzed using Sysmex XE-2100 hematology analyzer (Sysmex, Kobe, Japan).", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["The routine blood test", "TEST", 0, 22], ["Sysmex XE", "TEST", 42, 51], ["Sysmex", "TEST", 78, 84]]], ["The Cobas C8000 (Roche, Mannheim, Germany) was used to measure the biochemical parameters.", [["The Cobas C8000", "TEST", 0, 15]]], ["Coagulation tests were detected by STA-R MAX coagulation analyzer (Diagnostica Stago, Saint-Denis, France).", [["Coagulation tests", "TEST", 0, 17], ["STA", "TEST", 35, 38], ["coagulation analyzer", "TEST", 45, 65]]], ["Throat swab samples were collected and were tested for SARS-CoV-2 with commercial real-time reverse transcription polymerase chain reaction (RT-PCR) kit from DAAN GENE (Guangzhou, China)9.", [["Throat swab samples", "ANATOMY", 0, 19], ["Throat swab samples", "ORGANISM_SUBSTANCE", 0, 19], ["SARS-CoV", "SPECIES", 55, 63], ["Throat swab samples", "TEST", 0, 19], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["chain reaction", "TEST", 125, 139]]], ["The diagnostic criteria and all clinical procedures in this study followed \u201cDiagnosis and Treatment of Pneumonia Caused by New Coronavirus (Trial version 1 to 7) promulgated by the National Health and Health Commission of China.Statistical analysis ::: MethodsSummary statistics of baseline characteristics of all patients and stratification by prealbumin tertiles were expressed as frequency and proportion for categorical variables, mean \u00b1 standard deviation (SD) (Gaussian distribution) or median (range) (Skewed distribution) for continuous variables, and as percentages for categorical variables.", [["Pneumonia", "DISEASE", 103, 112], ["patients", "ORGANISM", 314, 322], ["prealbumin", "GENE_OR_GENE_PRODUCT", 345, 355], ["prealbumin", "PROTEIN", 345, 355], ["patients", "SPECIES", 314, 322], ["all clinical procedures", "TEST", 28, 51], ["this study", "TEST", 55, 65], ["Pneumonia", "PROBLEM", 103, 112], ["New Coronavirus (Trial version", "TREATMENT", 123, 153], ["prealbumin tertiles", "TEST", 345, 364], ["categorical variables", "TEST", 412, 433], ["mean \u00b1 standard deviation (SD) (Gaussian distribution)", "PROBLEM", 435, 489], ["continuous variables", "TEST", 534, 554], ["Pneumonia", "OBSERVATION", 103, 112], ["New", "OBSERVATION_MODIFIER", 123, 126], ["Coronavirus", "OBSERVATION", 127, 138]]], ["The differences between groups were analyzed using the \u03c72 (categorical variables), One-Way ANOVA test (normal distribution), or Kruskal-Whallis H test (skewed distribution).Statistical analysis ::: MethodsWe examined the relationship of the prealbumin as categorized into tertiles with the outcomes of all-cause death, ICU admission and mechanical ventilation.", [["death", "DISEASE", 312, 317], ["prealbumin", "GENE_OR_GENE_PRODUCT", 241, 251], ["prealbumin", "PROTEIN", 241, 251], ["One-Way ANOVA test", "TEST", 83, 101], ["Kruskal", "TEST", 128, 135], ["the prealbumin", "TEST", 237, 251], ["mechanical ventilation", "TREATMENT", 337, 359], ["mechanical ventilation", "OBSERVATION", 337, 359]]], ["Univariate and multivariate logistic regression models were used to evaluate these relationships, then unadjusted and adjusted odds ratio (ORs) and 95% confidence intervals (CIs) were calculated.", [["Univariate", "TREATMENT", 0, 10], ["multivariate logistic regression models", "TREATMENT", 15, 54], ["CIs", "TEST", 174, 177]]], ["Model 2 is the fully-adjusted model with covariates including age, sex, smoking status, history of hypertension, history of coronary heart disease, history of diabetes, history of chronic kidney disease, history of carcinoma, history of chronic liver disease, neutrophil, lymphocyte, prothrombin time, activated partial thromboplastin time, d-dimer, alanine transaminase, aspartate aminotransferase, total bilirubin, blood urea nitrogen, creatinine, C-reactive protein and neutrophil-to-lymphocyte ratio.", [["coronary", "ANATOMY", 124, 132], ["heart", "ANATOMY", 133, 138], ["kidney", "ANATOMY", 188, 194], ["carcinoma", "ANATOMY", 215, 224], ["liver", "ANATOMY", 245, 250], ["neutrophil", "ANATOMY", 260, 270], ["lymphocyte", "ANATOMY", 272, 282], ["blood", "ANATOMY", 417, 422], ["neutrophil", "ANATOMY", 473, 483], ["lymphocyte", "ANATOMY", 487, 497], ["hypertension", "DISEASE", 99, 111], ["coronary heart disease", "DISEASE", 124, 146], ["diabetes", "DISEASE", 159, 167], ["chronic kidney disease", "DISEASE", 180, 202], ["carcinoma", "DISEASE", 215, 224], ["chronic liver disease", "DISEASE", 237, 258], ["alanine", "CHEMICAL", 350, 357], ["aspartate", "CHEMICAL", 372, 381], ["bilirubin", "CHEMICAL", 406, 415], ["blood urea nitrogen", "CHEMICAL", 417, 436], ["creatinine", "CHEMICAL", 438, 448], ["alanine", "CHEMICAL", 350, 357], ["aspartate", "CHEMICAL", 372, 381], ["bilirubin", "CHEMICAL", 406, 415], ["urea", "CHEMICAL", 423, 427], ["nitrogen", "CHEMICAL", 428, 436], ["creatinine", "CHEMICAL", 438, 448], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 124, 138], ["kidney", "ORGAN", 188, 194], ["carcinoma", "CANCER", 215, 224], ["liver", "ORGAN", 245, 250], ["neutrophil", "CELL", 260, 270], ["lymphocyte", "CELL", 272, 282], ["prothrombin", "GENE_OR_GENE_PRODUCT", 284, 295], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 320, 334], ["d-dimer", "SIMPLE_CHEMICAL", 341, 348], ["alanine", "AMINO_ACID", 350, 357], ["transaminase", "GENE_OR_GENE_PRODUCT", 358, 370], ["aspartate", "SIMPLE_CHEMICAL", 372, 381], ["aminotransferase", "SIMPLE_CHEMICAL", 382, 398], ["bilirubin", "SIMPLE_CHEMICAL", 406, 415], ["blood", "ORGANISM_SUBSTANCE", 417, 422], ["urea", "SIMPLE_CHEMICAL", 423, 427], ["creatinine", "SIMPLE_CHEMICAL", 438, 448], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 450, 468], ["neutrophil", "CELL", 473, 483], ["lymphocyte", "CELL", 487, 497], ["neutrophil", "CELL_TYPE", 260, 270], ["prothrombin", "PROTEIN", 284, 295], ["d-dimer", "PROTEIN", 341, 348], ["alanine transaminase", "PROTEIN", 350, 370], ["aspartate aminotransferase", "PROTEIN", 372, 398], ["C-reactive protein", "PROTEIN", 450, 468], ["neutrophil", "CELL_TYPE", 473, 483], ["hypertension", "PROBLEM", 99, 111], ["coronary heart disease", "PROBLEM", 124, 146], ["diabetes", "PROBLEM", 159, 167], ["chronic kidney disease", "PROBLEM", 180, 202], ["carcinoma", "PROBLEM", 215, 224], ["chronic liver disease", "PROBLEM", 237, 258], ["neutrophil", "TEST", 260, 270], ["lymphocyte", "TEST", 272, 282], ["prothrombin time", "TEST", 284, 300], ["activated partial thromboplastin time", "PROBLEM", 302, 339], ["d-dimer", "PROBLEM", 341, 348], ["alanine transaminase", "TEST", 350, 370], ["aspartate aminotransferase", "TEST", 372, 398], ["total bilirubin", "TEST", 400, 415], ["blood urea nitrogen", "TEST", 417, 436], ["creatinine", "TEST", 438, 448], ["C", "TEST", 450, 451], ["reactive protein", "TEST", 452, 468], ["neutrophil", "TEST", 473, 483], ["lymphocyte ratio", "TEST", 487, 503], ["hypertension", "OBSERVATION", 99, 111], ["coronary heart", "ANATOMY", 124, 138], ["disease", "OBSERVATION", 139, 146], ["diabetes", "OBSERVATION", 159, 167], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["kidney", "ANATOMY", 188, 194], ["disease", "OBSERVATION", 195, 202], ["carcinoma", "OBSERVATION", 215, 224], ["chronic", "OBSERVATION_MODIFIER", 237, 244], ["liver", "ANATOMY", 245, 250], ["disease", "OBSERVATION", 251, 258], ["neutrophil", "ANATOMY_MODIFIER", 260, 270], ["lymphocyte", "ANATOMY", 272, 282], ["partial", "OBSERVATION_MODIFIER", 312, 319], ["thromboplastin time", "OBSERVATION", 320, 339], ["reactive protein", "OBSERVATION", 452, 468]]], ["The highest tertile was the reference for prealbumin.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 42, 52], ["prealbumin", "PROTEIN", 42, 52], ["prealbumin", "TEST", 42, 52]]], ["We performed test for linear trend by entering the median value of each category of prealbumin tertile as continuous variable to examine the possibility of nonlinearity.Statistical analysis ::: MethodsTo ensure the robustness of our results, we also performed stratified analyses with the prealbumin as a continuous variable for the overall population and stratified by gender, age, hypertension status and coronary heart disease status at baseline.", [["coronary", "ANATOMY", 407, 415], ["heart", "ANATOMY", 416, 421], ["hypertension", "DISEASE", 383, 395], ["coronary heart disease", "DISEASE", 407, 429], ["prealbumin", "GENE_OR_GENE_PRODUCT", 84, 94], ["prealbumin", "GENE_OR_GENE_PRODUCT", 289, 299], ["coronary", "MULTI-TISSUE_STRUCTURE", 407, 415], ["heart", "ORGAN", 416, 421], ["prealbumin", "PROTEIN", 84, 94], ["prealbumin", "PROTEIN", 289, 299], ["test", "TEST", 13, 17], ["prealbumin tertile", "TEST", 84, 102], ["Methods", "TREATMENT", 194, 201], ["the prealbumin", "TREATMENT", 285, 299], ["hypertension status", "PROBLEM", 383, 402], ["coronary heart disease status", "PROBLEM", 407, 436], ["hypertension", "OBSERVATION", 383, 395], ["coronary", "ANATOMY", 407, 415], ["heart", "ANATOMY", 416, 421], ["disease", "OBSERVATION", 422, 429]]], ["Generalized additive models were used to visually confirm the relationship between prealbumin as continuous variable and the risk of outcomes (all-cause death, ICU admission and mechanical ventilation).Statistical analysis ::: MethodsModeling was performed with the statistical software packages R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc, Boston, MA).", [["death", "DISEASE", 153, 158], ["prealbumin", "GENE_OR_GENE_PRODUCT", 83, 93], ["prealbumin", "PROTEIN", 83, 93], ["Generalized additive models", "PROBLEM", 0, 27], ["prealbumin", "TREATMENT", 83, 93], ["death", "PROBLEM", 153, 158], ["mechanical ventilation", "TREATMENT", 178, 200], ["EmpowerStats", "TREATMENT", 347, 359]]], ["P values less than 0.05 (two-sided) were considered statistically significant.Missing data addressing ::: MethodsIn our study, 447 cases were excluded.", [["P values", "TEST", 0, 8], ["our study", "TEST", 116, 125], ["significant", "OBSERVATION_MODIFIER", 66, 77]]], ["To avoid selection bias due to missing data, we performed a sensitivity analysis.", [["a sensitivity analysis", "TEST", 58, 80]]], ["The results showed that there was no statistical difference between missing group and non-missing group (supplemental table 1).RESULTSOf 446 elderly inpatients included in the final analysis, the mean age was 72.95 (6.39) years, ranging from 65 years to 95 years, and most patients were male (table 1).", [["inpatients", "ORGANISM", 149, 159], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["no", "UNCERTAINTY", 34, 36]]], ["The baseline characteristics of these included participants were listed in table1.", [["participants", "ORGANISM", 47, 59], ["table1", "DNA", 75, 81], ["participants", "SPECIES", 47, 59]]], ["The day of sample drawing after admission was 0.67 \u00b1 0.65 day.", [["sample", "ANATOMY", 11, 17]]], ["No significant statistical difference in sex, smoking status, body weight, BMI, comorbidity (hypertension, coronary heart disease, chronic kidney disease, cerebral vascular disease, carcinoma, chronic liver disease), symptoms (fever, cough, headache, diarrhea and myalgia/fatigue at admission) were detected across different groups of prealbumin (tertile).", [["body", "ANATOMY", 62, 66], ["coronary", "ANATOMY", 107, 115], ["heart", "ANATOMY", 116, 121], ["kidney", "ANATOMY", 139, 145], ["cerebral vascular", "ANATOMY", 155, 172], ["carcinoma", "ANATOMY", 182, 191], ["liver", "ANATOMY", 201, 206], ["hypertension", "DISEASE", 93, 105], ["coronary heart disease", "DISEASE", 107, 129], ["chronic kidney disease", "DISEASE", 131, 153], ["cerebral vascular disease", "DISEASE", 155, 180], ["carcinoma", "DISEASE", 182, 191], ["chronic liver disease", "DISEASE", 193, 214], ["fever", "DISEASE", 227, 232], ["cough", "DISEASE", 234, 239], ["headache", "DISEASE", 241, 249], ["diarrhea", "DISEASE", 251, 259], ["myalgia", "DISEASE", 264, 271], ["fatigue", "DISEASE", 272, 279], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["heart", "ORGAN", 116, 121], ["kidney", "ORGAN", 139, 145], ["cerebral vascular", "MULTI-TISSUE_STRUCTURE", 155, 172], ["carcinoma", "CANCER", 182, 191], ["liver", "ORGAN", 201, 206], ["prealbumin", "GENE_OR_GENE_PRODUCT", 335, 345], ["prealbumin", "PROTEIN", 335, 345], ["BMI", "PROBLEM", 75, 78], ["comorbidity", "PROBLEM", 80, 91], ["hypertension", "PROBLEM", 93, 105], ["coronary heart disease", "PROBLEM", 107, 129], ["chronic kidney disease", "PROBLEM", 131, 153], ["cerebral vascular disease", "PROBLEM", 155, 180], ["carcinoma", "PROBLEM", 182, 191], ["chronic liver disease)", "PROBLEM", 193, 215], ["symptoms", "PROBLEM", 217, 225], ["fever", "PROBLEM", 227, 232], ["cough", "PROBLEM", 234, 239], ["headache", "PROBLEM", 241, 249], ["diarrhea", "PROBLEM", 251, 259], ["myalgia", "PROBLEM", 264, 271], ["fatigue", "PROBLEM", 272, 279], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["statistical", "OBSERVATION_MODIFIER", 15, 26], ["difference", "OBSERVATION_MODIFIER", 27, 37], ["hypertension", "OBSERVATION", 93, 105], ["coronary heart", "ANATOMY", 107, 121], ["disease", "OBSERVATION", 122, 129], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["kidney", "ANATOMY", 139, 145], ["disease", "OBSERVATION", 146, 153], ["cerebral", "ANATOMY_MODIFIER", 155, 163], ["vascular", "ANATOMY", 164, 172], ["disease", "OBSERVATION", 173, 180], ["carcinoma", "OBSERVATION", 182, 191], ["chronic", "OBSERVATION_MODIFIER", 193, 200], ["liver", "ANATOMY", 201, 206], ["disease", "OBSERVATION", 207, 214]]], ["When compared with subjects in the highest tertile, those in the lowest tertile were older, more likely to have diabetes medical history, with higher Neutrophil count, lower lymphocyte count, worse coagulation function and liver function.", [["Neutrophil", "ANATOMY", 150, 160], ["lymphocyte", "ANATOMY", 174, 184], ["liver", "ANATOMY", 223, 228], ["diabetes", "DISEASE", 112, 120], ["Neutrophil", "CELL", 150, 160], ["lymphocyte", "CELL", 174, 184], ["liver", "ORGAN", 223, 228], ["diabetes medical history", "PROBLEM", 112, 136], ["Neutrophil count", "TEST", 150, 166], ["lower lymphocyte count", "PROBLEM", 168, 190], ["coagulation function", "TEST", 198, 218], ["liver function", "TEST", 223, 237], ["Neutrophil count", "OBSERVATION", 150, 166], ["lower lymphocyte count", "OBSERVATION", 168, 190], ["liver", "ANATOMY", 223, 228]]], ["A total of 95 (21.3%) patients required mechanical ventilation, 69 (15.47%) patients admitted to intensive care unit and 66 (14.79%) patients died during hospitalization.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 133, 141], ["mechanical ventilation", "TREATMENT", 40, 62], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The incidence of all-cause death, ICU admission and mechanical ventilation were significantly decreased across prealbumin tertiles (all-cause death, 35.14% vs. 7.43% vs. 2.01% for tertile 1 vs. tertile 2 vs. tertile 3; ICU admission, 37.16% vs. 6.08% vs. 3.33% for tertile 1 vs. tertile 2 vs. tertile 3, mechanical ventilation, 42.57% vs. 13.15% vs. 8.05% for tertile 1 vs. tertile 2 vs. tertile 3, respectively).RESULTSTo investigate the correlation between prealbumin and in-hospital outcomes, we constructed three models using univariate and multivariate logistic regression models (table 2).", [["death", "DISEASE", 27, 32], ["death", "DISEASE", 142, 147], ["prealbumin", "GENE_OR_GENE_PRODUCT", 111, 121], ["prealbumin", "GENE_OR_GENE_PRODUCT", 459, 469], ["prealbumin", "PROTEIN", 111, 121], ["death", "PROBLEM", 27, 32], ["mechanical ventilation", "TREATMENT", 52, 74], ["prealbumin tertiles", "TEST", 111, 130], ["death", "PROBLEM", 142, 147], ["tertile", "TEST", 293, 300], ["mechanical ventilation", "TREATMENT", 304, 326], ["prealbumin", "TEST", 459, 469], ["mechanical ventilation", "OBSERVATION", 304, 326]]], ["In the unadjusted model, the ORs of all-cause death, ICU admission and mechanical ventilation was significantly increased as the prealbumin tertiles downgraded.", [["death", "DISEASE", 46, 51], ["prealbumin", "GENE_OR_GENE_PRODUCT", 129, 139], ["prealbumin", "PROTEIN", 129, 139], ["mechanical ventilation", "TREATMENT", 71, 93], ["the prealbumin tertiles", "TEST", 125, 148]]], ["The OR for tertile 1 was significantly higher than the OR for tertile 3 (OR = 26.36; 95% CI, 8.00 to 86.81; P <0.0001 for all-cause death; OR = 17.15; 95% CI, 6.62 to 44.43; P <0.0001 for ICU admission; OR = 8.46; 95% CI, 4.31 to 16.6; P <0.0001 for mechanical ventilation).", [["death", "DISEASE", 132, 137], ["CI", "TEST", 89, 91], ["P", "TEST", 108, 109], ["death", "PROBLEM", 132, 137], ["CI", "TEST", 155, 157], ["P", "TEST", 174, 175], ["CI", "TEST", 218, 220], ["P", "TEST", 236, 237], ["mechanical ventilation", "TREATMENT", 250, 272]]], ["Additional adjustment for the demographic variables and comorbidities did not reduce the ORs for the association between prealbumin tertiles and in-hospital outcomes.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 121, 131], ["prealbumin", "PROTEIN", 121, 131], ["the demographic variables", "PROBLEM", 26, 51], ["comorbidities", "PROBLEM", 56, 69], ["prealbumin tertiles", "TEST", 121, 140]]], ["Further adjusting for the baseline levels of blood examinations, including blood routine (neutrophil, lymphocyte, neutrophil-to-lymphocyte ratio), coagulation function (prothrombin time, activated partial thromboplastin time, d-dimer), liver fuction (alanine transaminase, aspartate aminotransferase, total bilirubin), renal function (blood urea nitrogen, creatinine) and infection indicators (C-reactive protein) did not affect the relationships in the fully adjusted models (OR = 20.09; 95% CI, 3.62 to 111.64; P =0.0006 for all-cause death; OR = 26.39; 95% CI, 4.04 to 172.39; P 0.0006 for ICU admission; OR = 2.8; 95% CI, 1.15 to 6.78; P = 0.0227 for mechanical ventilation).", [["blood", "ANATOMY", 45, 50], ["blood", "ANATOMY", 75, 80], ["neutrophil", "ANATOMY", 90, 100], ["lymphocyte", "ANATOMY", 102, 112], ["neutrophil", "ANATOMY", 114, 124], ["lymphocyte", "ANATOMY", 128, 138], ["liver", "ANATOMY", 236, 241], ["renal", "ANATOMY", 319, 324], ["blood", "ANATOMY", 335, 340], ["alanine", "CHEMICAL", 251, 258], ["aspartate", "CHEMICAL", 273, 282], ["bilirubin", "CHEMICAL", 307, 316], ["blood urea nitrogen", "CHEMICAL", 335, 354], ["creatinine", "CHEMICAL", 356, 366], ["infection", "DISEASE", 372, 381], ["death", "DISEASE", 537, 542], ["alanine", "CHEMICAL", 251, 258], ["aspartate", "CHEMICAL", 273, 282], ["bilirubin", "CHEMICAL", 307, 316], ["urea", "CHEMICAL", 341, 345], ["nitrogen", "CHEMICAL", 346, 354], ["creatinine", "CHEMICAL", 356, 366], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["neutrophil", "CELL", 90, 100], ["lymphocyte", "CELL", 102, 112], ["neutrophil", "CELL", 114, 124], ["lymphocyte", "CELL", 128, 138], ["prothrombin", "GENE_OR_GENE_PRODUCT", 169, 180], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 205, 219], ["d-dimer", "SIMPLE_CHEMICAL", 226, 233], ["liver", "ORGAN", 236, 241], ["alanine", "AMINO_ACID", 251, 258], ["transaminase", "GENE_OR_GENE_PRODUCT", 259, 271], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 273, 299], ["bilirubin", "SIMPLE_CHEMICAL", 307, 316], ["renal", "ORGAN", 319, 324], ["blood", "ORGANISM_SUBSTANCE", 335, 340], ["urea", "SIMPLE_CHEMICAL", 341, 345], ["creatinine", "SIMPLE_CHEMICAL", 356, 366], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 394, 412], ["neutrophil", "CELL_TYPE", 90, 100], ["lymphocyte", "CELL_TYPE", 102, 112], ["neutrophil", "CELL_TYPE", 114, 124], ["alanine transaminase", "PROTEIN", 251, 271], ["aspartate aminotransferase", "PROTEIN", 273, 299], ["C-reactive protein", "PROTEIN", 394, 412], ["blood examinations", "TEST", 45, 63], ["blood routine", "TEST", 75, 88], ["neutrophil", "TEST", 90, 100], ["lymphocyte", "TEST", 102, 112], ["neutrophil", "TEST", 114, 124], ["lymphocyte ratio", "TEST", 128, 144], ["coagulation function", "TEST", 147, 167], ["prothrombin time", "TEST", 169, 185], ["activated partial thromboplastin time", "TEST", 187, 224], ["d-dimer", "TEST", 226, 233], ["liver fuction", "TEST", 236, 249], ["alanine transaminase", "TEST", 251, 271], ["aspartate aminotransferase", "TEST", 273, 299], ["total bilirubin", "TEST", 301, 316], ["renal function", "TEST", 319, 333], ["blood urea nitrogen", "TEST", 335, 354], ["creatinine", "TEST", 356, 366], ["infection indicators", "PROBLEM", 372, 392], ["C-reactive protein", "TEST", 394, 412], ["CI", "TEST", 493, 495], ["P", "TEST", 513, 514], ["death", "PROBLEM", 537, 542], ["CI", "TEST", 560, 562], ["P", "TEST", 580, 581], ["CI", "TEST", 622, 624], ["P", "TEST", 640, 641], ["mechanical ventilation", "TREATMENT", 655, 677], ["liver", "ANATOMY", 236, 241], ["renal", "ANATOMY", 319, 324]]], ["Therefore, lower tertile of prealbumin exhibited an increased risk of worse in-hospital outcomes (full adjusted P for trend for all-cause death, ICU admission and mechanical ventilation: P < 0.0001, P <0.0001 and P = 0.0066 respectively).RESULTSGeneralized additive models (Fig 2A through 2C) were used to visually assess functional relationships between the prealbumin as continuous variate and the risk of in-hospital outcomes.", [["death", "DISEASE", 138, 143], ["prealbumin", "GENE_OR_GENE_PRODUCT", 28, 38], ["prealbumin", "GENE_OR_GENE_PRODUCT", 359, 369], ["prealbumin", "PROTEIN", 359, 369], ["lower tertile of prealbumin", "PROBLEM", 11, 38], ["death", "PROBLEM", 138, 143], ["mechanical ventilation", "TREATMENT", 163, 185], ["P", "TEST", 199, 200], ["P", "TEST", 213, 214], ["the prealbumin", "TEST", 355, 369], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["Serum prealbumin was found to have negative linear relationship with the risk of all-cause death, ICU admission and mechanical ventilation.RESULTSTo determine the consistency of the relationship between baseline prealbumin as a continuous variable and in-hospital outcomes, we conducted stratified analyses (Table 3).", [["Serum", "ANATOMY", 0, 5], ["death", "DISEASE", 91, 96], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["prealbumin", "GENE_OR_GENE_PRODUCT", 6, 16], ["prealbumin", "GENE_OR_GENE_PRODUCT", 212, 222], ["Serum prealbumin", "TEST", 0, 16], ["death", "PROBLEM", 91, 96], ["mechanical ventilation", "TREATMENT", 116, 138], ["baseline prealbumin", "TEST", 203, 222], ["mechanical ventilation", "OBSERVATION", 116, 138]]], ["For each unit increase of prealbumin, the adjusted OR for all-cause death was 0.98 in males (P = 0.0388) and 0.98 in females (P = 0.01).", [["death", "DISEASE", 68, 73], ["prealbumin", "GENE_OR_GENE_PRODUCT", 26, 36], ["prealbumin", "PROTEIN", 26, 36], ["prealbumin", "TREATMENT", 26, 36], ["death", "PROBLEM", 68, 73], ["P", "TEST", 93, 94]]], ["The adjusted OR for all-cause death for persons less than 70 years of age was 0.97 (P = 0.0672) compared with 0.98 (p = 0.0019) for persons 70 years and older (P interaction = 0.1252).", [["death", "DISEASE", 30, 35], ["persons", "ORGANISM", 40, 47], ["persons", "ORGANISM", 132, 139], ["persons", "SPECIES", 40, 47], ["persons", "SPECIES", 132, 139]]], ["For each unit increase of the prealbumin, the OR for all-cause death was 0.98 (P = 0.0253) and 0.98 (P = 0.0059) for normotensives and hypertensives, 0.98 (P = 0.0003) and 0.98 (P = 0.0966) for non-diabetic and diabetes respectively.", [["death", "DISEASE", 63, 68], ["non-diabetic", "DISEASE", 194, 206], ["diabetes", "DISEASE", 211, 219], ["prealbumin", "GENE_OR_GENE_PRODUCT", 30, 40], ["prealbumin", "PROTEIN", 30, 40], ["the prealbumin", "TREATMENT", 26, 40], ["death", "PROBLEM", 63, 68], ["P", "TEST", 79, 80], ["P", "TEST", 101, 102], ["normotensives", "PROBLEM", 117, 130], ["hypertensives", "TEST", 135, 148], ["P", "TEST", 156, 157], ["P", "TEST", 178, 179], ["non-diabetic and diabetes", "PROBLEM", 194, 219]]], ["The difference of interaction was not significant between two groups (P interaction = 0.2416, 0.1252, 0.9886 and 0.8430 stratified for gender, age, hypertention and diabetes respectively).", [["hypertention", "DISEASE", 148, 160], ["diabetes", "DISEASE", 165, 173], ["hypertention", "PROBLEM", 148, 160], ["diabetes", "PROBLEM", 165, 173]]], ["Moreover, the relationship between baseline prealbumin with ICU admission and mechanical ventilation stratified by gender, age, hypertention and diabetes are consistent.DISCUSSIONIn this study, we found that lower serum prealbumin significantly associated with an increased risk of worse outcomes and all-cause death during hospitalization.", [["serum", "ANATOMY", 214, 219], ["hypertention", "DISEASE", 128, 140], ["diabetes", "DISEASE", 145, 153], ["death", "DISEASE", 311, 316], ["prealbumin", "GENE_OR_GENE_PRODUCT", 44, 54], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["prealbumin", "GENE_OR_GENE_PRODUCT", 220, 230], ["serum prealbumin", "PROTEIN", 214, 230], ["ICU admission", "TREATMENT", 60, 73], ["mechanical ventilation", "TREATMENT", 78, 100], ["hypertention", "PROBLEM", 128, 140], ["diabetes", "PROBLEM", 145, 153], ["this study", "TEST", 182, 192], ["lower serum prealbumin", "PROBLEM", 208, 230], ["death", "PROBLEM", 311, 316], ["mechanical ventilation", "OBSERVATION", 78, 100], ["diabetes", "OBSERVATION", 145, 153], ["increased", "OBSERVATION_MODIFIER", 264, 273]]], ["Patients in the lowest tertile of prealbumin were older, and with higher Neutrophil count, lower lymphocyte count, worse coagulation function and liver function compared with subjects in the highest tertile.", [["Neutrophil", "ANATOMY", 73, 83], ["lymphocyte", "ANATOMY", 97, 107], ["liver", "ANATOMY", 146, 151], ["Patients", "ORGANISM", 0, 8], ["prealbumin", "GENE_OR_GENE_PRODUCT", 34, 44], ["Neutrophil", "CELL", 73, 83], ["lymphocyte", "CELL", 97, 107], ["liver", "ORGAN", 146, 151], ["prealbumin", "PROTEIN", 34, 44], ["Patients", "SPECIES", 0, 8], ["prealbumin", "TEST", 34, 44], ["Neutrophil count", "TEST", 73, 89], ["lower lymphocyte count", "TEST", 91, 113], ["coagulation function", "TEST", 121, 141], ["liver function", "TEST", 146, 160], ["Neutrophil count", "OBSERVATION", 73, 89], ["lower lymphocyte count", "OBSERVATION", 91, 113], ["liver", "ANATOMY", 146, 151]]], ["Then we adjusted relevant covariates including age, sex, smoking status, comorbidities, neutrophil, lymphocyte, coagulation function, liver function, renal function and C-reactive protein to minimize the potential impact of confounding.", [["neutrophil", "ANATOMY", 88, 98], ["lymphocyte", "ANATOMY", 100, 110], ["liver", "ANATOMY", 134, 139], ["renal", "ANATOMY", 150, 155], ["neutrophil", "CELL", 88, 98], ["lymphocyte", "CELL", 100, 110], ["liver", "ORGAN", 134, 139], ["renal", "ORGAN", 150, 155], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 169, 187], ["neutrophil", "CELL_TYPE", 88, 98], ["C-reactive protein", "PROTEIN", 169, 187], ["comorbidities", "PROBLEM", 73, 86], ["neutrophil", "TEST", 88, 98], ["lymphocyte", "TEST", 100, 110], ["coagulation function", "TEST", 112, 132], ["liver function", "TEST", 134, 148], ["renal function", "TEST", 150, 164], ["C-reactive protein", "TREATMENT", 169, 187], ["liver", "ANATOMY", 134, 139], ["renal", "ANATOMY", 150, 155]]], ["Compared with crude regression analyses, this association still persisted when adjusting for demographic and clinical variables in the multivariable regression analyses.", [["crude regression analyses", "TEST", 14, 39], ["the multivariable regression analyses", "TEST", 131, 168]]], ["Moreover, stratified by gender, age, hypertension and diabetes, increased level of serum prealbumin was associated with the decreased risk of all-cause death, ICU admission and mechanical ventilation, which determine the consistency of the relationship between lowest serum prealbumin tertile and the increased risk of worse outcomes in elderly COVID-19 patients.DISCUSSIONSeveral previous studies have demonstrated baseline prealbumin change in COVID-19 patients.", [["serum", "ANATOMY", 83, 88], ["serum", "ANATOMY", 268, 273], ["hypertension", "DISEASE", 37, 49], ["diabetes", "DISEASE", 54, 62], ["death", "DISEASE", 152, 157], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["prealbumin", "GENE_OR_GENE_PRODUCT", 89, 99], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["prealbumin", "GENE_OR_GENE_PRODUCT", 274, 284], ["patients", "ORGANISM", 354, 362], ["prealbumin", "GENE_OR_GENE_PRODUCT", 425, 435], ["patients", "ORGANISM", 455, 463], ["serum prealbumin", "PROTEIN", 83, 99], ["serum prealbumin", "PROTEIN", 268, 284], ["prealbumin", "PROTEIN", 425, 435], ["patients", "SPECIES", 354, 362], ["patients", "SPECIES", 455, 463], ["hypertension", "PROBLEM", 37, 49], ["diabetes", "PROBLEM", 54, 62], ["increased level of serum prealbumin", "PROBLEM", 64, 99], ["death", "PROBLEM", 152, 157], ["mechanical ventilation", "TREATMENT", 177, 199], ["lowest serum prealbumin tertile", "PROBLEM", 261, 292], ["previous studies", "TEST", 381, 397], ["baseline prealbumin change", "PROBLEM", 416, 442], ["COVID", "TEST", 446, 451], ["hypertension", "OBSERVATION", 37, 49], ["diabetes", "OBSERVATION", 54, 62], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["mechanical ventilation", "OBSERVATION", 177, 199], ["increased", "OBSERVATION_MODIFIER", 301, 310]]], ["Decreased level of prealbumin was observed among COVID-19 patients10.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 19, 29], ["patients", "ORGANISM", 58, 66], ["prealbumin", "PROTEIN", 19, 29], ["patients", "SPECIES", 58, 66], ["Decreased level of prealbumin", "PROBLEM", 0, 29], ["COVID", "TEST", 49, 54]]], ["Wu C et al investigated 201 patients with COVID-19 and observed that prealbumin was associated with the development of ARDS, indicating the potential value of prealbumin level on COVID-19 clinical ending11.", [["ARDS", "DISEASE", 119, 123], ["patients", "ORGANISM", 28, 36], ["prealbumin", "GENE_OR_GENE_PRODUCT", 69, 79], ["prealbumin", "GENE_OR_GENE_PRODUCT", 159, 169], ["prealbumin", "PROTEIN", 159, 169], ["patients", "SPECIES", 28, 36], ["COVID", "TEST", 42, 47], ["prealbumin", "TEST", 69, 79], ["ARDS", "PROBLEM", 119, 123], ["prealbumin level", "TEST", 159, 175], ["COVID", "TEST", 179, 184], ["ARDS", "OBSERVATION", 119, 123]]], ["Till date, no report exists on the effect of prealbumin in COVID-19 elderly patients.DISCUSSIONHigh proportion of severe to critical cases and high fatality rate were observed in the elderlyDISCUSSIONCOVID-19 patients, and rapid disease progress was noted in the dead5.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 45, 55], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 209, 217], ["dead5", "DNA", 263, 268], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 209, 217], ["prealbumin in COVID", "TREATMENT", 45, 64], ["high fatality rate", "PROBLEM", 143, 161], ["rapid disease progress", "PROBLEM", 223, 245], ["severe", "OBSERVATION_MODIFIER", 114, 120]]], ["One possible explanation involves the greater potential of seniors to be in a state of inflammation, nutritional deficiency and other complications.", [["inflammation", "DISEASE", 87, 99], ["nutritional deficiency", "DISEASE", 101, 123], ["inflammation", "PROBLEM", 87, 99], ["nutritional deficiency", "PROBLEM", 101, 123], ["other complications", "PROBLEM", 128, 147], ["inflammation", "OBSERVATION", 87, 99], ["nutritional deficiency", "OBSERVATION", 101, 123]]], ["Prealbumin is a globular, non-glycosilated protein, synthesized by the liver, and complexed with a retinol-binding protein, which acts as a transporter of retinol/vitamin A and thyroid hormones7.", [["liver", "ANATOMY", 71, 76], ["Prealbumin", "CHEMICAL", 0, 10], ["retinol", "CHEMICAL", 99, 106], ["retinol", "CHEMICAL", 155, 162], ["vitamin A", "CHEMICAL", 163, 172], ["retinol", "CHEMICAL", 99, 106], ["retinol", "CHEMICAL", 155, 162], ["vitamin A", "CHEMICAL", 163, 172], ["Prealbumin", "GENE_OR_GENE_PRODUCT", 0, 10], ["liver", "ORGAN", 71, 76], ["retinol", "SIMPLE_CHEMICAL", 99, 106], ["retinol", "SIMPLE_CHEMICAL", 155, 162], ["vitamin A", "SIMPLE_CHEMICAL", 163, 172], ["thyroid hormones7", "GENE_OR_GENE_PRODUCT", 177, 194], ["Prealbumin", "PROTEIN", 0, 10], ["globular, non-glycosilated protein", "PROTEIN", 16, 50], ["retinol-binding protein", "PROTEIN", 99, 122], ["Prealbumin", "TEST", 0, 10], ["a globular, non-glycosilated protein", "PROBLEM", 14, 50], ["a retinol-binding protein", "TREATMENT", 97, 122], ["retinol/vitamin A", "TREATMENT", 155, 172], ["globular", "OBSERVATION_MODIFIER", 16, 24], ["liver", "ANATOMY", 71, 76], ["thyroid", "ANATOMY", 177, 184]]], ["Low plasma prealbumin level has far-back emerged as an earliest laboratory indicator of poor nutritional status12,13.", [["plasma", "ANATOMY", 4, 10], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["prealbumin", "GENE_OR_GENE_PRODUCT", 11, 21], ["Low plasma prealbumin level", "PROBLEM", 0, 27], ["poor nutritional status", "PROBLEM", 88, 111]]], ["In addition, prealbumin are also associated with inflammation.", [["inflammation", "DISEASE", 49, 61], ["prealbumin", "GENE_OR_GENE_PRODUCT", 13, 23], ["prealbumin", "PROTEIN", 13, 23], ["prealbumin", "TEST", 13, 23], ["inflammation", "PROBLEM", 49, 61], ["prealbumin", "OBSERVATION", 13, 23], ["associated with", "UNCERTAINTY", 33, 48], ["inflammation", "OBSERVATION", 49, 61]]], ["Previous studies showed that in response to the inflammation, the body responds by synthesizing a large number of cytokines.", [["body", "ANATOMY", 66, 70], ["inflammation", "DISEASE", 48, 60], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["cytokines", "PROTEIN", 114, 123], ["Previous studies", "TEST", 0, 16], ["the inflammation", "PROBLEM", 44, 60], ["inflammation", "OBSERVATION", 48, 60], ["large", "OBSERVATION_MODIFIER", 98, 103], ["number", "OBSERVATION_MODIFIER", 104, 110]]], ["These include interleukins and tumor necrosis factors that down-regulate, decrease, plasma concentrations of albumin and prealbumin14,15.", [["tumor", "ANATOMY", 31, 36], ["plasma", "ANATOMY", 84, 90], ["tumor necrosis", "DISEASE", 31, 45], ["interleukins", "GENE_OR_GENE_PRODUCT", 14, 26], ["tumor necrosis factors", "GENE_OR_GENE_PRODUCT", 31, 53], ["plasma", "ORGANISM_SUBSTANCE", 84, 90], ["albumin", "GENE_OR_GENE_PRODUCT", 109, 116], ["prealbumin", "GENE_OR_GENE_PRODUCT", 121, 131], ["interleukins", "PROTEIN", 14, 26], ["tumor necrosis factors", "PROTEIN", 31, 53], ["albumin", "PROTEIN", 109, 116], ["prealbumin14,15", "PROTEIN", 121, 136], ["interleukins", "PROBLEM", 14, 26], ["tumor necrosis factors", "PROBLEM", 31, 53], ["plasma concentrations of albumin", "TEST", 84, 116], ["prealbumin", "TEST", 121, 131], ["interleukins", "OBSERVATION", 14, 26], ["tumor", "OBSERVATION_MODIFIER", 31, 36], ["necrosis", "OBSERVATION", 37, 45], ["decrease", "OBSERVATION_MODIFIER", 74, 82]]], ["Therefore, assay of serum prealbumin concentration is recommended by some investigators as a screening marker for both malnutrition and inflammation.DISCUSSIONElderly with low plasma prealbumin levels mean that those people are at greater risk of malnutrition and inflammatory conditions, which may lead to poor prognosis.", [["serum", "ANATOMY", 20, 25], ["plasma", "ANATOMY", 176, 182], ["malnutrition", "DISEASE", 119, 131], ["inflammation", "DISEASE", 136, 148], ["malnutrition", "DISEASE", 247, 259], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["prealbumin", "GENE_OR_GENE_PRODUCT", 26, 36], ["plasma", "ORGANISM_SUBSTANCE", 176, 182], ["prealbumin", "GENE_OR_GENE_PRODUCT", 183, 193], ["people", "ORGANISM", 217, 223], ["people", "SPECIES", 217, 223], ["assay of serum prealbumin concentration", "TEST", 11, 50], ["a screening marker", "TEST", 91, 109], ["both malnutrition", "PROBLEM", 114, 131], ["inflammation", "PROBLEM", 136, 148], ["low plasma prealbumin levels", "PROBLEM", 172, 200], ["malnutrition", "PROBLEM", 247, 259], ["inflammatory conditions", "PROBLEM", 264, 287], ["malnutrition", "OBSERVATION", 119, 131], ["inflammation", "OBSERVATION", 136, 148], ["malnutrition", "OBSERVATION", 247, 259], ["inflammatory", "OBSERVATION", 264, 276]]], ["Malnutrition is commonly seen in hospitalized patients in both the developed and developing world, especially among elderly patients.", [["Malnutrition", "DISEASE", 0, 12], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 124, 132], ["Malnutrition", "PROBLEM", 0, 12]]], ["A review of 110 published studies of acute care patients reported that malnutrition incidence ranged from 42\u201391% of hospitalized elderly16.", [["malnutrition", "DISEASE", 71, 83], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["malnutrition incidence", "PROBLEM", 71, 93]]], ["It was found that compared to non-famine regions of India, experiencing famine had significantly higher influenza mortality rates during the 1918 Influenza pandemic17.", [["influenza", "DISEASE", 104, 113], ["significantly higher influenza mortality rates", "PROBLEM", 83, 129], ["Influenza pandemic17", "TREATMENT", 146, 166]]], ["Aging, frailty, and chronic diseases are associated with impaired immune function and are compounded by immune dysregulation from malnutrition.", [["Aging", "DISEASE", 0, 5], ["frailty", "DISEASE", 7, 14], ["chronic diseases", "DISEASE", 20, 36], ["impaired immune function", "DISEASE", 57, 81], ["malnutrition", "DISEASE", 130, 142], ["frailty", "PROBLEM", 7, 14], ["chronic diseases", "PROBLEM", 20, 36], ["impaired immune function", "PROBLEM", 57, 81], ["immune dysregulation", "PROBLEM", 104, 124], ["malnutrition", "PROBLEM", 130, 142], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["diseases", "OBSERVATION", 28, 36], ["impaired", "OBSERVATION_MODIFIER", 57, 65], ["immune function", "OBSERVATION", 66, 81], ["immune dysregulation", "OBSERVATION", 104, 124], ["malnutrition", "OBSERVATION", 130, 142]]], ["When immune response is dysregulated, it would result in an excessive inflammation, even death.", [["inflammation", "DISEASE", 70, 82], ["death", "DISEASE", 89, 94], ["dysregulated", "PROBLEM", 24, 36], ["an excessive inflammation", "PROBLEM", 57, 82], ["excessive", "OBSERVATION_MODIFIER", 60, 69], ["inflammation", "OBSERVATION", 70, 82]]], ["In the current COVID-19 study, it was found that elderly patients have higher levels of white blood cells counts, CRP, inflammatory cytokines and are more likely to experience critical disease than did those younger patients4,18.DISCUSSIONThis retrospective cohort study included 446 elderly COVID-19 patients, until the date of February 17, 2020, 21.3% of patients required mechanical ventilation, 15.47% of patients admitted to intensive care unit, and the total in-hospital mortality was 14.79%.", [["white blood cells", "ANATOMY", 88, 105], ["patients", "ORGANISM", 57, 65], ["white blood cells", "CELL", 88, 105], ["CRP", "GENE_OR_GENE_PRODUCT", 114, 117], ["patient", "ORGANISM", 216, 223], ["patients", "ORGANISM", 301, 309], ["patients", "ORGANISM", 357, 365], ["patients", "ORGANISM", 409, 417], ["white blood cells", "CELL_TYPE", 88, 105], ["CRP", "PROTEIN", 114, 117], ["inflammatory cytokines", "PROTEIN", 119, 141], ["patients", "SPECIES", 57, 65], ["patient", "SPECIES", 216, 223], ["patients", "SPECIES", 301, 309], ["patients", "SPECIES", 357, 365], ["patients", "SPECIES", 409, 417], ["white blood cells counts", "TEST", 88, 112], ["CRP", "TEST", 114, 117], ["inflammatory cytokines", "PROBLEM", 119, 141], ["critical disease", "PROBLEM", 176, 192], ["retrospective cohort study", "TEST", 244, 270], ["mechanical ventilation", "TREATMENT", 375, 397], ["inflammatory cytokines", "OBSERVATION", 119, 141], ["more likely", "UNCERTAINTY", 150, 161], ["mechanical ventilation", "OBSERVATION", 375, 397]]], ["The mortality rate was lower than that reported by wang L et al5 among elderly COVID-19 patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["The mortality rate", "TEST", 0, 18]]], ["This may have been the reason for some patients at the date of February 17, 2020 are still in hospital.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Nevertheless, this would not bias the relationship between prealbumin and in-hospital outcomes because of the definite observation time we set previously.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 59, 69], ["prealbumin", "TEST", 59, 69]]], ["Moreover, Wuhan tongji Hospital as one of the largest third-grade Class A hospitals equipped with advanced life support training and equipment may partly account for the moderate mortality.DISCUSSIONThe results of this study have several clinical implications and strengths.", [["advanced life support training", "TREATMENT", 98, 128], ["equipment", "TREATMENT", 133, 142], ["the moderate mortality", "PROBLEM", 166, 188], ["this study", "TEST", 214, 224], ["moderate", "OBSERVATION_MODIFIER", 170, 178], ["mortality", "OBSERVATION", 179, 188]]], ["A low prealbumin concentration can therefore be regarded primarily as a signal identifying the at-risk elderly patient who would suffer worse outcomes and requires careful assessment and monitoring for whom nutritional support and Inflammation detection may be needed as part of the treatment plan19.", [["Inflammation", "DISEASE", 231, 243], ["prealbumin", "GENE_OR_GENE_PRODUCT", 6, 16], ["patient", "ORGANISM", 111, 118], ["prealbumin", "PROTEIN", 6, 16], ["patient", "SPECIES", 111, 118], ["A low prealbumin concentration", "TREATMENT", 0, 30], ["careful assessment", "TEST", 164, 182], ["monitoring", "TEST", 187, 197], ["nutritional support", "TREATMENT", 207, 226], ["Inflammation detection", "TEST", 231, 253], ["the treatment plan19", "TREATMENT", 279, 299]]], ["As observational study was susceptible to various confounders, we adjusted many variables that may affect the relationship between prealbumin and in-hospital outcomes to minimize potential confounding.", [["prealbumin", "GENE_OR_GENE_PRODUCT", 131, 141], ["observational study", "TEST", 3, 22], ["prealbumin", "TEST", 131, 141]]], ["In addition, we tested the robustness of the results by repeating the analyses in different subgroups of gender, age, history of hypertension and history of diabetes.DISCUSSIONOur study has some limitations.", [["hypertension", "DISEASE", 129, 141], ["diabetes", "DISEASE", 157, 165], ["hypertension", "PROBLEM", 129, 141], ["diabetes", "PROBLEM", 157, 165], ["DISCUSSIONOur study", "TEST", 166, 185], ["hypertension", "OBSERVATION", 129, 141], ["diabetes", "OBSERVATION", 157, 165]]], ["First, by including patients still in hospital as of J February 17, 2020, the case fatality ratio in our study cannot reflect the true mortality of elderly COVID-19.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["our study", "TEST", 101, 110], ["elderly COVID", "TEST", 148, 161]]], ["Second, the record of data may be affected by prehospital medication and the time interval between admission and onset.", [["prehospital medication", "TREATMENT", 46, 68]]], ["Third, since all subjects in our study were hospitalized Chinese elderly patients diagnosed with COVID-19, results of this study might not directly be applied to other ethnicities and age groups.DISCUSSIONIn conclusion, this retrospective cohort study revealed that the prealbumin is an independent risk factor for the in-hospital mortality in the Chinese COVID-19 elderly patients.", [["patients", "ORGANISM", 73, 81], ["prealbumin", "GENE_OR_GENE_PRODUCT", 270, 280], ["patients", "ORGANISM", 373, 381], ["prealbumin", "PROTEIN", 270, 280], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 373, 381], ["our study", "TEST", 29, 38], ["COVID", "TEST", 97, 102], ["this study", "TEST", 118, 128], ["this retrospective cohort study", "TEST", 220, 251], ["the prealbumin", "TEST", 266, 280]]], ["Nutritional support and Inflammation detection should be careful assessment and monitoring for the elderly patients with low prealbumin concentration.CRediT authorship contribution statement", [["patients", "ORGANISM", 107, 115], ["prealbumin", "GENE_OR_GENE_PRODUCT", 125, 135], ["prealbumin", "PROTEIN", 125, 135], ["patients", "SPECIES", 107, 115], ["Nutritional support", "TREATMENT", 0, 19], ["Inflammation detection", "TEST", 24, 46], ["careful assessment", "TEST", 57, 75], ["monitoring", "TEST", 80, 90], ["low prealbumin concentration", "TREATMENT", 121, 149], ["Inflammation", "OBSERVATION", 24, 36]]]], "PMC4787606": [["Patients and Study Criteria ::: METHODSPatients presented to 2 tertiary care hospitals in Edinburgh, United Kingdom, over an 18-month period between September 2012 and February 2014.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Consecutive cases with clinical and radiological evidence of CAP were identified through daily retrospective electronic review of all respiratory samples received by our microbiology laboratory.", [["respiratory samples", "ANATOMY", 134, 153], ["CAP", "DISEASE", 61, 64], ["CAP", "PROBLEM", 61, 64], ["CAP", "OBSERVATION_MODIFIER", 61, 64]]], ["Inclusion criteria for the study included the following: adult (aged \u226518 years); LRT specimen obtained within 48 hours of admission to the hospital; new radiographic infiltrate as determined by radiologist or consultant respiratory physician; and 3 of more of the following signs or symptoms: new or worsening cough, new or worsening expectoration of sputum, hemoptysis, new or worsening dyspnea, pleuritic chest pain, fever, headache, or abnormalities on chest auscultation or percussion.", [["specimen", "ANATOMY", 85, 93], ["sputum", "ANATOMY", 351, 357], ["chest", "ANATOMY", 407, 412], ["chest", "ANATOMY", 456, 461], ["cough", "DISEASE", 310, 315], ["sputum", "DISEASE", 351, 357], ["hemoptysis", "DISEASE", 359, 369], ["dyspnea", "DISEASE", 388, 395], ["chest pain", "DISEASE", 407, 417], ["fever", "DISEASE", 419, 424], ["headache", "DISEASE", 426, 434], ["chest", "ORGANISM_SUBDIVISION", 456, 461], ["the study", "TEST", 23, 32], ["LRT specimen", "TEST", 81, 93], ["new radiographic infiltrate", "PROBLEM", 149, 176], ["symptoms", "PROBLEM", 283, 291], ["new or worsening cough", "PROBLEM", 293, 315], ["new or worsening expectoration of sputum", "PROBLEM", 317, 357], ["hemoptysis", "PROBLEM", 359, 369], ["new or worsening dyspnea", "PROBLEM", 371, 395], ["pleuritic chest pain", "PROBLEM", 397, 417], ["fever", "PROBLEM", 419, 424], ["headache", "PROBLEM", 426, 434], ["abnormalities", "PROBLEM", 439, 452], ["chest auscultation", "TEST", 456, 474], ["percussion", "TEST", 478, 488], ["infiltrate", "OBSERVATION", 166, 176], ["worsening", "OBSERVATION_MODIFIER", 300, 309], ["cough", "OBSERVATION", 310, 315], ["new", "OBSERVATION_MODIFIER", 317, 320], ["worsening", "OBSERVATION_MODIFIER", 324, 333], ["hemoptysis", "OBSERVATION", 359, 369], ["new", "OBSERVATION_MODIFIER", 371, 374], ["worsening", "OBSERVATION_MODIFIER", 378, 387], ["dyspnea", "OBSERVATION", 388, 395], ["pleuritic", "ANATOMY", 397, 406], ["chest", "ANATOMY", 407, 412], ["chest", "ANATOMY", 456, 461], ["percussion", "OBSERVATION", 478, 488]]], ["Exclusion criteria included the following: bronchiectasis, cystic fibrosis, or healthcare-associated pneumonia (hospitalized in an acute care hospital for 2 or more days within 90 days of the infection or resided in a nursing home or long-term care facility) [34].", [["cystic", "ANATOMY", 59, 65], ["bronchiectasis", "DISEASE", 43, 57], ["cystic fibrosis", "DISEASE", 59, 74], ["pneumonia", "DISEASE", 101, 110], ["infection", "DISEASE", 192, 201], ["bronchiectasis", "PROBLEM", 43, 57], ["cystic fibrosis", "PROBLEM", 59, 74], ["healthcare-associated pneumonia", "PROBLEM", 79, 110], ["the infection", "PROBLEM", 188, 201], ["bronchiectasis", "OBSERVATION", 43, 57], ["cystic", "OBSERVATION_MODIFIER", 59, 65], ["fibrosis", "OBSERVATION", 66, 74], ["pneumonia", "OBSERVATION", 101, 110], ["infection", "OBSERVATION", 192, 201]]], ["Radiology reports were reviewed for all patients, and only patients with radiological changes consistent with pneumonia were included.", [["pneumonia", "DISEASE", 110, 119], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 59, 67], ["radiological changes", "PROBLEM", 73, 93], ["pneumonia", "PROBLEM", 110, 119], ["consistent with", "UNCERTAINTY", 94, 109], ["pneumonia", "OBSERVATION", 110, 119]]], ["Where there was any uncertainty, the images were reviewed by an experienced respiratory physician (A. T. H.).", [["A. T. H.", "SPECIES", 99, 107], ["the images", "TEST", 33, 43]]], ["Clinical data including comorbidities, outcomes, and antibiotic prescriptions were collected retrospectively from patient hospital records using a standard pro forma as part of a clinical audit of pneumonia management (approved by the Quality Improvement Team, Royal Infirmary of Edinburgh).", [["pneumonia", "DISEASE", 197, 206], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["Clinical data", "TEST", 0, 13], ["comorbidities", "PROBLEM", 24, 37], ["antibiotic prescriptions", "TREATMENT", 53, 77], ["a standard pro forma", "TREATMENT", 145, 165], ["pneumonia management", "TREATMENT", 197, 217], ["pneumonia", "OBSERVATION", 197, 206]]], ["Drug administration prior to hospitalization, including antibiotic prescription, was obtained from the electronic primary care prescription records on admission and later verified by a pharmacist.Microbiological Culture and Molecular Testing ::: METHODSLRT specimens were cultured according to national standard protocols to detect common respiratory bacteria [35].", [["specimens", "ANATOMY", 257, 266], ["Drug administration", "TREATMENT", 0, 19], ["antibiotic prescription", "TREATMENT", 56, 79], ["Microbiological Culture", "TEST", 196, 219], ["Molecular Testing", "TEST", 224, 241], ["METHODSLRT specimens", "TEST", 246, 266], ["common respiratory bacteria", "PROBLEM", 332, 359]]], ["Isolates were identified using standard biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (Bruker, Coventry, United Kingdom).", [["Isolates", "TEST", 0, 8], ["standard biochemical methods", "TREATMENT", 31, 59], ["matrix-assisted laser desorption/ionization", "TREATMENT", 67, 110]]], ["Specimens with any named bacterial species identified by culture were considered to be culture positive.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["any named bacterial species", "PROBLEM", 15, 42], ["culture", "TEST", 57, 64], ["culture", "TEST", 87, 94], ["bacterial species", "OBSERVATION", 25, 42]]], ["Following routine culture, LRT specimens were centrifuged, and mucopurulent material was stored at \u221280\u00b0C for up to 15 months.", [["LRT specimens", "ANATOMY", 27, 40], ["LRT specimens", "CANCER", 27, 40], ["C", "GENE_OR_GENE_PRODUCT", 103, 104], ["routine culture", "TEST", 10, 25], ["LRT specimens", "TEST", 27, 40], ["mucopurulent material", "PROBLEM", 63, 84]]], ["As part of the study protocol, specimens and associated clinical data were collected and anonymized before molecular testing in accordance with local ethical approval (South East Scotland Scottish Academic Health Sciences Collaboration Human Annotated BioResource reference no. 10/S1402/33).", [["specimens", "ANATOMY", 31, 40], ["Human", "SPECIES", 236, 241], ["the study protocol", "TEST", 11, 29], ["clinical data", "TEST", 56, 69], ["molecular testing", "TEST", 107, 124]]], ["Thawed specimens were homogenized by vortexing with sterile glass beads, and a 200-\u03bcL aliquot was treated with lysozyme at 37\u00b0C followed by proteinase K at 56\u00b0C for 1 hour each.", [["specimens", "ANATOMY", 7, 16], ["K", "CHEMICAL", 151, 152], ["lysozyme", "GENE_OR_GENE_PRODUCT", 111, 119], ["proteinase K", "GENE_OR_GENE_PRODUCT", 140, 152], ["lysozyme", "PROTEIN", 111, 119], ["proteinase K", "PROTEIN", 140, 152], ["Thawed specimens", "TEST", 0, 16], ["sterile glass beads", "TREATMENT", 52, 71], ["a 200-\u03bcL aliquot", "TREATMENT", 77, 93], ["lysozyme", "TREATMENT", 111, 119], ["proteinase K", "TEST", 140, 152]]], ["Total nucleic acid was then extracted using the automated nucliSENS easyMAG (BioM\u00e9rieux, Basingstoke, United Kingdom) instrument with an off-board lysis protocol, including the addition of phocine herpes virus as an internal extraction control.", [["nucleic acid", "CHEMICAL", 6, 18], ["phocine", "ORGANISM", 189, 196], ["herpes virus", "ORGANISM", 197, 209], ["phocine herpes virus", "SPECIES", 189, 209], ["phocine herpes virus", "SPECIES", 189, 209], ["Total nucleic acid", "TEST", 0, 18], ["an off-board lysis protocol", "TREATMENT", 134, 161], ["phocine herpes virus", "TREATMENT", 189, 209], ["an internal extraction control", "TREATMENT", 213, 243], ["nucleic acid", "OBSERVATION", 6, 18]]], ["Extracts were stored at 4\u00b0C for up to 5 days or longer at \u221280\u00b0C. Fast multiplex real-time PCR was performed using a combination of multiplex assays developed or adapted in-house for the following 26 pathogens: Streptococcus pneumoniae; Haemophilus influenzae; Moraxella catarrhalis; Staphylococcus aureus; Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa; Acinetobacter baumannii; Mycoplasma pneumoniae; Chlamydophila pneumoniae; Chlamydophila psittaci; Legionella pneumophila; Legionella spp.; influenza A; influenza B; respiratory syncytial virus; parainfluenza virus types 1\u20133; adenovirus; human coronaviruses 229E, HKU1, NL63, and OC43; human metapneumovirus; and rhinovirus [10\u201315, 33].", [["Extracts", "ANATOMY", 0, 8], ["Streptococcus pneumoniae", "DISEASE", 210, 234], ["Haemophilus influenzae", "DISEASE", 236, 258], ["Staphylococcus aureus", "DISEASE", 283, 304], ["Klebsiella pneumoniae", "DISEASE", 324, 345], ["Mycoplasma pneumoniae", "DISEASE", 396, 417], ["Chlamydophila pneumoniae", "DISEASE", 419, 443], ["Chlamydophila psittaci", "DISEASE", 445, 467], ["Legionella pneumophila", "DISEASE", 469, 491], ["Legionella spp.", "DISEASE", 493, 508], ["influenza A", "DISEASE", 510, 521], ["influenza B", "DISEASE", 523, 534], ["respiratory syncytial virus", "DISEASE", 536, 563], ["parainfluenza virus", "DISEASE", 565, 584], ["human metapneumovirus", "DISEASE", 656, 677], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["C", "GENE_OR_GENE_PRODUCT", 26, 27], ["Streptococcus pneumoniae", "ORGANISM", 210, 234], ["Haemophilus influenzae", "ORGANISM", 236, 258], ["Moraxella catarrhalis", "ORGANISM", 260, 281], ["Staphylococcus aureus", "ORGANISM", 283, 304], ["Escherichia coli", "ORGANISM", 306, 322], ["Klebsiella pneumoniae", "ORGANISM", 324, 345], ["Pseudomonas aeruginosa", "ORGANISM", 347, 369], ["Acinetobacter baumannii", "ORGANISM", 371, 394], ["Mycoplasma pneumoniae", "ORGANISM", 396, 417], ["Chlamydophila pneumoniae", "ORGANISM", 419, 443], ["Chlamydophila psittaci", "ORGANISM", 445, 467], ["Legionella pneumophila", "ORGANISM", 469, 491], ["Legionella spp.", "ORGANISM", 493, 508], ["influenza A;", "ORGANISM", 510, 522], ["influenza B;", "ORGANISM", 523, 535], ["respiratory syncytial virus", "ORGANISM", 536, 563], ["parainfluenza virus types 1\u20133", "ORGANISM", 565, 594], ["adenovirus", "ORGANISM", 596, 606], ["human", "ORGANISM", 608, 613], ["coronaviruses 229E", "ORGANISM", 614, 632], ["HKU1", "GENE_OR_GENE_PRODUCT", 634, 638], ["NL63", "GENE_OR_GENE_PRODUCT", 640, 644], ["OC43", "GENE_OR_GENE_PRODUCT", 650, 654], ["human metapneumovirus", "ORGANISM", 656, 677], ["rhinovirus", "ORGANISM", 683, 693], ["Streptococcus pneumoniae", "SPECIES", 210, 234], ["Haemophilus influenzae", "SPECIES", 236, 258], ["Moraxella catarrhalis", "SPECIES", 260, 281], ["Staphylococcus aureus", "SPECIES", 283, 304], ["Escherichia coli", "SPECIES", 306, 322], ["Klebsiella pneumoniae", "SPECIES", 324, 345], ["Pseudomonas aeruginosa", "SPECIES", 347, 369], ["Acinetobacter baumannii", "SPECIES", 371, 394], ["Mycoplasma pneumoniae", "SPECIES", 396, 417], ["Chlamydophila pneumoniae", "SPECIES", 419, 443], ["Chlamydophila psittaci", "SPECIES", 445, 467], ["Legionella pneumophila", "SPECIES", 469, 491], ["Legionella spp.", "SPECIES", 493, 508], ["influenza A", "SPECIES", 510, 521], ["influenza B", "SPECIES", 523, 534], ["respiratory syncytial virus", "SPECIES", 536, 563], ["parainfluenza virus", "SPECIES", 565, 584], ["human", "SPECIES", 608, 613], ["human", "SPECIES", 656, 661], ["metapneumovirus", "SPECIES", 662, 677], ["Streptococcus pneumoniae", "SPECIES", 210, 234], ["Haemophilus influenzae", "SPECIES", 236, 258], ["Moraxella catarrhalis", "SPECIES", 260, 281], ["Staphylococcus aureus", "SPECIES", 283, 304], ["Escherichia coli", "SPECIES", 306, 322], ["Klebsiella pneumoniae", "SPECIES", 324, 345], ["Pseudomonas aeruginosa", "SPECIES", 347, 369], ["Acinetobacter baumannii", "SPECIES", 371, 394], ["Mycoplasma pneumoniae", "SPECIES", 396, 417], ["Chlamydophila pneumoniae", "SPECIES", 419, 443], ["Chlamydophila psittaci", "SPECIES", 445, 467], ["Legionella pneumophila", "SPECIES", 469, 491], ["Legionella spp.; influenza A; influenza B; respiratory syncytial virus", "SPECIES", 493, 563], ["human coronaviruses 229E", "SPECIES", 608, 632], ["human metapneumovirus", "SPECIES", 656, 677], ["Fast multiplex real-time PCR", "TEST", 65, 93], ["multiplex assays", "TEST", 131, 147], ["Streptococcus pneumoniae", "PROBLEM", 210, 234], ["Haemophilus influenzae", "PROBLEM", 236, 258], ["Moraxella catarrhalis", "PROBLEM", 260, 281], ["Staphylococcus aureus", "PROBLEM", 283, 304], ["Escherichia coli", "PROBLEM", 306, 322], ["Klebsiella pneumoniae", "PROBLEM", 324, 345], ["Pseudomonas aeruginosa", "PROBLEM", 347, 369], ["Acinetobacter baumannii", "PROBLEM", 371, 394], ["Mycoplasma pneumoniae", "PROBLEM", 396, 417], ["Chlamydophila pneumoniae", "PROBLEM", 419, 443], ["Chlamydophila psittaci", "PROBLEM", 445, 467], ["Legionella pneumophila", "PROBLEM", 469, 491], ["Legionella spp.", "TEST", 493, 508], ["influenza", "PROBLEM", 510, 519], ["influenza B", "PROBLEM", 523, 534], ["respiratory syncytial virus", "PROBLEM", 536, 563], ["parainfluenza virus types", "PROBLEM", 565, 590], ["adenovirus", "PROBLEM", 596, 606], ["human coronaviruses", "TEST", 608, 627], ["HKU1", "TEST", 634, 638], ["NL63", "TEST", 640, 644], ["OC43", "TEST", 650, 654], ["human metapneumovirus", "PROBLEM", 656, 677], ["rhinovirus", "PROBLEM", 683, 693], ["Streptococcus pneumoniae", "OBSERVATION", 210, 234], ["Escherichia coli", "OBSERVATION", 306, 322], ["Klebsiella pneumoniae", "OBSERVATION", 324, 345], ["Mycoplasma pneumoniae", "OBSERVATION", 396, 417], ["Chlamydophila pneumoniae", "OBSERVATION", 419, 443], ["respiratory syncytial", "ANATOMY", 536, 557]]], ["As previously described [33], bacterial loads for S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii were expressed as colony forming units (CFUs) per milliliter of purulent material and calculated from standard curves generated by target gene plasmid dilution series on each PCR run.", [["S. pneumoniae", "ORGANISM", 50, 63], ["H. influenzae", "ORGANISM", 65, 78], ["M. catarrhalis", "ORGANISM", 80, 94], ["S. aureus", "ORGANISM", 96, 105], ["E. coli", "ORGANISM", 107, 114], ["K. pneumoniae", "ORGANISM", 116, 129], ["P. aeruginosa", "ORGANISM", 131, 144], ["A. baumannii", "ORGANISM", 150, 162], ["S. pneumoniae", "SPECIES", 50, 63], ["H. influenzae", "SPECIES", 65, 78], ["M. catarrhalis", "SPECIES", 80, 94], ["S. aureus", "SPECIES", 96, 105], ["E. coli", "SPECIES", 107, 114], ["K. pneumoniae", "SPECIES", 116, 129], ["P. aeruginosa", "SPECIES", 131, 144], ["A. baumannii", "SPECIES", 150, 162], ["S. pneumoniae", "SPECIES", 50, 63], ["H. influenzae", "SPECIES", 65, 78], ["M. catarrhalis", "SPECIES", 80, 94], ["S. aureus", "SPECIES", 96, 105], ["E. coli", "SPECIES", 107, 114], ["K. pneumoniae", "SPECIES", 116, 129], ["P. aeruginosa", "SPECIES", 131, 144], ["A. baumannii", "SPECIES", 150, 162], ["bacterial loads", "TEST", 30, 45], ["S. pneumoniae", "PROBLEM", 50, 63], ["H. influenzae", "PROBLEM", 65, 78], ["M. catarrhalis", "PROBLEM", 80, 94], ["S. aureus", "PROBLEM", 96, 105], ["E. coli", "PROBLEM", 107, 114], ["K. pneumoniae", "PROBLEM", 116, 129], ["P. aeruginosa", "PROBLEM", 131, 144], ["A. baumannii", "PROBLEM", 150, 162], ["purulent material", "PROBLEM", 227, 244], ["standard curves", "TEST", 265, 280], ["target gene plasmid dilution series", "TREATMENT", 294, 329], ["pneumoniae", "OBSERVATION", 53, 63], ["E. coli", "OBSERVATION", 107, 114], ["baumannii", "OBSERVATION", 153, 162], ["purulent", "OBSERVATION", 227, 235]]], ["Quality control reactions (quantitative real-time PCR for GAPDH human gene and qualitative real-time PCR for gB phocine herpes virus internal control [IC]) were carried out on all specimens [33].", [["specimens", "ANATOMY", 180, 189], ["GAPDH", "GENE_OR_GENE_PRODUCT", 58, 63], ["human", "ORGANISM", 64, 69], ["gB phocine herpes virus", "ORGANISM", 109, 132], ["GAPDH human gene", "DNA", 58, 74], ["gB", "PROTEIN", 109, 111], ["human", "SPECIES", 64, 69], ["phocine herpes virus", "SPECIES", 112, 132], ["human", "SPECIES", 64, 69], ["gB phocine herpes virus", "SPECIES", 109, 132], ["Quality control reactions", "PROBLEM", 0, 25], ["quantitative real-time PCR", "TEST", 27, 53], ["GAPDH human gene", "TEST", 58, 74], ["qualitative real-time PCR", "TEST", 79, 104], ["gB phocine herpes virus internal control [IC])", "TREATMENT", 109, 155]]], ["Quantitative GAPDH PCR was used as an indication of the cell content of each specimen because the GAPDH gene is present in human DNA.", [["cell", "ANATOMY", 56, 60], ["specimen", "ANATOMY", 77, 85], ["GAPDH", "GENE_OR_GENE_PRODUCT", 13, 18], ["cell", "CELL", 56, 60], ["GAPDH", "GENE_OR_GENE_PRODUCT", 98, 103], ["human", "ORGANISM", 123, 128], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["GAPDH gene", "DNA", 98, 108], ["human DNA", "DNA", 123, 132], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["Quantitative GAPDH PCR", "TEST", 0, 22], ["the cell content", "TEST", 52, 68], ["cell content", "OBSERVATION", 56, 68], ["GAPDH gene", "OBSERVATION", 98, 108], ["human DNA", "OBSERVATION", 123, 132]]], ["Negative (no template) controls were included on every extraction and PCR run to check purity of reagents.", [["every extraction", "TREATMENT", 49, 65], ["PCR", "TEST", 70, 73]]], ["Qualitative results were accepted if the internal control was positive or if at least 1 other target was positive.", [["positive", "OBSERVATION", 105, 113]]], ["Quantitative results were accepted if the internal control quantification cycle (Cq) value fell within the range \u00b11 log Cq difference to negative extraction controls.", [["the internal control quantification cycle", "TEST", 38, 79]]], ["Outside of this range, quantitative results were not accepted due to the potential for partial PCR inhibition leading to inaccuracy of measurement.Estimating Impact on Antimicrobial Prescribing ::: METHODSThe prescribed empirical therapy for each patient was compared with what antimicrobial(s) would have been appropriate for pathogen-directed therapy, based on the molecular identification result.", [["patient", "ORGANISM", 247, 254], ["patient", "SPECIES", 247, 254], ["partial PCR inhibition", "TREATMENT", 87, 109], ["measurement", "TEST", 135, 146], ["METHODSThe", "TREATMENT", 198, 208], ["empirical therapy", "TREATMENT", 220, 237], ["antimicrobial(s", "TREATMENT", 278, 293], ["pathogen-directed therapy", "TREATMENT", 327, 352]]], ["Appropriate pathogen-directed therapy was determined using UK national guidelines adapted for local antimicrobial susceptibility patterns (Supplementary Table 1) [1].Statistical Analyses ::: METHODSCategorical variables were compared using Fisher exact test or \u03c72 test.", [["Appropriate pathogen-directed therapy", "TREATMENT", 0, 37], ["UK national guidelines", "TREATMENT", 59, 81], ["local antimicrobial susceptibility patterns", "TREATMENT", 94, 137], ["Fisher exact test", "TEST", 240, 257], ["\u03c72 test", "TEST", 261, 268]]], ["Continuous data were assessed using the Shapiro\u2013Wilk W test for nonnormality and analyzed using the Mann\u2013Whitney U test or t test.", [["the Shapiro\u2013Wilk W test", "TEST", 36, 59], ["the Mann\u2013Whitney U test", "TEST", 96, 119], ["t test", "TEST", 123, 129]]], ["The McNemar test was used to compare paired proportions.", [["The McNemar test", "TEST", 0, 16]]], ["The Bonferroni method was used to correct for multiple comparisons during significance testing.", [["The Bonferroni method", "TREATMENT", 0, 21], ["significance testing", "TEST", 74, 94]]], ["To control for potential confounding factors that affect associations with the outcome of infection, we used logistic regression analysis.", [["infection", "DISEASE", 90, 99], ["potential confounding factors", "PROBLEM", 15, 44], ["infection", "PROBLEM", 90, 99], ["logistic regression analysis", "TEST", 109, 137], ["infection", "OBSERVATION", 90, 99]]], ["For the analysis of the outcome of infection, a combined outcome measure of 30-day mortality and/or intensive care unit (ICU) admission was used because of the infrequent occurrence of either event in our cohort.", [["infection", "DISEASE", 35, 44], ["infection", "PROBLEM", 35, 44], ["infection", "OBSERVATION", 35, 44]]], ["Data were analyzed using StatsDirect software, version 2.8 0 (Altrincham, United Kingdom).Patient Characteristics ::: RESULTSA total of 323 hospitalized adult patients with CAP were included in the study cohort; 55% were male and the median age was 67 years (Table 1).", [["CAP", "DISEASE", 173, 176], ["patients", "ORGANISM", 159, 167], ["Patient", "SPECIES", 90, 97], ["patients", "SPECIES", 159, 167], ["StatsDirect software", "TEST", 25, 45], ["version", "TEST", 47, 54], ["CAP", "PROBLEM", 173, 176]]], ["Critical care admission (ICU or high-dependency unit) was required for 18.6% of patients, with 12.4% admitted specifically to the ICU.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]]], "4d2622f35bf337f9b1cbb1d9125ff02865dfe514": [["The CoMSES Model Library has more than 780 publicly available models with over 40,000 downloads a year, but we are cognizant that building a tool does not mean that people will use it.", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171]]], ["We have bootstrapped the contents of this database by manually inspecting the publications on agent based and individual based models and entering categorical metadata on model code availability and documentation for these publications.Introduction MethodologyThere are many places and formats in which model code can be shared -an appendix of a journal article, an author's personal or institutional webpage, a GitHub repository, or a digital repository like the CoMSES Net Model Library.", [["agent", "TREATMENT", 94, 99]]], ["Sharing code on a personal or institutional website or as an appendix of a journal is a good start, but it is not a good long-term solution.", [["a good long-term solution", "TREATMENT", 114, 139]]], ["We believe that the only acceptable long-term solution is for model code to be documented and archived in a citable, trusted digital repository that adheres to the FORCE11 Software Citation Principles (Smith et al. 2016) .", [["acceptable long-term solution", "TREATMENT", 25, 54]]], ["That said, GitHub repositories can be integrated with a trusted digital repository like Zenodo (Zenodo, 2020) to create a citable software archive.", [["Zenodo (Zenodo", "TREATMENT", 88, 102]]], ["Trusted digital repositories provide guarantees for digital permanence and have backup and contingency plans for migrating content should the repository cease operations (Lin et al. 2020) .Introduction MethodologyAfter creating a database of model publications and links to model code, we contacted authors to inform them about best practices on archival of model code (Figure 1 ).", [["digital permanence", "TREATMENT", 52, 70], ["backup", "TREATMENT", 80, 86]]], ["Types of model sharing we distinguish include archives (e.g., the CoMSES Model Library, Zenodo, Open Science Framework), web-based version control repositories (e.g., GitHub, BitBucket, SourceForge), Journal, Personal or Organizational (e.g., Dropbox, Google Drive, a personal or institutional webpage), and framework websites (e.g., the NetLogo Modeling Commons, Cormas).Creating the databaseWe rely on the information we found in the publication, and we recognize that the model code may have been published online but not mentioned in the article or can be provided by authors upon request.", [["Zenodo", "TREATMENT", 88, 94], ["web-based version control repositories", "TREATMENT", 121, 159], ["Dropbox", "TREATMENT", 243, 250]]], ["Did it use a standard protocol called Overview-Design-Details (ODD) (Grimm et al. 2006 (Grimm et al. , 2020 , or did it use a nonprescriptive narrative? \u2022 Visualized Relationships.", [["a standard protocol", "TREATMENT", 11, 30]]], ["How were the algorithmic procedures documented?", [["the algorithmic procedures", "TEST", 9, 35]]], ["Did they describe the model in pseudocode or use mathematical equations to describe (parts) of the model?", [["mathematical equations", "TREATMENT", 49, 71]]], ["This information was included in our database, and as such, we will be able to perform citation and network analysis of the database.ResultsWe present the basic statistics of the current version of the database containing 7,500 publications on individual and agent-based models.", [["network analysis", "TEST", 100, 116]]], ["Those articles were published in more than 1,500 journals, which demonstrate the breadth of the application of this type of modeling, but also the fragmentation of the field.", [["breadth", "OBSERVATION_MODIFIER", 81, 88], ["fragmentation", "OBSERVATION", 147, 160]]], ["The increasing fraction of papers where code is available and the rapid increase of the absolute number of publications a year demonstrate the exponential growth of the number of models for which code is available.", [["increasing", "OBSERVATION_MODIFIER", 4, 14], ["fraction", "OBSERVATION_MODIFIER", 15, 23], ["rapid", "OBSERVATION_MODIFIER", 66, 71], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["exponential", "OBSERVATION_MODIFIER", 143, 154], ["growth", "OBSERVATION_MODIFIER", 155, 161]]], ["Those include a substantial number of ecology journals that report on findings from individual-based models and complexity related journals where the use of individual-based and agent-based modeling is a standard method.", [["a standard method", "TREATMENT", 202, 219], ["substantial", "OBSERVATION_MODIFIER", 16, 27]]], ["There is a substantial variation in the percentage of papers that share their model code.", [["substantial", "OBSERVATION_MODIFIER", 11, 22], ["variation", "OBSERVATION_MODIFIER", 23, 32]]], ["The Journal of Artificial Societies and Social Simulation, an open-access journal that recommends sharing model code, has the highest level with 45%.", [["Artificial Societies", "OBSERVATION", 15, 35]]], ["Since we distinguish 9.5% of all publications which use the ODD protocol of Grimm et al. (2006) and additional ODD variations, and those who do not use the ODD protocol, we provided in Table 2 information on potential differences.", [["the ODD protocol", "TREATMENT", 56, 72], ["the ODD protocol", "TREATMENT", 152, 168]]], ["If scholars use the ODD protocol, they are more likely to use flow charts and pseudocode and more likely to share the code.", [["the ODD protocol", "TREATMENT", 16, 32], ["pseudocode", "TREATMENT", 78, 88]]], ["Those correlations do not imply causation of using more ways to describe models and to share model code, as they may relate to the attributes of scholars adopting the ODD protocol.", [["ODD", "DISEASE", 167, 170], ["the ODD protocol", "TREATMENT", 163, 179]]], ["Moreover, we found that many publications which use the ODD protocol in name did not provide a detailed description of the model, which is acknowledged by Grimm et al. (2020) as one of the challenges of the adoption for the ODD protocol.", [["ODD", "DISEASE", 224, 227], ["the ODD protocol", "TREATMENT", 52, 68], ["the ODD protocol", "TREATMENT", 220, 236], ["many", "OBSERVATION_MODIFIER", 24, 28], ["publications", "OBSERVATION", 29, 41]]], ["Although all publications report simulation results, the majority of the publications do not mention which modeling platform or programming language was used for their study.", [["their study", "TEST", 162, 173]]], ["It is no surprise that NetLogo and Repast are popular platforms since they are specifically targeted for individual-based and agent-based modeling.", [["NetLogo", "CHEMICAL", 23, 30], ["NetLogo", "SIMPLE_CHEMICAL", 23, 30], ["no surprise", "UNCERTAINTY", 6, 17]]], ["For example, a Java model using Repast libraries might be listed as a Repast model based on the references in the article.", [["Repast libraries", "DNA", 32, 48], ["Repast libraries", "TREATMENT", 32, 48], ["a Repast model", "TEST", 68, 82]]], ["What might be interesting from Table 3 is the prominence of Python, which is not used in a prominent ABM modeling platform yet, and it's a high percentage of code sharing.", [["prominence", "OBSERVATION_MODIFIER", 46, 56], ["Python", "OBSERVATION", 60, 66]]], ["Perhaps this reflects the new generation of modelers who adopt new languages and different practices of code sharing.", [["new", "OBSERVATION_MODIFIER", 26, 29]]], ["Furthermore, it is notable that there are a substantial number of individual-based and agent-based models implemented in Fortran.", [["substantial", "OBSERVATION_MODIFIER", 44, 55], ["number", "OBSERVATION_MODIFIER", 56, 62]]], ["A possible explanation in differences in model descriptions are differences in awareness of the importance of sharing details of the model implementation leading to the published results.", [["possible explanation in", "UNCERTAINTY", 2, 25]]], ["58.9% of the publications mention one or more external sponsors that provided financial support for the research leading to the publication.", [["financial support", "TREATMENT", 78, 95]]], ["Table 6 demonstrates that there is a wide variety of where the model code is archived.", [["wide", "OBSERVATION_MODIFIER", 37, 41], ["variety", "OBSERVATION_MODIFIER", 42, 49]]], ["Using public archives is the golden standard, and 236 articles, 3.1% of the database, archives their code in permanent archives.", [["the database", "TEST", 72, 84]]], ["172 articles have been archived in repositories, especially Github, which provides public access but might not be permanent, and it might not be obvious which version is used for the publication.", [["public access", "TREATMENT", 83, 96]]], ["261 articles have model code included as an appendix, whether it is a code file or a print of the model code.", [["appendix", "ANATOMY", 44, 52]]], ["Figure 3 shows the fraction of the publications storing the code in different locations.", [["fraction", "OBSERVATION_MODIFIER", 19, 27], ["publications", "OBSERVATION", 35, 47]]], ["We see a rapid increase in archives and repositories in recent years.", [["rapid", "OBSERVATION_MODIFIER", 9, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23]]], ["This visualization of the network is to uses a modularity algorithm to find groups of nodes that are more connected with each other than others (Blondel et al. 2008) .", [["a modularity algorithm", "TREATMENT", 45, 67], ["nodes", "PROBLEM", 86, 91], ["nodes", "OBSERVATION", 86, 91]]], ["Figure 4 shows the nodes of the 10 biggest clusters.", [["nodes", "OBSERVATION", 19, 24]]], ["There is also a large medicine application cluster at the left of the network.", [["a large medicine application", "TREATMENT", 14, 42], ["large", "OBSERVATION_MODIFIER", 16, 21], ["left", "ANATOMY_MODIFIER", 58, 62]]], ["As a final step in the analysis, we ask whether the way scholars document their models and share their code affects whether their model is used.", [["the analysis", "TEST", 19, 31]]], ["With our current database we have we cannot test whether there is an increase of general citations due to code sharing.", [["increase", "OBSERVATION_MODIFIER", 69, 77]]], ["However, we can evaluate whether there are characteristics for publications in the database which explain why they have more citations by other model papers.", [["publications in the database", "PROBLEM", 63, 91]]], ["We are aware that a citation does not mean a reuse of the model or an endorsement of the quality of the model in the cited publication.J o u r n a l P r e -p r o o fIn order to evaluate whether there is any effect of citation by other model papers within the database, we performed a linear regression to explain the number of citations as a function of various factors, and we find that it is the way the model is described, not the code availability, that impacts the number of citations (Table 7) .", [["a l P r e -p r o o fIn order", "TEST", 145, 173], ["a linear regression", "PROBLEM", 282, 301]]], ["This is in line with the Milkowski et al. (2018) .J o u r n a l P r e -p r o o fSince the rapid increase in the number of papers in recent years as well as the fraction of publication for which model code is available, we have to be careful with this analysis.", [["the rapid", "PROBLEM", 86, 95], ["this analysis", "TEST", 246, 259], ["rapid", "OBSERVATION_MODIFIER", 90, 95], ["increase", "OBSERVATION", 96, 104]]], ["It takes some time for publications to gain citations due to the slow nature of publications.", [["the slow nature of publications", "PROBLEM", 61, 92], ["publications", "OBSERVATION", 80, 92]]], ["In a few years, this analysis should be repeated if a larger number of model publications are available with years of model code availability.", [["this analysis", "TEST", 16, 29]]], ["Doing such an analysis might focus on a specific field, such as ecological modeling, since there are different J o u r n a l P r e -p r o o f citation cultures among different fields of study.", [["an analysis", "TEST", 11, 22], ["citation cultures", "TEST", 142, 159], ["study", "TEST", 186, 191]]], ["In such a future analysis in a specific field, an a control variable might be included for the reputation or impact factor of the journal where the article is published.DiscussionResults published from computational science should, in principle, be reproducible, and the code should be available to be reused and built on.", [["a future analysis", "TEST", 8, 25]]], ["We see an increase in the fraction of publications for which code is available (about 18% in 2018).", [["increase", "OBSERVATION_MODIFIER", 10, 18], ["fraction", "OBSERVATION_MODIFIER", 26, 34]]], ["This is a promising trend, but since in many cases those models are available on a personal website or as an appendix to the journal article (only available for subscribers), current availability does not mean availability in the long run.", [["appendix", "ANATOMY", 109, 117]]], ["A large number of several projections of the COVID-19 crisis are difficult to put into context since there is no transparency about the underlying assumptions.", [["the COVID", "TEST", 41, 50], ["crisis", "PROBLEM", 54, 60], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["no", "UNCERTAINTY", 110, 112], ["transparency", "OBSERVATION", 113, 125]]], ["Some responses included URLs where code is currently available, and other responses indicated that the author no longer had access to the code.DiscussionIncreasing use of empirical data of human subjects to make empirical-grounded agentbased models could be a concern for sharing model code on models of human social dynamics.", [["human", "ORGANISM", 189, 194], ["human", "ORGANISM", 304, 309], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 304, 309], ["empirical data of human subjects", "TREATMENT", 171, 203], ["empirical-grounded agentbased models", "TREATMENT", 212, 248]]], ["However, sharing processed data about human subjects is a common practice in the social science (Yoon and Kim, 2017) .", [["human", "ORGANISM", 38, 43], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43]]], ["There are ethical and moral objections raised to share data in the social sciences, and alternative policies for data sharing are part of the debate (Mauthner and Parry, 2013; Tenopir et al., 2015) .", [["ethical and moral objections", "PROBLEM", 10, 38]]], ["There is no lack of technical solutions, such as public archives.", [["no", "UNCERTAINTY", 9, 11], ["lack", "OBSERVATION_MODIFIER", 12, 16]]], ["At COMSES Net, we have created an open code badge that various journals have begun to adopt to signal best practices and provide durable links to model code (https://www.comses.net/resources/open-code-badge/).DiscussionAlthough we see some positive trends in the fraction of code availability in publications, the transition towards a desirable level of practice will be a long-term process.", [["a long-term process", "PROBLEM", 371, 390]]], ["It requires a change in norms and habits.", [["a change in norms and habits", "PROBLEM", 12, 40]]], ["The new generation of scholars using computational models must be trained in the tools available to derive best practices.", [["computational models", "TREATMENT", 37, 57], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Table A1 shows the most cited articles, which are mainly within ecological modeling.", [["most cited", "OBSERVATION_MODIFIER", 19, 29]]], ["Table A2 presents the most prolific authors within the database.", [["most prolific", "OBSERVATION_MODIFIER", 22, 35]]], ["There is quite a vast diversity of code availability practices among those scholars.", [["vast", "OBSERVATION_MODIFIER", 17, 21], ["diversity", "OBSERVATION", 22, 31]]], ["As such, it is not a surprise that a network of journals connected by co-citations and where size relates to the number of citations has Ecological Modeling in the center.", [["size", "OBSERVATION_MODIFIER", 93, 97]]], ["We used the software Voxviewer to visualize the network of journals (Van Eck and Waltman, 2010).", [["the software Voxviewer", "TREATMENT", 8, 30]]], ["We see a dominant cluster of ecological models (red), a small cluster on fisheries (yellow), a more theoryoriented ecology cluster (green), and a more interdisciplinary cluster that includes physics and modeling journals (blue).DiscussionJ o u r n a l P r e -p r o o f Figure A1 : Journals where most cited references are published.", [["a small cluster on fisheries (yellow", "PROBLEM", 54, 90], ["dominant", "OBSERVATION_MODIFIER", 9, 17], ["cluster", "OBSERVATION_MODIFIER", 18, 25], ["ecological models", "OBSERVATION", 29, 46], ["small", "OBSERVATION_MODIFIER", 56, 61], ["cluster", "OBSERVATION_MODIFIER", 62, 69]]], ["Colors refer to clusters of journals based on co-citation patterns.DiscussionLike the journals, we can look at the most cited authors by all 7,500 articles, and Volker Grimm has co-authored 5 of the top 10 most cited references (Table A4) , it is no surprise that we see Volker Grimm having the most significant node, representing the largest number of citations ( Figure A2 ).", [["node", "ANATOMY", 312, 316], ["node", "MULTI-TISSUE_STRUCTURE", 312, 316], ["no", "UNCERTAINTY", 247, 249], ["significant", "OBSERVATION_MODIFIER", 300, 311], ["node", "OBSERVATION", 312, 316], ["largest", "OBSERVATION_MODIFIER", 335, 342]]], ["The blue cluster is ecology oriented, while the red cluster contains classic authors from complexity science and social dilemmas, such as Robert Axelrod, Thomas Schelling, and Martin Nowak.", [["blue", "OBSERVATION_MODIFIER", 4, 8], ["cluster", "OBSERVATION_MODIFIER", 9, 16]]], ["A third cluster, the green color, is dominated by scholars from economics such as Herbert Simon, Brian Arthur, and Leah Tesfatsion.", [["A third cluster, the green color", "PROBLEM", 0, 32], ["green color", "OBSERVATION", 21, 32]]], ["The fourth, yellow cluster features scholars working on human-environmental interactions, including Fran\u00e7ois Bousquet, Dawn Parker, and Michael Batty.DiscussionJ o u r n a l P r e -p r o o f Figure A2 : Most cited authors connected via co-citation patterns.DiscussionWe do not see obvious specific clusters in the network of 7,500 articles, remarkably having a different pattern of making code available ( Figure A3 ).", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["fourth", "OBSERVATION_MODIFIER", 4, 10]]], ["Figure A3 : The network of the 7,500 publications colored for availability of code (Left with green referring to code available), and modeling platform used (right).Dear X,We are contacting you on behalf of CoMSES Net, an open research community dedicated to advancing transparency in scientific computing.", [["right", "ANATOMY_MODIFIER", 158, 163]]], ["As you may be aware, there is an increasing demand for transparency and sharing of data and model code used to accomplish the research described in scientific publications.", [["an increasing demand", "PROBLEM", 30, 50], ["increasing", "OBSERVATION_MODIFIER", 33, 43]]], ["The widespread use of computation and digital data across science makes this critical for replicability and scientific advancement.", [["digital data", "TEST", 38, 50], ["scientific advancement", "TREATMENT", 108, 130], ["widespread", "OBSERVATION_MODIFIER", 4, 14]]], ["If your model source code is not yet archived, we encourage you to do so at a trusted DOI issuing digital repository.", [["DOI", "CHEMICAL", 86, 89], ["DOI", "CHEMICAL", 86, 89]]]], "PMC7121766": [["James Hardy performed the firstlung transplant in 1963 at the University of Mississippi Medical Center in a 58 year old convict serving a life sentence.", [["the firstlung transplant", "TREATMENT", 22, 46]]], ["The patient succumbed to renal failure 18 days after the procedure.", [["renal", "ANATOMY", 25, 30], ["renal failure", "DISEASE", 25, 38], ["patient", "ORGANISM", 4, 11], ["renal", "ORGAN", 25, 30], ["patient", "SPECIES", 4, 11], ["renal failure", "PROBLEM", 25, 38], ["the procedure", "TREATMENT", 53, 66], ["renal", "ANATOMY", 25, 30], ["failure", "OBSERVATION", 31, 38]]], ["There were many subsequent attempts, but it was not until 1983 at the University of Toronto that Dr. Joel Cooper performed the first successful long-term lung transplant.", [["lung", "ANATOMY", 154, 158], ["lung", "ORGAN", 154, 158], ["the first successful long-term lung transplant", "TREATMENT", 123, 169], ["lung", "ANATOMY", 154, 158], ["transplant", "OBSERVATION", 159, 169]]], ["Dr. Denton Cooley attempted the first heart-lung transplantation in a child in 1968.", [["heart-lung", "ANATOMY", 38, 48], ["heart", "ORGAN", 38, 43], ["lung", "ORGAN", 44, 48], ["the first heart-lung transplantation", "TREATMENT", 28, 64], ["heart", "ANATOMY", 38, 43], ["lung", "ANATOMY", 44, 48], ["transplantation", "OBSERVATION", 49, 64]]], ["The patient was a 2 month old with pulmonary hypertension and a complete AV canal, but they only survived for 14 hours.", [["pulmonary", "ANATOMY", 35, 44], ["AV canal", "ANATOMY", 73, 81], ["pulmonary hypertension", "DISEASE", 35, 57], ["patient", "ORGANISM", 4, 11], ["pulmonary", "ORGAN", 35, 44], ["AV canal", "MULTI-TISSUE_STRUCTURE", 73, 81], ["patient", "SPECIES", 4, 11], ["pulmonary hypertension", "PROBLEM", 35, 57], ["a complete AV canal", "PROBLEM", 62, 81], ["pulmonary", "ANATOMY", 35, 44], ["hypertension", "OBSERVATION", 45, 57], ["AV canal", "ANATOMY", 73, 81]]], ["The first successful isolated lung transplant in a child was performed at theUniversity of Toronto in 1987 in a 16 year old boy with pulmonary fibrosis.", [["lung", "ANATOMY", 30, 34], ["pulmonary", "ANATOMY", 133, 142], ["pulmonary fibrosis", "DISEASE", 133, 151], ["lung", "ORGAN", 30, 34], ["boy", "ORGANISM", 124, 127], ["pulmonary", "ORGAN", 133, 142], ["boy", "SPECIES", 124, 127], ["The first successful isolated lung transplant", "TREATMENT", 0, 45], ["pulmonary fibrosis", "PROBLEM", 133, 151], ["lung", "ANATOMY", 30, 34], ["transplant", "OBSERVATION", 35, 45], ["pulmonary", "ANATOMY", 133, 142], ["fibrosis", "OBSERVATION", 143, 151]]], ["The 1990s witnessed a rapid growth in the number of pediatric lung transplants performed annually.", [["lung", "ANATOMY", 62, 66], ["lung", "ORGAN", 62, 66], ["a rapid growth", "PROBLEM", 20, 34], ["pediatric lung transplants", "TREATMENT", 52, 78], ["rapid", "OBSERVATION_MODIFIER", 22, 27], ["growth", "OBSERVATION_MODIFIER", 28, 34], ["lung", "ANATOMY", 62, 66], ["transplants", "OBSERVATION", 67, 78]]], ["However, unlike lung transplantation in adults, that growth has not continued in the 2000s.", [["lung", "ANATOMY", 16, 20], ["lung", "ORGAN", 16, 20], ["lung transplantation", "TREATMENT", 16, 36], ["lung", "ANATOMY", 16, 20], ["transplantation", "OBSERVATION", 21, 36]]], ["At present, there areapproximately 100 lung transplants done worldwide per year in children.IndicationsIn general, lung transplantationshould be considered in children suffering from life threatening end-stage lung disease or pulmonary vascular disease refractory to medical therapy.", [["lung", "ANATOMY", 39, 43], ["lung", "ANATOMY", 115, 119], ["lung", "ANATOMY", 210, 214], ["pulmonary vascular", "ANATOMY", 226, 244], ["end-stage lung disease", "DISEASE", 200, 222], ["pulmonary vascular disease", "DISEASE", 226, 252], ["lung", "ORGAN", 39, 43], ["children", "ORGANISM", 83, 91], ["lung", "ORGAN", 115, 119], ["children", "ORGANISM", 159, 167], ["lung", "ORGAN", 210, 214], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 226, 244], ["children", "SPECIES", 83, 91], ["children", "SPECIES", 159, 167], ["lung transplants", "TREATMENT", 39, 55], ["life threatening end-stage lung disease", "PROBLEM", 183, 222], ["pulmonary vascular disease", "PROBLEM", 226, 252], ["medical therapy", "TREATMENT", 267, 282], ["lung", "ANATOMY", 39, 43], ["transplants", "OBSERVATION", 44, 55], ["lung", "ANATOMY", 115, 119], ["-stage", "OBSERVATION_MODIFIER", 203, 209], ["lung", "ANATOMY", 210, 214], ["disease", "OBSERVATION", 215, 222], ["pulmonary", "ANATOMY_MODIFIER", 226, 235], ["vascular", "ANATOMY", 236, 244], ["disease", "OBSERVATION", 245, 252]]], ["Pulmonary hypertension, secondary to congenital heart disease or other pulmonary vascular disorders, is the leading indication in infancy followed by interstitial lung disease, including surfactant protein abnormalities.", [["Pulmonary", "ANATOMY", 0, 9], ["heart", "ANATOMY", 48, 53], ["pulmonary vascular", "ANATOMY", 71, 89], ["interstitial lung", "ANATOMY", 150, 167], ["Pulmonary hypertension", "DISEASE", 0, 22], ["congenital heart disease", "DISEASE", 37, 61], ["pulmonary vascular disorders", "DISEASE", 71, 99], ["interstitial lung disease", "DISEASE", 150, 175], ["Pulmonary", "ORGAN", 0, 9], ["heart", "ORGAN", 48, 53], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 71, 89], ["lung", "ORGAN", 163, 167], ["Pulmonary hypertension", "PROBLEM", 0, 22], ["congenital heart disease", "PROBLEM", 37, 61], ["other pulmonary vascular disorders", "PROBLEM", 65, 99], ["interstitial lung disease", "PROBLEM", 150, 175], ["surfactant protein abnormalities", "PROBLEM", 187, 219], ["hypertension", "OBSERVATION", 10, 22], ["congenital", "OBSERVATION_MODIFIER", 37, 47], ["heart", "ANATOMY", 48, 53], ["disease", "OBSERVATION", 54, 61], ["pulmonary vascular", "ANATOMY", 71, 89], ["disorders", "OBSERVATION", 90, 99], ["interstitial", "ANATOMY_MODIFIER", 150, 162], ["lung", "ANATOMY", 163, 167], ["disease", "OBSERVATION", 168, 175], ["surfactant protein", "OBSERVATION", 187, 205]]], ["For older children and adolescents cystic fibrosis (CF) accounts for half tothree quarters of all lung transplant procedures.", [["cystic", "ANATOMY", 35, 41], ["lung", "ANATOMY", 98, 102], ["cystic fibrosis", "DISEASE", 35, 50], ["CF", "DISEASE", 52, 54], ["children", "ORGANISM", 10, 18], ["lung", "ORGAN", 98, 102], ["children", "SPECIES", 10, 18], ["adolescents", "SPECIES", 23, 34], ["cystic fibrosis", "PROBLEM", 35, 50], ["all lung transplant procedures", "TREATMENT", 94, 124], ["cystic", "OBSERVATION_MODIFIER", 35, 41], ["fibrosis", "OBSERVATION", 42, 50], ["lung", "ANATOMY", 98, 102], ["transplant", "OBSERVATION", 103, 113]]], ["Although the most common diagnoses for children receiving lung transplants are listed in Table 74.1 determining which children may benefit from lung transplantation is often not as straightforward.", [["lung", "ANATOMY", 58, 62], ["lung", "ANATOMY", 144, 148], ["children", "ORGANISM", 39, 47], ["lung", "ORGAN", 58, 62], ["children", "ORGANISM", 118, 126], ["lung", "ORGAN", 144, 148], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 118, 126], ["lung transplants", "TREATMENT", 58, 74], ["lung transplantation", "TREATMENT", 144, 164], ["lung", "ANATOMY", 58, 62], ["transplants", "OBSERVATION", 63, 74], ["lung", "ANATOMY", 144, 148], ["transplantation", "OBSERVATION", 149, 164]]], ["Transplant physicians thoughtfully gage when a patient has entered the transplant window.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["the transplant window", "TREATMENT", 67, 88], ["transplant", "OBSERVATION", 71, 81]]], ["This is the point intime where the patient is sick enough to warrant lung transplantation but not so sick that the odds of a good outcome have markedly deteriorated.", [["lung", "ANATOMY", 69, 73], ["patient", "ORGANISM", 35, 42], ["lung", "ORGAN", 69, 73], ["patient", "SPECIES", 35, 42], ["lung transplantation", "TREATMENT", 69, 89], ["lung", "ANATOMY", 69, 73], ["transplantation", "OBSERVATION", 74, 89], ["markedly", "OBSERVATION_MODIFIER", 143, 151], ["deteriorated", "OBSERVATION_MODIFIER", 152, 164]]], ["Multiple variables must be carefully considered including the trajectory of the underlying disease.", [["Multiple variables", "PROBLEM", 0, 18], ["the underlying disease", "PROBLEM", 76, 98], ["disease", "OBSERVATION", 91, 98]]], ["Lung transplantation is a procedure of last resort and, when performed, should provide the patient with not only an improved likelihood of survival over theirunderlying disease but also an improvement in their quality of life.IndicationsLung transplantation is a lifelong commitment to a complex and demanding regimen that includes daily immunosuppressive therapy, frequent physician visits, routine surveillance procedures, including bronchoscopy,transbronchial biopsy, radiographic examinations, and blood work.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ANATOMY", 237, 241], ["blood", "ANATOMY", 502, 507], ["Lung", "ORGAN", 0, 4], ["patient", "ORGANISM", 91, 98], ["Lung", "ORGAN", 237, 241], ["blood", "ORGANISM_SUBSTANCE", 502, 507], ["patient", "SPECIES", 91, 98], ["Lung transplantation", "TREATMENT", 0, 20], ["a procedure", "TREATMENT", 24, 35], ["theirunderlying disease", "PROBLEM", 153, 176], ["Lung transplantation", "TREATMENT", 237, 257], ["a complex and demanding regimen", "TREATMENT", 286, 317], ["daily immunosuppressive therapy", "TREATMENT", 332, 363], ["routine surveillance procedures", "TEST", 392, 423], ["bronchoscopy", "TEST", 435, 447], ["transbronchial biopsy", "TEST", 448, 469], ["radiographic examinations", "TEST", 471, 496], ["blood work", "TEST", 502, 512], ["transplantation", "OBSERVATION", 5, 20], ["improvement", "OBSERVATION_MODIFIER", 189, 200], ["Lung", "ANATOMY", 237, 241], ["transplantation", "OBSERVATION", 242, 257], ["transbronchial", "ANATOMY", 448, 462]]], ["Therefore, the pediatric patient must have adequate family support and access to transplant services and medications as well as demonstrate a willingness and ability to adhere to this admittedly complex regimen.IndicationsFor the referring center, the correct timing of the referral to a transplant center is at times difficult to determine.", [["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["transplant services", "TREATMENT", 81, 100], ["medications", "TREATMENT", 105, 116], ["this admittedly complex regimen", "TREATMENT", 179, 210]]], ["Even for CF, where many investigators have rigorously studied this question, the answer remains unclear.", [["CF", "PROBLEM", 9, 11]]], ["Therefore, it is best for the referring center to consider the possibility of lung transplantation in a child whose pulmonary disease has a well defined trajectory of continued decline and whose life expectancy is severely limited by the disease process.ContraindicationsContraindications can bedivided into two categories: absolute and relative (Table 74.2).", [["lung", "ANATOMY", 78, 82], ["pulmonary", "ANATOMY", 116, 125], ["pulmonary disease", "DISEASE", 116, 133], ["lung", "ORGAN", 78, 82], ["pulmonary", "ORGAN", 116, 125], ["lung transplantation", "TREATMENT", 78, 98], ["pulmonary disease", "PROBLEM", 116, 133], ["the disease process", "PROBLEM", 234, 253], ["lung", "ANATOMY", 78, 82], ["transplantation", "OBSERVATION", 83, 98], ["pulmonary", "ANATOMY", 116, 125], ["disease", "OBSERVATION", 126, 133], ["disease", "OBSERVATION", 238, 245]]], ["These often vary from one transplant program and the difference is based on experience, expertise, and the center\u2019s view of the available data.", [["one transplant program", "TREATMENT", 22, 44]]], ["There is general agreement that multi-organ disorders, active malignancy, or certain types of active infection are absolute contraindications to transplant.", [["multi-organ", "ANATOMY", 32, 43], ["multi-organ disorders", "DISEASE", 32, 53], ["malignancy", "DISEASE", 62, 72], ["infection", "DISEASE", 101, 110], ["multi-organ disorders", "PROBLEM", 32, 53], ["active malignancy", "PROBLEM", 55, 72], ["active infection", "PROBLEM", 94, 110], ["transplant", "TREATMENT", 145, 155], ["multi-organ", "ANATOMY", 32, 43], ["active", "OBSERVATION_MODIFIER", 55, 61], ["malignancy", "OBSERVATION", 62, 72], ["active", "OBSERVATION_MODIFIER", 94, 100], ["infection", "OBSERVATION", 101, 110]]], ["At some centers multi-organ transplantation may be possible in select individuals.", [["multi-organ", "ANATOMY", 16, 27], ["multi-organ transplantation", "TREATMENT", 16, 43], ["multi-organ transplantation", "OBSERVATION", 16, 43], ["may be possible", "UNCERTAINTY", 44, 59]]], ["This may include heart-lung transplantation and in patients with CF combined liver\u2013lung transplantation.Specific indications ::: Cystic Fibrosis ::: Disease Specific Indications and ContraindicationsProgressive lung disease and worsening quality of life despite optimal medical therapy; FEV1 <30% predicted.Specific contraindications ::: Cystic Fibrosis ::: Disease Specific Indications and ContraindicationsVaries by individual transplant centers, but most commonly center around microbiologic concerns with Burkholderia cenocepacia constituting one of the more common absolute contraindications.", [["heart", "ANATOMY", 17, 22], ["lung", "ANATOMY", 23, 27], ["liver\u2013lung", "ANATOMY", 77, 87], ["Cystic", "ANATOMY", 129, 135], ["lung", "ANATOMY", 211, 215], ["Cystic", "ANATOMY", 338, 344], ["Fibrosis", "DISEASE", 136, 144], ["lung disease", "DISEASE", 211, 223], ["Fibrosis", "DISEASE", 345, 353], ["heart", "ORGAN", 17, 22], ["lung", "ORGAN", 23, 27], ["patients", "ORGANISM", 51, 59], ["lung", "ORGAN", 211, 215], ["Burkholderia cenocepacia", "ORGANISM", 509, 533], ["patients", "SPECIES", 51, 59], ["Burkholderia cenocepacia", "SPECIES", 509, 533], ["Burkholderia cenocepacia", "SPECIES", 509, 533], ["heart-lung transplantation", "TREATMENT", 17, 43], ["CF combined liver\u2013lung transplantation", "TREATMENT", 65, 103], ["Cystic Fibrosis", "PROBLEM", 129, 144], ["Progressive lung disease", "PROBLEM", 199, 223], ["worsening quality of life", "PROBLEM", 228, 253], ["optimal medical therapy", "TREATMENT", 262, 285], ["FEV1", "TEST", 287, 291], ["Cystic Fibrosis", "PROBLEM", 338, 353], ["Burkholderia cenocepacia", "PROBLEM", 509, 533], ["heart", "ANATOMY", 17, 22], ["lung", "ANATOMY", 23, 27], ["transplantation", "OBSERVATION", 28, 43], ["liver\u2013lung", "ANATOMY", 77, 87], ["transplantation", "OBSERVATION", 88, 103], ["Fibrosis", "OBSERVATION", 136, 144], ["lung", "ANATOMY", 211, 215], ["disease", "OBSERVATION", 216, 223], ["worsening", "OBSERVATION_MODIFIER", 228, 237], ["Fibrosis", "OBSERVATION", 345, 353]]], ["Many centers now consider infection with Mycobacterium abscessus either an absolute or relative contraindication and this can vary from center to center based on whether the patient is only culture positive and smear negative or culture positive and smear positive.", [["infection", "DISEASE", 26, 35], ["Mycobacterium abscessus", "DISEASE", 41, 64], ["Mycobacterium abscessus", "ORGANISM", 41, 64], ["patient", "ORGANISM", 174, 181], ["Mycobacterium abscessus", "SPECIES", 41, 64], ["patient", "SPECIES", 174, 181], ["Mycobacterium abscessus", "SPECIES", 41, 64], ["infection", "PROBLEM", 26, 35], ["Mycobacterium abscessus", "PROBLEM", 41, 64], ["culture", "TEST", 190, 197], ["smear", "TEST", 211, 216], ["culture", "TEST", 229, 236], ["smear positive", "PROBLEM", 250, 264], ["infection", "OBSERVATION", 26, 35], ["Mycobacterium abscessus", "OBSERVATION", 41, 64]]], ["The data presently available suggest that outcomes for patients infected with other nontuberculous mycobacteria are not substantially different than for patients not infected with those organisms.", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 153, 161], ["The data", "TEST", 0, 8], ["patients infected with other nontuberculous mycobacteria", "PROBLEM", 55, 111], ["nontuberculous", "OBSERVATION_MODIFIER", 84, 98], ["mycobacteria", "OBSERVATION", 99, 111], ["substantially different", "OBSERVATION_MODIFIER", 120, 143]]], ["Other potential relative contraindications may include malnutrition, poorly controlled diabetes, osteoporosis, previous pleurodesis (especially talc), and liver failure, if the center cannot perform a combined liver\u2013lung transplant.Specific indications ::: Surfactant Dysfunction Syndromes ::: Disease Specific Indications and ContraindicationsOnce a decision to pursue transplant has been made, patients with SPB deficiency should be transferred as soon as a possible to the transplant center.", [["liver", "ANATOMY", 155, 160], ["liver\u2013lung", "ANATOMY", 210, 220], ["malnutrition", "DISEASE", 55, 67], ["diabetes", "DISEASE", 87, 95], ["osteoporosis", "DISEASE", 97, 109], ["pleurodesis", "DISEASE", 120, 131], ["talc", "DISEASE", 144, 148], ["liver failure", "DISEASE", 155, 168], ["Dysfunction Syndromes", "DISEASE", 268, 289], ["SPB deficiency", "DISEASE", 410, 424], ["liver", "ORGAN", 155, 160], ["patients", "ORGANISM", 396, 404], ["SPB", "CELLULAR_COMPONENT", 410, 413], ["patients", "SPECIES", 396, 404], ["malnutrition", "PROBLEM", 55, 67], ["poorly controlled diabetes", "PROBLEM", 69, 95], ["osteoporosis", "PROBLEM", 97, 109], ["previous pleurodesis", "TREATMENT", 111, 131], ["liver failure", "PROBLEM", 155, 168], ["a combined liver\u2013lung transplant", "TREATMENT", 199, 231], ["Surfactant Dysfunction Syndromes", "PROBLEM", 257, 289], ["transplant", "TREATMENT", 370, 380], ["SPB deficiency", "PROBLEM", 410, 424], ["malnutrition", "OBSERVATION", 55, 67], ["poorly controlled", "OBSERVATION_MODIFIER", 69, 86], ["diabetes", "OBSERVATION", 87, 95], ["osteoporosis", "OBSERVATION", 97, 109], ["pleurodesis", "OBSERVATION", 120, 131], ["liver", "ANATOMY", 155, 160], ["failure", "OBSERVATION", 161, 168], ["liver\u2013lung", "ANATOMY", 210, 220], ["transplant", "OBSERVATION", 221, 231]]], ["For the other surfactant processing abnormalities, lung transplantation is indicated for refractory respiratory failure or progressive respiratory insufficiency unresponsive to medical interventions.Specific contraindications ::: Surfactant Dysfunction Syndromes ::: Disease Specific Indications and ContraindicationsSignificant neurologic injury and, at some centers, VA-ECMO.Specific indications ::: Pulmonary Vascular Disorders ::: Disease Specific Indications and ContraindicationsIdiopathic pulmonary hypertension \u2013 patients who have failed medical managementSpecific indications ::: Pulmonary Vascular Disorders ::: Disease Specific Indications and ContraindicationsPulmonary venous anomalies \u2013 upon making the diagnosis urgent referral is recommendedSpecific indications ::: Pulmonary Vascular Disorders ::: Disease Specific Indications and ContraindicationsCongenital heart disease or inadequate pulmonary vascular bed \u2013 progressive severe hypoxia, syncope, massive hemoptysisSpecific contraindications ::: Pulmonary Vascular Disorders ::: Disease Specific Indications and ContraindicationsMultiple prior thoracotomies associated with development of extensive collateral circulation and/or significant presence of preformed antibodies.Donor EvaluationUnfortunately, not only does therecontinue to be a shortage of donors but data from the OPTN/SRTR database in the United States shows that, in 2012, of the 8143 organ donors only 1708 donated lungs.", [["lung", "ANATOMY", 51, 55], ["respiratory", "ANATOMY", 100, 111], ["respiratory", "ANATOMY", 135, 146], ["neurologic", "ANATOMY", 329, 339], ["Vascular", "ANATOMY", 412, 420], ["pulmonary", "ANATOMY", 496, 505], ["Vascular", "ANATOMY", 599, 607], ["Pulmonary venous", "ANATOMY", 672, 688], ["Vascular", "ANATOMY", 792, 800], ["heart", "ANATOMY", 876, 881], ["pulmonary vascular", "ANATOMY", 904, 922], ["Vascular", "ANATOMY", 1025, 1033], ["collateral", "ANATOMY", 1168, 1178], ["organ", "ANATOMY", 1420, 1425], ["lungs", "ANATOMY", 1451, 1456], ["respiratory failure", "DISEASE", 100, 119], ["respiratory insufficiency", "DISEASE", 135, 160], ["Dysfunction Syndromes", "DISEASE", 241, 262], ["neurologic injury", "DISEASE", 329, 346], ["Pulmonary Vascular Disorders", "DISEASE", 402, 430], ["ContraindicationsIdiopathic pulmonary hypertension", "DISEASE", 468, 518], ["Pulmonary Vascular Disorders", "DISEASE", 589, 617], ["Pulmonary venous anomalies", "DISEASE", 672, 698], ["Pulmonary Vascular Disorders", "DISEASE", 782, 810], ["Congenital heart disease", "DISEASE", 865, 889], ["hypoxia", "DISEASE", 948, 955], ["syncope", "DISEASE", 957, 964], ["Pulmonary Vascular Disorders", "DISEASE", 1015, 1043], ["lung", "ORGAN", 51, 55], ["Vascular", "MULTI-TISSUE_STRUCTURE", 412, 420], ["pulmonary", "ORGAN", 496, 505], ["patients", "ORGANISM", 521, 529], ["Vascular", "MULTI-TISSUE_STRUCTURE", 599, 607], ["Pulmonary venous", "MULTI-TISSUE_STRUCTURE", 672, 688], ["Vascular", "MULTI-TISSUE_STRUCTURE", 792, 800], ["heart", "ORGAN", 876, 881], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 904, 922], ["Vascular", "MULTI-TISSUE_STRUCTURE", 1025, 1033], ["collateral circulation", "MULTI-TISSUE_STRUCTURE", 1168, 1190], ["donors", "ORGANISM", 1322, 1328], ["organ", "ORGAN", 1420, 1425], ["lungs", "ORGAN", 1451, 1456], ["preformed antibodies", "PROTEIN", 1222, 1242], ["OPTN", "DNA", 1347, 1351], ["patients", "SPECIES", 521, 529], ["the other surfactant processing abnormalities", "PROBLEM", 4, 49], ["lung transplantation", "TREATMENT", 51, 71], ["refractory respiratory failure", "PROBLEM", 89, 119], ["progressive respiratory insufficiency", "PROBLEM", 123, 160], ["medical interventions", "TREATMENT", 177, 198], ["Surfactant Dysfunction Syndromes", "PROBLEM", 230, 262], ["Significant neurologic injury", "PROBLEM", 317, 346], ["ECMO", "TREATMENT", 372, 376], ["Pulmonary Vascular Disorders", "PROBLEM", 402, 430], ["ContraindicationsIdiopathic pulmonary hypertension", "PROBLEM", 468, 518], ["failed medical management", "TREATMENT", 539, 564], ["Pulmonary Vascular Disorders", "PROBLEM", 589, 617], ["Pulmonary venous anomalies", "PROBLEM", 672, 698], ["Pulmonary Vascular Disorders", "PROBLEM", 782, 810], ["Congenital heart disease", "PROBLEM", 865, 889], ["inadequate pulmonary vascular bed", "PROBLEM", 893, 926], ["progressive severe hypoxia", "PROBLEM", 929, 955], ["syncope", "PROBLEM", 957, 964], ["massive hemoptysisSpecific contraindications", "PROBLEM", 966, 1010], ["Pulmonary Vascular Disorders", "PROBLEM", 1015, 1043], ["ContraindicationsMultiple prior thoracotomies", "TREATMENT", 1081, 1126], ["extensive collateral circulation", "PROBLEM", 1158, 1190], ["preformed antibodies", "PROBLEM", 1222, 1242], ["lung", "ANATOMY", 51, 55], ["transplantation", "OBSERVATION", 56, 71], ["refractory", "OBSERVATION_MODIFIER", 89, 99], ["respiratory failure", "OBSERVATION", 100, 119], ["progressive", "OBSERVATION_MODIFIER", 123, 134], ["respiratory insufficiency", "OBSERVATION", 135, 160], ["injury", "OBSERVATION", 340, 346], ["Vascular", "ANATOMY", 412, 420], ["Disorders", "OBSERVATION", 421, 430], ["pulmonary", "ANATOMY", 496, 505], ["hypertension", "OBSERVATION", 506, 518], ["Vascular", "ANATOMY", 599, 607], ["Disorders", "OBSERVATION", 608, 617], ["venous", "ANATOMY", 682, 688], ["anomalies", "OBSERVATION", 689, 698], ["Vascular", "ANATOMY", 792, 800], ["Disorders", "OBSERVATION", 801, 810], ["heart", "ANATOMY", 876, 881], ["disease", "OBSERVATION", 882, 889], ["pulmonary vascular", "ANATOMY", 904, 922], ["progressive", "OBSERVATION_MODIFIER", 929, 940], ["severe", "OBSERVATION_MODIFIER", 941, 947], ["hypoxia", "OBSERVATION", 948, 955], ["massive", "OBSERVATION_MODIFIER", 966, 973], ["Vascular", "ANATOMY", 1025, 1033], ["Disorders", "OBSERVATION", 1034, 1043], ["thoracotomies", "OBSERVATION", 1113, 1126], ["extensive", "OBSERVATION_MODIFIER", 1158, 1167], ["collateral circulation", "OBSERVATION", 1168, 1190], ["antibodies", "OBSERVATION", 1232, 1242], ["lungs", "ANATOMY", 1451, 1456]]], ["In other words, only 21% of organ donors had lungs that were deemed suitable for procurement.", [["organ", "ANATOMY", 28, 33], ["lungs", "ANATOMY", 45, 50], ["organ", "ORGAN", 28, 33], ["donors", "ORGANISM", 34, 40], ["lungs", "ORGAN", 45, 50], ["lungs", "ANATOMY", 45, 50]]], ["The reasons are varied and include the mechanism of death, consequences of mechanical ventilation, and donormanagement, but they highlight the importance of understanding what characteristics make a donor acceptable.", [["death", "DISEASE", 52, 57], ["death", "PROBLEM", 52, 57], ["mechanical ventilation", "TREATMENT", 75, 97], ["donormanagement", "TREATMENT", 103, 118], ["mechanical ventilation", "OBSERVATION", 75, 97]]], ["Beyond the basics of matching for size and blood type, the characteristics outlined in Table 74.3 may contribute to both short- and long-term outcomes and determine whether the donor lungs will be accepted by a transplant center.Surgical TechniqueThe surgical technique used inchildren is similar to that used in adults with the following exceptions: (i) virtually all children will require cardiopulmonary bypass, (ii) in children bilateral, as opposed to single, lung transplantation is much more common.", [["blood", "ANATOMY", 43, 48], ["lungs", "ANATOMY", 183, 188], ["cardiopulmonary", "ANATOMY", 391, 406], ["lung", "ANATOMY", 465, 469], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["lungs", "ORGAN", 183, 188], ["children", "ORGANISM", 369, 377], ["children", "ORGANISM", 423, 431], ["lung", "ORGAN", 465, 469], ["children", "SPECIES", 369, 377], ["children", "SPECIES", 423, 431], ["size and blood type", "PROBLEM", 34, 53], ["both short- and long-term outcomes", "PROBLEM", 116, 150], ["Surgical Technique", "TREATMENT", 229, 247], ["The surgical technique", "TREATMENT", 247, 269], ["cardiopulmonary bypass", "TREATMENT", 391, 413], ["single, lung transplantation", "TREATMENT", 457, 485], ["size", "OBSERVATION_MODIFIER", 34, 38], ["lungs", "ANATOMY", 183, 188], ["cardiopulmonary", "ANATOMY", 391, 406], ["bypass", "OBSERVATION", 407, 413], ["bilateral", "ANATOMY_MODIFIER", 432, 441], ["lung", "ANATOMY", 465, 469], ["transplantation", "OBSERVATION", 470, 485]]], ["The typical approach is a bilateral sequential procedure with a transsternal bilateral anterior thoracotomy, referred to as the clamshell incision, which provides excellent access and visualization for the procedure.", [["a bilateral sequential procedure", "TREATMENT", 24, 56], ["a transsternal bilateral anterior thoracotomy", "TREATMENT", 62, 107], ["the clamshell incision", "TREATMENT", 124, 146], ["the procedure", "TREATMENT", 202, 215], ["bilateral", "ANATOMY_MODIFIER", 26, 35], ["transsternal", "ANATOMY", 64, 76], ["bilateral", "ANATOMY_MODIFIER", 77, 86], ["anterior", "ANATOMY_MODIFIER", 87, 95], ["thoracotomy", "OBSERVATION", 96, 107], ["incision", "OBSERVATION", 138, 146]]], ["At our center, an end-to-end anastomosis is favored for the airway because of the higher incidence of stenosis seen with atelescopic anastomosis.", [["airway", "ANATOMY", 60, 66], ["stenosis", "DISEASE", 102, 110], ["airway", "MULTI-TISSUE_STRUCTURE", 60, 66], ["an end-to-end anastomosis", "TREATMENT", 15, 40], ["stenosis", "PROBLEM", 102, 110], ["atelescopic anastomosis", "TREATMENT", 121, 144], ["anastomosis", "OBSERVATION", 29, 40], ["airway", "ANATOMY", 60, 66], ["higher", "OBSERVATION_MODIFIER", 82, 88], ["stenosis", "OBSERVATION", 102, 110], ["atelescopic anastomosis", "OBSERVATION", 121, 144]]], ["Many centers will cover the anastomosis with peribronchial lymphatic tissue.", [["peribronchial lymphatic tissue", "ANATOMY", 45, 75], ["peribronchial lymphatic tissue", "TISSUE", 45, 75], ["the anastomosis", "TREATMENT", 24, 39], ["peribronchial lymphatic tissue", "PROBLEM", 45, 75], ["anastomosis", "OBSERVATION", 28, 39], ["peribronchial", "ANATOMY_MODIFIER", 45, 58], ["lymphatic tissue", "OBSERVATION", 59, 75]]], ["It is important to note that the bronchial circulation, lymphatic system, and nervous system are not reanastomosed.", [["bronchial", "ANATOMY", 33, 42], ["lymphatic system", "ANATOMY", 56, 72], ["nervous system", "ANATOMY", 78, 92], ["bronchial circulation", "MULTI-TISSUE_STRUCTURE", 33, 54], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 56, 72], ["nervous system", "ANATOMICAL_SYSTEM", 78, 92], ["bronchial circulation", "ANATOMY", 33, 54], ["lymphatic system", "ANATOMY", 56, 72], ["nervous system", "ANATOMY", 78, 92]]], ["However, a few centers do advocate direct bronchial revascularization.Surgical TechniqueIf a cardiac repair is necessary, it is done after the pneumonectomies but prior to implantation as this provides the surgeon with abloodless operative field.", [["bronchial", "ANATOMY", 42, 51], ["cardiac", "ANATOMY", 93, 100], ["bronchial", "MULTI-TISSUE_STRUCTURE", 42, 51], ["cardiac", "ORGAN", 93, 100], ["direct bronchial revascularization", "TREATMENT", 35, 69], ["Surgical Technique", "TREATMENT", 70, 88], ["a cardiac repair", "TREATMENT", 91, 107], ["the pneumonectomies", "TREATMENT", 139, 158], ["implantation", "TREATMENT", 172, 184], ["abloodless operative field", "TREATMENT", 219, 245], ["bronchial", "ANATOMY", 42, 51], ["revascularization", "OBSERVATION", 52, 69], ["cardiac", "ANATOMY", 93, 100], ["repair", "OBSERVATION", 101, 107], ["pneumonectomies", "OBSERVATION", 143, 158]]], ["After the second lung has been implanted, they are inflated to expand all of the atelectatic portions.", [["lung", "ANATOMY", 17, 21], ["lung", "ORGAN", 17, 21], ["lung", "ANATOMY", 17, 21], ["implanted", "OBSERVATION", 31, 40], ["inflated", "OBSERVATION", 51, 59], ["atelectatic", "OBSERVATION", 81, 92]]], ["The patient is then weaned off of bypass.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["bypass", "TREATMENT", 34, 40], ["bypass", "OBSERVATION", 34, 40]]], ["Two chest tubes are left in each pleural space.", [["chest tubes", "ANATOMY", 4, 15], ["pleural space", "ANATOMY", 33, 46], ["chest tubes", "MULTI-TISSUE_STRUCTURE", 4, 15], ["pleural space", "MULTI-TISSUE_STRUCTURE", 33, 46], ["Two chest tubes", "TREATMENT", 0, 15], ["chest", "ANATOMY", 4, 9], ["tubes", "OBSERVATION", 10, 15], ["left", "ANATOMY_MODIFIER", 20, 24], ["each", "ANATOMY_MODIFIER", 28, 32], ["pleural", "ANATOMY", 33, 40], ["space", "ANATOMY_MODIFIER", 41, 46]]], ["The pulmonary veins can be assessed at this time with transesophageal echocardiography, and the pulmonary artery anastomoses can be evaluated upon arrival to cardiac intensivecare unit with a perfusion scan.Surgical TechniqueLiving lobar transplantation has fallen out of favor in the United States because lungs are allocated on the basis of a disease severity score rather than just time spent on the list.", [["pulmonary veins", "ANATOMY", 4, 19], ["pulmonary artery", "ANATOMY", 96, 112], ["cardiac", "ANATOMY", 158, 165], ["lobar", "ANATOMY", 232, 237], ["lungs", "ANATOMY", 307, 312], ["pulmonary veins", "MULTI-TISSUE_STRUCTURE", 4, 19], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 96, 112], ["lungs", "ORGAN", 307, 312], ["transesophageal echocardiography", "TEST", 54, 86], ["a perfusion scan", "TEST", 190, 206], ["Surgical TechniqueLiving lobar transplantation", "TREATMENT", 207, 253], ["a disease severity score", "PROBLEM", 343, 367], ["pulmonary veins", "ANATOMY", 4, 19], ["pulmonary artery", "ANATOMY", 96, 112], ["anastomoses", "OBSERVATION", 113, 124], ["lobar", "OBSERVATION_MODIFIER", 232, 237], ["transplantation", "OBSERVATION", 238, 253], ["lungs", "ANATOMY", 307, 312], ["disease", "OBSERVATION", 345, 352]]], ["This has obviated the most common reason for living lobar transplantation, presenting to a transplant center in extremis and not having accrued enough time on the list to realistically receive an organ in time.", [["lobar", "ANATOMY", 52, 57], ["organ", "ANATOMY", 196, 201], ["organ", "ORGAN", 196, 201], ["living lobar transplantation", "TREATMENT", 45, 73], ["transplantation", "OBSERVATION", 58, 73]]], ["However,this procedure is commonly used in Japan with excellent outcomes reported.ImmunosuppressionImmunosuppressive regimens vary between transplant centers.", [["this procedure", "TREATMENT", 8, 22], ["ImmunosuppressionImmunosuppressive regimens", "TREATMENT", 82, 125], ["transplant centers", "TREATMENT", 139, 157]]], ["About half of the lung transplant centers throughout the world use induction in the hopes of preventing early acute rejection.", [["lung", "ANATOMY", 18, 22], ["lung", "ORGAN", 18, 22], ["the lung transplant centers", "TREATMENT", 14, 41], ["induction", "TREATMENT", 67, 76], ["early acute rejection", "PROBLEM", 104, 125], ["lung", "ANATOMY", 18, 22], ["transplant", "OBSERVATION", 23, 33], ["early", "OBSERVATION_MODIFIER", 104, 109], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["rejection", "OBSERVATION", 116, 125]]], ["There is also a great deal of variability in the induction regimen of choice.", [["the induction regimen", "TREATMENT", 45, 66], ["great", "OBSERVATION_MODIFIER", 16, 21], ["variability", "OBSERVATION_MODIFIER", 30, 41]]], ["Some centers will utilize an interleukin (IL)-2 receptor antagonist such as basiliximab.", [["basiliximab", "CHEMICAL", 76, 87], ["basiliximab", "CHEMICAL", 76, 87], ["interleukin (IL)-2 receptor antagonist", "GENE_OR_GENE_PRODUCT", 29, 67], ["basiliximab", "SIMPLE_CHEMICAL", 76, 87], ["interleukin (IL)-2 receptor", "PROTEIN", 29, 56], ["an interleukin (IL)", "TREATMENT", 26, 45], ["receptor antagonist", "TREATMENT", 48, 67], ["basiliximab", "TREATMENT", 76, 87]]], ["Other centers will use a lympholytic agent such as rabbit antithymocyte globulin (RATG) or equine antithymocyte globulin (ATGAM).", [["antithymocyte globulin", "CHEMICAL", 58, 80], ["RATG", "CHEMICAL", 82, 86], ["antithymocyte globulin", "CHEMICAL", 98, 120], ["rabbit", "ORGANISM", 51, 57], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 58, 80], ["RATG", "SIMPLE_CHEMICAL", 82, 86], ["equine", "ORGANISM", 91, 97], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 98, 120], ["ATGAM", "SIMPLE_CHEMICAL", 122, 127], ["rabbit antithymocyte globulin", "PROTEIN", 51, 80], ["RATG", "PROTEIN", 82, 86], ["equine antithymocyte globulin", "PROTEIN", 91, 120], ["ATGAM", "PROTEIN", 122, 127], ["rabbit", "SPECIES", 51, 57], ["equine", "SPECIES", 91, 97], ["rabbit", "SPECIES", 51, 57], ["equine", "SPECIES", 91, 97], ["a lympholytic agent", "TREATMENT", 23, 42], ["rabbit antithymocyte globulin (RATG", "TREATMENT", 51, 86], ["equine antithymocyte globulin", "TREATMENT", 91, 120]]], ["These preparations are derived from animal serum and contain antibodies to human lymphocytes that can induce opsonization and phagocytosis of T lymphocytes, modulating their activation.ImmunosuppressionBecause of the relative high frequency of acute rejection among lung transplant recipients, a maintenance strategy of triple drug immunosuppression is commonly employed (Table 74.4).", [["serum", "ANATOMY", 43, 48], ["lymphocytes", "ANATOMY", 81, 92], ["T lymphocytes", "ANATOMY", 142, 155], ["lung transplant", "ANATOMY", 266, 281], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["human", "ORGANISM", 75, 80], ["lymphocytes", "CELL", 81, 92], ["T lymphocytes", "CELL", 142, 155], ["lung", "ORGAN", 266, 270], ["antibodies", "PROTEIN", 61, 71], ["human lymphocytes", "CELL_TYPE", 75, 92], ["T lymphocytes", "CELL_TYPE", 142, 155], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["animal serum", "TEST", 36, 48], ["human lymphocytes", "TEST", 75, 92], ["opsonization", "TEST", 109, 121], ["phagocytosis of T lymphocytes", "PROBLEM", 126, 155], ["acute rejection", "PROBLEM", 244, 259], ["lung transplant recipients", "TREATMENT", 266, 292], ["triple drug immunosuppression", "TREATMENT", 320, 349], ["high", "OBSERVATION_MODIFIER", 226, 230], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["rejection", "OBSERVATION", 250, 259], ["lung", "ANATOMY", 266, 270], ["transplant", "OBSERVATION", 271, 281]]], ["The three drugs will typically consist of a calcineurin inhibitor (CNI), a cell cycle toxin inhibitor, and systemic corticosteroids.", [["cell", "ANATOMY", 75, 79], ["CNI", "CHEMICAL", 67, 70], ["CNI", "CHEMICAL", 67, 70], ["calcineurin", "GENE_OR_GENE_PRODUCT", 44, 55], ["CNI", "SIMPLE_CHEMICAL", 67, 70], ["cell", "CELL", 75, 79], ["calcineurin", "PROTEIN", 44, 55], ["The three drugs", "TREATMENT", 0, 15], ["a calcineurin inhibitor (CNI", "TREATMENT", 42, 70], ["a cell cycle toxin inhibitor", "TREATMENT", 73, 101], ["systemic corticosteroids", "TREATMENT", 107, 131]]], ["In pediatrics especially, we attempt to minimize steroid exposure, and during the first post-transplant year we wean the steroid dose from 0.5 mg/kg to 0.2 mg/kg; at our center it typically remains at that dose.Fluids and Nutrition Management ::: Post-operative Monitoring and ManagementOwing to both capillary leak andinterrupted lymphatic drainage, the transplanted lungs are particularly fluid sensitive, and thus reaching a negative fluid balance within the first 48 hours post-operatively is important.", [["capillary", "ANATOMY", 301, 310], ["lymphatic", "ANATOMY", 331, 340], ["lungs", "ANATOMY", 368, 373], ["fluid", "ANATOMY", 437, 442], ["steroid", "CHEMICAL", 49, 56], ["steroid", "CHEMICAL", 121, 128], ["steroid", "CHEMICAL", 49, 56], ["steroid", "CHEMICAL", 121, 128], ["steroid", "SIMPLE_CHEMICAL", 49, 56], ["steroid", "SIMPLE_CHEMICAL", 121, 128], ["capillary", "TISSUE", 301, 310], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 331, 340], ["lungs", "ORGAN", 368, 373], ["steroid exposure", "PROBLEM", 49, 65], ["the steroid dose", "TREATMENT", 117, 133], ["Post-operative Monitoring", "TEST", 247, 272], ["ManagementOwing", "TREATMENT", 277, 292], ["both capillary leak andinterrupted lymphatic drainage", "TREATMENT", 296, 349], ["fluid sensitive", "PROBLEM", 391, 406], ["a negative fluid balance", "TEST", 426, 450], ["capillary leak", "OBSERVATION", 301, 315], ["lymphatic drainage", "OBSERVATION", 331, 349], ["transplanted", "ANATOMY_MODIFIER", 355, 367], ["lungs", "ANATOMY", 368, 373], ["fluid sensitive", "OBSERVATION", 391, 406], ["negative", "OBSERVATION_MODIFIER", 428, 436], ["fluid balance", "OBSERVATION", 437, 450]]], ["Colloids and pressors should be used to reduce the amount of stress placed on the kidneys, as overly aggressive diuresis, when combined with CNInephrotoxicity, can quickly lead to renal failure, resulting in fluid overload and subsequent pulmonary compromise.", [["kidneys", "ANATOMY", 82, 89], ["renal", "ANATOMY", 180, 185], ["fluid", "ANATOMY", 208, 213], ["pulmonary", "ANATOMY", 238, 247], ["Colloids", "CHEMICAL", 0, 8], ["renal failure", "DISEASE", 180, 193], ["kidneys", "ORGAN", 82, 89], ["renal", "ORGAN", 180, 185], ["fluid", "ORGANISM_SUBSTANCE", 208, 213], ["pulmonary", "ORGAN", 238, 247], ["Colloids", "TREATMENT", 0, 8], ["pressors", "TREATMENT", 13, 21], ["aggressive diuresis", "TREATMENT", 101, 120], ["CNInephrotoxicity", "PROBLEM", 141, 158], ["renal failure", "PROBLEM", 180, 193], ["fluid overload", "PROBLEM", 208, 222], ["subsequent pulmonary compromise", "PROBLEM", 227, 258], ["stress", "OBSERVATION", 61, 67], ["kidneys", "ANATOMY", 82, 89], ["renal", "ANATOMY", 180, 185], ["failure", "OBSERVATION", 186, 193], ["fluid overload", "OBSERVATION", 208, 222], ["pulmonary", "ANATOMY", 238, 247], ["compromise", "OBSERVATION", 248, 258]]], ["Thus, while one will always use diuretics in this setting, one must do so carefully.", [["diuretics", "SIMPLE_CHEMICAL", 32, 41], ["diuretics", "TREATMENT", 32, 41]]], ["Enteral nutrition should be started as soon as is appropriate but may be delayed for anticipated extubation orother procedures.Ventilator Management ::: Post-operative Monitoring and ManagementForemost, the goal is to wean offthe ventilator rapidly with the goal of extubation.", [["Enteral", "ANATOMY", 0, 7], ["Enteral nutrition", "TREATMENT", 0, 17], ["anticipated extubation orother procedures", "TREATMENT", 85, 126], ["Ventilator Management", "TREATMENT", 127, 148], ["Post-operative Monitoring", "TEST", 153, 178], ["offthe ventilator", "TREATMENT", 223, 240], ["extubation", "TREATMENT", 266, 276]]], ["Pressure-controlled ventilation is recommended because it places limits on peak airway pressures that protect not only the parenchyma but also the healing airway anastomoses.", [["airway", "ANATOMY", 80, 86], ["parenchyma", "ANATOMY", 123, 133], ["airway", "ANATOMY", 155, 161], ["airway", "MULTI-TISSUE_STRUCTURE", 80, 86], ["parenchyma", "TISSUE", 123, 133], ["airway anastomoses", "PATHOLOGICAL_FORMATION", 155, 173], ["Pressure-controlled ventilation", "TREATMENT", 0, 31], ["peak airway pressures", "TREATMENT", 75, 96], ["the healing airway anastomoses", "PROBLEM", 143, 173], ["ventilation", "OBSERVATION", 20, 31], ["parenchyma", "OBSERVATION", 123, 133], ["healing", "OBSERVATION_MODIFIER", 147, 154], ["airway anastomoses", "OBSERVATION", 155, 173]]], ["At our center, a bronchoscopy is performed 1 day post-operatively to inspect the anastomoses, and to obtain BAL if infection is suspected.", [["BAL", "ANATOMY", 108, 111], ["infection", "DISEASE", 115, 124], ["a bronchoscopy", "TEST", 15, 29], ["the anastomoses", "TREATMENT", 77, 92], ["infection", "PROBLEM", 115, 124], ["anastomoses", "OBSERVATION", 81, 92], ["infection", "OBSERVATION", 115, 124]]], ["Airway clearance is important in the initial post-operativeperiod, with appropriate limits in place to avoid anastomotic complications.", [["Airway", "ANATOMY", 0, 6], ["anastomotic", "ANATOMY", 109, 120], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["Airway clearance", "TEST", 0, 16], ["anastomotic complications", "PROBLEM", 109, 134], ["clearance", "OBSERVATION", 7, 16], ["anastomotic complications", "OBSERVATION", 109, 134]]], ["Physiotherapy and mobilization are also important, as these will not only helpmobilize secretions but will also enhance chest tube drainage and alveolar recruitment.Surgical Complications ::: Post-operative Monitoring and ManagementAirway anastomotic complicationsoccur in ~13% of recipients.", [["secretions", "ANATOMY", 87, 97], ["chest tube", "ANATOMY", 120, 130], ["alveolar", "ANATOMY", 144, 152], ["chest tube", "MULTI-TISSUE_STRUCTURE", 120, 130], ["alveolar", "MULTI-TISSUE_STRUCTURE", 144, 152], ["recipients", "ORGANISM", 281, 291], ["Physiotherapy", "TREATMENT", 0, 13], ["mobilization", "TREATMENT", 18, 30], ["secretions", "PROBLEM", 87, 97], ["chest tube drainage", "TREATMENT", 120, 139], ["alveolar recruitment", "PROBLEM", 144, 164], ["Post-operative Monitoring", "TEST", 192, 217], ["ManagementAirway anastomotic", "TREATMENT", 222, 250], ["chest", "ANATOMY", 120, 125], ["tube drainage", "OBSERVATION", 126, 139], ["alveolar recruitment", "OBSERVATION", 144, 164], ["anastomotic", "OBSERVATION_MODIFIER", 239, 250]]], ["They primarily manifest as stenosis with resulting airflow obstruction.", [["stenosis", "DISEASE", 27, 35], ["airflow obstruction", "DISEASE", 51, 70], ["stenosis", "PROBLEM", 27, 35], ["resulting airflow obstruction", "PROBLEM", 41, 70], ["stenosis", "OBSERVATION", 27, 35], ["airflow obstruction", "OBSERVATION", 51, 70]]], ["This can generally be managed with bronchoscopic interventions.", [["bronchoscopic interventions", "TREATMENT", 35, 62]]], ["As the bronchi of children grow with the recipient, stents are avoided if possible in favor of repeated balloon dilation.", [["bronchi", "ANATOMY", 7, 14], ["balloon", "ANATOMY", 104, 111], ["bronchi", "MULTI-TISSUE_STRUCTURE", 7, 14], ["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26], ["the recipient", "TREATMENT", 37, 50], ["stents", "TREATMENT", 52, 58], ["repeated balloon dilation", "TREATMENT", 95, 120], ["bronchi", "ANATOMY", 7, 14], ["stents", "OBSERVATION", 52, 58], ["balloon dilation", "OBSERVATION", 104, 120]]], ["Partial or complete dehiscence of the anastomosisis rarely seen but can be catastrophic.Surgical Complications ::: Post-operative Monitoring and ManagementVascular anastomotic complications are also rare.", [["Vascular", "ANATOMY", 155, 163], ["anastomosisis", "DISEASE", 38, 51], ["Vascular anastomotic complications", "DISEASE", 155, 189], ["Vascular", "MULTI-TISSUE_STRUCTURE", 155, 163], ["Partial or complete dehiscence of the anastomosisis", "PROBLEM", 0, 51], ["catastrophic", "PROBLEM", 75, 87], ["Post-operative Monitoring", "TEST", 115, 140], ["Management", "TREATMENT", 145, 155], ["Vascular anastomotic complications", "PROBLEM", 155, 189], ["complete", "OBSERVATION_MODIFIER", 11, 19], ["dehiscence", "OBSERVATION", 20, 30], ["anastomosisis", "OBSERVATION", 38, 51], ["catastrophic", "OBSERVATION_MODIFIER", 75, 87], ["Vascular", "ANATOMY", 155, 163], ["anastomotic complications", "OBSERVATION", 164, 189]]], ["At our center, a perfusion lung scan is routinely performed within 24 hours of the transplantation to evaluate the vascular anastomoses.", [["lung", "ANATOMY", 27, 31], ["vascular", "ANATOMY", 115, 123], ["lung", "ORGAN", 27, 31], ["vascular anastomoses", "MULTI-TISSUE_STRUCTURE", 115, 135], ["a perfusion lung scan", "TEST", 15, 36], ["the transplantation", "TREATMENT", 79, 98], ["lung", "ANATOMY", 27, 31], ["vascular", "ANATOMY", 115, 123], ["anastomoses", "OBSERVATION", 124, 135]]], ["Any significant discrepancy between right- and left-sided perfusion should be immediately evaluated inconsultation with the cardiothoracic surgeons.Primary Graft Dysfunction ::: Post-operative Monitoring and ManagementPrimary Graft Dysfunction (PGD) occurs within 72 hours of transplant and is characterized by non-specific alveolar injury, non-cardiogenic pulmonary edema, and resulting decreased compliance and hypoxemia.", [["Graft", "ANATOMY", 156, 161], ["Graft", "ANATOMY", 226, 231], ["alveolar", "ANATOMY", 324, 332], ["pulmonary", "ANATOMY", 357, 366], ["alveolar injury", "DISEASE", 324, 339], ["non-cardiogenic pulmonary edema", "DISEASE", 341, 372], ["hypoxemia", "DISEASE", 413, 422], ["Graft", "TISSUE", 156, 161], ["Graft", "TISSUE", 226, 231], ["alveolar", "MULTI-TISSUE_STRUCTURE", 324, 332], ["pulmonary", "ORGAN", 357, 366], ["Any significant discrepancy", "PROBLEM", 0, 27], ["Primary Graft Dysfunction", "PROBLEM", 148, 173], ["Post-operative Monitoring", "TEST", 178, 203], ["ManagementPrimary Graft Dysfunction", "PROBLEM", 208, 243], ["transplant", "TREATMENT", 276, 286], ["non-specific alveolar injury", "PROBLEM", 311, 339], ["non-cardiogenic pulmonary edema", "PROBLEM", 341, 372], ["resulting decreased compliance", "PROBLEM", 378, 408], ["hypoxemia", "PROBLEM", 413, 422], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["discrepancy", "OBSERVATION", 16, 27], ["right", "ANATOMY_MODIFIER", 36, 41], ["left", "ANATOMY_MODIFIER", 47, 51], ["sided", "ANATOMY_MODIFIER", 52, 57], ["perfusion", "OBSERVATION", 58, 67], ["Graft Dysfunction", "OBSERVATION", 156, 173], ["Graft Dysfunction", "OBSERVATION", 226, 243], ["non-specific", "OBSERVATION_MODIFIER", 311, 323], ["alveolar", "ANATOMY_MODIFIER", 324, 332], ["injury", "OBSERVATION", 333, 339], ["non-cardiogenic", "OBSERVATION_MODIFIER", 341, 356], ["pulmonary", "ANATOMY", 357, 366], ["edema", "OBSERVATION", 367, 372], ["decreased", "OBSERVATION_MODIFIER", 388, 397], ["compliance", "OBSERVATION_MODIFIER", 398, 408], ["hypoxemia", "OBSERVATION", 413, 422]]], ["It is caused by multiple factors, including ischemia\u2013reperfusion injury, inflammation secondary to donor death, and other factors.", [["ischemia\u2013reperfusion injury", "DISEASE", 44, 71], ["inflammation", "DISEASE", 73, 85], ["death", "DISEASE", 105, 110], ["ischemia\u2013reperfusion injury", "PROBLEM", 44, 71], ["inflammation", "PROBLEM", 73, 85], ["donor death", "PROBLEM", 99, 110], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["factors", "OBSERVATION", 25, 32], ["inflammation", "OBSERVATION", 73, 85], ["donor death", "OBSERVATION", 99, 110]]], ["In 2005, the ISHLT developed a classification system using chest X-ray infiltrates and PaO2/FiO2 ratio to grade PGD 0\u20133.", [["FiO2", "CHEMICAL", 92, 96], ["chest X-ray infiltrates", "TEST", 59, 82], ["PaO2", "TEST", 87, 91], ["FiO2 ratio", "TEST", 92, 102], ["grade PGD", "PROBLEM", 106, 115], ["chest", "ANATOMY", 59, 64], ["infiltrates", "OBSERVATION", 71, 82]]], ["On the basis of this classification, severe PGD (PaO2/FiO2 <200 at 48 hours post-transplant) occurs in 15% of recipients, which is concerning as severe PGD is associated with increased graft failure and mortality.", [["graft", "ANATOMY", 185, 190], ["PGD", "DISEASE", 44, 47], ["PGD", "DISEASE", 152, 155], ["increased graft failure", "DISEASE", 175, 198], ["recipients", "ORGANISM", 110, 120], ["graft", "TISSUE", 185, 190], ["this classification", "TEST", 16, 35], ["severe PGD", "PROBLEM", 37, 47], ["PaO2/FiO2", "TEST", 49, 58], ["transplant", "TREATMENT", 81, 91], ["severe PGD", "PROBLEM", 145, 155], ["increased graft failure", "PROBLEM", 175, 198], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["associated with", "UNCERTAINTY", 159, 174], ["increased", "OBSERVATION_MODIFIER", 175, 184], ["graft failure", "OBSERVATION", 185, 198]]], ["Management of severe PGD is similar to the management of patients with acute respiratory distress syndrome (ARDS), including fluid restriction while maintaining perfusion to end organs, lung protective ventilator strategies, and nitric oxide.", [["respiratory", "ANATOMY", 77, 88], ["fluid", "ANATOMY", 125, 130], ["organs", "ANATOMY", 178, 184], ["lung", "ANATOMY", 186, 190], ["PGD", "DISEASE", 21, 24], ["acute respiratory distress syndrome", "DISEASE", 71, 106], ["ARDS", "DISEASE", 108, 112], ["nitric oxide", "CHEMICAL", 229, 241], ["nitric oxide", "CHEMICAL", 229, 241], ["patients", "ORGANISM", 57, 65], ["organs", "ORGAN", 178, 184], ["lung", "ORGAN", 186, 190], ["nitric oxide", "SIMPLE_CHEMICAL", 229, 241], ["patients", "SPECIES", 57, 65], ["severe PGD", "PROBLEM", 14, 24], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["ARDS", "PROBLEM", 108, 112], ["fluid restriction", "TREATMENT", 125, 142], ["lung protective ventilator strategies", "TREATMENT", 186, 223], ["nitric oxide", "TREATMENT", 229, 241], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["PGD", "OBSERVATION", 21, 24], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory", "ANATOMY", 77, 88], ["distress", "OBSERVATION", 89, 97], ["fluid restriction", "OBSERVATION", 125, 142], ["lung", "ANATOMY", 186, 190], ["protective ventilator", "OBSERVATION", 191, 212], ["nitric oxide", "OBSERVATION", 229, 241]]], ["When the amount of oxygen and ventilator support is high and thus contributing to further lung injury, early ECMO is an important option to consider to both provide lung rest and minimize iatrogenic trauma to the graft.Post-transplantation MonitoringAfter the perioperative recoveryperiod, recipients continue to require monitoring.", [["lung", "ANATOMY", 90, 94], ["lung", "ANATOMY", 165, 169], ["graft", "ANATOMY", 213, 218], ["oxygen", "CHEMICAL", 19, 25], ["lung injury", "DISEASE", 90, 101], ["trauma", "DISEASE", 199, 205], ["oxygen", "CHEMICAL", 19, 25], ["oxygen", "SIMPLE_CHEMICAL", 19, 25], ["lung", "ORGAN", 90, 94], ["lung", "ORGAN", 165, 169], ["graft", "TISSUE", 213, 218], ["recipients", "ORGANISM", 290, 300], ["oxygen", "TREATMENT", 19, 25], ["ventilator support", "TREATMENT", 30, 48], ["further lung injury", "PROBLEM", 82, 101], ["early ECMO", "TREATMENT", 103, 113], ["lung rest", "TREATMENT", 165, 174], ["iatrogenic trauma", "PROBLEM", 188, 205], ["the graft", "TREATMENT", 209, 218], ["the perioperative recoveryperiod", "TREATMENT", 256, 288], ["monitoring", "TEST", 321, 331], ["amount", "OBSERVATION_MODIFIER", 9, 15], ["oxygen", "OBSERVATION_MODIFIER", 19, 25], ["lung", "ANATOMY", 90, 94], ["injury", "OBSERVATION", 95, 101], ["lung", "ANATOMY", 165, 169], ["graft", "OBSERVATION", 213, 218], ["transplantation", "OBSERVATION", 224, 239]]], ["Regular evaluation, initially at the transplant center, followed by close monitoring by a local physician with discussion with the transplant team, is necessary to identify and manage post-transplant complications.", [["Regular evaluation", "TEST", 0, 18], ["post-transplant complications", "PROBLEM", 184, 213], ["complications", "OBSERVATION", 200, 213]]], ["Routine monitoring includes measurement of CNI and antimetabolite levels, routine laboratory tests, pulmonary function testing, and chest imaging.", [["pulmonary", "ANATOMY", 100, 109], ["chest", "ANATOMY", 132, 137], ["antimetabolite", "CHEMICAL", 51, 65], ["CNI", "CHEMICAL", 43, 46], ["CNI", "SIMPLE_CHEMICAL", 43, 46], ["antimetabolite", "SIMPLE_CHEMICAL", 51, 65], ["pulmonary", "ORGAN", 100, 109], ["Routine monitoring", "TEST", 0, 18], ["CNI", "TREATMENT", 43, 46], ["antimetabolite levels", "TEST", 51, 72], ["routine laboratory tests", "TEST", 74, 98], ["pulmonary function testing", "TEST", 100, 126], ["chest imaging", "TEST", 132, 145], ["pulmonary", "ANATOMY", 100, 109], ["chest", "ANATOMY", 132, 137]]], ["While controversial, we believe thatbronchoscopy with BAL and transbronchial biopsies by trained bronchoscopists an important part of post-transplant surveillance.", [["transbronchial biopsies", "MULTI-TISSUE_STRUCTURE", 62, 85], ["BAL", "TEST", 54, 57], ["transbronchial biopsies", "TEST", 62, 85], ["post-transplant surveillance", "TEST", 134, 162], ["transbronchial", "ANATOMY", 62, 76]]], ["Although scheduled surveillance bronchoscopy can detect asymptomatic acute rejection, allowing therapeutic interventions to occur sooner, a clear benefit in terms of outcomes has not been found.", [["scheduled surveillance bronchoscopy", "TEST", 9, 44], ["asymptomatic acute rejection", "PROBLEM", 56, 84], ["therapeutic interventions", "TREATMENT", 95, 120], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["rejection", "OBSERVATION", 75, 84]]], ["In infant lung transplant recipients, the use of surveillance bronchoscopy is more important as ambulatory lung function testing isnot possible and patients are less able to report symptoms.Infections ::: Post-transplantation ComplicationsGiven the degree of immunosuppression needed to prevent acute rejection of the lung, infections are a predictable complication of lung transplantation.", [["lung", "ANATOMY", 10, 14], ["lung", "ANATOMY", 107, 111], ["lung", "ANATOMY", 318, 322], ["lung", "ANATOMY", 369, 373], ["infections", "DISEASE", 324, 334], ["lung", "ORGAN", 10, 14], ["lung", "ORGAN", 107, 111], ["patients", "ORGANISM", 148, 156], ["lung", "ORGAN", 318, 322], ["lung", "ORGAN", 369, 373], ["infant", "SPECIES", 3, 9], ["patients", "SPECIES", 148, 156], ["infant lung transplant recipients", "TREATMENT", 3, 36], ["surveillance bronchoscopy", "TEST", 49, 74], ["ambulatory lung function testing", "TEST", 96, 128], ["symptoms", "PROBLEM", 181, 189], ["Post-transplantation Complications", "TREATMENT", 205, 239], ["immunosuppression", "TREATMENT", 259, 276], ["acute rejection of the lung", "PROBLEM", 295, 322], ["infections", "PROBLEM", 324, 334], ["lung transplantation", "TREATMENT", 369, 389], ["lung", "ANATOMY", 10, 14], ["transplant recipients", "OBSERVATION", 15, 36], ["transplantation", "OBSERVATION", 210, 225], ["immunosuppression", "OBSERVATION", 259, 276], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["rejection", "OBSERVATION", 301, 310], ["lung", "ANATOMY", 318, 322], ["infections", "OBSERVATION", 324, 334], ["lung", "ANATOMY", 369, 373], ["transplantation", "OBSERVATION", 374, 389]]], ["Selected infections are discussed in Table 74.5.", [["infections", "DISEASE", 9, 19], ["Selected infections", "PROBLEM", 0, 19], ["infections", "OBSERVATION", 9, 19]]], ["However, virtually any pathogen, known and unknown, can present post-lung transplant.", [["lung", "ANATOMY", 69, 73], ["lung", "ORGAN", 69, 73], ["any pathogen", "PROBLEM", 19, 31], ["-lung transplant", "TREATMENT", 68, 84], ["pathogen", "OBSERVATION", 23, 31], ["lung", "ANATOMY", 69, 73], ["transplant", "OBSERVATION", 74, 84]]], ["Clinicians must be vigilant and aggressive in managing these infections to preserve both graft function and the patient\u2019s well-being.", [["graft", "ANATOMY", 89, 94], ["infections", "DISEASE", 61, 71], ["graft", "TISSUE", 89, 94], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["these infections", "PROBLEM", 55, 71], ["infections", "OBSERVATION", 61, 71], ["graft", "OBSERVATION", 89, 94]]], ["A close working relationship with infectious disease specialists is extremely advantageous to lung transplant programs, with some programs including one on their transplant team.Post-transplant Lymphoproliferative Disease (PTLD) ::: Post-transplantation ComplicationsBy 5 years post-transplant, 14% of pediatric recipients have had a malignancy of some type, nearly all of which are PTLD.", [["lung", "ANATOMY", 94, 98], ["infectious disease", "DISEASE", 34, 52], ["Post-transplant Lymphoproliferative Disease", "DISEASE", 178, 221], ["PTLD", "DISEASE", 223, 227], ["malignancy", "DISEASE", 334, 344], ["PTLD", "DISEASE", 383, 387], ["lung", "ORGAN", 94, 98], ["recipients", "ORGANISM", 312, 322], ["lung transplant programs", "TREATMENT", 94, 118], ["Post-transplant Lymphoproliferative Disease", "PROBLEM", 178, 221], ["transplant", "TREATMENT", 283, 293], ["pediatric recipients", "TREATMENT", 302, 322], ["a malignancy of some type", "PROBLEM", 332, 357], ["PTLD", "PROBLEM", 383, 387], ["lung", "ANATOMY", 94, 98], ["transplant", "OBSERVATION", 99, 109], ["transplant", "ANATOMY", 183, 193], ["Lymphoproliferative Disease", "OBSERVATION", 194, 221], ["malignancy", "OBSERVATION", 334, 344], ["some type", "OBSERVATION_MODIFIER", 348, 357], ["PTLD", "OBSERVATION", 383, 387]]], ["The most common form of PTLD is caused by Epstein\u2013Barr virus infection causing transformation of a CD20 cell, resulting in a B-cell lymphoma, most commonly polymorphic.", [["CD20 cell", "ANATOMY", 99, 108], ["B-cell lymphoma", "ANATOMY", 125, 140], ["PTLD", "DISEASE", 24, 28], ["Epstein\u2013Barr virus infection", "DISEASE", 42, 70], ["B-cell lymphoma", "DISEASE", 125, 140], ["PTLD", "CANCER", 24, 28], ["Epstein\u2013Barr virus", "ORGANISM", 42, 60], ["CD20", "GENE_OR_GENE_PRODUCT", 99, 103], ["B-cell lymphoma", "CANCER", 125, 140], ["CD20 cell", "CELL_TYPE", 99, 108], ["Epstein\u2013Barr virus", "SPECIES", 42, 60], ["PTLD", "PROBLEM", 24, 28], ["Epstein\u2013Barr virus infection", "PROBLEM", 42, 70], ["a CD20 cell", "PROBLEM", 97, 108], ["a B-cell lymphoma", "PROBLEM", 123, 140], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["PTLD", "OBSERVATION", 24, 28], ["Barr virus infection", "OBSERVATION", 50, 70], ["CD20 cell", "OBSERVATION", 99, 108], ["B-cell lymphoma", "OBSERVATION", 125, 140]]], ["Patients who develop primary EBV infection post-transplant are at greatest risk.", [["primary EBV infection", "DISEASE", 21, 42], ["Patients", "ORGANISM", 0, 8], ["EBV", "ORGANISM", 29, 32], ["Patients", "SPECIES", 0, 8], ["EBV", "SPECIES", 29, 32], ["primary EBV infection", "PROBLEM", 21, 42], ["transplant", "TREATMENT", 48, 58], ["EBV", "OBSERVATION_MODIFIER", 29, 32], ["infection", "OBSERVATION", 33, 42], ["transplant", "OBSERVATION", 48, 58]]], ["For CD20 positive PTLD, anti-CD20 antibody ( rituximab) therapy has revolutionized the management and allows successful treatment when combined with regimens of low-dose chemotherapy and reduced baseline immunosuppression.", [["PTLD", "DISEASE", 18, 22], ["rituximab", "CHEMICAL", 45, 54], ["CD20", "GENE_OR_GENE_PRODUCT", 4, 8], ["anti-CD20 antibody", "GENE_OR_GENE_PRODUCT", 24, 42], ["rituximab", "SIMPLE_CHEMICAL", 45, 54], ["CD20", "PROTEIN", 4, 8], ["anti-CD20 antibody", "PROTEIN", 24, 42], ["CD20 positive PTLD", "PROBLEM", 4, 22], ["anti-CD20 antibody", "TREATMENT", 24, 42], ["rituximab) therapy", "TREATMENT", 45, 63], ["the management", "TREATMENT", 83, 97], ["successful treatment", "TREATMENT", 109, 129], ["regimens", "TREATMENT", 149, 157], ["low-dose chemotherapy", "TREATMENT", 161, 182], ["reduced baseline immunosuppression", "TREATMENT", 187, 221]]], ["This approach causes far less toxicity than prior treatment options.", [["toxicity", "DISEASE", 30, 38], ["This approach", "TREATMENT", 0, 13], ["far less toxicity", "PROBLEM", 21, 38], ["prior treatment options", "TREATMENT", 44, 67], ["less toxicity", "OBSERVATION_MODIFIER", 25, 38]]], ["Prognosis is substantially worse for CD20-negative PTLD, due to a combination of a lack of good therapeutic options and the toxicity of the available regimens.", [["PTLD", "DISEASE", 51, 55], ["toxicity", "DISEASE", 124, 132], ["CD20", "GENE_OR_GENE_PRODUCT", 37, 41], ["CD20", "PROTEIN", 37, 41], ["CD20", "TEST", 37, 41], ["PTLD", "PROBLEM", 51, 55], ["the toxicity", "PROBLEM", 120, 132], ["the available regimens", "TREATMENT", 136, 158]]], ["Overall, per the ISHLT registry (1/1992\u20136/2012), PTLD caused 3.3% of deaths in pediatric lung recipients, with other malignancies causing 0.8% of deaths.Post-transplant Lymphoproliferative Disease (PTLD) ::: Post-transplantation ComplicationsThe major challenge in PTLD is diagnosis, as it can present with anything from asymptomatic pulmonary nodules on CT scan, neurological or gastrointestinal symptoms, bone pain, or sinus pain.", [["lung", "ANATOMY", 89, 93], ["malignancies", "ANATOMY", 117, 129], ["pulmonary nodules", "ANATOMY", 334, 351], ["neurological", "ANATOMY", 364, 376], ["gastrointestinal", "ANATOMY", 380, 396], ["bone", "ANATOMY", 407, 411], ["sinus", "ANATOMY", 421, 426], ["PTLD", "DISEASE", 49, 53], ["deaths", "DISEASE", 69, 75], ["malignancies", "DISEASE", 117, 129], ["deaths", "DISEASE", 146, 152], ["Post-transplant Lymphoproliferative Disease", "DISEASE", 153, 196], ["PTLD", "DISEASE", 198, 202], ["PTLD", "DISEASE", 265, 269], ["neurological or gastrointestinal symptoms", "DISEASE", 364, 405], ["bone pain", "DISEASE", 407, 416], ["sinus pain", "DISEASE", 421, 431], ["lung", "ORGAN", 89, 93], ["malignancies", "CANCER", 117, 129], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 334, 351], ["gastrointestinal", "ORGAN", 380, 396], ["bone", "TISSUE", 407, 411], ["sinus", "ORGANISM_SUBDIVISION", 421, 426], ["PTLD", "PROBLEM", 49, 53], ["pediatric lung recipients", "TREATMENT", 79, 104], ["other malignancies", "PROBLEM", 111, 129], ["Post-transplant Lymphoproliferative Disease", "PROBLEM", 153, 196], ["asymptomatic pulmonary nodules", "PROBLEM", 321, 351], ["CT scan", "TEST", 355, 362], ["neurological or gastrointestinal symptoms", "PROBLEM", 364, 405], ["bone pain", "PROBLEM", 407, 416], ["sinus pain", "PROBLEM", 421, 431], ["lung", "ANATOMY", 89, 93], ["recipients", "OBSERVATION", 94, 104], ["transplant", "ANATOMY", 158, 168], ["Lymphoproliferative Disease", "OBSERVATION", 169, 196], ["PTLD", "OBSERVATION", 265, 269], ["pulmonary", "ANATOMY", 334, 343], ["nodules", "OBSERVATION", 344, 351], ["gastrointestinal", "ANATOMY", 380, 396], ["bone", "ANATOMY", 407, 411], ["sinus", "ANATOMY", 421, 426]]], ["Further, although peak incidence is at 6 months post-transplant, it can be seen as a late complication as well.", [["transplant", "TREATMENT", 53, 63], ["a late complication", "PROBLEM", 83, 102], ["transplant", "OBSERVATION", 53, 63], ["late", "OBSERVATION_MODIFIER", 85, 89], ["complication", "OBSERVATION", 90, 102]]], ["Thus, careful evaluation and assessment, including biopsies and imaging, are needed to make the diagnosis.Gastrointestinal Complications ::: Post-transplantation ComplicationsGastrointestinal complications are seen in up to 50% of recipients.", [["Gastrointestinal", "ANATOMY", 106, 122], ["Gastrointestinal", "ANATOMY", 175, 191], ["Gastrointestinal", "ORGAN", 106, 122], ["recipients", "ORGANISM", 231, 241], ["careful evaluation", "TEST", 6, 24], ["assessment", "TEST", 29, 39], ["biopsies", "TEST", 51, 59], ["imaging", "TEST", 64, 71], ["Gastrointestinal complications", "PROBLEM", 175, 205], ["Complications", "OBSERVATION", 123, 136], ["Gastrointestinal", "ANATOMY", 175, 191], ["complications", "OBSERVATION", 192, 205]]], ["Clostriduim difficile is an important consideration, covered previously.", [["Clostriduim difficile", "DISEASE", 0, 21], ["Clostriduim difficile", "ORGANISM", 0, 21], ["Clostriduim difficile", "SPECIES", 0, 21], ["Clostriduim difficile", "SPECIES", 0, 21], ["Clostriduim difficile", "PROBLEM", 0, 21], ["difficile", "OBSERVATION", 12, 21], ["important consideration", "UNCERTAINTY", 28, 51]]], ["Other GI issues seen include esophagitis, pancreatitis, gastroparesis, ileus, CMV infections of the gut and liver, cholecystitis, peptic ulcer disease, gastroesophageal reflux, and peptic ulcer disease.", [["gut", "ANATOMY", 100, 103], ["liver", "ANATOMY", 108, 113], ["peptic ulcer", "ANATOMY", 130, 142], ["gastroesophageal", "ANATOMY", 152, 168], ["peptic ulcer", "ANATOMY", 181, 193], ["esophagitis", "DISEASE", 29, 40], ["pancreatitis", "DISEASE", 42, 54], ["gastroparesis", "DISEASE", 56, 69], ["ileus", "DISEASE", 71, 76], ["CMV infections of the gut and liver, cholecystitis", "DISEASE", 78, 128], ["peptic ulcer disease", "DISEASE", 130, 150], ["gastroesophageal reflux", "DISEASE", 152, 175], ["peptic ulcer disease", "DISEASE", 181, 201], ["CMV", "ORGANISM", 78, 81], ["gut", "ORGANISM_SUBDIVISION", 100, 103], ["liver", "ORGAN", 108, 113], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 181, 193], ["CMV", "SPECIES", 78, 81], ["Other GI issues", "PROBLEM", 0, 15], ["esophagitis", "PROBLEM", 29, 40], ["pancreatitis", "PROBLEM", 42, 54], ["gastroparesis", "PROBLEM", 56, 69], ["ileus", "PROBLEM", 71, 76], ["CMV infections of the gut and liver", "PROBLEM", 78, 113], ["cholecystitis", "PROBLEM", 115, 128], ["peptic ulcer disease", "PROBLEM", 130, 150], ["gastroesophageal reflux", "PROBLEM", 152, 175], ["peptic ulcer disease", "PROBLEM", 181, 201], ["esophagitis", "OBSERVATION", 29, 40], ["pancreatitis", "OBSERVATION", 42, 54], ["gastroparesis", "OBSERVATION", 56, 69], ["ileus", "OBSERVATION", 71, 76], ["CMV infections", "OBSERVATION", 78, 92], ["gut", "ANATOMY", 100, 103], ["liver", "ANATOMY", 108, 113], ["cholecystitis", "OBSERVATION", 115, 128], ["peptic", "OBSERVATION_MODIFIER", 130, 136], ["ulcer disease", "OBSERVATION", 137, 150], ["gastroesophageal", "ANATOMY", 152, 168], ["reflux", "OBSERVATION", 169, 175], ["peptic", "OBSERVATION_MODIFIER", 181, 187], ["ulcer disease", "OBSERVATION", 188, 201]]], ["Patients with cystic fibrosis continue to be at risk for distal intestinal obstruction syndrome and must continue to take pancreatic enzyme supplements, along with bowel regimens (i.e., lactulose or Miralax), particularly in the early post-operative period to avoid obstruction.", [["cystic", "ANATOMY", 14, 20], ["intestinal", "ANATOMY", 64, 74], ["pancreatic", "ANATOMY", 122, 132], ["bowel", "ANATOMY", 164, 169], ["cystic fibrosis", "DISEASE", 14, 29], ["intestinal obstruction syndrome", "DISEASE", 64, 95], ["lactulose", "CHEMICAL", 186, 195], ["obstruction", "DISEASE", 266, 277], ["lactulose", "CHEMICAL", 186, 195], ["Patients", "ORGANISM", 0, 8], ["intestinal", "ORGAN", 64, 74], ["pancreatic", "ORGAN", 122, 132], ["bowel", "ORGAN", 164, 169], ["lactulose", "SIMPLE_CHEMICAL", 186, 195], ["Miralax", "SIMPLE_CHEMICAL", 199, 206], ["Patients", "SPECIES", 0, 8], ["cystic fibrosis", "PROBLEM", 14, 29], ["distal intestinal obstruction syndrome", "PROBLEM", 57, 95], ["pancreatic enzyme supplements", "TREATMENT", 122, 151], ["bowel regimens", "TREATMENT", 164, 178], ["lactulose", "TREATMENT", 186, 195], ["Miralax", "TREATMENT", 199, 206], ["obstruction", "PROBLEM", 266, 277], ["cystic", "OBSERVATION_MODIFIER", 14, 20], ["fibrosis", "OBSERVATION", 21, 29], ["distal", "ANATOMY_MODIFIER", 57, 63], ["intestinal", "ANATOMY", 64, 74], ["obstruction", "OBSERVATION", 75, 86], ["bowel", "ANATOMY", 164, 169], ["obstruction", "OBSERVATION", 266, 277]]], ["Gastroesophageal reflux deserves special mention, as data suggest that diagnosis and treatment of GER with anti-reflux surgery may prevent the development of bronchiolitis obliterans and ameliorate its progression if present, but these data have not been replicated in children.", [["Gastroesophageal", "ANATOMY", 0, 16], ["Gastroesophageal reflux", "DISEASE", 0, 23], ["GER", "DISEASE", 98, 101], ["bronchiolitis obliterans", "DISEASE", 158, 182], ["Gastroesophageal", "ORGAN", 0, 16], ["children", "ORGANISM", 269, 277], ["children", "SPECIES", 269, 277], ["Gastroesophageal reflux deserves", "PROBLEM", 0, 32], ["treatment", "TREATMENT", 85, 94], ["GER", "PROBLEM", 98, 101], ["anti-reflux surgery", "TREATMENT", 107, 126], ["bronchiolitis obliterans", "PROBLEM", 158, 182], ["reflux", "OBSERVATION", 17, 23], ["bronchiolitis obliterans", "OBSERVATION", 158, 182]]], ["As mentioned above, PTLD can present as intussusception, obstruction, bowel perforation, feeding intolerance or abdominal pain.", [["bowel", "ANATOMY", 70, 75], ["abdominal", "ANATOMY", 112, 121], ["PTLD", "DISEASE", 20, 24], ["intussusception", "DISEASE", 40, 55], ["obstruction", "DISEASE", 57, 68], ["bowel perforation", "DISEASE", 70, 87], ["feeding intolerance", "DISEASE", 89, 108], ["abdominal pain", "DISEASE", 112, 126], ["bowel", "ORGAN", 70, 75], ["abdominal", "ORGANISM_SUBDIVISION", 112, 121], ["PTLD", "PROBLEM", 20, 24], ["intussusception", "PROBLEM", 40, 55], ["obstruction", "PROBLEM", 57, 68], ["bowel perforation", "PROBLEM", 70, 87], ["feeding intolerance", "PROBLEM", 89, 108], ["abdominal pain", "PROBLEM", 112, 126], ["intussusception", "OBSERVATION", 40, 55], ["obstruction", "OBSERVATION", 57, 68], ["bowel", "ANATOMY", 70, 75], ["perforation", "OBSERVATION", 76, 87], ["feeding intolerance", "OBSERVATION", 89, 108], ["abdominal", "ANATOMY", 112, 121], ["pain", "OBSERVATION", 122, 126]]], ["For GI complications, medical management for resolution is preferred.", [["GI", "ANATOMY", 4, 6], ["GI complications", "PROBLEM", 4, 20], ["medical management", "TREATMENT", 22, 40], ["complications", "OBSERVATION", 7, 20]]], ["If this is not possible, elective surgical procedures are well tolerated, while data suggests that emergent surgical procedures carry a high morbidity and mortality risk.Neurological Complications ::: Post-transplantation ComplicationsForty-seven percent of recipientshave some neurological complications.", [["Neurological", "ANATOMY", 170, 182], ["neurological", "ANATOMY", 278, 290], ["neurological complications", "DISEASE", 278, 304], ["elective surgical procedures", "TREATMENT", 25, 53], ["emergent surgical procedures", "TREATMENT", 99, 127], ["a high morbidity and mortality risk", "PROBLEM", 134, 169], ["some neurological complications", "PROBLEM", 273, 304], ["not possible", "UNCERTAINTY", 11, 23], ["transplantation", "OBSERVATION", 206, 221], ["some", "OBSERVATION_MODIFIER", 273, 277], ["neurological complications", "OBSERVATION", 278, 304]]], ["The most common complication is seizures, generally felt to be related to calcineurin inhibitor induced cerebral vasoconstriction.", [["cerebral", "ANATOMY", 104, 112], ["seizures", "DISEASE", 32, 40], ["cerebral vasoconstriction", "DISEASE", 104, 129], ["calcineurin", "GENE_OR_GENE_PRODUCT", 74, 85], ["cerebral", "ORGAN", 104, 112], ["calcineurin", "PROTEIN", 74, 85], ["The most common complication", "PROBLEM", 0, 28], ["seizures", "PROBLEM", 32, 40], ["calcineurin inhibitor", "TREATMENT", 74, 95], ["cerebral vasoconstriction", "PROBLEM", 104, 129], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["complication", "OBSERVATION", 16, 28], ["seizures", "OBSERVATION", 32, 40], ["cerebral", "ANATOMY", 104, 112], ["vasoconstriction", "OBSERVATION", 113, 129]]], ["Posterior reversible encephalopathy syndrome (PRES) can also be seen.", [["Posterior reversible encephalopathy syndrome", "DISEASE", 0, 44], ["PRES", "DISEASE", 46, 50], ["Posterior reversible encephalopathy syndrome", "PROBLEM", 0, 44], ["reversible", "OBSERVATION_MODIFIER", 10, 20], ["encephalopathy", "OBSERVATION", 21, 35]]], ["PRES consists of seizure activity in 92% of cases, along with headaches, visual abnormalities, nausea/vomiting,other focal neurological signs, and varying degrees of impaired consciousness, ranging from confusion, somnolence, and lethargy to encephalopathy or coma.", [["neurological", "ANATOMY", 123, 135], ["PRES", "DISEASE", 0, 4], ["seizure", "DISEASE", 17, 24], ["headaches", "DISEASE", 62, 71], ["visual abnormalities", "DISEASE", 73, 93], ["nausea", "DISEASE", 95, 101], ["vomiting", "DISEASE", 102, 110], ["impaired consciousness", "DISEASE", 166, 188], ["confusion", "DISEASE", 203, 212], ["somnolence", "DISEASE", 214, 224], ["lethargy", "DISEASE", 230, 238], ["encephalopathy", "DISEASE", 242, 256], ["coma", "DISEASE", 260, 264], ["seizure activity", "PROBLEM", 17, 33], ["headaches", "PROBLEM", 62, 71], ["visual abnormalities", "PROBLEM", 73, 93], ["nausea", "PROBLEM", 95, 101], ["vomiting", "PROBLEM", 102, 110], ["other focal neurological signs", "PROBLEM", 111, 141], ["varying degrees of impaired consciousness", "PROBLEM", 147, 188], ["confusion", "PROBLEM", 203, 212], ["somnolence", "PROBLEM", 214, 224], ["lethargy", "PROBLEM", 230, 238], ["encephalopathy", "PROBLEM", 242, 256], ["coma", "PROBLEM", 260, 264], ["seizure activity", "OBSERVATION", 17, 33], ["focal", "OBSERVATION_MODIFIER", 117, 122]]], ["The diagnosis requires both symptoms and neuroimaging findings, with MRI being superior to CT scan for identifying PRES.", [["PRES", "DISEASE", 115, 119], ["both symptoms", "PROBLEM", 23, 36], ["neuroimaging findings", "TEST", 41, 62], ["MRI", "TEST", 69, 72], ["CT scan", "TEST", 91, 98], ["PRES", "PROBLEM", 115, 119]]], ["Consultation with a neurologist is also recommended; however, long-term medication is not generally needed for seizures related to lung transplantation.", [["lung", "ANATOMY", 131, 135], ["seizures", "DISEASE", 111, 119], ["lung", "ORGAN", 131, 135], ["long-term medication", "TREATMENT", 62, 82], ["seizures", "PROBLEM", 111, 119], ["lung transplantation", "TREATMENT", 131, 151], ["lung", "ANATOMY", 131, 135], ["transplantation", "OBSERVATION", 136, 151]]], ["Hypertension can be present and contributory, and should be managed accordingly.", [["Hypertension", "DISEASE", 0, 12], ["Hypertension", "PROBLEM", 0, 12]]], ["While calcineurin inhibitor toxicity is felt to contribute to both seizures and PRES, the correlation with levels and severity or incidence is incomplete.", [["toxicity", "DISEASE", 28, 36], ["seizures", "DISEASE", 67, 75], ["PRES", "DISEASE", 80, 84], ["calcineurin", "GENE_OR_GENE_PRODUCT", 6, 17], ["calcineurin", "PROTEIN", 6, 17], ["calcineurin inhibitor toxicity", "PROBLEM", 6, 36], ["seizures", "PROBLEM", 67, 75], ["PRES", "PROBLEM", 80, 84], ["seizures", "OBSERVATION", 67, 75]]], ["Although some patients respond to switchingCNI (i.e., from tacrolimus to cyclosporine or vice versa) or alternative regimens, no general recommendation exists.Diabetes ::: Post-transplantation ComplicationsDiabetes is seen in 20% of recipients in 1 year, 30% at 5 years, and is seen most commonly in patients with cystic fibrosis and is thus likely related to pre-existing and ongoing pancreatic islet cell injury.", [["cystic", "ANATOMY", 314, 320], ["pancreatic islet cell", "ANATOMY", 385, 406], ["tacrolimus", "CHEMICAL", 59, 69], ["cyclosporine", "CHEMICAL", 73, 85], ["Diabetes", "DISEASE", 159, 167], ["Diabetes", "DISEASE", 206, 214], ["fibrosis", "DISEASE", 321, 329], ["pancreatic islet cell injury", "DISEASE", 385, 413], ["tacrolimus", "CHEMICAL", 59, 69], ["cyclosporine", "CHEMICAL", 73, 85], ["patients", "ORGANISM", 14, 22], ["tacrolimus", "SIMPLE_CHEMICAL", 59, 69], ["cyclosporine", "SIMPLE_CHEMICAL", 73, 85], ["recipients", "ORGANISM", 233, 243], ["patients", "ORGANISM", 300, 308], ["cystic", "ORGAN", 314, 320], ["pancreatic islet cell", "CELL", 385, 406], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 300, 308], ["switchingCNI", "TREATMENT", 34, 46], ["tacrolimus", "TREATMENT", 59, 69], ["cyclosporine", "TREATMENT", 73, 85], ["alternative regimens", "TREATMENT", 104, 124], ["Diabetes", "PROBLEM", 159, 167], ["Diabetes", "PROBLEM", 206, 214], ["cystic fibrosis", "PROBLEM", 314, 329], ["pre-existing and ongoing pancreatic islet cell injury", "PROBLEM", 360, 413], ["transplantation", "OBSERVATION_MODIFIER", 177, 192], ["Complications", "OBSERVATION", 193, 206], ["cystic", "OBSERVATION_MODIFIER", 314, 320], ["fibrosis", "OBSERVATION", 321, 329], ["thus likely related to", "UNCERTAINTY", 337, 359], ["pancreatic", "ANATOMY", 385, 395], ["islet cell injury", "OBSERVATION", 396, 413]]], ["Tacrolimus and corticosteroids both appear to increase the risk of diabetes.Renal Dysfunction ::: Post-transplantation ComplicationsNearly all recipients develop hypomagnesemia post-transplant, with some developing renal tubular acidosis, and both are generally managed with oral supplements.", [["Renal", "ANATOMY", 76, 81], ["renal tubular", "ANATOMY", 215, 228], ["oral", "ANATOMY", 275, 279], ["Tacrolimus", "CHEMICAL", 0, 10], ["corticosteroids", "CHEMICAL", 15, 30], ["diabetes", "DISEASE", 67, 75], ["Renal Dysfunction", "DISEASE", 76, 93], ["hypomagnesemia", "DISEASE", 162, 176], ["renal tubular acidosis", "DISEASE", 215, 237], ["Tacrolimus", "CHEMICAL", 0, 10], ["corticosteroids", "CHEMICAL", 15, 30], ["Tacrolimus", "SIMPLE_CHEMICAL", 0, 10], ["corticosteroids", "SIMPLE_CHEMICAL", 15, 30], ["Renal", "ORGAN", 76, 81], ["recipients", "ORGANISM", 143, 153], ["renal tubular", "MULTI-TISSUE_STRUCTURE", 215, 228], ["oral", "ORGANISM_SUBDIVISION", 275, 279], ["Tacrolimus", "TREATMENT", 0, 10], ["corticosteroids", "TREATMENT", 15, 30], ["diabetes", "PROBLEM", 67, 75], ["Renal Dysfunction", "PROBLEM", 76, 93], ["Post-transplantation Complications", "TREATMENT", 98, 132], ["hypomagnesemia", "PROBLEM", 162, 176], ["transplant", "TREATMENT", 182, 192], ["some developing renal tubular acidosis", "PROBLEM", 199, 237], ["oral supplements", "TREATMENT", 275, 291], ["diabetes", "OBSERVATION", 67, 75], ["Dysfunction", "OBSERVATION", 82, 93], ["transplantation", "OBSERVATION", 103, 118], ["hypomagnesemia", "OBSERVATION", 162, 176], ["transplant", "OBSERVATION", 182, 192], ["renal", "ANATOMY", 215, 220], ["tubular", "ANATOMY_MODIFIER", 221, 228], ["acidosis", "OBSERVATION", 229, 237], ["generally", "OBSERVATION_MODIFIER", 252, 261], ["managed", "OBSERVATION_MODIFIER", 262, 269]]], ["Early renal failure suggests pre-transplant renal insufficiency.", [["renal", "ANATOMY", 6, 11], ["renal", "ANATOMY", 44, 49], ["renal failure", "DISEASE", 6, 19], ["pre-transplant renal insufficiency", "DISEASE", 29, 63], ["renal", "ORGAN", 6, 11], ["renal", "ORGAN", 44, 49], ["Early renal failure", "PROBLEM", 0, 19], ["pre-transplant renal insufficiency", "PROBLEM", 29, 63], ["renal", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19], ["pre-transplant", "OBSERVATION", 29, 43], ["renal", "ANATOMY", 44, 49], ["insufficiency", "OBSERVATION", 50, 63]]], ["Thus, measurement of glomerular filtration rate is a mandatory aspect of pre-transplant evaluation, as patients with GFR <50 have a suspected risk for poor outcomes, and it thus represents a contraindication to transplant at some centers.", [["glomerular", "ANATOMY", 21, 31], ["glomerular", "TISSUE", 21, 31], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["glomerular filtration rate", "TEST", 21, 47], ["pre-transplant evaluation", "TEST", 73, 98], ["GFR", "TEST", 117, 120], ["poor outcomes", "PROBLEM", 151, 164], ["transplant", "TREATMENT", 211, 221], ["glomerular", "ANATOMY", 21, 31], ["filtration", "OBSERVATION", 32, 42], ["transplant", "OBSERVATION", 211, 221]]], ["Chronic effects of exposure to CNI and resulting renal vasoconsctriction contributes significantly to renal insufficiency and renovascular hypertension post-transplant.", [["renal", "ANATOMY", 49, 54], ["renal", "ANATOMY", 102, 107], ["renovascular", "ANATOMY", 126, 138], ["CNI", "CHEMICAL", 31, 34], ["renal insufficiency", "DISEASE", 102, 121], ["renovascular hypertension", "DISEASE", 126, 151], ["CNI", "CHEMICAL", 31, 34], ["CNI", "SIMPLE_CHEMICAL", 31, 34], ["renal", "ORGAN", 49, 54], ["renal", "ORGAN", 102, 107], ["renovascular", "ORGAN", 126, 138], ["CNI", "TREATMENT", 31, 34], ["resulting renal vasoconsctriction", "PROBLEM", 39, 72], ["renal insufficiency", "PROBLEM", 102, 121], ["renovascular hypertension", "PROBLEM", 126, 151], ["transplant", "TREATMENT", 157, 167], ["CNI", "OBSERVATION", 31, 34], ["renal", "ANATOMY", 49, 54], ["vasoconsctriction", "OBSERVATION", 55, 72], ["renal", "ANATOMY", 102, 107], ["insufficiency", "OBSERVATION", 108, 121], ["renovascular", "ANATOMY", 126, 138], ["hypertension", "OBSERVATION", 139, 151], ["transplant", "OBSERVATION", 157, 167]]], ["Generally, this is managed with calcium channel blockers.", [["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 32, 39], ["calcium channel blockers", "SIMPLE_CHEMICAL", 32, 56], ["calcium channel blockers", "TREATMENT", 32, 56]]], ["Five years of CNI based immunosuppression carries a 2.3% incidence of renal failure requiring dialysis, and 1% require renal transplantation at some point post-transplant.Acute Rejection ::: RejectionAcute cellular rejection is common in the first weeks to months post-transplant.", [["renal", "ANATOMY", 70, 75], ["renal", "ANATOMY", 119, 124], ["cellular", "ANATOMY", 206, 214], ["CNI", "CHEMICAL", 14, 17], ["renal failure", "DISEASE", 70, 83], ["CNI", "CHEMICAL", 14, 17], ["renal", "ORGAN", 70, 75], ["renal", "ORGAN", 119, 124], ["cellular", "CELL", 206, 214], ["CNI based immunosuppression", "TREATMENT", 14, 41], ["renal failure", "PROBLEM", 70, 83], ["dialysis", "TREATMENT", 94, 102], ["renal transplantation", "TREATMENT", 119, 140], ["transplant", "TREATMENT", 160, 170], ["Acute Rejection", "PROBLEM", 171, 186], ["RejectionAcute cellular rejection", "PROBLEM", 191, 224], ["renal", "ANATOMY", 70, 75], ["failure", "OBSERVATION", 76, 83], ["dialysis", "OBSERVATION", 94, 102], ["renal", "ANATOMY", 119, 124], ["transplantation", "OBSERVATION", 125, 140], ["transplant", "OBSERVATION", 160, 170], ["Rejection", "OBSERVATION", 177, 186], ["cellular rejection", "OBSERVATION", 206, 224]]], ["While often asymptomatic, fever, hypoxemia, and dyspnea can be seen.", [["fever", "DISEASE", 26, 31], ["hypoxemia", "DISEASE", 33, 42], ["dyspnea", "DISEASE", 48, 55], ["asymptomatic", "PROBLEM", 12, 24], ["fever", "PROBLEM", 26, 31], ["hypoxemia", "PROBLEM", 33, 42], ["dyspnea", "PROBLEM", 48, 55], ["fever", "OBSERVATION", 26, 31], ["hypoxemia", "OBSERVATION", 33, 42], ["dyspnea", "OBSERVATION", 48, 55]]], ["CXR findings include infiltrates and bilateral pleural effusions.", [["pleural effusions", "ANATOMY", 47, 64], ["pleural effusions", "DISEASE", 47, 64], ["pleural effusions", "PATHOLOGICAL_FORMATION", 47, 64], ["CXR", "PROTEIN", 0, 3], ["CXR findings", "TEST", 0, 12], ["infiltrates", "PROBLEM", 21, 32], ["bilateral pleural effusions", "PROBLEM", 37, 64], ["infiltrates", "OBSERVATION", 21, 32], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["pleural", "ANATOMY", 47, 54], ["effusions", "OBSERVATION", 55, 64]]], ["Similarly, a 10% decrease in either FEV1 or FVC on home spirometric monitoring should prompt further evaluation.", [["FEV1", "TEST", 36, 40], ["FVC", "TREATMENT", 44, 47], ["home spirometric monitoring", "TEST", 51, 78], ["prompt further evaluation", "TEST", 86, 111], ["decrease", "OBSERVATION_MODIFIER", 17, 25]]], ["Biopsies are graded per the 2007 Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.", [["Biopsies", "ANATOMY", 0, 8], ["lung", "ANATOMY", 134, 138], ["Biopsies", "CANCER", 0, 8], ["lung", "ORGAN", 134, 138], ["Biopsies", "TEST", 0, 8], ["lung rejection", "PROBLEM", 134, 148], ["lung", "ANATOMY", 134, 138], ["rejection", "OBSERVATION", 139, 148]]], ["The score consists of two components.", [["two", "OBSERVATION_MODIFIER", 22, 25], ["components", "OBSERVATION_MODIFIER", 26, 36]]], ["The A score reflects the intensity and composition of infiltrating immune cells and the extent of parenchymal involvement (A0, no rejection, A1\u20134 minimal to severe acute rejection).", [["infiltrating immune cells", "ANATOMY", 54, 79], ["parenchymal", "ANATOMY", 98, 109], ["infiltrating immune cells", "CELL", 54, 79], ["parenchymal", "TISSUE", 98, 109], ["infiltrating immune cells", "CELL_TYPE", 54, 79], ["infiltrating immune cells", "PROBLEM", 54, 79], ["parenchymal involvement", "PROBLEM", 98, 121], ["rejection", "PROBLEM", 130, 139], ["severe acute rejection", "PROBLEM", 157, 179], ["intensity", "OBSERVATION_MODIFIER", 25, 34], ["infiltrating immune cells", "OBSERVATION", 54, 79], ["extent", "OBSERVATION_MODIFIER", 88, 94], ["parenchymal", "ANATOMY_MODIFIER", 98, 109], ["involvement", "OBSERVATION", 110, 121], ["no", "UNCERTAINTY", 127, 129], ["rejection", "OBSERVATION", 130, 139], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["rejection", "OBSERVATION", 170, 179]]], ["The B score reflects airway involvement.Acute Rejection ::: RejectionOnly acute rejection episodes graded A2 or higher are treated, generally with 3\u20134 days of pulse IV methylprednisolone (10\u201320 mg/kg/day), with follow-up biopsy in 2\u20134 weeks.", [["airway", "ANATOMY", 21, 27], ["methylprednisolone", "CHEMICAL", 168, 186], ["methylprednisolone", "CHEMICAL", 168, 186], ["airway", "MULTI-TISSUE_STRUCTURE", 21, 27], ["methylprednisolone", "SIMPLE_CHEMICAL", 168, 186], ["The B score", "TEST", 0, 11], ["airway involvement", "PROBLEM", 21, 39], ["Acute Rejection", "PROBLEM", 40, 55], ["RejectionOnly acute rejection episodes graded A2", "PROBLEM", 60, 108], ["pulse IV methylprednisolone", "TREATMENT", 159, 186], ["follow-up biopsy", "TEST", 211, 227], ["airway", "ANATOMY", 21, 27], ["involvement", "OBSERVATION", 28, 39], ["Rejection", "OBSERVATION", 46, 55], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["rejection", "OBSERVATION", 80, 89], ["A2", "OBSERVATION_MODIFIER", 106, 108], ["higher", "OBSERVATION_MODIFIER", 112, 118]]], ["Persistent acute rejection is treated with additional pulse steroids, anti-T-cell antibody therapy, and augmented baseline immunosuppression.", [["cell", "ANATOMY", 77, 81], ["steroids", "CHEMICAL", 60, 68], ["steroids", "CHEMICAL", 60, 68], ["anti-T-cell antibody", "GENE_OR_GENE_PRODUCT", 70, 90], ["Persistent acute rejection", "PROBLEM", 0, 26], ["additional pulse steroids", "TREATMENT", 43, 68], ["anti-T-cell antibody therapy", "TREATMENT", 70, 98], ["augmented baseline immunosuppression", "TREATMENT", 104, 140], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["rejection", "OBSERVATION", 17, 26], ["antibody therapy", "OBSERVATION", 82, 98]]], ["Acute rejection is infrequent after the first year post-transplant and is less common in infants than in older children.Antibody Mediated Rejection ::: RejectionWhile hyperacute antibody-mediated rejection caused by pre-formed anti-donor antibodies present at the time of transplant is a well established cause of acute graft failure, it is rare.", [["graft", "ANATOMY", 320, 325], ["acute graft failure", "DISEASE", 314, 333], ["infants", "ORGANISM", 89, 96], ["children", "ORGANISM", 111, 119], ["graft", "TISSUE", 320, 325], ["anti-donor antibodies", "PROTEIN", 227, 248], ["infants", "SPECIES", 89, 96], ["children", "SPECIES", 111, 119], ["Acute rejection", "PROBLEM", 0, 15], ["RejectionWhile hyperacute antibody", "PROBLEM", 152, 186], ["mediated rejection", "PROBLEM", 187, 205], ["pre-formed anti-donor antibodies", "PROBLEM", 216, 248], ["transplant", "TREATMENT", 272, 282], ["acute graft failure", "PROBLEM", 314, 333], ["rejection", "OBSERVATION", 6, 15], ["less common", "OBSERVATION_MODIFIER", 74, 85], ["Rejection", "OBSERVATION", 138, 147], ["rejection", "OBSERVATION", 196, 205], ["anti-donor antibodies", "OBSERVATION", 227, 248], ["acute", "OBSERVATION_MODIFIER", 314, 319], ["graft failure", "OBSERVATION", 320, 333]]], ["Antibody mediated rejection (AMR) outside that context is now recognized as an important complication in lung transplantation.", [["lung", "ANATOMY", 105, 109], ["AMR", "DISEASE", 29, 32], ["lung", "ORGAN", 105, 109], ["Antibody mediated rejection", "PROBLEM", 0, 27], ["lung transplantation", "TREATMENT", 105, 125], ["rejection", "OBSERVATION", 18, 27], ["important", "OBSERVATION_MODIFIER", 79, 88], ["complication", "OBSERVATION", 89, 101], ["lung", "ANATOMY", 105, 109], ["transplantation", "OBSERVATION", 110, 125]]], ["As diagnostic criteria are still evolving, and retrospective evaluations in progress, the exact incidence of AMR in pediatric lung transplantation is as yet unknown.", [["lung", "ANATOMY", 126, 130], ["AMR", "DISEASE", 109, 112], ["lung", "ORGAN", 126, 130], ["retrospective evaluations", "TEST", 47, 72], ["AMR", "PROBLEM", 109, 112], ["pediatric lung transplantation", "TREATMENT", 116, 146], ["lung", "ANATOMY", 126, 130], ["transplantation", "OBSERVATION", 131, 146]]], ["AMR can present as progressive worsening of lung function in the absence of acute or chronic rejection, and can rapidly result in death due to graft failure.Antibody Mediated Rejection ::: RejectionCurrently, diagnosis of AMR requires three features be present, including evidence of allograft dysfunction, presence of circulating donor-specific antibodies, and histopathologic findings of AMR.", [["lung", "ANATOMY", 44, 48], ["graft", "ANATOMY", 143, 148], ["allograft", "ANATOMY", 284, 293], ["AMR", "DISEASE", 0, 3], ["death", "DISEASE", 130, 135], ["AMR", "DISEASE", 222, 225], ["allograft dysfunction", "DISEASE", 284, 305], ["AMR", "DISEASE", 390, 393], ["lung", "ORGAN", 44, 48], ["graft", "TISSUE", 143, 148], ["allograft", "TISSUE", 284, 293], ["circulating donor-specific antibodies", "PROTEIN", 319, 356], ["lung function", "PROBLEM", 44, 57], ["acute or chronic rejection", "PROBLEM", 76, 102], ["death", "PROBLEM", 130, 135], ["graft failure", "PROBLEM", 143, 156], ["AMR", "PROBLEM", 222, 225], ["allograft dysfunction", "PROBLEM", 284, 305], ["circulating donor-specific antibodies", "TEST", 319, 356], ["AMR", "PROBLEM", 390, 393], ["progressive", "OBSERVATION_MODIFIER", 19, 30], ["worsening", "OBSERVATION_MODIFIER", 31, 40], ["lung", "ANATOMY", 44, 48], ["function", "OBSERVATION", 49, 57], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["rejection", "OBSERVATION", 93, 102], ["graft failure", "OBSERVATION", 143, 156], ["Rejection", "OBSERVATION", 175, 184], ["AMR", "OBSERVATION", 222, 225], ["allograft", "OBSERVATION", 284, 293], ["donor-specific antibodies", "OBSERVATION", 331, 356]]], ["However, this is complicated by the significant overlap of these patterns with pathology seen in other forms of lung injury, including high-grade or persistent acute cellular rejection, diffuse alveolar damage, high-grade or persistent lymphocytic bronchiolitis, obliterative bronchiolitis, arteritis without rejection, or other graft dysfunction without clear morphological explanation.Antibody Mediated Rejection ::: RejectionTreatment of antibody mediated rejection is still evolving.", [["lung", "ANATOMY", 112, 116], ["cellular", "ANATOMY", 166, 174], ["alveolar", "ANATOMY", 194, 202], ["lymphocytic", "ANATOMY", 236, 247], ["graft", "ANATOMY", 329, 334], ["lung injury", "DISEASE", 112, 123], ["alveolar damage", "DISEASE", 194, 209], ["bronchiolitis", "DISEASE", 248, 261], ["bronchiolitis", "DISEASE", 276, 289], ["arteritis", "DISEASE", 291, 300], ["lung", "ORGAN", 112, 116], ["cellular", "CELL", 166, 174], ["alveolar", "TISSUE", 194, 202], ["graft", "TISSUE", 329, 334], ["pathology", "PROBLEM", 79, 88], ["lung injury", "PROBLEM", 112, 123], ["high-grade or persistent acute cellular rejection", "PROBLEM", 135, 184], ["diffuse alveolar damage", "PROBLEM", 186, 209], ["high-grade or persistent lymphocytic bronchiolitis", "PROBLEM", 211, 261], ["obliterative bronchiolitis", "PROBLEM", 263, 289], ["arteritis", "PROBLEM", 291, 300], ["rejection", "PROBLEM", 309, 318], ["other graft dysfunction", "PROBLEM", 323, 346], ["antibody mediated rejection", "PROBLEM", 441, 468], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["overlap", "OBSERVATION", 48, 55], ["pathology", "OBSERVATION", 79, 88], ["lung", "ANATOMY", 112, 116], ["injury", "OBSERVATION", 117, 123], ["high-grade", "OBSERVATION_MODIFIER", 135, 145], ["persistent", "OBSERVATION_MODIFIER", 149, 159], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["cellular rejection", "OBSERVATION", 166, 184], ["diffuse", "OBSERVATION_MODIFIER", 186, 193], ["alveolar damage", "OBSERVATION", 194, 209], ["high", "OBSERVATION_MODIFIER", 211, 215], ["-grade", "OBSERVATION_MODIFIER", 215, 221], ["persistent", "OBSERVATION_MODIFIER", 225, 235], ["lymphocytic bronchiolitis", "OBSERVATION", 236, 261], ["obliterative", "OBSERVATION_MODIFIER", 263, 275], ["bronchiolitis", "OBSERVATION", 276, 289], ["arteritis", "OBSERVATION", 291, 300], ["without", "UNCERTAINTY", 301, 308], ["rejection", "OBSERVATION", 309, 318], ["graft dysfunction", "OBSERVATION", 329, 346], ["without", "UNCERTAINTY", 347, 354], ["Rejection", "OBSERVATION", 405, 414], ["antibody mediated", "OBSERVATION", 441, 458], ["rejection", "OBSERVATION", 459, 468]]], ["As such, the components of therapy, rather than specific regimens, will be discussed.", [["therapy", "TREATMENT", 27, 34], ["specific regimens", "TREATMENT", 48, 65]]], ["Plasmapheresis or therapeutic plasma exchange is a process for removal of antibodies and other circulating proteins from the recipient\u2019s bloodstream by filtration and thus directly removes the responsible antibodies.", [["plasma", "ANATOMY", 30, 36], ["bloodstream", "ANATOMY", 137, 148], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["antibodies", "PROTEIN", 74, 84], ["circulating proteins", "PROTEIN", 95, 115], ["antibodies", "PROTEIN", 205, 215], ["Plasmapheresis", "TREATMENT", 0, 14], ["therapeutic plasma exchange", "TREATMENT", 18, 45], ["removal of antibodies", "TREATMENT", 63, 84], ["other circulating proteins", "PROBLEM", 89, 115], ["the responsible antibodies", "PROBLEM", 189, 215]]], ["Pulse corticosteroids are also generally used and have been found to impair T-cell and B-cell function, impair antibody and complement binding, and decrease levels of serum immunoglobulins.", [["T-cell", "ANATOMY", 76, 82], ["B-cell", "ANATOMY", 87, 93], ["serum", "ANATOMY", 167, 172], ["T-cell", "CELL", 76, 82], ["B-cell", "CELL", 87, 93], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 173, 188], ["serum immunoglobulins", "PROTEIN", 167, 188], ["Pulse corticosteroids", "TREATMENT", 0, 21], ["B-cell function", "TEST", 87, 102], ["impair antibody and complement binding", "PROBLEM", 104, 142], ["serum immunoglobulins", "TEST", 167, 188], ["corticosteroids", "OBSERVATION", 6, 21]]], ["Rituximab, an anti-CD20 antibody used for PTLD, is also used in AMR, as it targets the B-cells that make antibody.", [["B-cells", "ANATOMY", 87, 94], ["Rituximab", "CHEMICAL", 0, 9], ["PTLD", "DISEASE", 42, 46], ["AMR", "DISEASE", 64, 67], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["B-cells", "CELL", 87, 94], ["anti-CD20 antibody", "PROTEIN", 14, 32], ["B-cells", "CELL_TYPE", 87, 94], ["Rituximab", "TREATMENT", 0, 9], ["an anti-CD20 antibody", "TREATMENT", 11, 32], ["PTLD", "PROBLEM", 42, 46], ["antibody", "PROBLEM", 105, 113]]], ["Its use in AMR mirrors its successful use in antibody-mediated autoimmune diseases such as rheumatoid arthritis.", [["AMR", "DISEASE", 11, 14], ["autoimmune diseases", "DISEASE", 63, 82], ["rheumatoid arthritis", "DISEASE", 91, 111], ["autoimmune diseases", "PROBLEM", 63, 82], ["rheumatoid arthritis", "PROBLEM", 91, 111], ["autoimmune diseases", "OBSERVATION", 63, 82], ["rheumatoid arthritis", "OBSERVATION", 91, 111]]], ["Together, these three interventions make up the initial treatment of AMR.Antibody Mediated Rejection ::: RejectionIn summary, while antibody mediated rejection is clearly an important process, the exact pathobiology, incidence, diagnostic approach, treatment, and understanding outcomes remain in evolution.", [["AMR", "DISEASE", 69, 72], ["AMR", "PROBLEM", 69, 72], ["antibody mediated rejection", "PROBLEM", 132, 159], ["treatment", "TREATMENT", 249, 258], ["Rejection", "OBSERVATION", 91, 100], ["rejection", "OBSERVATION", 150, 159]]], ["Ongoing studies will help to determine how to best diagnose and treat this entity in pediatric lung recipients.Chronic Lung Allograft Dysfunction ::: RejectionChronic lung allograft dysfunction (CLAD) is a newer term used to define the varying patterns of long-term respiratory decline and failure seen in lung recipients.", [["lung", "ANATOMY", 95, 99], ["Lung", "ANATOMY", 119, 123], ["lung allograft", "ANATOMY", 167, 181], ["respiratory", "ANATOMY", 266, 277], ["lung", "ANATOMY", 306, 310], ["lung allograft dysfunction", "DISEASE", 167, 193], ["CLAD", "DISEASE", 195, 199], ["respiratory decline", "DISEASE", 266, 285], ["lung", "ORGAN", 95, 99], ["Lung", "ORGAN", 119, 123], ["lung allograft", "MULTI-TISSUE_STRUCTURE", 167, 181], ["lung", "ORGAN", 306, 310], ["Ongoing studies", "TEST", 0, 15], ["pediatric lung recipients", "TREATMENT", 85, 110], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 111, 145], ["RejectionChronic lung allograft dysfunction", "PROBLEM", 150, 193], ["long-term respiratory decline", "PROBLEM", 256, 285], ["failure", "PROBLEM", 290, 297], ["lung recipients", "TREATMENT", 306, 321], ["lung", "ANATOMY", 95, 99], ["recipients", "OBSERVATION", 100, 110], ["Lung", "ANATOMY", 119, 123], ["Allograft", "OBSERVATION", 124, 133], ["lung", "ANATOMY", 167, 171], ["allograft", "OBSERVATION", 172, 181], ["long-term", "OBSERVATION_MODIFIER", 256, 265], ["respiratory decline", "OBSERVATION", 266, 285], ["failure", "OBSERVATION", 290, 297], ["lung", "ANATOMY", 306, 310], ["recipients", "OBSERVATION", 311, 321]]], ["It encompasses both bronchiolitis obliterans and restrictive long-term allograft dysfunction.Chronic Lung Allograft Dysfunction ::: RejectionAcute lung allograft dysfunction (ALAD) is defined as any acute cause of a drop in lung function, defined as a 10% drop from baseline in post-bronchodilator FEV1 and/or FVC, including acute rejection and infection.", [["allograft", "ANATOMY", 71, 80], ["Lung", "ANATOMY", 101, 105], ["lung allograft", "ANATOMY", 147, 161], ["lung", "ANATOMY", 224, 228], ["bronchiolitis obliterans", "DISEASE", 20, 44], ["lung allograft dysfunction", "DISEASE", 147, 173], ["ALAD", "DISEASE", 175, 179], ["infection", "DISEASE", 345, 354], ["allograft", "TISSUE", 71, 80], ["Lung", "ORGAN", 101, 105], ["lung allograft", "MULTI-TISSUE_STRUCTURE", 147, 161], ["lung", "ORGAN", 224, 228], ["both bronchiolitis obliterans", "PROBLEM", 15, 44], ["restrictive long-term allograft dysfunction", "PROBLEM", 49, 92], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 93, 127], ["RejectionAcute lung allograft dysfunction (ALAD)", "PROBLEM", 132, 180], ["a drop in lung function", "PROBLEM", 214, 237], ["a 10% drop", "PROBLEM", 250, 260], ["post-bronchodilator FEV1", "TEST", 278, 302], ["FVC", "PROBLEM", 310, 313], ["acute rejection", "PROBLEM", 325, 340], ["infection", "PROBLEM", 345, 354], ["both", "OBSERVATION_MODIFIER", 15, 19], ["bronchiolitis obliterans", "OBSERVATION", 20, 44], ["restrictive", "OBSERVATION_MODIFIER", 49, 60], ["long-term", "OBSERVATION_MODIFIER", 61, 70], ["allograft dysfunction", "OBSERVATION", 71, 92], ["Lung", "ANATOMY", 101, 105], ["Allograft", "OBSERVATION", 106, 115], ["lung", "ANATOMY", 147, 151], ["allograft", "OBSERVATION", 152, 161], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["drop", "OBSERVATION_MODIFIER", 216, 220], ["lung", "ANATOMY", 224, 228], ["function", "OBSERVATION", 229, 237], ["acute", "OBSERVATION_MODIFIER", 325, 330], ["rejection", "OBSERVATION", 331, 340], ["infection", "OBSERVATION", 345, 354]]], ["If this persists for more than 3 weeks, it is termed suspected CLAD, and evaluation should include bronchoscopy with biopsies.", [["CLAD", "DISEASE", 63, 67], ["CLAD", "CANCER", 63, 67], ["evaluation", "TEST", 73, 83], ["bronchoscopy", "TEST", 99, 111], ["biopsies", "TEST", 117, 125], ["termed suspected", "UNCERTAINTY", 46, 62], ["CLAD", "OBSERVATION", 63, 67]]], ["Should these prove non-diagnostic, and should lung function not recover, open lung biopsy is also an important consideration in pediatric recipients, particularly smaller children in which the diagnostic yield of transbronchial biopsies is limited by the use of small forceps.", [["lung", "ANATOMY", 46, 50], ["lung", "ANATOMY", 78, 82], ["transbronchial biopsies", "ANATOMY", 213, 236], ["lung", "ORGAN", 46, 50], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 78, 89], ["recipients", "ORGANISM", 138, 148], ["children", "ORGANISM", 171, 179], ["transbronchial biopsies", "MULTI-TISSUE_STRUCTURE", 213, 236], ["children", "SPECIES", 171, 179], ["open lung biopsy", "TEST", 73, 89], ["transbronchial biopsies", "TEST", 213, 236], ["small forceps", "TREATMENT", 262, 275], ["lung", "ANATOMY", 78, 82], ["biopsy", "OBSERVATION", 83, 89], ["transbronchial", "ANATOMY", 213, 227], ["biopsies", "OBSERVATION", 228, 236], ["small forceps", "OBSERVATION", 262, 275]]], ["If there is evidence of persistent acute rejection, infection, anastomotic complication, diaphragm dysfunction, or other causes, CLAD is not diagnosed.Chronic Lung Allograft Dysfunction ::: RejectionCLAD is divided into restrictive CLAD and obstructive CLAD.", [["anastomotic", "ANATOMY", 63, 74], ["diaphragm", "ANATOMY", 89, 98], ["Lung", "ANATOMY", 159, 163], ["infection", "DISEASE", 52, 61], ["diaphragm dysfunction", "DISEASE", 89, 110], ["CLAD", "DISEASE", 129, 133], ["RejectionCLAD", "DISEASE", 190, 203], ["CLAD", "DISEASE", 232, 236], ["obstructive CLAD", "DISEASE", 241, 257], ["diaphragm", "ORGAN", 89, 98], ["Lung", "ORGAN", 159, 163], ["persistent acute rejection", "PROBLEM", 24, 50], ["infection", "PROBLEM", 52, 61], ["anastomotic complication", "PROBLEM", 63, 87], ["diaphragm dysfunction", "PROBLEM", 89, 110], ["CLAD", "PROBLEM", 129, 133], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 151, 185], ["RejectionCLAD", "TEST", 190, 203], ["restrictive CLAD and obstructive CLAD", "PROBLEM", 220, 257], ["evidence of", "UNCERTAINTY", 12, 23], ["persistent", "OBSERVATION_MODIFIER", 24, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["rejection", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 52, 61], ["anastomotic complication", "OBSERVATION", 63, 87], ["diaphragm", "ANATOMY", 89, 98], ["dysfunction", "OBSERVATION", 99, 110], ["Lung", "ANATOMY", 159, 163], ["Allograft", "OBSERVATION", 164, 173], ["restrictive CLAD", "OBSERVATION", 220, 236], ["obstructive CLAD", "OBSERVATION", 241, 257]]], ["Restrictive CLAD, also called restrictive allograft syndrome, is named for the pulmonary function picture, which includes TLC \u2264 90% baseline and/or FEV1/FVC normal or increased, with FEV1 and/or FVC decline \u2264 80% of baseline.", [["allograft", "ANATOMY", 42, 51], ["pulmonary", "ANATOMY", 79, 88], ["CLAD", "DISEASE", 12, 16], ["restrictive allograft syndrome", "DISEASE", 30, 60], ["pulmonary", "ORGAN", 79, 88], ["Restrictive CLAD", "PROBLEM", 0, 16], ["restrictive allograft syndrome", "PROBLEM", 30, 60], ["the pulmonary function picture", "PROBLEM", 75, 105], ["TLC", "TEST", 122, 125], ["FEV1", "TEST", 148, 152], ["FVC", "TEST", 153, 156], ["FEV1", "TEST", 183, 187], ["FVC decline", "PROBLEM", 195, 206], ["CLAD", "OBSERVATION", 12, 16], ["restrictive allograft syndrome", "OBSERVATION", 30, 60], ["pulmonary", "ANATOMY", 79, 88], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["HRCT findings will include infiltrates, ground glass opacities, and upper lung zone fibrotic changes.", [["upper lung zone", "ANATOMY", 68, 83], ["lung", "MULTI-TISSUE_STRUCTURE", 74, 78], ["HRCT findings", "TEST", 0, 13], ["infiltrates", "PROBLEM", 27, 38], ["ground glass opacities", "PROBLEM", 40, 62], ["upper lung zone fibrotic changes", "PROBLEM", 68, 100], ["infiltrates", "OBSERVATION", 27, 38], ["ground glass opacities", "OBSERVATION", 40, 62], ["upper", "ANATOMY_MODIFIER", 68, 73], ["lung", "ANATOMY", 74, 78], ["zone", "ANATOMY_MODIFIER", 79, 83], ["fibrotic", "OBSERVATION", 84, 92]]], ["Restrictive CLAD (R-CLAD) carries a significantly worse prognosis than BOS, with median survival of 541 days for patients with R-CLAD compared to 1421 for patients with BOS.Chronic Lung Allograft Dysfunction ::: RejectionAfter 3 years post-transplant, obstructive CLAD or BOS becomes the major cause of death in pediatric recipients, and at 5 years, 50% of surviving recipients carry a diagnosis of BOS.", [["Lung", "ANATOMY", 181, 185], ["CLAD", "DISEASE", 12, 16], ["BOS", "DISEASE", 71, 74], ["CLAD", "DISEASE", 129, 133], ["BOS", "DISEASE", 169, 172], ["obstructive CLAD", "DISEASE", 252, 268], ["BOS", "DISEASE", 272, 275], ["death", "DISEASE", 303, 308], ["BOS", "DISEASE", 399, 402], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 155, 163], ["Lung", "ORGAN", 181, 185], ["recipients", "ORGANISM", 322, 332], ["recipients", "ORGANISM", 367, 377], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 155, 163], ["Restrictive CLAD (R-CLAD)", "PROBLEM", 0, 25], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 173, 207], ["transplant", "TREATMENT", 240, 250], ["obstructive CLAD", "PROBLEM", 252, 268], ["BOS", "PROBLEM", 272, 275], ["death", "PROBLEM", 303, 308], ["BOS", "PROBLEM", 399, 402], ["CLAD", "OBSERVATION", 12, 16], ["Lung", "ANATOMY", 181, 185], ["Allograft", "OBSERVATION", 186, 195], ["transplant", "OBSERVATION", 240, 250], ["obstructive CLAD", "OBSERVATION", 252, 268]]], ["In obstructive CLAD or BOS, the picture is dominated by the drop in FEV1, and FVC and TLC are stable or significantly less affected.", [["obstructive CLAD", "DISEASE", 3, 19], ["BOS", "DISEASE", 23, 26], ["FVC", "GENE_OR_GENE_PRODUCT", 78, 81], ["obstructive CLAD", "PROBLEM", 3, 19], ["BOS", "PROBLEM", 23, 26], ["the drop in FEV1", "PROBLEM", 56, 72], ["FVC", "TEST", 78, 81], ["TLC", "TEST", 86, 89], ["obstructive", "OBSERVATION_MODIFIER", 3, 14], ["CLAD", "OBSERVATION", 15, 19], ["BOS", "OBSERVATION", 23, 26], ["drop", "OBSERVATION_MODIFIER", 60, 64], ["FVC", "ANATOMY", 78, 81], ["TLC", "ANATOMY", 86, 89], ["stable", "OBSERVATION_MODIFIER", 94, 100], ["significantly", "OBSERVATION_MODIFIER", 104, 117], ["less", "OBSERVATION_MODIFIER", 118, 122]]], ["HRCT findings will include air trapping.Chronic Lung Allograft Dysfunction ::: RejectionIn terms of diagnosing BOS, the new CLAD classification system overlaps with the prior definitions of bronchiolitis obliterans syndrome (BOS).", [["Lung", "ANATOMY", 48, 52], ["BOS", "DISEASE", 111, 114], ["bronchiolitis obliterans syndrome", "DISEASE", 190, 223], ["BOS", "DISEASE", 225, 228], ["Lung", "ORGAN", 48, 52], ["HRCT findings", "TEST", 0, 13], ["air trapping", "PROBLEM", 27, 39], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 40, 74], ["diagnosing BOS", "PROBLEM", 100, 114], ["bronchiolitis obliterans syndrome", "PROBLEM", 190, 223], ["air trapping", "OBSERVATION", 27, 39], ["Lung", "ANATOMY", 48, 52], ["Allograft", "OBSERVATION", 53, 62], ["new", "OBSERVATION_MODIFIER", 120, 123], ["CLAD", "OBSERVATION", 124, 128], ["bronchiolitis obliterans syndrome", "OBSERVATION", 190, 223]]], ["For example, BOS 0p is defined as a \u2265 10 but <20% drop in post-bronchodilator FEV1 from baseline or FEF25\u201375 < 75% of baseline.", [["BOS", "TEST", 13, 16], ["post-bronchodilator FEV1", "TEST", 58, 82], ["FEF25\u201375", "TEST", 100, 108]]], ["In this group there appears to be a group of patients with what has been termed azithromycin-responsive allograft dysfunction (ARAD).", [["allograft", "ANATOMY", 104, 113], ["azithromycin", "CHEMICAL", 80, 92], ["allograft dysfunction", "DISEASE", 104, 125], ["ARAD", "DISEASE", 127, 131], ["azithromycin", "CHEMICAL", 80, 92], ["patients", "ORGANISM", 45, 53], ["azithromycin", "SIMPLE_CHEMICAL", 80, 92], ["allograft", "TISSUE", 104, 113], ["patients", "SPECIES", 45, 53], ["termed azithromycin", "TREATMENT", 73, 92], ["responsive allograft dysfunction", "PROBLEM", 93, 125], ["appears to be", "UNCERTAINTY", 20, 33], ["azithromycin", "OBSERVATION", 80, 92], ["responsive allograft dysfunction", "OBSERVATION", 93, 125]]], ["Azithromycin entered use in bronchiolitis obliterans syndrome in the early 2000s, after it was noted that patients on thrice-weekly azithromycin, as used in cystic fibrosis, could have stabilization and even improvement of lung function in the setting of bronchiolitis obliterans, despite lack of a clear mechanism of action, though both anti-inflammatory and anti-fibrotic activities of azithromycin are posited as being responsible for this therapeutic efficacy.Chronic Lung Allograft Dysfunction ::: RejectionOnce pulmonary function testing suggests BOS, either by a drop in FEV1, or a drop in FEF25\u201375, which has been shown to be more sensitive and detects small airways dysfunction earlier, diagnosis requires biopsy to confirm the presence of small airway obliteration by a fibrotic process.", [["cystic", "ANATOMY", 157, 163], ["lung", "ANATOMY", 223, 227], ["Lung", "ANATOMY", 472, 476], ["pulmonary", "ANATOMY", 517, 526], ["airways", "ANATOMY", 667, 674], ["airway", "ANATOMY", 755, 761], ["Azithromycin", "CHEMICAL", 0, 12], ["bronchiolitis obliterans syndrome", "DISEASE", 28, 61], ["azithromycin", "CHEMICAL", 132, 144], ["fibrosis", "DISEASE", 164, 172], ["bronchiolitis obliterans", "DISEASE", 255, 279], ["azithromycin", "CHEMICAL", 388, 400], ["BOS", "DISEASE", 553, 556], ["FEF25\u201375", "CHEMICAL", 597, 605], ["airways dysfunction", "DISEASE", 667, 686], ["Azithromycin", "CHEMICAL", 0, 12], ["azithromycin", "CHEMICAL", 132, 144], ["azithromycin", "CHEMICAL", 388, 400], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 106, 114], ["azithromycin", "SIMPLE_CHEMICAL", 132, 144], ["lung", "ORGAN", 223, 227], ["azithromycin", "SIMPLE_CHEMICAL", 388, 400], ["Lung", "ORGAN", 472, 476], ["pulmonary", "ORGAN", 517, 526], ["FEF25\u201375", "GENE_OR_GENE_PRODUCT", 597, 605], ["airways", "MULTI-TISSUE_STRUCTURE", 667, 674], ["airway", "MULTI-TISSUE_STRUCTURE", 755, 761], ["patients", "SPECIES", 106, 114], ["Azithromycin", "TREATMENT", 0, 12], ["bronchiolitis obliterans syndrome", "PROBLEM", 28, 61], ["azithromycin", "TREATMENT", 132, 144], ["cystic fibrosis", "PROBLEM", 157, 172], ["lung function", "PROBLEM", 223, 236], ["bronchiolitis obliterans", "PROBLEM", 255, 279], ["azithromycin", "TREATMENT", 388, 400], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 464, 498], ["RejectionOnce pulmonary function testing", "TEST", 503, 543], ["BOS", "PROBLEM", 553, 556], ["a drop in FEV1", "PROBLEM", 568, 582], ["a drop in FEF25", "PROBLEM", 587, 602], ["small airways dysfunction", "PROBLEM", 661, 686], ["biopsy", "TEST", 715, 721], ["small airway obliteration", "PROBLEM", 749, 774], ["a fibrotic process", "PROBLEM", 778, 796], ["bronchiolitis obliterans syndrome", "OBSERVATION", 28, 61], ["cystic", "OBSERVATION_MODIFIER", 157, 163], ["fibrosis", "OBSERVATION", 164, 172], ["lung", "ANATOMY", 223, 227], ["bronchiolitis obliterans", "OBSERVATION", 255, 279], ["anti-inflammatory", "OBSERVATION_MODIFIER", 338, 355], ["Lung", "ANATOMY", 472, 476], ["Allograft", "OBSERVATION", 477, 486], ["pulmonary", "ANATOMY", 517, 526], ["drop", "OBSERVATION_MODIFIER", 589, 593], ["small", "OBSERVATION_MODIFIER", 661, 666], ["airways dysfunction", "OBSERVATION", 667, 686], ["small", "OBSERVATION_MODIFIER", 749, 754], ["airway", "ANATOMY", 755, 761], ["obliteration", "OBSERVATION", 762, 774], ["fibrotic", "OBSERVATION", 780, 788]]], ["Currently, open or thoracoscopic lung biopsy is used at our center when BOS is suspected but cannot be confirmed by transbronchial biopsies.Chronic Lung Allograft Dysfunction ::: RejectionTreatment of BOS is varied, and over time has included use of augmented immunosuppression, change in baseline immunosuppression, azithromycin, extracorporeal photopheresis (ECP), and total lymphoid irradiation.", [["lung", "ANATOMY", 33, 37], ["Lung", "ANATOMY", 148, 152], ["lymphoid", "ANATOMY", 377, 385], ["BOS", "DISEASE", 72, 75], ["BOS", "DISEASE", 201, 204], ["azithromycin", "CHEMICAL", 317, 329], ["azithromycin", "CHEMICAL", 317, 329], ["lung", "ORGAN", 33, 37], ["transbronchial biopsies", "MULTI-TISSUE_STRUCTURE", 116, 139], ["Lung", "ORGAN", 148, 152], ["azithromycin", "SIMPLE_CHEMICAL", 317, 329], ["thoracoscopic lung biopsy", "TEST", 19, 44], ["transbronchial biopsies", "TEST", 116, 139], ["Chronic Lung Allograft Dysfunction", "PROBLEM", 140, 174], ["RejectionTreatment of BOS", "PROBLEM", 179, 204], ["augmented immunosuppression", "TREATMENT", 250, 277], ["baseline immunosuppression", "TREATMENT", 289, 315], ["azithromycin", "TREATMENT", 317, 329], ["extracorporeal photopheresis", "TREATMENT", 331, 359], ["total lymphoid irradiation", "TREATMENT", 371, 397], ["thoracoscopic", "OBSERVATION", 19, 32], ["lung", "ANATOMY", 33, 37], ["biopsy", "OBSERVATION", 38, 44], ["transbronchial", "ANATOMY", 116, 130], ["biopsies", "OBSERVATION", 131, 139], ["Lung", "ANATOMY", 148, 152], ["Allograft", "OBSERVATION", 153, 162], ["BOS", "OBSERVATION", 201, 204], ["varied", "OBSERVATION_MODIFIER", 208, 214], ["immunosuppression", "OBSERVATION", 260, 277], ["total lymphoid irradiation", "OBSERVATION", 371, 397]]], ["Currently, our practice is to use pulse corticosteroids accompanied by 10 days of anti-thymocyte antibodies, along with initiation of azithromycin thrice-weekly.", [["azithromycin", "CHEMICAL", 134, 146], ["corticosteroids", "CHEMICAL", 40, 55], ["azithromycin", "CHEMICAL", 134, 146], ["anti-thymocyte antibodies", "GENE_OR_GENE_PRODUCT", 82, 107], ["azithromycin", "SIMPLE_CHEMICAL", 134, 146], ["anti-thymocyte antibodies", "PROTEIN", 82, 107], ["pulse corticosteroids", "TREATMENT", 34, 55], ["anti-thymocyte antibodies", "TREATMENT", 82, 107], ["azithromycin thrice", "TREATMENT", 134, 153]]], ["If this does not stabilize symptoms, ECP is initiated.", [["ECP", "PROTEIN", 37, 40], ["symptoms", "PROBLEM", 27, 35], ["ECP", "TEST", 37, 40]]], ["This is consistent with the current best evidence.", [["consistent with", "UNCERTAINTY", 8, 23]]], ["While inhaled cyclosporine and mTOR inhibitors have both been shown to be effective in small studies, larger trials have not found a consistent benefit in the use of either to prevent the development of BOS, or in its treatment.", [["cyclosporine", "CHEMICAL", 14, 26], ["BOS", "DISEASE", 203, 206], ["cyclosporine", "CHEMICAL", 14, 26], ["cyclosporine", "SIMPLE_CHEMICAL", 14, 26], ["mTOR", "GENE_OR_GENE_PRODUCT", 31, 35], ["inhaled cyclosporine", "TREATMENT", 6, 26], ["mTOR inhibitors", "TREATMENT", 31, 46], ["small studies", "TEST", 87, 100], ["BOS", "PROBLEM", 203, 206], ["its treatment", "TREATMENT", 214, 227], ["BOS", "OBSERVATION", 203, 206]]], ["Surgical treatment of gastroesophageal reflux has been shown to be beneficial in adults in managing and preventing BOS, but this has not been replicated in children.", [["gastroesophageal", "ANATOMY", 22, 38], ["gastroesophageal reflux", "DISEASE", 22, 45], ["BOS", "DISEASE", 115, 118], ["gastroesophageal", "ORGAN", 22, 38], ["children", "ORGANISM", 156, 164], ["children", "SPECIES", 156, 164], ["Surgical treatment", "TREATMENT", 0, 18], ["gastroesophageal reflux", "PROBLEM", 22, 45], ["gastroesophageal", "ANATOMY", 22, 38], ["reflux", "OBSERVATION", 39, 45]]], ["Similarly, retrospective reviews suggest that statin therapy can prevent BOS and may be beneficial in treating BOS.OutcomesOutcomes in lung transplantation as a whole continue to lag behind those of other solid organ transplants, and this is also true in children.", [["lung", "ANATOMY", 135, 139], ["organ", "ANATOMY", 211, 216], ["statin", "CHEMICAL", 46, 52], ["BOS", "DISEASE", 73, 76], ["BOS", "DISEASE", 111, 114], ["statin", "CHEMICAL", 46, 52], ["statin", "SIMPLE_CHEMICAL", 46, 52], ["lung", "ORGAN", 135, 139], ["organ", "ORGAN", 211, 216], ["children", "ORGANISM", 255, 263], ["children", "SPECIES", 255, 263], ["statin therapy", "TREATMENT", 46, 60], ["BOS", "PROBLEM", 73, 76], ["lung transplantation", "TREATMENT", 135, 155], ["other solid organ transplants", "TREATMENT", 199, 228], ["lung", "ANATOMY", 135, 139], ["transplantation", "OBSERVATION", 140, 155], ["organ", "ANATOMY", 211, 216], ["transplants", "OBSERVATION", 217, 228]]], ["While 1-year survival rates have improved to ~85%, 3 year survival is ~65%, and median survival is 4.9 years, lower but not statistically significantly different than the 5.4 year median survival in adult recipients.", [["recipients", "ORGANISM", 205, 215]]], ["As discussed previously, long-term survival is determined primarily by the development ofBOS.", [["long-term survival", "TREATMENT", 25, 43]]], ["While retransplantation continues to be offered at a small number of pediatric centers for allograft failure, outcomes are worse for retransplantation than primary transplantation (45% versus 58% survival at 3 years post-transplant), irrespective of whether or not re-transplantation was for BOS or other causes of graft failure.", [["allograft", "ANATOMY", 91, 100], ["graft", "ANATOMY", 315, 320], ["BOS", "DISEASE", 292, 295], ["graft failure", "DISEASE", 315, 328], ["allograft", "ORGAN", 91, 100], ["graft", "TISSUE", 315, 320], ["retransplantation", "TREATMENT", 6, 23], ["allograft failure", "PROBLEM", 91, 108], ["retransplantation", "TREATMENT", 133, 150], ["primary transplantation", "TREATMENT", 156, 179], ["transplant", "TREATMENT", 221, 231], ["re-transplantation", "TREATMENT", 265, 283], ["BOS", "PROBLEM", 292, 295], ["graft failure", "PROBLEM", 315, 328], ["allograft failure", "OBSERVATION", 91, 108], ["graft failure", "OBSERVATION", 315, 328]]], ["Data suggest that patients re-transplanted at least 1 year after their primary transplant had better outcomes, but the numbers of re-transplants are too small to make a definitive conclusion.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["their primary transplant", "TREATMENT", 65, 89], ["too small", "OBSERVATION_MODIFIER", 149, 158]]], ["Further, these outcomes have been relatively stable over the past 10 years, demonstrating the urgent need for new ways of managing recipients in order to preservegraft function and ultimately life.Future ConsiderationsSeveral areas of active research offer the possibility of improved outcomes in lung transplantation.", [["lung", "ANATOMY", 297, 301], ["recipients", "ORGANISM", 131, 141], ["lung", "ORGAN", 297, 301], ["managing recipients", "TREATMENT", 122, 141], ["lung transplantation", "TREATMENT", 297, 317], ["relatively", "OBSERVATION_MODIFIER", 34, 44], ["stable", "OBSERVATION_MODIFIER", 45, 51], ["active", "OBSERVATION_MODIFIER", 235, 241], ["lung", "ANATOMY", 297, 301], ["transplantation", "OBSERVATION", 302, 317]]], ["One such area is the expansion of donor lung availabilityusing ex vivo lung perfusion.", [["lung", "ANATOMY", 40, 44], ["lung", "ANATOMY", 71, 75], ["lung", "ORGAN", 40, 44], ["lung", "ORGAN", 71, 75], ["donor lung", "TREATMENT", 34, 44], ["expansion", "OBSERVATION_MODIFIER", 21, 30], ["donor", "OBSERVATION", 34, 39], ["lung", "ANATOMY", 40, 44], ["lung", "ANATOMY", 71, 75], ["perfusion", "OBSERVATION_MODIFIER", 76, 85]]], ["In this procedure, marginal donor lungs that are not accepted for transplant initially are ventilated and perfused ex vivo and allowed to recover.", [["lungs", "ANATOMY", 34, 39], ["lungs", "ORGAN", 34, 39], ["this procedure", "TREATMENT", 3, 17], ["marginal donor lungs", "TREATMENT", 19, 39], ["transplant", "TREATMENT", 66, 76], ["marginal", "OBSERVATION_MODIFIER", 19, 27], ["donor", "OBSERVATION", 28, 33], ["lungs", "ANATOMY", 34, 39], ["ventilated", "OBSERVATION", 91, 101]]], ["Lungs have been successfully transplanted this way, and expanding the donor pool provides the opportunity to save patients that still, at present, die waiting for organs.", [["Lungs", "ANATOMY", 0, 5], ["organs", "ANATOMY", 163, 169], ["Lungs", "ORGAN", 0, 5], ["patients", "ORGANISM", 114, 122], ["organs", "ORGAN", 163, 169], ["patients", "SPECIES", 114, 122], ["successfully", "OBSERVATION_MODIFIER", 16, 28], ["transplanted", "OBSERVATION", 29, 41]]], ["This procedure needs to be extended into children as soon as possible.", [["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["This procedure", "TREATMENT", 0, 14]]], ["Another such area is the use ofpumpless oxygenators as a bridge to lung transplantation.", [["lung", "ANATOMY", 67, 71], ["lung", "ORGAN", 67, 71], ["ofpumpless oxygenators", "TREATMENT", 29, 51], ["a bridge to lung transplantation", "TREATMENT", 55, 87], ["lung", "ANATOMY", 67, 71], ["transplantation", "OBSERVATION", 72, 87]]], ["In conventional ECMO, a pump takes blood from the patient, into the oxygenator then returns it.", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["conventional ECMO", "TREATMENT", 3, 20], ["a pump", "TREATMENT", 22, 28], ["the oxygenator", "TREATMENT", 64, 78], ["ECMO", "OBSERVATION", 16, 20]]], ["Recently, pumpless oxygenator systems have been used in candidates awaiting lung transplantation (i.e., NovaLung).", [["lung", "ANATOMY", 76, 80], ["lung", "ORGAN", 76, 80], ["pumpless oxygenator systems", "TREATMENT", 10, 37], ["lung transplantation", "TREATMENT", 76, 96], ["lung", "ANATOMY", 76, 80], ["transplantation", "OBSERVATION", 81, 96]]], ["While pediatric specific systems are still being developed, we have used a neonatal membrane oxygenator (Quadrox) to successfully bridge an infant suffering from alveolar capillary dysplasia to transplant.", [["neonatal membrane", "ANATOMY", 75, 92], ["alveolar capillary dysplasia", "ANATOMY", 162, 190], ["alveolar capillary dysplasia", "DISEASE", 162, 190], ["alveolar capillary dysplasia", "PATHOLOGICAL_FORMATION", 162, 190], ["a neonatal membrane oxygenator (Quadrox)", "TREATMENT", 73, 113], ["alveolar capillary dysplasia", "PROBLEM", 162, 190], ["transplant", "TREATMENT", 194, 204], ["alveolar capillary dysplasia", "OBSERVATION", 162, 190], ["transplant", "OBSERVATION", 194, 204]]], ["Both pumpless oxygenators and venovenous ECMO are being increasingly used as ways to less invasively bridge candidates to transplant for longer periods of time than conventional ECMO, which requires significant sedation, mechanical ventilation, and immobility, which while buying some time, also leads to progression of the primary lung disease, all of which limit the time a candidate can be bridged on conventional ECMO.", [["primary lung", "ANATOMY", 324, 336], ["primary lung disease", "DISEASE", 324, 344], ["lung", "ORGAN", 332, 336], ["Both pumpless oxygenators", "TREATMENT", 0, 25], ["venovenous ECMO", "TREATMENT", 30, 45], ["transplant", "TREATMENT", 122, 132], ["conventional ECMO", "TREATMENT", 165, 182], ["significant sedation", "TREATMENT", 199, 219], ["mechanical ventilation", "TREATMENT", 221, 243], ["immobility", "PROBLEM", 249, 259], ["the primary lung disease", "PROBLEM", 320, 344], ["conventional ECMO", "TREATMENT", 404, 421], ["oxygenators", "OBSERVATION_MODIFIER", 14, 25], ["venovenous ECMO", "OBSERVATION", 30, 45], ["significant", "OBSERVATION_MODIFIER", 199, 210], ["mechanical ventilation", "OBSERVATION", 221, 243], ["progression", "OBSERVATION_MODIFIER", 305, 316], ["primary", "OBSERVATION_MODIFIER", 324, 331], ["lung", "ANATOMY", 332, 336], ["disease", "OBSERVATION", 337, 344]]], ["Last, an array of anti-cytokine therapeutic antibodies being developed for other therapeutic indications (i.e., anti-IL-13, anti-IL-5R, anti-IL-17, and others) provide an opportunity to manipulate these mediators, all seen in different forms and stages of lung transplant rejection, in order to treat or prevent rejection, and potentially to promote engraftment.Future ConsiderationsIn pediatrics, the small number of recipients worldwide limits performing adequately powered trials.", [["lung", "ANATOMY", 256, 260], ["anti-IL-13", "GENE_OR_GENE_PRODUCT", 112, 122], ["-IL-5R", "SIMPLE_CHEMICAL", 128, 134], ["anti-IL-17", "GENE_OR_GENE_PRODUCT", 136, 146], ["lung", "ORGAN", 256, 260], ["recipients", "ORGANISM", 418, 428], ["anti-cytokine therapeutic antibodies", "PROTEIN", 18, 54], ["anti-cytokine therapeutic antibodies", "TREATMENT", 18, 54], ["anti-IL", "TEST", 112, 119], ["anti-IL", "TREATMENT", 124, 131], ["anti-IL", "TREATMENT", 136, 143], ["lung transplant rejection", "PROBLEM", 256, 281], ["rejection", "PROBLEM", 312, 321], ["lung", "ANATOMY", 256, 260], ["transplant", "OBSERVATION", 261, 271], ["rejection", "OBSERVATION", 272, 281], ["rejection", "OBSERVATION", 312, 321], ["engraftment", "OBSERVATION", 350, 361], ["small", "OBSERVATION_MODIFIER", 402, 407]]], ["While this is not the case in adult recipients, trials are generally done at single centers, and this has resulted in underpowered studies that have failed to show differences between therapies that have beneficial trends (i.e., everolimus compared to MMF, inhaled cyclosporine).", [["everolimus", "CHEMICAL", 229, 239], ["MMF", "CHEMICAL", 252, 255], ["cyclosporine", "CHEMICAL", 265, 277], ["everolimus", "CHEMICAL", 229, 239], ["MMF", "CHEMICAL", 252, 255], ["cyclosporine", "CHEMICAL", 265, 277], ["everolimus", "SIMPLE_CHEMICAL", 229, 239], ["MMF", "SIMPLE_CHEMICAL", 252, 255], ["cyclosporine", "SIMPLE_CHEMICAL", 265, 277], ["underpowered studies", "TEST", 118, 138], ["therapies", "TREATMENT", 184, 193], ["everolimus", "TREATMENT", 229, 239], ["MMF", "TREATMENT", 252, 255], ["inhaled cyclosporine", "TREATMENT", 257, 277]]], ["Multicenter trials should become the standard in lung transplantation as they have in many other indications.", [["lung", "ANATOMY", 49, 53], ["lung", "ORGAN", 49, 53], ["Multicenter trials", "TREATMENT", 0, 18], ["the standard in lung transplantation", "TREATMENT", 33, 69], ["lung", "ANATOMY", 49, 53], ["transplantation", "OBSERVATION", 54, 69]]], ["In pediatrics, the International Pediatric Lung Transplant Collaborative works to make this a reality.", [["Lung", "ANATOMY", 43, 47], ["Lung", "ANATOMY", 43, 47], ["Transplant", "OBSERVATION", 48, 58]]], ["As outcomes from BOS remain poor despite therapies, with BOS causing 40% of all mortality beyond the first year of transplant, such studies, along with work in recently established animal models of orthotopic lung transplantation, are desperatelyneeded to improve outcomes in pediatric lung transplantation.", [["lung", "ANATOMY", 209, 213], ["lung", "ANATOMY", 286, 290], ["BOS", "DISEASE", 17, 20], ["BOS", "DISEASE", 57, 60], ["lung", "ORGAN", 209, 213], ["lung", "ORGAN", 286, 290], ["therapies", "TREATMENT", 41, 50], ["BOS", "PROBLEM", 57, 60], ["transplant", "TREATMENT", 115, 125], ["such studies", "TEST", 127, 139], ["orthotopic lung transplantation", "TREATMENT", 198, 229], ["pediatric lung transplantation", "TREATMENT", 276, 306], ["poor", "OBSERVATION", 28, 32], ["transplant", "OBSERVATION", 115, 125], ["orthotopic", "OBSERVATION", 198, 208], ["lung", "ANATOMY", 209, 213], ["transplantation", "OBSERVATION", 214, 229], ["lung", "ANATOMY", 286, 290], ["transplantation", "OBSERVATION", 291, 306]]]], "71b8c50ee0e1f4e79e6618301b768befbf943a5d": [["incidence of positive bacterial isolates.", [["positive bacterial isolates", "PROBLEM", 13, 40], ["positive", "OBSERVATION_MODIFIER", 13, 21], ["bacterial isolates", "OBSERVATION", 22, 40]]], ["Compared to the mechanical ventilation group, days on mechanical ventilation were significantly greater in the ECMO cohort (13\u00b112 versus 5\u00b18 days, p=0.006).", [["the mechanical ventilation group", "TREATMENT", 12, 44], ["mechanical ventilation", "TREATMENT", 54, 76], ["greater", "OBSERVATION_MODIFIER", 96, 103]]], ["Higher CRP levels on admission to hospital were associated with a more prolonged hospital and ICU stay in the mechanical ventilation group only ( p<0.001).", [["CRP", "GENE_OR_GENE_PRODUCT", 7, 10], ["CRP", "PROTEIN", 7, 10], ["Higher CRP levels", "PROBLEM", 0, 17], ["the mechanical ventilation", "TREATMENT", 106, 132], ["mechanical ventilation", "OBSERVATION", 110, 132]]], ["All ECMO patients survived to hospital discharge; however, two mechanically ventilated patients died during their ICU admission.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 87, 95]]], ["In this retrospective review of adult asthmatics admitted to intensive care for a near-fatal acute exacerbation, we report that the requirement for ECMO was associated with younger age, female sex and the presence of either fungal or rhinoviral infection in the lower airway.", [["rhinoviral", "ANATOMY", 234, 244], ["lower airway", "ANATOMY", 262, 274], ["asthmatics", "DISEASE", 38, 48], ["fungal or rhinoviral infection", "DISEASE", 224, 254], ["asthmatics", "ORGANISM", 38, 48], ["lower airway", "ORGANISM_SUBDIVISION", 262, 274], ["adult asthmatics", "PROBLEM", 32, 48], ["a near-fatal acute exacerbation", "PROBLEM", 80, 111], ["ECMO", "TREATMENT", 148, 152], ["either fungal or rhinoviral infection in the lower airway", "PROBLEM", 217, 274], ["asthmatics", "OBSERVATION", 38, 48], ["fatal", "OBSERVATION_MODIFIER", 87, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["exacerbation", "OBSERVATION", 99, 111], ["fungal", "OBSERVATION", 224, 230], ["rhinoviral", "OBSERVATION_MODIFIER", 234, 244], ["infection", "OBSERVATION", 245, 254], ["lower", "ANATOMY_MODIFIER", 262, 267], ["airway", "ANATOMY", 268, 274]]], ["In addition, a higher white cell count, a more profound degree of hypercapnia and acidaemia, as well as an increased LoS in the ICU and hospital overall, were observed in those requiring ECMO support.", [["white cell", "ANATOMY", 22, 32], ["hypercapnia", "DISEASE", 66, 77], ["acidaemia", "DISEASE", 82, 91], ["cell", "CELL", 28, 32], ["a higher white cell count", "PROBLEM", 13, 38], ["hypercapnia", "PROBLEM", 66, 77], ["acidaemia", "PROBLEM", 82, 91], ["an increased LoS", "PROBLEM", 104, 120], ["ECMO support", "TREATMENT", 187, 199], ["more profound", "OBSERVATION_MODIFIER", 42, 55], ["degree", "OBSERVATION_MODIFIER", 56, 62], ["hypercapnia", "OBSERVATION", 66, 77], ["acidaemia", "OBSERVATION", 82, 91], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["LoS", "OBSERVATION_MODIFIER", 117, 120]]]], "7c62056ce999786da33f162065249194208574b4": [["Globally, SARS-CoV-2 has infected 3,113,447 people and killed 216,930 as of April 29, 2020.", [["SARS", "DISEASE", 10, 14], ["SARS-CoV-2", "ORGANISM", 10, 20], ["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["SARS-CoV", "SPECIES", 10, 18], ["CoV", "TEST", 15, 18]]], ["Identifying populations vulnerable to infection and their disease progression is critical to mitigating the negative impacts on healthcare systems.", [["infection", "DISEASE", 38, 47], ["infection", "PROBLEM", 38, 47], ["their disease progression", "PROBLEM", 52, 77], ["infection", "OBSERVATION", 38, 47]]], ["Recent studies have shown that angiotensin converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 to enter human cells (Zhou et al., 2020) , raising the possibility that a higher ACE2 expression level could facilitate SARS-CoV-2 infection.", [["cells", "ANATOMY", 116, 121], ["angiotensin", "CHEMICAL", 31, 42], ["infection", "DISEASE", 232, 241], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 31, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["human", "ORGANISM", 110, 115], ["cells", "CELL", 116, 121], ["ACE2", "GENE_OR_GENE_PRODUCT", 182, 186], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 221, 231], ["angiotensin converting enzyme 2", "PROTEIN", 31, 62], ["ACE2", "PROTEIN", 64, 68], ["human cells", "CELL_TYPE", 110, 121], ["ACE2", "PROTEIN", 182, 186], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["SARS-CoV", "SPECIES", 221, 229], ["Recent studies", "TEST", 0, 14], ["angiotensin converting enzyme", "TEST", 31, 60], ["ACE2", "TEST", 64, 68], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["a higher ACE2 expression level", "PROBLEM", 173, 203], ["SARS", "PROBLEM", 221, 225], ["CoV-2 infection", "PROBLEM", 226, 241], ["infection", "OBSERVATION", 232, 241]]]], "PMC7123566": [["He saw a 4-year-old boy with fever and a constellation of clinical features that did not seem to fit into any known clinical disease entity.", [["fever", "DISEASE", 29, 34], ["boy", "ORGANISM", 20, 23], ["boy", "SPECIES", 20, 23], ["fever", "PROBLEM", 29, 34], ["any known clinical disease entity", "PROBLEM", 106, 139], ["fever", "OBSERVATION", 29, 34]]], ["By 1967, he had collected 50 such cases of mucocutaneous lymph node syndrome and published his series in the Japanese Journal of Allergy (Arerugi) [4].", [["lymph node", "ANATOMY", 57, 67], ["mucocutaneous lymph node syndrome", "DISEASE", 43, 76], ["lymph node", "MULTI-TISSUE_STRUCTURE", 57, 67], ["mucocutaneous lymph node syndrome", "PROBLEM", 43, 76], ["mucocutaneous", "OBSERVATION_MODIFIER", 43, 56], ["lymph node syndrome", "OBSERVATION", 57, 76]]], ["It is remarkable that to this day, the case definition proposed by Dr. Kawasaki in 1967 has remained largely unchanged.EpidemiologyKD is arguably the second commonest vasculitis of childhood after Henoch\u2013Schonlein purpura.", [["Kawasaki", "DISEASE", 71, 79], ["EpidemiologyKD", "DISEASE", 119, 133], ["vasculitis", "DISEASE", 167, 177], ["Henoch\u2013Schonlein purpura", "DISEASE", 197, 221], ["Henoch\u2013Schonlein purpura", "SPECIES", 197, 221], ["Schonlein purpura", "PROBLEM", 204, 221], ["largely", "OBSERVATION_MODIFIER", 101, 108], ["unchanged", "OBSERVATION", 109, 118], ["vasculitis", "OBSERVATION", 167, 177], ["Schonlein purpura", "OBSERVATION", 204, 221]]], ["It is a disease of young children with 80% of affected patients being below the age of 5.", [["children", "ORGANISM", 25, 33], ["patients", "ORGANISM", 55, 63], ["children", "SPECIES", 25, 33], ["patients", "SPECIES", 55, 63]]], ["KD occurs more commonly in boys and the male female ratio is 1.3:1 [5].", [["boys", "SPECIES", 27, 31], ["more commonly", "OBSERVATION_MODIFIER", 10, 23]]], ["Siblings can be affected in 3% of patients [6].EpidemiologyKD has been reported from all continents and is now increasingly being identified in many resource-challenged countries (Fig. 4.1).", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Although this disease is being diagnosed worldwide, the highest number of cases has been reported from the North-East Asian countries, viz.", [["this disease", "PROBLEM", 9, 21], ["disease", "OBSERVATION", 14, 21]]], ["The current incidence of KD in Japan is more than 300 per 100,000 children <5 years (highest worldwide) [8].", [["KD", "DISEASE", 25, 27], ["children", "SPECIES", 66, 74]]], ["Approximately 1% of Japanese children develop KD by age 10 [9].", [["KD", "DISEASE", 46, 48], ["children", "ORGANISM", 29, 37], ["children", "SPECIES", 29, 37]]], ["Incidence rates from Korea and Taiwan are 194.7 and 69.5, respectively [10, 11].", [["Incidence rates", "TEST", 0, 15]]], ["Incidence of KD in Europe and the United States has plateaued and ranges from 5 to 30/100,000 children below 5.", [["KD", "DISEASE", 13, 15], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["KD", "OBSERVATION", 13, 15]]], ["Data from North America show that there is significant ethnic variation with higher rates being reported in African Americans and Pacific islanders [7].", [["significant ethnic variation", "PROBLEM", 43, 71], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["ethnic variation", "OBSERVATION", 55, 71]]], ["In North India, the KD incidence is 4\u20135/100,000 children below 5 [16].EpidemiologyEpidemiologic studies have shown distinct seasonality in occurrence of KD.", [["KD", "DISEASE", 153, 155], ["children", "SPECIES", 48, 56], ["EpidemiologyEpidemiologic studies", "TEST", 70, 103], ["distinct", "OBSERVATION_MODIFIER", 115, 123], ["seasonality", "OBSERVATION", 124, 135]]], ["In Chandigarh (India), the peak incidence is in April and October, with a nadir in February [16].GeneticsKD is a complex disorder in which an infectious/environmental agent is believed to trigger the onset of disease in a genetically susceptible host [18].", [["GeneticsKD", "DISEASE", 97, 107], ["a complex disorder", "PROBLEM", 111, 129], ["disease", "PROBLEM", 209, 216], ["complex", "OBSERVATION_MODIFIER", 113, 120], ["disorder", "OBSERVATION", 121, 129], ["infectious", "OBSERVATION", 142, 152], ["disease", "OBSERVATION", 209, 216]]], ["Various susceptibility genes have been identified to have association with KD.", [["susceptibility genes", "DNA", 8, 28], ["Various susceptibility genes", "PROBLEM", 0, 28], ["susceptibility genes", "OBSERVATION", 8, 28]]], ["These includes inositol 1,4,5-trisphosphate 3-kinase C (ITPKC), Caspase-3 calcium release-activated calcium modulator 1 (ORAI1), and CD 40 [19\u201321].", [["inositol 1,4,5-trisphosphate", "CHEMICAL", 15, 43], ["calcium", "CHEMICAL", 74, 81], ["calcium", "CHEMICAL", 100, 107], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 15, 43], ["calcium", "CHEMICAL", 74, 81], ["calcium", "CHEMICAL", 100, 107], ["inositol 1,4,5-trisphosphate 3-kinase C", "GENE_OR_GENE_PRODUCT", 15, 54], ["ITPKC", "GENE_OR_GENE_PRODUCT", 56, 61], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 64, 73], ["calcium release-activated calcium modulator 1", "GENE_OR_GENE_PRODUCT", 74, 119], ["ORAI1", "GENE_OR_GENE_PRODUCT", 121, 126], ["CD 40", "GENE_OR_GENE_PRODUCT", 133, 138], ["inositol 1,4,5-trisphosphate 3-kinase C", "PROTEIN", 15, 54], ["ITPKC", "PROTEIN", 56, 61], ["Caspase-3 calcium release-activated calcium modulator 1", "PROTEIN", 64, 119], ["ORAI1", "PROTEIN", 121, 126], ["inositol", "TEST", 15, 23], ["trisphosphate", "TEST", 30, 43], ["kinase C (ITPKC)", "TREATMENT", 46, 62], ["Caspase", "TREATMENT", 64, 71], ["calcium release", "TREATMENT", 74, 89], ["activated calcium modulator", "TREATMENT", 90, 117]]], ["Knowledge about these susceptibility genes may provide new insights in etiopathogenesis of KD.", [["KD", "DISEASE", 91, 93], ["susceptibility genes", "DNA", 22, 42], ["these susceptibility genes", "PROBLEM", 16, 42]]], ["Reports have suggested association of transforming growth factor (TGF)-\u03b2 variants with development of CAAs in patients with KD [22].Etiopathogenesis of KDAlthough etiopathogenesis of KD is not clear, various epidemiological and laboratory studies have shown that an infectious agent triggers a cascade that causes the illness (Fig. 4.2).", [["CAAs", "DISEASE", 102, 106], ["KD", "DISEASE", 183, 185], ["illness", "DISEASE", 318, 325], ["transforming growth factor (TGF)-\u03b2", "GENE_OR_GENE_PRODUCT", 38, 72], ["CAAs", "CANCER", 102, 106], ["patients", "ORGANISM", 110, 118], ["transforming growth factor (TGF)-\u03b2 variants", "PROTEIN", 38, 81], ["patients", "SPECIES", 110, 118], ["transforming growth factor", "PROBLEM", 38, 64], ["CAAs", "PROBLEM", 102, 106], ["Etiopathogenesis of KDAlthough etiopathogenesis of KD", "PROBLEM", 132, 185], ["laboratory studies", "TEST", 228, 246], ["an infectious agent", "PROBLEM", 263, 282], ["the illness", "PROBLEM", 314, 325], ["CAAs", "OBSERVATION", 102, 106], ["KD", "OBSERVATION", 183, 185], ["not", "UNCERTAINTY", 189, 192], ["clear", "OBSERVATION", 193, 198], ["infectious", "OBSERVATION", 266, 276]]], ["Histopathologic studies have emanated from children with KD who have died from unrelated causes [23].", [["KD", "DISEASE", 57, 59], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["Histopathologic studies", "TEST", 0, 23]]], ["The vasculitic process shows three distinct phases [24]:Acute necrotizing arteritis phase: in which there is neutrophilic infiltration of intima and media.Subacute/chronic arteritis phase: in which the neutrophilic infiltrate gets replaced by lymphocytes, plasma cells, and macrophages.Luminal myofibroblastic phase: in which there is proliferation of smooth muscle cells in the media that can result in luminal narrowing [24, 25].Etiopathogenesis of KDThe etiopathogenesis of KD is closely linked to an infectious process.", [["neutrophilic", "ANATOMY", 109, 121], ["intima", "ANATOMY", 138, 144], ["neutrophilic infiltrate", "ANATOMY", 202, 225], ["lymphocytes", "ANATOMY", 243, 254], ["plasma cells", "ANATOMY", 256, 268], ["macrophages", "ANATOMY", 274, 285], ["smooth muscle cells", "ANATOMY", 352, 371], ["luminal", "ANATOMY", 404, 411], ["necrotizing arteritis", "DISEASE", 62, 83], ["arteritis", "DISEASE", 172, 181], ["luminal", "CHEMICAL", 404, 411], ["KD", "DISEASE", 477, 479], ["intima", "TISSUE", 138, 144], ["lymphocytes", "CELL", 243, 254], ["plasma cells", "CELL", 256, 268], ["macrophages", "CELL", 274, 285], ["smooth muscle cells", "CELL", 352, 371], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 404, 411], ["lymphocytes", "CELL_TYPE", 243, 254], ["plasma cells", "CELL_TYPE", 256, 268], ["macrophages", "CELL_TYPE", 274, 285], ["smooth muscle cells", "CELL_TYPE", 352, 371], ["The vasculitic process", "PROBLEM", 0, 22], ["Acute necrotizing arteritis phase", "PROBLEM", 56, 89], ["neutrophilic infiltration of intima and media", "PROBLEM", 109, 154], ["Subacute/chronic arteritis phase", "PROBLEM", 155, 187], ["the neutrophilic infiltrate", "PROBLEM", 198, 225], ["lymphocytes", "TEST", 243, 254], ["plasma cells", "TEST", 256, 268], ["macrophages", "PROBLEM", 274, 285], ["Luminal myofibroblastic phase", "TEST", 286, 315], ["proliferation of smooth muscle cells", "PROBLEM", 335, 371], ["luminal narrowing", "PROBLEM", 404, 421], ["KD", "PROBLEM", 477, 479], ["an infectious process", "PROBLEM", 501, 522], ["vasculitic", "OBSERVATION", 4, 14], ["three distinct", "OBSERVATION_MODIFIER", 29, 43], ["necrotizing", "OBSERVATION_MODIFIER", 62, 73], ["arteritis", "OBSERVATION", 74, 83], ["neutrophilic", "OBSERVATION_MODIFIER", 109, 121], ["infiltration", "OBSERVATION", 122, 134], ["intima", "ANATOMY", 138, 144], ["chronic", "OBSERVATION_MODIFIER", 164, 171], ["arteritis", "OBSERVATION", 172, 181], ["neutrophilic", "OBSERVATION_MODIFIER", 202, 214], ["infiltrate", "OBSERVATION", 215, 225], ["lymphocytes", "ANATOMY", 243, 254], ["plasma cells", "OBSERVATION", 256, 268], ["macrophages", "ANATOMY", 274, 285], ["myofibroblastic phase", "OBSERVATION", 294, 315], ["proliferation", "OBSERVATION", 335, 348], ["smooth muscle cells", "OBSERVATION", 352, 371], ["luminal", "ANATOMY_MODIFIER", 404, 411], ["narrowing", "OBSERVATION", 412, 421], ["KD", "OBSERVATION", 477, 479], ["infectious", "OBSERVATION", 504, 514]]], ["The presence of febrile exanthemata and cervical lymphadenopathy, uncommon occurrence in babies below 3 months, and the rarity of cases in adults, further lends support to this hypothesis.", [["cervical", "ANATOMY", 40, 48], ["febrile exanthemata", "DISEASE", 16, 35], ["cervical lymphadenopathy", "DISEASE", 40, 64], ["cervical lymphadenopathy", "PATHOLOGICAL_FORMATION", 40, 64], ["febrile exanthemata", "PROBLEM", 16, 35], ["cervical lymphadenopathy", "PROBLEM", 40, 64], ["this hypothesis", "PROBLEM", 172, 187], ["febrile", "OBSERVATION_MODIFIER", 16, 23], ["exanthemata", "OBSERVATION", 24, 35], ["cervical", "ANATOMY", 40, 48], ["lymphadenopathy", "OBSERVATION", 49, 64]]], ["Some of the infectious agents that have been linked to the etiology of KD are parvovirus, Epstein\u2013Barr virus, Staphylococcus aureus, chlamydia, and mycobacteria.", [["KD", "DISEASE", 71, 73], ["parvovirus", "DISEASE", 78, 88], ["Epstein\u2013Barr virus", "DISEASE", 90, 108], ["Staphylococcus aureus, chlamydia", "DISEASE", 110, 142], ["parvovirus", "ORGANISM", 78, 88], ["Epstein\u2013Barr virus", "ORGANISM", 90, 108], ["Staphylococcus aureus", "ORGANISM", 110, 131], ["Staphylococcus aureus", "SPECIES", 110, 131], ["Epstein\u2013Barr virus", "SPECIES", 90, 108], ["Staphylococcus aureus", "SPECIES", 110, 131], ["the infectious agents", "TREATMENT", 8, 29], ["KD", "PROBLEM", 71, 73], ["parvovirus", "PROBLEM", 78, 88], ["Epstein\u2013Barr virus", "PROBLEM", 90, 108], ["Staphylococcus aureus", "PROBLEM", 110, 131], ["chlamydia", "PROBLEM", 133, 142], ["mycobacteria", "PROBLEM", 148, 160], ["infectious", "OBSERVATION", 12, 22], ["Staphylococcus aureus", "OBSERVATION", 110, 131], ["mycobacteria", "OBSERVATION", 148, 160]]], ["It has been hypothesized that the putative infectious trigger sets up a cytokine storm that manifests as KD [23].", [["cytokine", "PROTEIN", 72, 80], ["the putative infectious trigger", "PROBLEM", 30, 61], ["infectious", "OBSERVATION_MODIFIER", 43, 53]]], ["Some investigators have also proposed a super-antigen theory that triggers an immune response against vascular endothelium [27].Clinical Features and DiagnosisDiagnosis of KD is essentially clinical.", [["vascular endothelium", "ANATOMY", 102, 122], ["vascular endothelium", "TISSUE", 102, 122], ["KD", "PROBLEM", 172, 174]]], ["Criteria for diagnosis of KD have been updated from time to time.", [["KD", "PROBLEM", 26, 28]]], ["Currently there are two sets of guidelines\u2014American Heart Association (AHA) guidelines (2004 [3] and 2017 [28]) and Kawasaki Disease Research Committee guidelines (Japanese guidelines), 2002 (Table 4.1) [29].", [["Kawasaki Disease", "DISEASE", 116, 132], ["Kawasaki Disease", "PROBLEM", 116, 132]]], ["AHA 2017 guidelines (clinical criteria) for diagnosis of KD are given in Table 4.2.", [["KD", "DISEASE", 57, 59], ["KD", "PROBLEM", 57, 59]]], ["Patients who fulfil the criteria are classified as having complete KD (also known as classical or typical KD), while those who do not fulfil criteria are classified as incomplete KD [28].", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Principal clinical features in KD are reviewed in Table 4.3.Clinical Features and DiagnosisThe clinical course of KD has three distinct phases: (a) acute febrile phase, (b) subacute phase, and (c) convalescent phase [4].", [["KD", "DISEASE", 114, 116], ["acute febrile phase", "PROBLEM", 148, 167]]], ["However in clinical practice, these features often overlap.Clinical Features and DiagnosisAcute phase: This phase starts with abrupt onset of high grade fever that is characteristically accompanied by significant irritability.", [["fever", "DISEASE", 153, 158], ["irritability", "DISEASE", 213, 225], ["high grade fever", "PROBLEM", 142, 158], ["significant irritability", "PROBLEM", 201, 225], ["high grade", "OBSERVATION_MODIFIER", 142, 152], ["fever", "OBSERVATION", 153, 158], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["irritability", "OBSERVATION", 213, 225]]], ["Fever with marked irritability may be the initial clinical presentation of KD, especially in young infants [30].", [["Fever", "DISEASE", 0, 5], ["irritability", "DISEASE", 18, 30], ["KD", "DISEASE", 75, 77], ["infants", "SPECIES", 99, 106], ["Fever", "PROBLEM", 0, 5], ["marked irritability", "PROBLEM", 11, 30], ["marked", "OBSERVATION_MODIFIER", 11, 17], ["irritability", "OBSERVATION", 18, 30]]], ["Presence of intermittent or remittent fever is not characteristic of KD.", [["fever", "DISEASE", 38, 43], ["intermittent or remittent fever", "PROBLEM", 12, 43], ["KD", "PROBLEM", 69, 71], ["intermittent", "OBSERVATION_MODIFIER", 12, 24], ["fever", "OBSERVATION", 38, 43]]], ["Cough can be present in a small subset of patients but nasal catarrh is unusual for KD.", [["nasal catarrh", "ANATOMY", 55, 68], ["Cough", "DISEASE", 0, 5], ["nasal catarrh", "DISEASE", 55, 68], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Cough", "PROBLEM", 0, 5], ["small", "OBSERVATION_MODIFIER", 26, 31], ["nasal", "ANATOMY", 55, 60]]], ["Rash in KD is usually generalized, erythematous, polymorphic (Fig. 4.3b), but is never vesicular or bullous.", [["vesicular", "ANATOMY", 87, 96], ["Rash", "DISEASE", 0, 4], ["bullous", "DISEASE", 100, 107], ["Rash in KD", "PROBLEM", 0, 10], ["erythematous", "PROBLEM", 35, 47], ["bullous", "PROBLEM", 100, 107], ["KD", "ANATOMY", 8, 10], ["generalized", "OBSERVATION_MODIFIER", 22, 33], ["erythematous", "OBSERVATION_MODIFIER", 35, 47], ["polymorphic", "OBSERVATION_MODIFIER", 49, 60], ["vesicular", "OBSERVATION_MODIFIER", 87, 96], ["bullous", "OBSERVATION", 100, 107]]], ["Cervical lymphadenopathy (\u22651.5 cm size) is usually unilateral and is often more commonly seen in the anterior cervical triangle.", [["Cervical lymphadenopathy", "ANATOMY", 0, 24], ["anterior cervical triangle", "ANATOMY", 101, 127], ["Cervical lymphadenopathy", "DISEASE", 0, 24], ["Cervical lymphadenopathy", "CANCER", 0, 24], ["anterior cervical", "MULTI-TISSUE_STRUCTURE", 101, 118], ["Cervical lymphadenopathy", "PROBLEM", 0, 24], ["lymphadenopathy", "OBSERVATION", 9, 24], ["1.5 cm", "OBSERVATION_MODIFIER", 27, 33], ["size", "OBSERVATION_MODIFIER", 34, 38], ["unilateral", "OBSERVATION", 51, 61], ["anterior", "ANATOMY_MODIFIER", 101, 109], ["cervical triangle", "ANATOMY", 110, 127]]], ["Cervical lymphadenopathy may be mistaken for suppurative lymphadenitis.", [["Cervical lymphadenopathy", "ANATOMY", 0, 24], ["Cervical lymphadenopathy", "DISEASE", 0, 24], ["lymphadenitis", "DISEASE", 57, 70], ["Cervical lymphadenopathy", "PROBLEM", 0, 24], ["suppurative lymphadenitis", "PROBLEM", 45, 70], ["lymphadenopathy", "OBSERVATION", 9, 24], ["suppurative", "OBSERVATION_MODIFIER", 45, 56], ["lymphadenitis", "OBSERVATION", 57, 70]]], ["AHA 2017 guidelines have highlighted the importance of ultrasonogram and computed tomography (CT) for differentiation of bacterial lymphadenitis from KD lymphadenopathy.", [["lymphadenitis", "DISEASE", 131, 144], ["lymphadenopathy", "DISEASE", 153, 168], ["ultrasonogram", "TEST", 55, 68], ["computed tomography", "TEST", 73, 92], ["CT", "TEST", 94, 96], ["bacterial lymphadenitis", "PROBLEM", 121, 144], ["KD lymphadenopathy", "PROBLEM", 150, 168], ["bacterial", "OBSERVATION_MODIFIER", 121, 130], ["lymphadenitis", "OBSERVATION", 131, 144], ["KD", "OBSERVATION_MODIFIER", 150, 152], ["lymphadenopathy", "OBSERVATION", 153, 168]]], ["In KD, there is enlargement of multiple lymph nodes along with retropharyngeal edema while bacterial lymphadenitis is mostly associated with a single lymph node with a central hypoechoic region [28].", [["lymph nodes", "ANATOMY", 40, 51], ["retropharyngeal edema", "ANATOMY", 63, 84], ["lymph node", "ANATOMY", 150, 160], ["central hypoechoic region", "ANATOMY", 168, 193], ["KD", "DISEASE", 3, 5], ["retropharyngeal edema", "DISEASE", 63, 84], ["lymphadenitis", "DISEASE", 101, 114], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 40, 51], ["retropharyngeal edema", "PATHOLOGICAL_FORMATION", 63, 84], ["lymph node", "MULTI-TISSUE_STRUCTURE", 150, 160], ["enlargement of multiple lymph nodes", "PROBLEM", 16, 51], ["retropharyngeal edema", "PROBLEM", 63, 84], ["bacterial lymphadenitis", "PROBLEM", 91, 114], ["a single lymph node", "PROBLEM", 141, 160], ["a central hypoechoic region", "PROBLEM", 166, 193], ["enlargement", "OBSERVATION_MODIFIER", 16, 27], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["lymph nodes", "OBSERVATION", 40, 51], ["retropharyngeal", "ANATOMY", 63, 78], ["edema", "OBSERVATION", 79, 84], ["bacterial", "OBSERVATION_MODIFIER", 91, 100], ["lymphadenitis", "OBSERVATION", 101, 114], ["single", "OBSERVATION_MODIFIER", 143, 149], ["lymph node", "OBSERVATION", 150, 160], ["central", "OBSERVATION_MODIFIER", 168, 175], ["hypoechoic", "OBSERVATION_MODIFIER", 176, 186]]], ["However, such differentiation on basis of ultrasound examination requires lot of expertise and that may not be readily available in the usual clinical setting.", [["ultrasound examination", "TEST", 42, 64]]], ["Oral cavity and lip changes include redness of lips with bleeding and vertical cracking, oral mucosa redness and a strawberry tongue (Fig. 4.3d).", [["Oral cavity", "ANATOMY", 0, 11], ["lip", "ANATOMY", 16, 19], ["lips", "ANATOMY", 47, 51], ["oral mucosa", "ANATOMY", 89, 100], ["tongue", "ANATOMY", 126, 132], ["bleeding", "DISEASE", 57, 65], ["strawberry tongue", "DISEASE", 115, 132], ["Oral cavity", "PATHOLOGICAL_FORMATION", 0, 11], ["lip", "ORGAN", 16, 19], ["lips", "ORGANISM_SUBDIVISION", 47, 51], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 89, 100], ["tongue", "ORGAN", 126, 132], ["Oral cavity and lip changes", "PROBLEM", 0, 27], ["redness of lips", "PROBLEM", 36, 51], ["bleeding", "PROBLEM", 57, 65], ["vertical cracking", "PROBLEM", 70, 87], ["oral mucosa redness", "PROBLEM", 89, 108], ["a strawberry tongue", "PROBLEM", 113, 132], ["cavity", "OBSERVATION", 5, 11], ["lip", "ANATOMY", 16, 19], ["redness", "OBSERVATION", 36, 43], ["lips", "ANATOMY", 47, 51], ["bleeding", "OBSERVATION", 57, 65], ["vertical", "OBSERVATION_MODIFIER", 70, 78], ["cracking", "OBSERVATION_MODIFIER", 79, 87], ["oral mucosa", "ANATOMY", 89, 100], ["redness", "OBSERVATION", 101, 108], ["strawberry tongue", "ANATOMY", 115, 132]]], ["Oral ulcers are distinctly unusual in KD.", [["Oral", "ANATOMY", 0, 4], ["ulcers", "DISEASE", 5, 11], ["Oral ulcers", "PATHOLOGICAL_FORMATION", 0, 11], ["Oral ulcers", "PROBLEM", 0, 11], ["ulcers", "OBSERVATION", 5, 11], ["distinctly", "OBSERVATION_MODIFIER", 16, 26], ["unusual", "OBSERVATION_MODIFIER", 27, 34]]], ["Conjunctival injection is characteristically nonexudative and with typical sparing of limbus (Fig. 4.3a).", [["Conjunctival", "ANATOMY", 0, 12], ["limbus", "ANATOMY", 86, 92], ["limbus", "TISSUE", 86, 92], ["Conjunctival injection", "PROBLEM", 0, 22], ["typical", "OBSERVATION_MODIFIER", 67, 74], ["sparing", "OBSERVATION_MODIFIER", 75, 82], ["limbus", "ANATOMY", 86, 92]]], ["Conjunctivitis with discharge is a strong pointer towards an alternative diagnosis.", [["Conjunctivitis", "DISEASE", 0, 14], ["Conjunctivitis", "PROBLEM", 0, 14]]], ["Edema of the dorsum of extremities is an early sign and is usually transient (Fig. 4.3e).", [["dorsum", "ANATOMY", 13, 19], ["extremities", "ANATOMY", 23, 34], ["Edema", "DISEASE", 0, 5], ["dorsum", "ORGAN", 13, 19], ["extremities", "ORGAN", 23, 34], ["Edema of the dorsum of extremities", "PROBLEM", 0, 34], ["dorsum", "ANATOMY", 13, 19], ["extremities", "ANATOMY", 23, 34], ["early", "OBSERVATION_MODIFIER", 41, 46], ["sign", "OBSERVATION", 47, 51], ["transient", "OBSERVATION_MODIFIER", 67, 76]]], ["Perianal desquamation is virtually pathognomonic of KD and is a useful clinical sign for diagnosis of the disease during the acute phase (Fig. 4.3c).", [["desquamation", "DISEASE", 9, 21], ["KD", "DISEASE", 52, 54], ["Perianal desquamation", "PROBLEM", 0, 21], ["the disease", "PROBLEM", 102, 113], ["desquamation", "OBSERVATION", 9, 21], ["disease", "OBSERVATION", 106, 113]]], ["Arthritis in KD is typically oligoarthritis, involving large joints and resolves without sequelae [31].", [["joints", "ANATOMY", 61, 67], ["Arthritis", "DISEASE", 0, 9], ["KD", "DISEASE", 13, 15], ["oligoarthritis", "DISEASE", 29, 43], ["joints", "MULTI-TISSUE_STRUCTURE", 61, 67], ["Arthritis in KD", "PROBLEM", 0, 15], ["typically oligoarthritis", "PROBLEM", 19, 43], ["large joints", "PROBLEM", 55, 67], ["sequelae", "PROBLEM", 89, 97], ["typically", "OBSERVATION_MODIFIER", 19, 28], ["oligoarthritis", "OBSERVATION", 29, 43], ["large", "OBSERVATION_MODIFIER", 55, 60], ["joints", "ANATOMY", 61, 67]]], ["Erythema at BCG injection site is an important clinical sign during acute stage of KD and more common in infants [32].", [["Erythema", "DISEASE", 0, 8], ["KD", "DISEASE", 83, 85], ["infants", "ORGANISM", 105, 112], ["infants", "SPECIES", 105, 112], ["Erythema at BCG injection site", "PROBLEM", 0, 30]]], ["Hydrops of gall bladder is also an important finding during acute stage.", [["gall bladder", "ANATOMY", 11, 23], ["gall bladder", "DISEASE", 11, 23], ["gall bladder", "ORGAN", 11, 23], ["Hydrops of gall bladder", "PROBLEM", 0, 23], ["acute stage", "PROBLEM", 60, 71], ["gall bladder", "ANATOMY", 11, 23], ["acute", "OBSERVATION_MODIFIER", 60, 65]]], ["Mild pericardial effusion is a common finding on 2Dechocardiography (2DE).", [["pericardial", "ANATOMY", 5, 16], ["pericardial effusion", "DISEASE", 5, 25], ["pericardial", "ORGAN", 5, 16], ["Mild pericardial effusion", "PROBLEM", 0, 25], ["pericardial", "ANATOMY", 5, 16], ["effusion", "OBSERVATION", 17, 25]]], ["CAAs are usually not seen during the first week of illness.Clinical Features and DiagnosisSubacute phase: This stage usually lasts for another 2\u20133 weeks during which fever usually subsides.", [["fever", "DISEASE", 166, 171], ["CAAs", "SIMPLE_CHEMICAL", 0, 4], ["illness", "PROBLEM", 51, 58], ["fever", "PROBLEM", 166, 171], ["DiagnosisSubacute phase", "OBSERVATION_MODIFIER", 81, 104]]], ["Periungual peeling is characteristically seen during this stage (Fig. 4.3f).", [["Periungual peeling", "PROBLEM", 0, 18], ["peeling", "OBSERVATION", 11, 18]]], ["Irritability that is prominent during acute phase subsides completely in this phase.", [["Irritability", "DISEASE", 0, 12], ["Irritability", "PROBLEM", 0, 12], ["prominent", "OBSERVATION_MODIFIER", 21, 30], ["acute phase", "OBSERVATION_MODIFIER", 38, 49]]], ["Arthritis in KD can also develop in subacute phase.", [["Arthritis", "DISEASE", 0, 9], ["Arthritis in KD", "PROBLEM", 0, 15], ["subacute phase", "OBSERVATION_MODIFIER", 36, 50]]], ["An important laboratory manifestation that is seen in the subacute phase is development of thrombocytosis and this in conjunction with periungual desquamation is very suggestive of KD.Clinical Features and DiagnosisChronic phase: It lasts for few weeks to months; there are no symptoms during this phase and the inflammation tends to subside.", [["thrombocytosis", "DISEASE", 91, 105], ["desquamation", "DISEASE", 146, 158], ["inflammation", "DISEASE", 312, 324], ["thrombocytosis", "PROBLEM", 91, 105], ["periungual desquamation", "PROBLEM", 135, 158], ["KD", "PROBLEM", 181, 183], ["symptoms", "PROBLEM", 277, 285], ["the inflammation", "PROBLEM", 308, 324], ["subacute", "OBSERVATION_MODIFIER", 58, 66], ["thrombocytosis", "OBSERVATION", 91, 105], ["very suggestive of", "UNCERTAINTY", 162, 180], ["KD", "OBSERVATION", 181, 183], ["no", "UNCERTAINTY", 274, 276], ["inflammation", "OBSERVATION", 312, 324]]], ["Beau\u2019s lines presents as horizontal ridging over nails and first manifest at the subsidence of the subacute phase (Fig. 4.3g).", [["Beau\u2019s lines", "CELL", 0, 12], ["horizontal ridging over nails", "PROBLEM", 25, 54], ["horizontal", "OBSERVATION_MODIFIER", 25, 35], ["ridging", "OBSERVATION_MODIFIER", 36, 43], ["subacute", "OBSERVATION_MODIFIER", 99, 107]]], ["This is the only clinical sign of KD that can be seen for several weeks.Differential DiagnosisMeasles can present with similar clinical features; however, the presence of a viral prodrome, exudative conjunctivitis and Koplik spots will help to differentiate measles from KD.", [["KD", "DISEASE", 34, 36], ["Measles", "DISEASE", 94, 101], ["viral prodrome", "DISEASE", 173, 187], ["conjunctivitis", "DISEASE", 199, 213], ["measles", "DISEASE", 258, 265], ["KD", "DISEASE", 271, 273], ["KD", "PROBLEM", 34, 36], ["a viral prodrome", "PROBLEM", 171, 187], ["exudative conjunctivitis", "PROBLEM", 189, 213], ["Koplik spots", "PROBLEM", 218, 230], ["viral", "OBSERVATION_MODIFIER", 173, 178], ["exudative", "OBSERVATION_MODIFIER", 189, 198], ["conjunctivitis", "OBSERVATION", 199, 213]]], ["In measles, lymphocytic leucocytosis is usually prominent (unless there is secondary infection) while children with KD have polymorphonuclear leucocytosis.", [["lymphocytic", "ANATOMY", 12, 23], ["measles", "DISEASE", 3, 10], ["lymphocytic leucocytosis", "DISEASE", 12, 36], ["infection", "DISEASE", 85, 94], ["KD", "DISEASE", 116, 118], ["polymorphonuclear leucocytosis", "DISEASE", 124, 154], ["children", "ORGANISM", 102, 110], ["polymorphonuclear", "CELL", 124, 141], ["children", "SPECIES", 102, 110], ["lymphocytic leucocytosis", "PROBLEM", 12, 36], ["secondary infection", "PROBLEM", 75, 94], ["polymorphonuclear leucocytosis", "PROBLEM", 124, 154], ["lymphocytic leucocytosis", "OBSERVATION", 12, 36], ["usually prominent", "OBSERVATION_MODIFIER", 40, 57], ["secondary", "OBSERVATION_MODIFIER", 75, 84], ["infection", "OBSERVATION", 85, 94], ["polymorphonuclear leucocytosis", "OBSERVATION", 124, 154]]], ["Procalcitonin levels are normal in measles but may be elevated in KD.", [["measles", "DISEASE", 35, 42], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["Procalcitonin levels", "TEST", 0, 20], ["measles", "PROBLEM", 35, 42], ["elevated in KD", "PROBLEM", 54, 68], ["normal", "OBSERVATION", 25, 31], ["may be", "UNCERTAINTY", 47, 53], ["elevated", "OBSERVATION_MODIFIER", 54, 62]]], ["Other infectious causes that can mimic KD include viral infections (cytomegalovirus, adenovirus, Epstein Barr virus, and enterovirus), bacterial infections (bacterial cervical lymphadenitis, scarlet fever, toxic shock syndrome, staphylococcal scalded skin syndrome, and leptospira), and systemic juvenile idiopathic arthritis.", [["cervical", "ANATOMY", 167, 175], ["skin", "ANATOMY", 251, 255], ["viral infections", "DISEASE", 50, 66], ["cytomegalovirus, adenovirus, Epstein Barr virus, and enterovirus)", "DISEASE", 68, 133], ["bacterial infections", "DISEASE", 135, 155], ["bacterial cervical lymphadenitis", "DISEASE", 157, 189], ["scarlet fever", "DISEASE", 191, 204], ["toxic shock syndrome", "DISEASE", 206, 226], ["staphylococcal scalded skin syndrome", "DISEASE", 228, 264], ["leptospira", "DISEASE", 270, 280], ["juvenile idiopathic arthritis", "DISEASE", 296, 325], ["cytomegalovirus", "ORGANISM", 68, 83], ["adenovirus", "ORGANISM", 85, 95], ["Epstein Barr virus", "ORGANISM", 97, 115], ["enterovirus", "ORGANISM", 121, 132], ["cervical", "ORGANISM_SUBDIVISION", 167, 175], ["skin", "ORGAN", 251, 255], ["Epstein Barr virus", "SPECIES", 97, 115], ["Other infectious causes", "PROBLEM", 0, 23], ["viral infections", "PROBLEM", 50, 66], ["cytomegalovirus", "PROBLEM", 68, 83], ["adenovirus", "PROBLEM", 85, 95], ["Epstein Barr virus", "PROBLEM", 97, 115], ["enterovirus", "PROBLEM", 121, 132], ["bacterial infections", "PROBLEM", 135, 155], ["bacterial cervical lymphadenitis", "PROBLEM", 157, 189], ["scarlet fever", "PROBLEM", 191, 204], ["toxic shock syndrome", "PROBLEM", 206, 226], ["staphylococcal scalded skin syndrome", "PROBLEM", 228, 264], ["leptospira", "PROBLEM", 270, 280], ["systemic juvenile idiopathic arthritis", "PROBLEM", 287, 325], ["infectious", "OBSERVATION", 6, 16], ["Epstein Barr virus", "OBSERVATION", 97, 115], ["bacterial", "OBSERVATION_MODIFIER", 135, 144], ["infections", "OBSERVATION", 145, 155], ["bacterial", "OBSERVATION_MODIFIER", 157, 166], ["cervical", "ANATOMY", 167, 175], ["lymphadenitis", "OBSERVATION", 176, 189], ["scarlet", "OBSERVATION_MODIFIER", 191, 198], ["toxic shock syndrome", "OBSERVATION", 206, 226], ["staphylococcal", "OBSERVATION_MODIFIER", 228, 242], ["scalded skin syndrome", "OBSERVATION", 243, 264], ["systemic", "OBSERVATION_MODIFIER", 287, 295], ["juvenile", "OBSERVATION_MODIFIER", 296, 304], ["idiopathic", "OBSERVATION_MODIFIER", 305, 315], ["arthritis", "OBSERVATION", 316, 325]]], ["Absence of eye changes and lip changes, presence of sand paper rash, elevated antistreptolysin O titres, and a brisk response to antimicrobials are pointers towards scarlet fever.", [["eye", "ANATOMY", 11, 14], ["lip", "ANATOMY", 27, 30], ["rash", "DISEASE", 63, 67], ["fever", "DISEASE", 173, 178], ["eye", "ORGAN", 11, 14], ["lip", "ORGAN", 27, 30], ["antistreptolysin O", "SIMPLE_CHEMICAL", 78, 96], ["eye changes", "PROBLEM", 11, 22], ["lip changes", "PROBLEM", 27, 38], ["sand paper rash", "PROBLEM", 52, 67], ["elevated antistreptolysin O titres", "PROBLEM", 69, 103], ["antimicrobials", "TREATMENT", 129, 143], ["scarlet fever", "PROBLEM", 165, 178], ["eye", "ANATOMY", 11, 14], ["lip", "ANATOMY", 27, 30]]], ["Presence of exudative conjunctivitis, ulcerative lesions in oral cavity, exudative pharyngitis, generalized lymphadenopathy and significant running nose are certain clinical features that make the diagnosis of KD less likely [28].Incomplete KD ::: KD in Special SituationsThe diagnosis of KD is challenging and requires experience.", [["ulcerative lesions", "ANATOMY", 38, 56], ["oral cavity", "ANATOMY", 60, 71], ["exudative conjunctivitis", "DISEASE", 12, 36], ["ulcerative lesions", "DISEASE", 38, 56], ["exudative pharyngitis", "DISEASE", 73, 94], ["lymphadenopathy", "DISEASE", 108, 123], ["KD", "DISEASE", 289, 291], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 38, 56], ["oral cavity", "PATHOLOGICAL_FORMATION", 60, 71], ["nose", "ORGAN", 148, 152], ["exudative conjunctivitis", "PROBLEM", 12, 36], ["ulcerative lesions in oral cavity", "PROBLEM", 38, 71], ["exudative pharyngitis", "PROBLEM", 73, 94], ["generalized lymphadenopathy", "PROBLEM", 96, 123], ["significant running nose", "PROBLEM", 128, 152], ["KD", "PROBLEM", 210, 212], ["KD", "PROBLEM", 289, 291], ["exudative", "OBSERVATION_MODIFIER", 12, 21], ["conjunctivitis", "OBSERVATION", 22, 36], ["ulcerative", "OBSERVATION_MODIFIER", 38, 48], ["lesions", "OBSERVATION", 49, 56], ["oral cavity", "ANATOMY", 60, 71], ["exudative", "OBSERVATION_MODIFIER", 73, 82], ["pharyngitis", "OBSERVATION", 83, 94], ["generalized", "OBSERVATION_MODIFIER", 96, 107], ["lymphadenopathy", "OBSERVATION", 108, 123], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["KD", "OBSERVATION", 289, 291]]], ["Clinical features of KD are nonspecific and overlap with various common childhood disorders especially infections [33].", [["KD", "DISEASE", 21, 23], ["infections", "DISEASE", 103, 113], ["KD", "PROBLEM", 21, 23], ["various common childhood disorders", "PROBLEM", 57, 91], ["infections", "PROBLEM", 103, 113], ["nonspecific", "OBSERVATION_MODIFIER", 28, 39]]], ["Patients who are not fulfilling clinical criteria completely are labelled as incomplete KD.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["In these situations, one has to rely largely on clinical assessment supplemented by laboratory parameters.", [["clinical assessment", "TEST", 48, 67], ["laboratory parameters", "TEST", 84, 105]]], ["Incomplete form of KD is more commonly seen in infants (especially in babies below 6 months).", [["KD", "DISEASE", 19, 21], ["infants", "ORGANISM", 47, 54], ["infants", "SPECIES", 47, 54], ["KD", "OBSERVATION", 19, 21], ["more commonly", "OBSERVATION_MODIFIER", 25, 38]]], ["Approach for diagnosis of incomplete KD has been simplified in new AHA 2017 guidelines [28].", [["incomplete KD", "PROBLEM", 26, 39]]], ["Incomplete KD should, by no means, be considered a milder form of KD.Atypical KD ::: KD in Special SituationsA patient can be said to have atypical KD if the clinical manifestations are unusual.", [["KD", "DISEASE", 66, 68], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["KD", "PROBLEM", 66, 68], ["atypical KD", "PROBLEM", 139, 150], ["the clinical manifestations", "PROBLEM", 154, 181]]], ["These atypical manifestations may include arthritis [31], nephritis [34], pneumonia [35], myositis, central nervous system involvement, uveitis [36], and retinal vasculitis [37].", [["myositis", "ANATOMY", 90, 98], ["central nervous system", "ANATOMY", 100, 122], ["retinal", "ANATOMY", 154, 161], ["arthritis", "DISEASE", 42, 51], ["nephritis", "DISEASE", 58, 67], ["pneumonia", "DISEASE", 74, 83], ["myositis", "DISEASE", 90, 98], ["central nervous system involvement", "DISEASE", 100, 134], ["uveitis", "DISEASE", 136, 143], ["retinal vasculitis", "DISEASE", 154, 172], ["nervous system", "ANATOMICAL_SYSTEM", 108, 122], ["retinal", "MULTI-TISSUE_STRUCTURE", 154, 161], ["These atypical manifestations", "PROBLEM", 0, 29], ["arthritis", "PROBLEM", 42, 51], ["nephritis", "PROBLEM", 58, 67], ["pneumonia", "PROBLEM", 74, 83], ["myositis", "PROBLEM", 90, 98], ["central nervous system involvement", "PROBLEM", 100, 134], ["uveitis", "PROBLEM", 136, 143], ["retinal vasculitis", "PROBLEM", 154, 172], ["may include", "UNCERTAINTY", 30, 41], ["arthritis", "OBSERVATION", 42, 51], ["nephritis", "OBSERVATION", 58, 67], ["pneumonia", "OBSERVATION", 74, 83], ["myositis", "OBSERVATION", 90, 98], ["central", "ANATOMY_MODIFIER", 100, 107], ["nervous system", "ANATOMY", 108, 122], ["uveitis", "OBSERVATION", 136, 143], ["retinal", "ANATOMY", 154, 161], ["vasculitis", "OBSERVATION", 162, 172]]], ["Common neurological findings include extreme irritability and aseptic meningitis.", [["neurological", "ANATOMY", 7, 19], ["irritability", "DISEASE", 45, 57], ["meningitis", "DISEASE", 70, 80], ["Common neurological findings", "PROBLEM", 0, 28], ["extreme irritability", "PROBLEM", 37, 57], ["aseptic meningitis", "PROBLEM", 62, 80], ["extreme", "OBSERVATION_MODIFIER", 37, 44], ["irritability", "OBSERVATION", 45, 57], ["aseptic", "OBSERVATION_MODIFIER", 62, 69], ["meningitis", "OBSERVATION", 70, 80]]], ["Rare neurological manifestations include transient peripheral facial nerve palsy (mostly unilateral) and profound sensorineural hearing loss.", [["neurological", "ANATOMY", 5, 17], ["peripheral facial nerve", "ANATOMY", 51, 74], ["peripheral facial nerve palsy", "DISEASE", 51, 80], ["sensorineural hearing loss", "DISEASE", 114, 140], ["facial nerve", "MULTI-TISSUE_STRUCTURE", 62, 74], ["Rare neurological manifestations", "PROBLEM", 0, 32], ["transient peripheral facial nerve palsy", "PROBLEM", 41, 80], ["profound sensorineural hearing loss", "PROBLEM", 105, 140], ["transient", "OBSERVATION_MODIFIER", 41, 50], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["facial nerve", "ANATOMY", 62, 74], ["palsy", "OBSERVATION", 75, 80], ["profound", "OBSERVATION_MODIFIER", 105, 113], ["sensorineural hearing loss", "OBSERVATION", 114, 140]]], ["Vomiting, diarrhea, and transient hepatitis are common gastrointestinal manifestations [38].", [["gastrointestinal", "ANATOMY", 55, 71], ["Vomiting", "DISEASE", 0, 8], ["diarrhea", "DISEASE", 10, 18], ["hepatitis", "DISEASE", 34, 43], ["gastrointestinal", "ORGAN", 55, 71], ["Vomiting", "PROBLEM", 0, 8], ["diarrhea", "PROBLEM", 10, 18], ["transient hepatitis", "PROBLEM", 24, 43], ["common gastrointestinal manifestations", "PROBLEM", 48, 86], ["diarrhea", "OBSERVATION", 10, 18], ["transient", "OBSERVATION_MODIFIER", 24, 33], ["hepatitis", "OBSERVATION", 34, 43]]], ["Other relatively uncommon findings include jaundice, gall bladder hydrops, and pancreatitis.", [["gall bladder", "ANATOMY", 53, 65], ["jaundice", "DISEASE", 43, 51], ["gall bladder hydrops", "DISEASE", 53, 73], ["pancreatitis", "DISEASE", 79, 91], ["gall bladder", "MULTI-TISSUE_STRUCTURE", 53, 65], ["jaundice", "PROBLEM", 43, 51], ["gall bladder hydrops", "PROBLEM", 53, 73], ["pancreatitis", "PROBLEM", 79, 91], ["jaundice", "OBSERVATION", 43, 51], ["gall bladder", "ANATOMY", 53, 65], ["hydrops", "OBSERVATION", 66, 73], ["pancreatitis", "OBSERVATION", 79, 91]]], ["Genitourinary findings include urethritis which usually presents as sterile pyuria [39].", [["Genitourinary", "ANATOMY", 0, 13], ["urethritis", "DISEASE", 31, 41], ["pyuria", "DISEASE", 76, 82], ["urethritis", "PROBLEM", 31, 41], ["sterile pyuria", "PROBLEM", 68, 82], ["urethritis", "OBSERVATION", 31, 41], ["pyuria", "OBSERVATION", 76, 82]]], ["Atypical presentations of KD can pose difficult clinical problems for the attending physician.KD in Infants ::: KD in Special SituationsIn infancy, and especially in babies below 6 months, KD is often a diagnostic challenge because it may present with incomplete manifestations.", [["KD", "DISEASE", 26, 28], ["Infants", "SPECIES", 100, 107], ["KD", "PROBLEM", 26, 28], ["difficult clinical problems", "PROBLEM", 38, 65], ["incomplete manifestations", "PROBLEM", 252, 277], ["infancy", "OBSERVATION", 139, 146]]], ["KD in this age group may often remain undiagnosed for several days, leading to increased incidence of development of CAAs .", [["KD", "DISEASE", 0, 2], ["CAAs", "DISEASE", 117, 121], ["CAAs", "CANCER", 117, 121], ["CAAs", "PROBLEM", 117, 121], ["undiagnosed", "OBSERVATION", 38, 49], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["CAAs", "OBSERVATION", 117, 121]]], ["This group of patients also has higher intravenous immunoglobulin (IVIg) resistance [28, 30, 40, 41].", [["intravenous", "ANATOMY", 39, 50], ["IVIg", "CHEMICAL", 67, 71], ["patients", "ORGANISM", 14, 22], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 51, 65], ["IVIg", "SIMPLE_CHEMICAL", 67, 71], ["intravenous immunoglobulin", "PROTEIN", 39, 65], ["patients", "SPECIES", 14, 22], ["higher intravenous immunoglobulin (IVIg) resistance", "TREATMENT", 32, 83]]], ["Sterile pyuria is another clinical presentation of KD in this age group and may mistakenly get treated as a urinary tract infection.", [["urinary tract", "ANATOMY", 108, 121], ["pyuria", "DISEASE", 8, 14], ["KD", "DISEASE", 51, 53], ["urinary tract infection", "DISEASE", 108, 131], ["urinary tract", "ORGANISM_SUBDIVISION", 108, 121], ["Sterile pyuria", "PROBLEM", 0, 14], ["KD", "PROBLEM", 51, 53], ["a urinary tract infection", "PROBLEM", 106, 131], ["pyuria", "OBSERVATION", 8, 14], ["urinary tract", "ANATOMY", 108, 121], ["infection", "OBSERVATION", 122, 131]]], ["The consequent delay in diagnosis can result in serious clinical sequelae [39].", [["serious clinical sequelae", "PROBLEM", 48, 73]]], ["Due to these reasons, KD in infants has been given special consideration in new AHA guidelines.", [["infants", "ORGANISM", 28, 35], ["infants", "SPECIES", 28, 35]]], ["It has been highlighted that if an infant has fever for more than 7 days without explanation, KD should always be in list of differential diagnosis.KD in Infants ::: KD in Special SituationsAccording to AHA 2017 guidelines KD should be considered as a clinical possibility in the following situations:Babies <6 months who present with fever and extensive irritability.Infants having prolonged fever and unexplained aseptic meningitis.Children presenting with longer duration of fever andCulture-negative hypotensive shock.Cervical adenopathy that is unresponsive to antibiotic therapy.Parapharyngeal or retropharyngeal phlegmon that is unresponsive to antibiotic therapy.KD in Older Children and Adolescents ::: KD in Special SituationsKD is uncommon in older children and may often go unrecognized.", [["Cervical adenopathy", "ANATOMY", 522, 541], ["Parapharyngeal", "ANATOMY", 585, 599], ["retropharyngeal phlegmon", "ANATOMY", 603, 627], ["fever", "DISEASE", 46, 51], ["fever", "DISEASE", 335, 340], ["irritability", "DISEASE", 355, 367], ["fever", "DISEASE", 393, 398], ["meningitis", "DISEASE", 423, 433], ["fever", "DISEASE", 478, 483], ["hypotensive shock", "DISEASE", 504, 521], ["adenopathy", "DISEASE", 531, 541], ["Parapharyngeal or retropharyngeal phlegmon", "DISEASE", 585, 627], ["infant", "ORGANISM", 35, 41], ["Infants", "ORGANISM", 368, 375], ["Children", "ORGANISM", 434, 442], ["Cervical", "ORGAN", 522, 530], ["retropharyngeal phlegmon", "CANCER", 603, 627], ["children", "ORGANISM", 760, 768], ["infant", "SPECIES", 35, 41], ["Infants", "SPECIES", 154, 161], ["Infants", "SPECIES", 368, 375], ["Children", "SPECIES", 434, 442], ["Children", "SPECIES", 683, 691], ["children", "SPECIES", 760, 768], ["fever", "PROBLEM", 46, 51], ["fever", "PROBLEM", 335, 340], ["extensive irritability", "PROBLEM", 345, 367], ["prolonged fever", "PROBLEM", 383, 398], ["unexplained aseptic meningitis", "PROBLEM", 403, 433], ["fever", "PROBLEM", 478, 483], ["Culture", "TEST", 487, 494], ["hypotensive shock", "PROBLEM", 504, 521], ["Cervical adenopathy", "PROBLEM", 522, 541], ["antibiotic therapy", "TREATMENT", 566, 584], ["Parapharyngeal or retropharyngeal phlegmon", "PROBLEM", 585, 627], ["antibiotic therapy", "TREATMENT", 652, 670], ["extensive", "OBSERVATION_MODIFIER", 345, 354], ["irritability", "OBSERVATION", 355, 367], ["prolonged", "OBSERVATION_MODIFIER", 383, 392], ["fever", "OBSERVATION", 393, 398], ["aseptic", "OBSERVATION_MODIFIER", 415, 422], ["meningitis", "OBSERVATION", 423, 433], ["hypotensive shock", "OBSERVATION", 504, 521], ["adenopathy", "OBSERVATION", 531, 541], ["retropharyngeal", "ANATOMY", 603, 618], ["phlegmon", "OBSERVATION", 619, 627]]], ["Due to missed or delayed diagnosis, there is higher risk of CAAs in this age group.", [["CAAs", "DISEASE", 60, 64], ["CAAs", "CANCER", 60, 64], ["CAAs", "PROBLEM", 60, 64], ["CAAs", "OBSERVATION", 60, 64]]], ["It may be difficult to assess CAAs by 2DE in this age group of patients because of limited acoustic window and thick chest wall [42, 43].KD Shock Syndrome ::: KD in Special SituationsMyocarditis in KD is said to be very common and may even be universal.", [["chest wall", "ANATOMY", 117, 127], ["Myocarditis", "DISEASE", 183, 194], ["CAAs", "CANCER", 30, 34], ["patients", "ORGANISM", 63, 71], ["chest wall", "MULTI-TISSUE_STRUCTURE", 117, 127], ["patients", "SPECIES", 63, 71], ["limited acoustic window", "PROBLEM", 83, 106], ["thick chest wall", "TEST", 111, 127], ["Shock Syndrome", "PROBLEM", 140, 154], ["Myocarditis", "PROBLEM", 183, 194], ["acoustic window", "OBSERVATION", 91, 106], ["chest wall", "ANATOMY", 117, 127]]], ["It is not often recognized and can, at times, be severe and symptomatic.", [["symptomatic", "PROBLEM", 60, 71], ["not often", "UNCERTAINTY", 6, 15], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["symptomatic", "OBSERVATION_MODIFIER", 60, 71]]], ["Myocarditis can develop during acute stage and manifest with unexplained tachycardia, hemodynamic compromise, or cardiovascular collapse [44].", [["cardiovascular", "ANATOMY", 113, 127], ["Myocarditis", "DISEASE", 0, 11], ["tachycardia", "DISEASE", 73, 84], ["cardiovascular collapse", "DISEASE", 113, 136], ["Myocarditis", "PROBLEM", 0, 11], ["unexplained tachycardia", "PROBLEM", 61, 84], ["hemodynamic compromise", "PROBLEM", 86, 108], ["cardiovascular collapse", "PROBLEM", 113, 136], ["hemodynamic compromise", "OBSERVATION", 86, 108], ["cardiovascular", "ANATOMY", 113, 127], ["collapse", "OBSERVATION", 128, 136]]], ["Approximately 5% patients with KD can present with cardiovascular collapse.", [["cardiovascular", "ANATOMY", 51, 65], ["KD", "DISEASE", 31, 33], ["cardiovascular collapse", "DISEASE", 51, 74], ["patients", "ORGANISM", 17, 25], ["cardiovascular", "ANATOMICAL_SYSTEM", 51, 65], ["patients", "SPECIES", 17, 25], ["cardiovascular collapse", "PROBLEM", 51, 74], ["cardiovascular", "ANATOMY", 51, 65], ["collapse", "OBSERVATION", 66, 74]]], ["This entity is known as KD shock syndrome (KDSS).", [["KD shock syndrome", "DISEASE", 24, 41], ["KDSS", "DISEASE", 43, 47], ["KD shock syndrome", "PROBLEM", 24, 41], ["shock syndrome", "OBSERVATION", 27, 41]]], ["The shock in these patients is multifactorial and may have both cardiogenic and distributive components.", [["shock", "DISEASE", 4, 9], ["cardiogenic", "DISEASE", 64, 75], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["The shock", "PROBLEM", 0, 9], ["cardiogenic", "PROBLEM", 64, 75], ["distributive components", "PROBLEM", 80, 103], ["shock", "OBSERVATION", 4, 9], ["cardiogenic", "OBSERVATION", 64, 75], ["distributive", "OBSERVATION_MODIFIER", 80, 92], ["components", "OBSERVATION_MODIFIER", 93, 103]]], ["The distributive shock may result from cytokine storm leading to uncontrolled inflammation [45].", [["shock", "DISEASE", 17, 22], ["inflammation", "DISEASE", 78, 90], ["cytokine", "PROTEIN", 39, 47], ["The distributive shock", "PROBLEM", 0, 22], ["cytokine storm", "PROBLEM", 39, 53], ["uncontrolled inflammation", "PROBLEM", 65, 90], ["distributive", "OBSERVATION_MODIFIER", 4, 16], ["shock", "OBSERVATION", 17, 22], ["cytokine storm", "OBSERVATION", 39, 53], ["uncontrolled", "OBSERVATION_MODIFIER", 65, 77], ["inflammation", "OBSERVATION", 78, 90]]], ["Patients with KDSS are usually present to emergency room and intensive care units with shock and may be inappropriately treated for bacterial sepsis and presumed septic shock.", [["KDSS", "DISEASE", 14, 18], ["shock", "DISEASE", 87, 92], ["sepsis", "DISEASE", 142, 148], ["septic shock", "DISEASE", 162, 174], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["shock", "PROBLEM", 87, 92], ["bacterial sepsis", "PROBLEM", 132, 148], ["septic shock", "PROBLEM", 162, 174], ["shock", "OBSERVATION", 87, 92], ["sepsis", "OBSERVATION", 142, 148], ["presumed", "UNCERTAINTY", 153, 161], ["septic shock", "OBSERVATION", 162, 174]]], ["Diagnosis of KD gets often delayed in these cases and can have devastating consequences.", [["KD", "DISEASE", 13, 15]]], ["Differentiation between KDSS and septic shock in the early phase of clinical diagnosis is often challenging.", [["septic shock", "DISEASE", 33, 45], ["KDSS", "TEST", 24, 28], ["septic shock", "PROBLEM", 33, 45], ["septic shock", "OBSERVATION", 33, 45], ["early phase", "OBSERVATION_MODIFIER", 53, 64]]], ["However, 2DE should always be performed in patients with fever and shock as presence of CAAs will suggest KDSS.", [["fever", "DISEASE", 57, 62], ["shock", "DISEASE", 67, 72], ["CAAs", "DISEASE", 88, 92], ["KDSS", "DISEASE", 106, 110], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["2DE", "TEST", 9, 12], ["fever", "PROBLEM", 57, 62], ["shock", "PROBLEM", 67, 72], ["KDSS", "PROBLEM", 106, 110]]], ["Differentiation of KDSS and septic shock is critical as management of both diseases is entirely different.", [["KDSS", "DISEASE", 19, 23], ["septic shock", "DISEASE", 28, 40], ["KDSS", "CANCER", 19, 23], ["KDSS", "PROBLEM", 19, 23], ["septic shock", "PROBLEM", 28, 40], ["both diseases", "PROBLEM", 70, 83], ["septic shock", "OBSERVATION", 28, 40], ["both", "OBSERVATION_MODIFIER", 70, 74], ["diseases", "OBSERVATION", 75, 83], ["different", "OBSERVATION_MODIFIER", 96, 105]]], ["Presence of conjunctival injection, dorsal edema, perineal desquamation, incomplete response to antimicrobials, and no microbiological evidence for infection are indicators towards KD in these patients.", [["conjunctival", "ANATOMY", 12, 24], ["dorsal edema", "ANATOMY", 36, 48], ["perineal", "ANATOMY", 50, 58], ["edema", "DISEASE", 43, 48], ["infection", "DISEASE", 148, 157], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 12, 24], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["conjunctival injection", "PROBLEM", 12, 34], ["dorsal edema", "PROBLEM", 36, 48], ["perineal desquamation", "PROBLEM", 50, 71], ["antimicrobials", "TREATMENT", 96, 110], ["infection", "PROBLEM", 148, 157], ["conjunctival", "ANATOMY", 12, 24], ["dorsal", "ANATOMY_MODIFIER", 36, 42], ["edema", "OBSERVATION", 43, 48], ["perineal", "ANATOMY", 50, 58], ["desquamation", "OBSERVATION", 59, 71], ["evidence for", "UNCERTAINTY", 135, 147], ["infection", "OBSERVATION", 148, 157]]], ["These patients are reported to have increased risk of having IVIg resistance, CAAs , and myocardial dysfunction [28, 46, 47].", [["myocardial", "ANATOMY", 89, 99], ["IVIg", "CHEMICAL", 61, 65], ["CAAs", "DISEASE", 78, 82], ["myocardial dysfunction", "DISEASE", 89, 111], ["patients", "ORGANISM", 6, 14], ["IVIg", "SIMPLE_CHEMICAL", 61, 65], ["myocardial", "MULTI-TISSUE_STRUCTURE", 89, 99], ["patients", "SPECIES", 6, 14], ["IVIg resistance", "PROBLEM", 61, 76], ["CAAs", "PROBLEM", 78, 82], ["myocardial dysfunction", "PROBLEM", 89, 111], ["IVIg resistance", "OBSERVATION", 61, 76], ["myocardial", "ANATOMY", 89, 99], ["dysfunction", "OBSERVATION", 100, 111]]], ["It is said that KDSS should always be considered in children presenting with fever, cardiovascular collapse and myocardial dysfunction.", [["cardiovascular", "ANATOMY", 84, 98], ["myocardial", "ANATOMY", 112, 122], ["fever", "DISEASE", 77, 82], ["cardiovascular collapse", "DISEASE", 84, 107], ["myocardial dysfunction", "DISEASE", 112, 134], ["children", "ORGANISM", 52, 60], ["myocardial", "MULTI-TISSUE_STRUCTURE", 112, 122], ["children", "SPECIES", 52, 60], ["fever", "PROBLEM", 77, 82], ["cardiovascular collapse", "PROBLEM", 84, 107], ["myocardial dysfunction", "PROBLEM", 112, 134], ["cardiovascular", "ANATOMY", 84, 98], ["collapse", "OBSERVATION", 99, 107], ["myocardial", "ANATOMY", 112, 122], ["dysfunction", "OBSERVATION", 123, 134]]], ["KDSS has been discussed at length in the AHA 2017 revised guidelines because of these highlighted facts [28].Infection Triggered KD ::: KD in Special SituationsInfections have been commonly considered as triggers for KD.", [["KDSS", "CHEMICAL", 0, 4], ["Infections", "DISEASE", 160, 170], ["Infection", "PROBLEM", 109, 118]]], ["At the bedside, it is often difficult to differentiate the clinical features of KD from that of viral exanthemata.", [["KD", "DISEASE", 80, 82], ["viral exanthemata", "DISEASE", 96, 113], ["KD", "PROBLEM", 80, 82], ["viral exanthemata", "PROBLEM", 96, 113], ["viral exanthemata", "OBSERVATION", 96, 113]]], ["However, if a child is having typical clinical features of the KD, the diagnosis cannot be excluded even in the presence of a documented infection.", [["infection", "DISEASE", 137, 146], ["a documented infection", "PROBLEM", 124, 146], ["cannot be excluded", "UNCERTAINTY", 81, 99], ["infection", "OBSERVATION", 137, 146]]], ["Adenovirus, coronavirus, dengue virus, enteroviruses, measles virus, respiratory syncytial virus have been reported to trigger the KD in children [23].", [["dengue virus", "DISEASE", 25, 37], ["enteroviruses", "DISEASE", 39, 52], ["measles virus", "DISEASE", 54, 67], ["respiratory syncytial virus", "DISEASE", 69, 96], ["Adenovirus", "ORGANISM", 0, 10], ["coronavirus", "ORGANISM", 12, 23], ["dengue virus", "ORGANISM", 25, 37], ["enteroviruses", "ORGANISM", 39, 52], ["measles virus", "ORGANISM", 54, 67], ["respiratory syncytial virus", "ORGANISM", 69, 96], ["children", "ORGANISM", 137, 145], ["coronavirus", "SPECIES", 12, 23], ["dengue virus", "SPECIES", 25, 37], ["measles virus", "SPECIES", 54, 67], ["respiratory syncytial virus", "SPECIES", 69, 96], ["children", "SPECIES", 137, 145], ["Adenovirus", "SPECIES", 0, 10], ["dengue virus", "SPECIES", 25, 37], ["measles virus", "SPECIES", 54, 67], ["respiratory syncytial virus", "SPECIES", 69, 96], ["Adenovirus", "PROBLEM", 0, 10], ["coronavirus", "PROBLEM", 12, 23], ["dengue virus", "PROBLEM", 25, 37], ["enteroviruses", "PROBLEM", 39, 52], ["measles virus", "PROBLEM", 54, 67], ["respiratory syncytial virus", "PROBLEM", 69, 96], ["coronavirus", "OBSERVATION", 12, 23], ["dengue virus", "OBSERVATION", 25, 37], ["syncytial virus", "OBSERVATION", 81, 96]]], ["Toxin-mediated diseases (e.g., staphylococcal and streptococcal infection) have also been also closely associated with the pathogenesis of KD [27].", [["Toxin", "CHEMICAL", 0, 5], ["staphylococcal and streptococcal infection", "DISEASE", 31, 73], ["Toxin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Toxin", "TEST", 0, 5], ["mediated diseases", "PROBLEM", 6, 23], ["staphylococcal", "PROBLEM", 31, 45], ["streptococcal infection", "PROBLEM", 50, 73], ["diseases", "OBSERVATION", 15, 23], ["streptococcal", "OBSERVATION_MODIFIER", 50, 63], ["infection", "OBSERVATION", 64, 73]]], ["Candida infection has been linked to the causation of KD in mice models and as well as in epidemiological studies carried out on tropospheric wind patterns in Japan and Hawaii [48].Laboratory InvestigationsThe acute phase is characterized by a mild normocytic normochromic anemia, polymorphonuclear leucocytosis, raised erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and usually a normal platelet count.", [["polymorphonuclear", "ANATOMY", 281, 298], ["erythrocyte", "ANATOMY", 320, 331], ["platelet", "ANATOMY", 405, 413], ["Candida infection", "DISEASE", 0, 17], ["KD", "DISEASE", 54, 56], ["anemia", "DISEASE", 273, 279], ["polymorphonuclear leucocytosis", "DISEASE", 281, 311], ["mice", "ORGANISM", 60, 64], ["polymorphonuclear", "CELL", 281, 298], ["erythrocyte", "CELL", 320, 331], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 358, 376], ["CRP", "GENE_OR_GENE_PRODUCT", 378, 381], ["platelet", "CELL", 405, 413], ["C-reactive protein", "PROTEIN", 358, 376], ["CRP", "PROTEIN", 378, 381], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["Candida infection", "PROBLEM", 0, 17], ["epidemiological studies", "TEST", 90, 113], ["Laboratory Investigations", "TEST", 181, 206], ["a mild normocytic normochromic anemia", "PROBLEM", 242, 279], ["polymorphonuclear leucocytosis", "PROBLEM", 281, 311], ["raised erythrocyte sedimentation rate", "PROBLEM", 313, 350], ["ESR", "TEST", 352, 355], ["C-reactive protein", "TEST", 358, 376], ["CRP", "TEST", 378, 381], ["infection", "OBSERVATION", 8, 17], ["acute phase", "OBSERVATION_MODIFIER", 210, 221], ["mild", "OBSERVATION_MODIFIER", 244, 248], ["normocytic", "OBSERVATION_MODIFIER", 249, 259], ["normochromic anemia", "OBSERVATION", 260, 279], ["polymorphonuclear leucocytosis", "OBSERVATION", 281, 311], ["erythrocyte sedimentation", "OBSERVATION", 320, 345], ["reactive protein", "OBSERVATION", 360, 376], ["normal platelet count", "OBSERVATION", 398, 419]]], ["Serum procalcitonin, that is usually thought to be a sensitive and specific marker for bacterial infection, may get elevated in KD as well.", [["Serum", "ANATOMY", 0, 5], ["bacterial infection", "DISEASE", 87, 106], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 6, 19], ["Serum procalcitonin", "TEST", 0, 19], ["bacterial infection", "PROBLEM", 87, 106], ["elevated in KD", "PROBLEM", 116, 130], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["Thrombocytosis develops during the end of second week or in the third week; however it may even develop earlier [49].", [["Thrombocytosis", "DISEASE", 0, 14], ["Thrombocytosis", "PROBLEM", 0, 14]]], ["Presence of thrombocytopenia during acute stage suggests either macrophage activation syndrome or thrombotic microangiopathy\u2014this is associated with poor prognosis [28].", [["macrophage", "ANATOMY", 64, 74], ["thrombocytopenia", "DISEASE", 12, 28], ["thrombotic microangiopathy\u2014this", "DISEASE", 98, 129], ["macrophage", "CELL", 64, 74], ["thrombocytopenia", "PROBLEM", 12, 28], ["acute stage", "PROBLEM", 36, 47], ["macrophage activation syndrome", "PROBLEM", 64, 94], ["thrombotic microangiopathy\u2014this", "PROBLEM", 98, 129], ["poor prognosis", "PROBLEM", 149, 163], ["thrombocytopenia", "OBSERVATION", 12, 28], ["acute stage", "OBSERVATION_MODIFIER", 36, 47], ["suggests either", "UNCERTAINTY", 48, 63], ["macrophage activation syndrome", "OBSERVATION", 64, 94], ["thrombotic", "OBSERVATION_MODIFIER", 98, 108]]], ["Progressive thrombocytosis has been correlated with development of CAAs .", [["thrombocytosis", "DISEASE", 12, 26], ["CAAs", "DISEASE", 67, 71], ["CAAs", "PATHOLOGICAL_FORMATION", 67, 71], ["Progressive thrombocytosis", "PROBLEM", 0, 26], ["CAAs", "PROBLEM", 67, 71], ["thrombocytosis", "OBSERVATION", 12, 26], ["CAAs", "OBSERVATION", 67, 71]]], ["Urine may show sterile pyuria, secondary to urethritis and easily mistaken as urinary tract infection especially during infancy, thereby resulting in delay in diagnosis of KD [39].", [["Urine", "ANATOMY", 0, 5], ["urinary tract", "ANATOMY", 78, 91], ["pyuria", "DISEASE", 23, 29], ["urethritis", "DISEASE", 44, 54], ["urinary tract infection", "DISEASE", 78, 101], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["urinary tract", "ORGANISM_SUBDIVISION", 78, 91], ["Urine", "TEST", 0, 5], ["sterile pyuria", "PROBLEM", 15, 29], ["urethritis", "PROBLEM", 44, 54], ["urinary tract infection", "PROBLEM", 78, 101], ["KD", "PROBLEM", 172, 174], ["pyuria", "OBSERVATION", 23, 29], ["urethritis", "OBSERVATION", 44, 54], ["urinary tract", "ANATOMY", 78, 91], ["infection", "OBSERVATION", 92, 101]]], ["It is said that KD is the commonest cause of sterile pyuria in children.Biomarkers in KDDiagnosis of KD is essentially clinical and there is no gold standard for confirmation of diagnosis.", [["pyuria", "DISEASE", 53, 59], ["KD", "DISEASE", 101, 103], ["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71], ["sterile pyuria", "PROBLEM", 45, 59], ["Biomarkers", "TEST", 72, 82], ["pyuria", "OBSERVATION", 53, 59], ["KD", "OBSERVATION", 101, 103]]], ["It is no surprise, therefore, that several biomarkers have been extensively evaluated for their role in diagnosis of this condition.", [["several biomarkers", "TEST", 35, 53], ["this condition", "PROBLEM", 117, 131], ["no", "UNCERTAINTY", 6, 8], ["surprise", "OBSERVATION", 9, 17]]], ["Various cytokines (e.g., tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin 6) have been found to be raised during the acute phase of KD and decrease promptly following IVIg administration.", [["IVIg", "CHEMICAL", 164, 168], ["tumour necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 25, 49], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 59, 72], ["IVIg", "SIMPLE_CHEMICAL", 164, 168], ["cytokines", "PROTEIN", 8, 17], ["tumour necrosis factor-\u03b1", "PROTEIN", 25, 49], ["TNF", "PROTEIN", 51, 54], ["\u03b1", "PROTEIN", 55, 56], ["interleukin 6", "PROTEIN", 59, 72], ["Various cytokines", "TEST", 0, 17], ["tumour necrosis factor", "TEST", 25, 47], ["TNF", "TEST", 51, 54], ["IVIg administration", "TREATMENT", 164, 183], ["cytokines", "OBSERVATION", 8, 17], ["tumour", "OBSERVATION_MODIFIER", 25, 31], ["necrosis", "OBSERVATION", 32, 40]]], ["In patients with refractory KD or CAAs levels of TNF-\u03b1 continue to remain elevated [50].", [["patients", "ORGANISM", 3, 11], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 49, 54], ["TNF-\u03b1", "PROTEIN", 49, 54], ["patients", "SPECIES", 3, 11], ["refractory KD", "PROBLEM", 17, 30], ["CAAs levels", "TEST", 34, 45], ["TNF", "TEST", 49, 52], ["elevated", "PROBLEM", 74, 82]]], ["Various microarray based studies have been carried out to identify the genes associated with KD.", [["Various microarray based studies", "TEST", 0, 32]]], ["Expression of these genes may be used as a novel diagnostic and prognostic biomarker for KD [51].Biomarkers in KDN terminal pro-B-type natriuretic peptide (NT-proBNP) is a cardiac biomarker that has recently been found to be raised in children with KD during the acute phase.", [["cardiac", "ANATOMY", 172, 179], ["NT-proBNP", "CHEMICAL", 156, 165], ["KDN terminal pro-B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 111, 154], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 156, 165], ["children", "ORGANISM", 235, 243], ["KDN", "PROTEIN", 111, 114], ["children", "SPECIES", 235, 243], ["Biomarkers", "TEST", 97, 107], ["KDN", "TEST", 111, 114], ["type natriuretic peptide", "PROBLEM", 130, 154], ["NT-proBNP", "TEST", 156, 165], ["a cardiac biomarker", "TEST", 170, 189], ["cardiac", "ANATOMY", 172, 179]]], ["Age-based nomograms for Pro-BNP are available.", [["Pro-BNP", "SIMPLE_CHEMICAL", 24, 31], ["Pro-BNP", "PROTEIN", 24, 31], ["Pro-BNP", "TEST", 24, 31]]], ["These are helpful in differentiation of KD from other febrile illnesses [52].", [["KD", "DISEASE", 40, 42], ["febrile illnesses", "DISEASE", 54, 71], ["other febrile illnesses", "PROBLEM", 48, 71]]], ["The values for Pro-BNP are comparatively higher in patients who develop CAAs as compared to patients with normal coronaries [53].", [["coronaries", "ANATOMY", 113, 123], ["CAAs", "DISEASE", 72, 76], ["Pro-BNP", "SIMPLE_CHEMICAL", 15, 22], ["patients", "ORGANISM", 51, 59], ["CAAs", "CANCER", 72, 76], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 92, 100], ["The values", "TEST", 0, 10], ["Pro-BNP", "TEST", 15, 22], ["CAAs", "PROBLEM", 72, 76], ["coronaries", "ANATOMY", 113, 123]]], ["ProBNP levels also correlate with myocardial dysfunction [45].Two-Dimensional Echocardiography (2DE)Cardiac evaluation is an essential component in patients with KD.", [["myocardial", "ANATOMY", 34, 44], ["myocardial dysfunction", "DISEASE", 34, 56], ["KD", "DISEASE", 162, 164], ["ProBNP", "SIMPLE_CHEMICAL", 0, 6], ["myocardial", "MULTI-TISSUE_STRUCTURE", 34, 44], ["patients", "ORGANISM", 148, 156], ["ProBNP", "PROTEIN", 0, 6], ["patients", "SPECIES", 148, 156], ["ProBNP levels", "TEST", 0, 13], ["myocardial dysfunction", "PROBLEM", 34, 56], ["Dimensional Echocardiography", "TEST", 66, 94], ["Cardiac evaluation", "TEST", 100, 118], ["myocardial", "ANATOMY", 34, 44], ["dysfunction", "OBSERVATION", 45, 56]]], ["2DE is an important tool for coronary artery assessment and, evaluation of cardiac structures during acute phase as well as on follow-up.", [["coronary artery", "ANATOMY", 29, 44], ["cardiac structures", "ANATOMY", 75, 93], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 29, 44], ["cardiac structures", "MULTI-TISSUE_STRUCTURE", 75, 93], ["coronary artery assessment", "TEST", 29, 55], ["evaluation", "TEST", 61, 71], ["coronary artery", "ANATOMY", 29, 44], ["cardiac", "ANATOMY", 75, 82]]], ["However, diagnosis of KD should never be ruled out on basis of normal 2DE examination.", [["KD", "DISEASE", 22, 24], ["KD", "PROBLEM", 22, 24], ["2DE examination", "TEST", 70, 85]]], ["The quality of scan obtained by 2DE is operator dependent [43].Two-Dimensional Echocardiography (2DE)Criteria for definition of CAAs have been given by AHA as well as by the Japanese Ministry of Health.", [["CAAs", "DISEASE", 128, 132], ["scan", "TEST", 15, 19], ["Dimensional Echocardiography", "TEST", 67, 95], ["CAAs", "PROBLEM", 128, 132]]], ["According to the latter coronary involvement in KD is categorized on basis of absolute internal diameter of coronary artery (Table 4.4) [54].", [["coronary", "ANATOMY", 24, 32], ["coronary artery", "ANATOMY", 108, 123], ["coronary", "MULTI-TISSUE_STRUCTURE", 24, 32], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 108, 123], ["coronary", "ANATOMY", 24, 32], ["diameter", "OBSERVATION_MODIFIER", 96, 104], ["coronary artery", "ANATOMY", 108, 123]]], ["Manlhiot et al. have proposed definition of CAAs on the basis of Z score which is widely accepted currently and also has been adapted by AHA 2017 guidelines (Table 4.4) [28, 55].", [["CAAs", "CANCER", 44, 48], ["Z score", "TEST", 65, 72]]], ["It is mandatory to use body surface area-adjusted \u2018Z\u2019 scores for grading the severity of CAAs .", [["body surface", "ANATOMY", 23, 35], ["CAAs", "DISEASE", 89, 93], ["CAAs", "PATHOLOGICAL_FORMATION", 89, 93], ["body surface", "TREATMENT", 23, 35], ["CAAs", "OBSERVATION", 89, 93]]], ["Patients with a maximal Z score >+2.5 are classified to have aneurysm, while between 2 and 2.5 is considered dilatation.", [["aneurysm", "ANATOMY", 61, 69], ["aneurysm", "DISEASE", 61, 69], ["Patients", "ORGANISM", 0, 8], ["aneurysm", "PATHOLOGICAL_FORMATION", 61, 69], ["Patients", "SPECIES", 0, 8], ["a maximal Z score", "TEST", 14, 31], ["aneurysm", "PROBLEM", 61, 69], ["dilatation", "PROBLEM", 109, 119], ["aneurysm", "OBSERVATION", 61, 69], ["dilatation", "OBSERVATION", 109, 119]]], ["CAAs can presents in the form of absence of tapering of coronary arteries, coronary artery ectasia, dilation and aneurysms.", [["coronary arteries", "ANATOMY", 56, 73], ["coronary artery", "ANATOMY", 75, 90], ["CAAs", "DISEASE", 0, 4], ["coronary artery ectasia", "DISEASE", 75, 98], ["aneurysms", "DISEASE", 113, 122], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 56, 73], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 75, 90], ["coronary artery ectasia", "PROBLEM", 75, 98], ["dilation", "PROBLEM", 100, 108], ["aneurysms", "PROBLEM", 113, 122], ["tapering", "OBSERVATION_MODIFIER", 44, 52], ["coronary arteries", "ANATOMY", 56, 73], ["coronary artery", "ANATOMY", 75, 90], ["ectasia", "OBSERVATION", 91, 98], ["dilation", "OBSERVATION", 100, 108], ["aneurysms", "OBSERVATION", 113, 122]]], ["Other than CAAs these patients can have myocardial dysfunction (reduced ejection fraction, fractional shortening), valvular regurgitation, pericardial effusion and aortic root dilation [44].", [["myocardial", "ANATOMY", 40, 50], ["valvular", "ANATOMY", 115, 123], ["pericardial", "ANATOMY", 139, 150], ["aortic root", "ANATOMY", 164, 175], ["myocardial dysfunction", "DISEASE", 40, 62], ["valvular regurgitation", "DISEASE", 115, 137], ["pericardial effusion", "DISEASE", 139, 159], ["patients", "ORGANISM", 22, 30], ["myocardial", "MULTI-TISSUE_STRUCTURE", 40, 50], ["aortic root", "MULTI-TISSUE_STRUCTURE", 164, 175], ["patients", "SPECIES", 22, 30], ["myocardial dysfunction", "PROBLEM", 40, 62], ["reduced ejection fraction", "PROBLEM", 64, 89], ["fractional shortening)", "PROBLEM", 91, 113], ["valvular regurgitation", "PROBLEM", 115, 137], ["pericardial effusion", "PROBLEM", 139, 159], ["aortic root dilation", "PROBLEM", 164, 184], ["myocardial", "ANATOMY", 40, 50], ["dysfunction", "OBSERVATION", 51, 62], ["ejection fraction", "OBSERVATION", 72, 89], ["fractional shortening", "OBSERVATION", 91, 112], ["valvular", "ANATOMY", 115, 123], ["regurgitation", "OBSERVATION", 124, 137], ["pericardial", "ANATOMY", 139, 150], ["effusion", "OBSERVATION", 151, 159], ["aortic root", "ANATOMY", 164, 175], ["dilation", "OBSERVATION", 176, 184]]], ["It is recommended to perform frequent 2DE examinations during acute phase of KD.", [["frequent 2DE examinations", "TEST", 29, 54]]], ["After discharge, 2DE should be done 2 weeks and then 4\u20136 weeks later.", [["2DE", "TEST", 17, 20]]], ["It should be noted that normal 2DE examination in first 7 days of illness does not exclude development of CAAs .", [["illness", "DISEASE", 66, 73], ["CAAs", "DISEASE", 106, 110], ["CAAs", "PATHOLOGICAL_FORMATION", 106, 110], ["2DE examination", "TEST", 31, 46], ["illness", "PROBLEM", 66, 73], ["CAAs", "PROBLEM", 106, 110], ["CAAs", "OBSERVATION", 106, 110]]], ["More frequent 2DE assessment should be carried out in children with KD having >2 Z score coronary artery diameters [28].Interpretation of 2DE Examination: A Word of Caution", [["coronary artery", "ANATOMY", 89, 104], ["children", "ORGANISM", 54, 62], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 89, 104], ["children", "SPECIES", 54, 62], ["frequent 2DE assessment", "TEST", 5, 28], ["2DE Examination", "TEST", 138, 153], ["coronary artery", "ANATOMY", 89, 104]]]], "PMC7294520": [["To the Editor:While immunosuppression may be beneficial in later phases of COVID-19, it can delay virus clearance if applied too early.", [["COVID-19", "CHEMICAL", 75, 83], ["immunosuppression", "TREATMENT", 20, 37], ["COVID", "TEST", 75, 80]]], ["In immunocompromised patients, such as allogeneic stem cell transplant (ASCT) recipients, testing strategies, disease outcomes, and choice of therapy remain largely unknown.To the Editor:Due to concerns of high rates of false-negative results with RT-PCR based assays, the American Society for Transplantation and Cellular Therapy (ASTCT) recommends repeat SARS-CoV-2 testing in ASCT patients if initial testing is negative [1].", [["stem cell", "ANATOMY", 50, 59], ["patients", "ORGANISM", 21, 29], ["stem cell", "CELL", 50, 59], ["recipients", "ORGANISM", 78, 88], ["patients", "ORGANISM", 384, 392], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 384, 392], ["allogeneic stem cell transplant", "TREATMENT", 39, 70], ["ASCT) recipients", "TREATMENT", 72, 88], ["disease outcomes", "PROBLEM", 110, 126], ["therapy", "TREATMENT", 142, 149], ["RT-PCR", "TEST", 248, 254], ["Transplantation", "TREATMENT", 294, 309], ["Cellular Therapy", "TREATMENT", 314, 330], ["repeat SARS", "TEST", 350, 361], ["CoV", "TEST", 362, 365], ["initial testing", "TEST", 396, 411], ["immunocompromised", "OBSERVATION", 3, 20], ["allogeneic stem cell transplant", "OBSERVATION", 39, 70]]], ["Bronchoalveolar lavage (BAL) might improve testing sensitivity, but is not routinely performed due to operator safety concerns [1, 2].", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["BAL", "ANATOMY", 24, 27], ["Bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 0, 22], ["BAL", "MULTI-TISSUE_STRUCTURE", 24, 27], ["Bronchoalveolar lavage (BAL)", "TEST", 0, 28], ["testing sensitivity", "TEST", 43, 62]]], ["Therefore, if upper respiratory tract RT-PCR testing is negative and clinical suspicion remains high, diagnosis may rely on pulmonary imaging and symptomatology [2].", [["pulmonary", "ANATOMY", 124, 133], ["pulmonary", "ORGAN", 124, 133], ["upper respiratory tract RT-PCR testing", "TEST", 14, 52], ["pulmonary imaging", "TEST", 124, 141], ["symptomatology", "PROBLEM", 146, 160], ["upper", "ANATOMY_MODIFIER", 14, 19], ["respiratory tract", "ANATOMY", 20, 37], ["pulmonary", "ANATOMY", 124, 133]]], ["In addition, while the viral genome has been detected in other bodily sources, such as blood, feces, and sputum, its clinical significance remains unclear and has not been studied in the setting of ASCT [2].", [["blood", "ANATOMY", 87, 92], ["feces", "ANATOMY", 94, 99], ["sputum", "ANATOMY", 105, 111], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["feces", "ORGANISM_SUBSTANCE", 94, 99], ["sputum", "ORGANISM_SUBSTANCE", 105, 111], ["viral genome", "DNA", 23, 35], ["the viral genome", "PROBLEM", 19, 35], ["blood, feces", "TEST", 87, 99], ["sputum", "PROBLEM", 105, 111], ["viral genome", "OBSERVATION", 23, 35]]], ["With their goal to improve sensitivity, the US Food and Drug Administration recently issued an Emergency Use Authorization to a highly sensitive clustered regularly interspaced short palindromic repeats (CRISPR)-based qualitative COVID-19 assay [3].To the Editor:Herein, we report two cases of COVID-19 infection in ASCT recipients using CRISPR diagnostics, followed by successful treatment with COVID-19 convalescent plasma (CCP).To the Editor:Case 1: A 53-year-old female with B-cell acute lymphoblastic leukemia, status post haploidentical ASCT (Supplementary Table 1), presented on day +157 post ASCT with fever, shortness of breath, and cough.", [["plasma", "ANATOMY", 418, 424], ["B-cell acute lymphoblastic leukemia", "ANATOMY", 479, 514], ["COVID-19", "CHEMICAL", 294, 302], ["infection", "DISEASE", 303, 312], ["COVID-19", "CHEMICAL", 396, 404], ["acute lymphoblastic leukemia", "DISEASE", 486, 514], ["fever", "DISEASE", 610, 615], ["shortness of breath", "DISEASE", 617, 636], ["cough", "DISEASE", 642, 647], ["COVID-19", "CELL", 294, 302], ["plasma", "ORGANISM_SUBSTANCE", 418, 424], ["female", "ORGANISM", 467, 473], ["B-cell acute lymphoblastic leukemia", "CANCER", 479, 514], ["CRISPR", "DNA", 204, 210], ["a highly sensitive clustered regularly interspaced short palindromic repeats", "PROBLEM", 126, 202], ["qualitative COVID", "TEST", 218, 235], ["COVID-19 infection", "PROBLEM", 294, 312], ["ASCT recipients", "TREATMENT", 316, 331], ["CRISPR diagnostics", "TEST", 338, 356], ["COVID", "TREATMENT", 396, 401], ["B-cell acute lymphoblastic leukemia", "PROBLEM", 479, 514], ["haploidentical ASCT", "TREATMENT", 528, 547], ["ASCT", "TREATMENT", 600, 604], ["fever", "PROBLEM", 610, 615], ["shortness of breath", "PROBLEM", 617, 636], ["cough", "PROBLEM", 642, 647], ["infection", "OBSERVATION", 303, 312], ["B-cell", "OBSERVATION", 479, 485], ["acute lymphoblastic leukemia", "OBSERVATION", 486, 514], ["fever", "OBSERVATION", 610, 615], ["cough", "OBSERVATION", 642, 647]]], ["Her case is complicated by steroid-dependent chronic graft-versus-host disease (cGVHD) of the skin and mouth, currently responding to weekly intravenous rituximab.", [["graft", "ANATOMY", 53, 58], ["skin", "ANATOMY", 94, 98], ["mouth", "ANATOMY", 103, 108], ["intravenous", "ANATOMY", 141, 152], ["steroid", "CHEMICAL", 27, 34], ["chronic graft-versus-host disease", "DISEASE", 45, 78], ["cGVHD", "DISEASE", 80, 85], [") of the skin and mouth", "DISEASE", 85, 108], ["rituximab", "CHEMICAL", 153, 162], ["steroid", "CHEMICAL", 27, 34], ["steroid", "SIMPLE_CHEMICAL", 27, 34], ["graft", "TISSUE", 53, 58], ["skin", "ORGAN", 94, 98], ["mouth", "ORGAN", 103, 108], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 152], ["rituximab", "SIMPLE_CHEMICAL", 153, 162], ["steroid-dependent chronic graft-versus-host disease", "PROBLEM", 27, 78], ["weekly intravenous rituximab", "TREATMENT", 134, 162], ["dependent", "OBSERVATION_MODIFIER", 35, 44], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["graft", "OBSERVATION", 53, 58], ["versus-host disease", "OBSERVATION", 59, 78], ["skin", "ANATOMY", 94, 98], ["mouth", "ANATOMY", 103, 108]]], ["A chest computed tomography (CT) scan revealed ground glass opacities suggestive of COVID-19 (Fig. 1a).", [["A chest computed tomography (CT) scan", "TEST", 0, 37], ["ground glass opacities", "PROBLEM", 47, 69], ["COVID", "TEST", 84, 89], ["chest", "ANATOMY", 2, 7], ["ground glass opacities", "OBSERVATION", 47, 69], ["suggestive of", "UNCERTAINTY", 70, 83]]], ["Both nasal and nasopharyngeal RT-PCR swab tests (Abbott and Roche) were negative for SARS-CoV-2.", [["nasal", "ANATOMY", 5, 10], ["nasopharyngeal", "ANATOMY", 15, 29], ["nasal", "MULTI-TISSUE_STRUCTURE", 5, 10], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["SARS-CoV", "SPECIES", 85, 93], ["Both nasal and nasopharyngeal RT-PCR swab tests", "TEST", 0, 47], ["Abbott and Roche)", "TEST", 49, 66], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93], ["nasal", "ANATOMY", 5, 10], ["nasopharyngeal RT", "ANATOMY", 15, 32]]], ["She was started on ceftriaxone, azithromycin, and vancomycin for pneumonia.", [["ceftriaxone", "CHEMICAL", 19, 30], ["azithromycin", "CHEMICAL", 32, 44], ["vancomycin", "CHEMICAL", 50, 60], ["pneumonia", "DISEASE", 65, 74], ["ceftriaxone", "CHEMICAL", 19, 30], ["azithromycin", "CHEMICAL", 32, 44], ["vancomycin", "CHEMICAL", 50, 60], ["ceftriaxone", "SIMPLE_CHEMICAL", 19, 30], ["azithromycin", "SIMPLE_CHEMICAL", 32, 44], ["vancomycin", "SIMPLE_CHEMICAL", 50, 60], ["ceftriaxone", "TREATMENT", 19, 30], ["azithromycin", "TREATMENT", 32, 44], ["vancomycin", "TREATMENT", 50, 60], ["pneumonia", "PROBLEM", 65, 74], ["pneumonia", "OBSERVATION", 65, 74]]], ["Intravenous immunoglobulin (IVIG) was administered for hypogammaglobulinemia.", [["hypogammaglobulinemia", "DISEASE", 55, 76], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 12, 26], ["IVIG", "SIMPLE_CHEMICAL", 28, 32], ["immunoglobulin", "PROTEIN", 12, 26], ["Intravenous immunoglobulin (IVIG)", "TREATMENT", 0, 33], ["hypogammaglobulinemia", "PROBLEM", 55, 76]]], ["Over the proceeding 48 hours, her respiratory status worsened, requiring oxygen at 4 L/min.", [["respiratory", "ANATOMY", 34, 45], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "SIMPLE_CHEMICAL", 73, 79], ["her respiratory status", "PROBLEM", 30, 52], ["oxygen", "TREATMENT", 73, 79], ["respiratory", "ANATOMY", 34, 45], ["worsened", "OBSERVATION_MODIFIER", 53, 61]]], ["Due to continued suspicion for COVID-19, investigational RT-PCR/CRISPR technology was performed as we have previously described (supplementary methods) [4], on nasal swab, saliva, blood, and plasma samples, and surprisingly tested positive for SARS-CoV-2 RNA (Fig. 1b).", [["nasal swab", "ANATOMY", 160, 170], ["saliva", "ANATOMY", 172, 178], ["blood", "ANATOMY", 180, 185], ["plasma samples", "ANATOMY", 191, 205], ["nasal swab", "ORGANISM_SUBSTANCE", 160, 170], ["saliva", "ORGANISM_SUBSTANCE", 172, 178], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["plasma samples", "ORGANISM_SUBSTANCE", 191, 205], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 244, 254], ["COVID-19", "DNA", 31, 39], ["CRISPR", "DNA", 64, 70], ["SARS-CoV-2 RNA", "RNA", 244, 258], ["SARS-CoV", "SPECIES", 244, 252], ["COVID", "TEST", 31, 36], ["investigational RT-PCR", "TEST", 41, 63], ["CRISPR technology", "TEST", 64, 81], ["nasal swab, saliva, blood, and plasma samples", "TEST", 160, 205], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252], ["nasal", "ANATOMY", 160, 165]]], ["One unit (200 ml) of CCP was given on hospital day 4 and day 13.", [["CCP", "TREATMENT", 21, 24]]], ["Within a day of receiving her first transfusion of CCP, she reported improvement in shortness of breath and cough, had fever resolution, and decreasing oxygen requirements.", [["shortness of breath", "DISEASE", 84, 103], ["cough", "DISEASE", 108, 113], ["fever", "DISEASE", 119, 124], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "SIMPLE_CHEMICAL", 152, 158], ["her first transfusion of CCP", "TREATMENT", 26, 54], ["shortness of breath", "PROBLEM", 84, 103], ["cough", "PROBLEM", 108, 113], ["fever resolution", "PROBLEM", 119, 135], ["decreasing oxygen requirements", "PROBLEM", 141, 171], ["improvement", "OBSERVATION_MODIFIER", 69, 80], ["cough", "OBSERVATION", 108, 113], ["decreasing", "OBSERVATION_MODIFIER", 141, 151], ["oxygen requirements", "OBSERVATION", 152, 171]]], ["In addition, a significant decrease in C-reactive protein and procalcitonin was also seen (Supplementary table 1).", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 39, 57], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 62, 75], ["C-reactive protein", "PROTEIN", 39, 57], ["procalcitonin", "PROTEIN", 62, 75], ["a significant decrease in C-reactive protein and procalcitonin", "PROBLEM", 13, 75], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["reactive protein", "OBSERVATION", 41, 57]]], ["The patient was discharged home without oxygen on hospital day 15.To the Editor:Case 2: A 67-year-old male with a history of ASCT for high-risk acute myeloid leukemia (Table S1), presented on day +319 post ASCT with shortness of breath, cough, and a worsening skin rash.", [["acute myeloid leukemia", "ANATOMY", 144, 166], ["skin", "ANATOMY", 260, 264], ["oxygen", "CHEMICAL", 40, 46], ["acute myeloid leukemia", "DISEASE", 144, 166], ["shortness of breath", "DISEASE", 216, 235], ["cough", "DISEASE", 237, 242], ["skin rash", "DISEASE", 260, 269], ["oxygen", "CHEMICAL", 40, 46], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 40, 46], ["male", "ORGANISM", 102, 106], ["high-risk acute myeloid leukemia", "CANCER", 134, 166], ["skin", "ORGAN", 260, 264], ["patient", "SPECIES", 4, 11], ["oxygen", "TREATMENT", 40, 46], ["ASCT", "TREATMENT", 125, 129], ["high-risk acute myeloid leukemia", "PROBLEM", 134, 166], ["ASCT", "TREATMENT", 206, 210], ["shortness of breath", "PROBLEM", 216, 235], ["cough", "PROBLEM", 237, 242], ["a worsening skin rash", "PROBLEM", 248, 269], ["acute myeloid leukemia", "OBSERVATION", 144, 166], ["cough", "OBSERVATION", 237, 242], ["worsening", "OBSERVATION_MODIFIER", 250, 259], ["skin", "ANATOMY", 260, 264], ["rash", "OBSERVATION", 265, 269]]], ["His transplant was complicated by steroid refractory cGVHD of the skin and lungs requiring treatment with the Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib in addition to prednisone and rituximab.", [["skin", "ANATOMY", 66, 70], ["lungs", "ANATOMY", 75, 80], ["steroid", "CHEMICAL", 34, 41], ["cGVHD of the skin", "DISEASE", 53, 70], ["tyrosine", "CHEMICAL", 119, 127], ["ibrutinib", "CHEMICAL", 151, 160], ["prednisone", "CHEMICAL", 176, 186], ["rituximab", "CHEMICAL", 191, 200], ["steroid", "CHEMICAL", 34, 41], ["tyrosine", "CHEMICAL", 119, 127], ["ibrutinib", "CHEMICAL", 151, 160], ["prednisone", "CHEMICAL", 176, 186], ["rituximab", "CHEMICAL", 191, 200], ["skin", "ORGAN", 66, 70], ["lungs", "ORGAN", 75, 80], ["Bruton\u2019s tyrosine kinase", "GENE_OR_GENE_PRODUCT", 110, 134], ["BTK", "GENE_OR_GENE_PRODUCT", 136, 139], ["ibrutinib", "SIMPLE_CHEMICAL", 151, 160], ["prednisone", "SIMPLE_CHEMICAL", 176, 186], ["rituximab", "SIMPLE_CHEMICAL", 191, 200], ["Bruton\u2019s tyrosine kinase", "PROTEIN", 110, 134], ["BTK", "PROTEIN", 136, 139], ["His transplant", "TREATMENT", 0, 14], ["steroid refractory cGVHD of the skin and lungs", "PROBLEM", 34, 80], ["treatment", "TREATMENT", 91, 100], ["the Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib", "TREATMENT", 106, 160], ["prednisone", "TREATMENT", 176, 186], ["rituximab", "TREATMENT", 191, 200], ["transplant", "OBSERVATION", 4, 14], ["steroid refractory cGVHD", "OBSERVATION", 34, 58], ["skin", "ANATOMY", 66, 70], ["lungs", "ANATOMY", 75, 80]]], ["A chest CT revealed ill-defined peribronchovascular opacities raising concern for COVID-19.", [["chest", "ANATOMY", 2, 7], ["peribronchovascular", "ANATOMY", 32, 51], ["opacities", "DISEASE", 52, 61], ["COVID-19", "CHEMICAL", 82, 90], ["A chest CT", "TEST", 0, 10], ["ill-defined peribronchovascular opacities", "PROBLEM", 20, 61], ["COVID", "TEST", 82, 87], ["chest", "ANATOMY", 2, 7], ["ill", "OBSERVATION_MODIFIER", 20, 23], ["peribronchovascular", "ANATOMY_MODIFIER", 32, 51], ["opacities", "OBSERVATION", 52, 61], ["raising concern for", "UNCERTAINTY", 62, 81]]], ["However, he tested negative for SARS-CoV-2 RNA via nasopharyngeal RT-PCR (Roche).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["SARS-CoV-2 RNA", "RNA", 32, 46], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["nasopharyngeal RT", "TEST", 51, 68], ["nasopharyngeal", "ANATOMY", 51, 65]]], ["He was started on ceftriaxone and doxycycline and received IVIG for hypogammaglobulinemia.", [["ceftriaxone", "CHEMICAL", 18, 29], ["doxycycline", "CHEMICAL", 34, 45], ["hypogammaglobulinemia", "DISEASE", 68, 89], ["ceftriaxone", "CHEMICAL", 18, 29], ["doxycycline", "CHEMICAL", 34, 45], ["He", "ORGANISM", 0, 2], ["ceftriaxone", "SIMPLE_CHEMICAL", 18, 29], ["doxycycline", "SIMPLE_CHEMICAL", 34, 45], ["IVIG", "SIMPLE_CHEMICAL", 59, 63], ["ceftriaxone", "TREATMENT", 18, 29], ["doxycycline", "TREATMENT", 34, 45], ["IVIG", "TREATMENT", 59, 63], ["hypogammaglobulinemia", "PROBLEM", 68, 89], ["hypogammaglobulinemia", "OBSERVATION", 68, 89]]], ["On hospital day 11, his respiratory culture grew multidrug resistant Stenotrophomonas maltophilia, and intravenous trimethoprim\u2013sulfamethoxazole was started.", [["intravenous", "ANATOMY", 103, 114], ["multidrug resistant Stenotrophomonas maltophilia", "DISEASE", 49, 97], ["trimethoprim\u2013sulfamethoxazole", "CHEMICAL", 115, 144], ["trimethoprim\u2013sulfamethoxazole", "CHEMICAL", 115, 144], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 114], ["trimethoprim\u2013sulfamethoxazole", "SIMPLE_CHEMICAL", 115, 144], ["Stenotrophomonas maltophilia", "SPECIES", 69, 97], ["his respiratory culture", "TEST", 20, 43], ["multidrug resistant Stenotrophomonas maltophilia", "PROBLEM", 49, 97], ["intravenous trimethoprim\u2013sulfamethoxazole", "TREATMENT", 103, 144], ["respiratory", "ANATOMY", 24, 35], ["multidrug resistant Stenotrophomonas maltophilia", "OBSERVATION", 49, 97]]], ["The patient\u2019s condition progressively worsened to acute respiratory distress requiring mechanical ventilation.", [["respiratory", "ANATOMY", 56, 67], ["respiratory distress", "DISEASE", 56, 76], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["acute respiratory distress", "PROBLEM", 50, 76], ["mechanical ventilation", "TREATMENT", 87, 109], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory distress", "OBSERVATION", 56, 76], ["mechanical ventilation", "OBSERVATION", 87, 109]]], ["Bronchoscopy was performed, but no definitive diagnosis was made.", [["Bronchoscopy", "TEST", 0, 12]]], ["Repeat SARS-CoV-2 RT-PCR was performed on a nasal swab and BAL specimen, but both were again negative.", [["nasal swab", "ANATOMY", 44, 54], ["BAL specimen", "ANATOMY", 59, 71], ["nasal swab", "ORGANISM_SUBSTANCE", 44, 54], ["BAL specimen", "CANCER", 59, 71], ["SARS-CoV-2 RT-PCR", "DNA", 7, 24], ["Repeat SARS", "TEST", 0, 11], ["CoV", "TEST", 12, 15], ["RT-PCR", "TEST", 18, 24], ["a nasal swab", "TEST", 42, 54], ["BAL specimen", "TEST", 59, 71], ["nasal", "ANATOMY", 44, 49]]], ["Despite aggressive antimicrobial therapy and supportive care, the patient developed multiorgan failure and died on hospital day 36 (+354 post ASCT).", [["multiorgan", "ANATOMY", 84, 94], ["multiorgan failure", "DISEASE", 84, 102], ["patient", "ORGANISM", 66, 73], ["multiorgan", "ORGAN", 84, 94], ["patient", "SPECIES", 66, 73], ["aggressive antimicrobial therapy", "TREATMENT", 8, 40], ["supportive care", "TREATMENT", 45, 60], ["multiorgan failure", "PROBLEM", 84, 102], ["aggressive", "OBSERVATION_MODIFIER", 8, 18], ["antimicrobial therapy", "OBSERVATION", 19, 40], ["multiorgan", "ANATOMY", 84, 94], ["failure", "OBSERVATION", 95, 102]]], ["An autopsy was not performed due to concern for possible COVID-19 and the risk it posed to the staff.", [["An autopsy", "TEST", 0, 10], ["COVID", "TEST", 57, 62]]], ["Shortly thereafter, RT-PCR/CRISPR was performed on a blood sample collected on hospital day 36 for clinical purposes and demonstrated strong detection of SARS-CoV-2 RNA (Fig. 1c).To the Editor:Here, we present two cases of ASCT recipients who presented with respiratory illnesses, initially testing negative for SARS-CoV-2 with conventional RT-PCR, then positive with the more sensitive RT-PCR/CRISPR technique.", [["blood sample", "ANATOMY", 53, 65], ["respiratory", "ANATOMY", 258, 269], ["respiratory illnesses", "DISEASE", 258, 279], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["ASCT", "CANCER", 223, 227], ["recipients", "ORGANISM", 228, 238], ["CRISPR", "DNA", 27, 33], ["SARS-CoV-2 RNA", "RNA", 154, 168], ["SARS-CoV", "SPECIES", 154, 162], ["SARS-CoV", "SPECIES", 312, 320], ["RT-PCR/CRISPR", "TEST", 20, 33], ["a blood sample", "TEST", 51, 65], ["clinical purposes", "TEST", 99, 116], ["SARS", "PROBLEM", 154, 158], ["CoV", "TEST", 159, 162], ["ASCT recipients", "TREATMENT", 223, 238], ["respiratory illnesses", "PROBLEM", 258, 279], ["SARS", "PROBLEM", 312, 316], ["CoV", "TEST", 317, 320], ["conventional RT-PCR", "TEST", 328, 347], ["respiratory", "ANATOMY", 258, 269], ["illnesses", "OBSERVATION", 270, 279]]], ["One patient was diagnosed with COVID-19 early in her course and was immediately treated with CCP and survived, while the other did not receive COVID-19 directed therapy and expired.", [["COVID-19", "CHEMICAL", 143, 151], ["COVID-19", "CHEMICAL", 143, 151], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["COVID", "TEST", 31, 36], ["COVID-19 directed therapy", "TREATMENT", 143, 168]]], ["Our findings suggest that ASCT recipients with negative nasopharyngeal SARS-CoV-2 RT-PCR, but evidence of lower respiratory tract disease, might indeed have COVID-19 that can be detected using a CRISPR-based platform.", [["lower respiratory tract", "ANATOMY", 106, 129], ["respiratory tract disease", "DISEASE", 112, 137], ["recipients", "ORGANISM", 31, 41], ["lower", "ORGANISM_SUBDIVISION", 106, 111], ["respiratory tract", "ORGANISM_SUBDIVISION", 112, 129], ["COVID-19", "DNA", 157, 165], ["CRISPR", "DNA", 195, 201], ["ASCT recipients", "TREATMENT", 26, 41], ["negative nasopharyngeal SARS", "PROBLEM", 47, 75], ["CoV", "TEST", 76, 79], ["RT-PCR", "TEST", 82, 88], ["lower respiratory tract disease", "PROBLEM", 106, 137], ["COVID", "TEST", 157, 162], ["a CRISPR", "TREATMENT", 193, 201], ["ASCT recipients", "OBSERVATION", 26, 41], ["nasopharyngeal", "ANATOMY", 56, 70], ["SARS", "OBSERVATION", 71, 75], ["evidence of", "UNCERTAINTY", 94, 105], ["lower", "ANATOMY_MODIFIER", 106, 111], ["respiratory tract", "ANATOMY", 112, 129]]], ["This challenges the established algorithm for evaluation and treatment of suspected/confirmed COVID-19 in ASCT recipients and illustrates the need for more sensitive tests.", [["evaluation", "TEST", 46, 56], ["treatment", "TREATMENT", 61, 70], ["COVID", "TEST", 94, 99], ["ASCT recipients", "TREATMENT", 106, 121], ["more sensitive tests", "TEST", 151, 171]]], ["Prompt diagnosis is essential in all patients, particularly in immunocompromised hosts, as earlier treatment will likely improve outcomes.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["earlier treatment", "TREATMENT", 91, 108]]], ["Antiviral agents, such as remdesivir, have recently been shown to shorten time to clinical improvement particularly with earlier initiation [5, 6].", [["remdesivir", "CHEMICAL", 26, 36], ["remdesivir", "CHEMICAL", 26, 36], ["remdesivir", "SIMPLE_CHEMICAL", 26, 36], ["Antiviral agents", "TREATMENT", 0, 16], ["remdesivir", "TREATMENT", 26, 36]]], ["Similarly in the SARS-CoV-1 2003 epidemic, the clinical benefit of convalescent plasma was more significant if given within the first 14 days of illness [7].To the Editor:Our cases tested positive for SARS-CoV-2 in samples other than a nasopharyngeal source.", [["plasma", "ANATOMY", 80, 86], ["samples", "ANATOMY", 215, 222], ["nasopharyngeal", "ANATOMY", 236, 250], ["SARS", "DISEASE", 17, 21], ["illness", "DISEASE", 145, 152], ["convalescent", "ORGANISM", 67, 79], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 211], ["samples", "CANCER", 215, 222], ["nasopharyngeal", "ORGAN", 236, 250], ["SARS-CoV-1", "SPECIES", 17, 27], ["SARS-CoV", "SPECIES", 201, 209], ["the SARS", "TEST", 13, 21], ["CoV", "TEST", 22, 25], ["convalescent plasma", "TEST", 67, 86], ["illness", "PROBLEM", 145, 152], ["Our cases", "TEST", 171, 180], ["SARS", "PROBLEM", 201, 205], ["CoV", "TEST", 206, 209], ["a nasopharyngeal source", "PROBLEM", 234, 257], ["nasopharyngeal", "ANATOMY", 236, 250], ["source", "OBSERVATION", 251, 257]]], ["This poses the question of whether patients with objective findings consistent with COVID-19 and a negative nasopharyngeal RT-PCR assay would benefit from testing of other tissue types [2].", [["nasopharyngeal", "ANATOMY", 108, 122], ["tissue", "ANATOMY", 172, 178], ["patients", "ORGANISM", 35, 43], ["nasopharyngeal", "ORGAN", 108, 122], ["tissue", "TISSUE", 172, 178], ["patients", "SPECIES", 35, 43], ["COVID", "TEST", 84, 89], ["nasopharyngeal RT-PCR assay", "TEST", 108, 135], ["nasopharyngeal", "ANATOMY", 108, 122]]], ["In the particular example of ASCT, the ASTCT suggests that a negative nasopharyngeal RT-PCR test does not rule out COVID-19 in patients with lower respiratory tract symptoms, as the virus might be detectable only in the lower airways.", [["nasopharyngeal", "ANATOMY", 70, 84], ["lower respiratory tract", "ANATOMY", 141, 164], ["lower airways", "ANATOMY", 220, 233], ["respiratory tract symptoms", "DISEASE", 147, 173], ["ASCT", "CANCER", 29, 33], ["nasopharyngeal", "ORGAN", 70, 84], ["patients", "ORGANISM", 127, 135], ["lower", "ORGANISM_SUBDIVISION", 141, 146], ["respiratory tract", "ORGANISM_SUBDIVISION", 147, 164], ["lower airways", "MULTI-TISSUE_STRUCTURE", 220, 233], ["patients", "SPECIES", 127, 135], ["ASCT", "TEST", 29, 33], ["the ASTCT", "TEST", 35, 44], ["nasopharyngeal RT-PCR test", "TEST", 70, 96], ["COVID", "TEST", 115, 120], ["lower respiratory tract symptoms", "PROBLEM", 141, 173], ["the virus", "PROBLEM", 178, 187], ["nasopharyngeal", "ANATOMY", 70, 84], ["lower", "ANATOMY_MODIFIER", 141, 146], ["respiratory tract", "ANATOMY", 147, 164], ["lower", "ANATOMY_MODIFIER", 220, 225], ["airways", "ANATOMY", 226, 233]]], ["While safety concerns with performing bronchoscopy remain high with this infection, and COVID-19-specific treatments depend on securing a positive test, it may be beneficial to pursue diagnosis with other tissue sources, such as whole blood or plasma.To the Editor:As our report demonstrates, ASCT recipients are at risk of developing more severe complications from COVID-19.", [["tissue", "ANATOMY", 205, 211], ["whole blood", "ANATOMY", 229, 240], ["plasma", "ANATOMY", 244, 250], ["infection", "DISEASE", 73, 82], ["COVID-19", "CHEMICAL", 366, 374], ["tissue", "TISSUE", 205, 211], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["plasma", "ORGANISM_SUBSTANCE", 244, 250], ["recipients", "ORGANISM", 298, 308], ["performing bronchoscopy", "TEST", 27, 50], ["this infection", "PROBLEM", 68, 82], ["COVID", "TEST", 88, 93], ["a positive test", "TEST", 136, 151], ["other tissue sources", "PROBLEM", 199, 219], ["whole blood", "TEST", 229, 240], ["ASCT recipients", "TREATMENT", 293, 308], ["more severe complications", "PROBLEM", 335, 360], ["COVID", "TEST", 366, 371], ["severe", "OBSERVATION_MODIFIER", 340, 346], ["complications", "OBSERVATION", 347, 360]]], ["T-cell lymphopenia has been correlated with higher risk of in-hospital death and severity of COVID-19 infection [8].", [["T-cell", "ANATOMY", 0, 6], ["lymphopenia", "DISEASE", 7, 18], ["death", "DISEASE", 71, 76], ["COVID-19", "CHEMICAL", 93, 101], ["infection", "DISEASE", 102, 111], ["T-cell", "CELL", 0, 6], ["COVID-19", "GENE_OR_GENE_PRODUCT", 93, 101], ["T-cell lymphopenia", "PROBLEM", 0, 18], ["in-hospital death", "PROBLEM", 59, 76], ["COVID-19 infection", "PROBLEM", 93, 111], ["cell lymphopenia", "OBSERVATION", 2, 18]]], ["Indeed, our patients have low baseline T-lymphocyte counts further decreased with cGVHD therapy with steroids, tacrolimus, and ibrutinib.", [["T-lymphocyte", "ANATOMY", 39, 51], ["cGVHD", "DISEASE", 82, 87], ["steroids", "CHEMICAL", 101, 109], ["tacrolimus", "CHEMICAL", 111, 121], ["ibrutinib", "CHEMICAL", 127, 136], ["steroids", "CHEMICAL", 101, 109], ["tacrolimus", "CHEMICAL", 111, 121], ["ibrutinib", "CHEMICAL", 127, 136], ["patients", "ORGANISM", 12, 20], ["T-lymphocyte", "CELL", 39, 51], ["steroids", "SIMPLE_CHEMICAL", 101, 109], ["tacrolimus", "SIMPLE_CHEMICAL", 111, 121], ["ibrutinib", "SIMPLE_CHEMICAL", 127, 136], ["patients", "SPECIES", 12, 20], ["low baseline T-lymphocyte counts", "PROBLEM", 26, 58], ["cGVHD therapy", "TREATMENT", 82, 95], ["steroids", "TREATMENT", 101, 109], ["tacrolimus", "TREATMENT", 111, 121], ["ibrutinib", "TREATMENT", 127, 136]]], ["Similarly, SARS-CoV-2 may cause a decrease in B-lymphocytes early in the disease course, thus hindering the ability to produce antibodies [9].", [["B-lymphocytes", "ANATOMY", 46, 59], ["SARS", "DISEASE", 11, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["B-lymphocytes", "CELL", 46, 59], ["B-lymphocytes", "CELL_TYPE", 46, 59], ["antibodies", "PROTEIN", 127, 137], ["SARS-CoV", "SPECIES", 11, 19], ["SARS-CoV", "TEST", 11, 19], ["a decrease in B-lymphocytes", "PROBLEM", 32, 59], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["-lymphocytes", "OBSERVATION_MODIFIER", 47, 59]]], ["In our patients, the ability to develop memory B-cells and plasma cells for antibody production is already impeded by steroids and rituximab.", [["memory B-cells", "ANATOMY", 40, 54], ["plasma cells", "ANATOMY", 59, 71], ["steroids", "CHEMICAL", 118, 126], ["rituximab", "CHEMICAL", 131, 140], ["steroids", "CHEMICAL", 118, 126], ["rituximab", "CHEMICAL", 131, 140], ["patients", "ORGANISM", 7, 15], ["memory B-cells", "CELL", 40, 54], ["plasma cells", "CELL", 59, 71], ["steroids", "SIMPLE_CHEMICAL", 118, 126], ["rituximab", "SIMPLE_CHEMICAL", 131, 140], ["memory B-cells", "CELL_TYPE", 40, 54], ["plasma cells", "CELL_TYPE", 59, 71], ["patients", "SPECIES", 7, 15], ["memory B-cells", "PROBLEM", 40, 54], ["plasma cells", "PROBLEM", 59, 71], ["antibody production", "PROBLEM", 76, 95], ["steroids", "TREATMENT", 118, 126], ["rituximab", "TREATMENT", 131, 140]]], ["Thus, passive immunity support with CCP is required to deliver the SARS-CoV-2 neutralizing antibodies needed to clear the infection.To the Editor:It may be most appropriate to preemptively treat with investigational therapeutics in patients where high clinical suspicion exists but test negative.", [["infection", "DISEASE", 122, 131], ["CCP", "GENE_OR_GENE_PRODUCT", 36, 39], ["SARS-CoV-2", "ORGANISM", 67, 77], ["patients", "ORGANISM", 232, 240], ["CCP", "PROTEIN", 36, 39], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 67, 101], ["patients", "SPECIES", 232, 240], ["passive immunity support", "TREATMENT", 6, 30], ["the SARS", "TEST", 63, 71], ["CoV", "TEST", 72, 75], ["2 neutralizing antibodies", "TREATMENT", 76, 101], ["the infection", "PROBLEM", 118, 131], ["investigational therapeutics", "TREATMENT", 200, 228], ["test", "TEST", 282, 286], ["infection", "OBSERVATION", 122, 131]]], ["In our case, we elected to treat with CCP; however, combination therapy could be considered.", [["CCP", "DISEASE", 38, 41], ["CCP", "PROBLEM", 38, 41], ["therapy", "TREATMENT", 64, 71]]], ["Interim remdesivir data have shown clinical benefit in symptom duration and overall survival [5].", [["Interim remdesivir data", "TEST", 0, 23]]], ["The addition of CCP should be considered adjunctively moving forward in this high-risk population due to a jeopardized active immunity.", [["CCP", "GENE_OR_GENE_PRODUCT", 16, 19]]], ["Our patient who received CCP significantly improved, which is consistent with other CCP reports [10].", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["consistent with", "UNCERTAINTY", 62, 77]]], ["However, as ASCT recipients on immunosuppression are less likely to generate adequate antibodies, multiple transfusions of CCP might be needed as in case 1.To the Editor:There were several differences between our two case patients (Table S1).", [["recipients", "ORGANISM", 17, 27], ["patients", "ORGANISM", 222, 230], ["antibodies", "PROTEIN", 86, 96], ["CCP", "PROTEIN", 123, 126], ["patients", "SPECIES", 222, 230], ["immunosuppression", "TREATMENT", 31, 48], ["multiple transfusions of CCP", "TREATMENT", 98, 126]]], ["Notably the clinical presentation, with case 1 presenting acutely, while case 2 had a progressive clinical course.", [["progressive", "OBSERVATION_MODIFIER", 86, 97]]], ["Both patients were taking steroids; however, case 2 was on ibrutinib.", [["steroids", "CHEMICAL", 26, 34], ["ibrutinib", "CHEMICAL", 59, 68], ["steroids", "CHEMICAL", 26, 34], ["ibrutinib", "CHEMICAL", 59, 68], ["patients", "ORGANISM", 5, 13], ["ibrutinib", "SIMPLE_CHEMICAL", 59, 68], ["patients", "SPECIES", 5, 13], ["steroids", "TREATMENT", 26, 34], ["ibrutinib", "TREATMENT", 59, 68]]], ["Intriguingly, the BTK inhibitors, ibrutinib and acalabrutinib, are being investigated for their ability to reduce COVID-19 induced respiratory distress [11, 12].", [["respiratory", "ANATOMY", 131, 142], ["ibrutinib", "CHEMICAL", 34, 43], ["acalabrutinib", "CHEMICAL", 48, 61], ["COVID-19", "CHEMICAL", 114, 122], ["respiratory distress", "DISEASE", 131, 151], ["ibrutinib", "CHEMICAL", 34, 43], ["acalabrutinib", "CHEMICAL", 48, 61], ["COVID-19", "CHEMICAL", 114, 122], ["BTK", "GENE_OR_GENE_PRODUCT", 18, 21], ["ibrutinib", "SIMPLE_CHEMICAL", 34, 43], ["acalabrutinib", "SIMPLE_CHEMICAL", 48, 61], ["the BTK inhibitors", "TREATMENT", 14, 32], ["ibrutinib", "TREATMENT", 34, 43], ["acalabrutinib", "TREATMENT", 48, 61], ["COVID", "TEST", 114, 119], ["induced respiratory distress", "PROBLEM", 123, 151], ["respiratory distress", "OBSERVATION", 131, 151]]], ["This is notable as case 2 intermittently continued ibrutinib due to his protracted illness and had a more insidious COVID-19 infection with slower progression to respiratory failure.To the Editor:In conclusion, early diagnosis and treatment of COVID-19 is crucial in ASCT recipients, and evaluation regarding the use of other tissue sources for detection of SARS-CoV-2 along with multimodality therapy is required in the continual evolution of this pandemic.", [["respiratory", "ANATOMY", 162, 173], ["tissue", "ANATOMY", 326, 332], ["ibrutinib", "CHEMICAL", 51, 60], ["infection", "DISEASE", 125, 134], ["respiratory failure", "DISEASE", 162, 181], ["SARS", "DISEASE", 358, 362], ["ibrutinib", "CHEMICAL", 51, 60], ["ibrutinib", "SIMPLE_CHEMICAL", 51, 60], ["tissue", "TISSUE", 326, 332], ["SARS-CoV-2", "ORGANISM", 358, 368], ["SARS-CoV", "SPECIES", 358, 366], ["his protracted illness", "PROBLEM", 68, 90], ["a more insidious COVID-19 infection", "PROBLEM", 99, 134], ["respiratory failure", "PROBLEM", 162, 181], ["COVID", "TEST", 244, 249], ["ASCT recipients", "TREATMENT", 267, 282], ["evaluation", "TEST", 288, 298], ["SARS", "PROBLEM", 358, 362], ["CoV", "TEST", 363, 366], ["multimodality therapy", "TREATMENT", 380, 401], ["this pandemic", "PROBLEM", 444, 457], ["infection", "OBSERVATION", 125, 134], ["respiratory failure", "OBSERVATION", 162, 181]]]]}